Organocatalytic synthesis of chiral non-racemic aziridines, labelled with 2H, 15N, 13C stable isotopes by Zdorichenko, Victor
 
 
 
 
 
Organocatalytic synthesis of chiral non-racemic aziridines, 
labelled with 2H, 15N, 13C stable isotopes 
 
 
 
 
Victor Zdorichenko 
 
 
 
Thesis submitted in part fulfilment of the requirements for the degree of Doctor of 
Philosophy 
 
Supervisor: Dr. Sean Patrick Bew 
 
 
 
 
 
 
 
 
 
 
 
 
 
School of Chemistry 
University of East Anglia 
Norwich Research Park 
 
May 2015 
 
This copy of the thesis has been supplied on condition that anyone who consults it is understood 
to recognise that its copyright rests with the author and that use of any information derived there 
from must be in accordance with current UK Copyright Law. In addition, any quotation or 
extract must include full attribution
i 
 
Declaration 
 
The research presented in this thesis is, to the best of my knowledge, original, except 
where due reference is made. 
Victor Zdorichenko 
 
 
Acknowledgements 
 
I would like to express my genuine appreciation to everyone who in one way or another 
has helped me, supported me and shared with me the past four years. I am very grateful 
for the opportunity to work at UEA, for which special thank you goes to my primary 
academic supervisor Dr. Sean Bew, without him it would be impossible to achieve all 
this. I want to say thank you to my industrial supervisor Prof. Brian Cox and Novartis 
for funding my research. Additionally, I want to thank my secondary supervisor Prof. 
Andrew Cammidge for his help and support. Big thank you goes to Dr. Colin 
Macdonald for his help with NMR data and specialised NMR experiments. Special 
appreciation goes to everyone in Dr. Bew’s group for their dedication, collaboration and 
hard-work. Thank you Glyn, Polly, Will, Dominika, Luis, Deeptee and many, many 
others! Big thanks goes to my friends for their good advice, support and encouragement. 
Cheers Dani, Sonia, César, Teresa, Hanae, Flavia, Desi, Franco, Łukasz, Davide, 
Simon, Lisa, Alex, Claudia, Francesca, Giulia, Marco, Melania, Ryan, Julien, Yohan, 
Tony, Emma, Ed, Dave, Brian, Fran, Ian, Jay, Johanna, Ketan, Mark, Michael, Oli, 
Ross, James, Doyle, Becky, Amanda, James, Jamie and others! I am increadibly lucky 
to have amazing teachers who taught me very well: Dawn, Malle, Joan, Caroline, Dan, 
Matthew. My teachers from Russia made my dream come true, they educated me to 
pursue my education and career abroad: Лилия Ивановна, Ольга Александровна, 
Ольга Семёновна, Анна Николаевна, Надежда Александровна, Лидия Николаевна, 
Людмила Юрьевна. I would also like to say thank you to Aiste Petraityte for her 
encouragement and being extremely helpful in keeping me on track and focused on my 
work. Her family is amazing! Thank you Vaida, Christopher, Jonas, Daiva, Valentinas, 
Anne, Richard. My deep gratitude goes to my parents and family: Ирина, Евгений, 
Галина, Борис, Надя, Александр, Сергей, Оксана, Надежда, Зинаида, Владислав. 
Without all of you I would have never achieved this, words will never be enough.      
ii 
 
Abstract 
Aziridines are ‘keystone’ synthetic building blocks - relatively reactive, three-
membered heterocycles with the potential for generating ‘secondary’ high value entities 
such as α- or β-amino acids via ring-opening reactions. Within this thesis, a one-pot 
asymmetric organocatalytic methodology is utilised for the synthesis of 
enantiomerically enriched cis-N-aryl-3-aryl-aziridine-2-carboxylates, labelled with 
stable isotopes: 2H, 13C and 15N. The reactions were catalysed by (S)-BINOL derived N-
triflylphosphoramide Brønsted acid and stable isotopes were selectively introduced 
within an aziridine ring with > 95% isotopic enrichment. The desired compounds were 
generated in yields of up to 81% and up to 87% e.e. Furthermore optically active β-
bromo-α-amino acid derivatives were generated via aziridine ring-opening methodology 
without loss of the isotopic label or e.e. 
α-Arylglycinols are α-amino-β-alcohols, that can be found as structural motifs 
in synthetic and natural compounds or used as building blocks to access other functional 
groups.  When oxidised, α-arylglycinols are converted to the α-arylglycines - a class of 
α-amino acids found in a wide range of bioactive compounds such as vancomycin and 
teicoplanin glycopeptide antibiotics. Successful incorporation of 2H or 13C stable 
isotopes at α- or β-positions of enantiomerically enriched N-Cbz protected α-
arylglycinols is reported with > 95% isotopic enrichment,  yields of up to 73% and up to 
98% e.e. 
Teicoplanin is a glycopeptide antibiotic, used against methicillin-resistant 
Staphylococcus aureus (MRSA), but the emerging bacterial resistance has escalated the 
search for new antibiotics. The synthesis of a non-labelled model fragment of the 
glycopeptide antibiotic teicoplanin is reported. The fragment is synthesised via an 
aziridination reaction and can be used as a template to generate teicoplanin analogues, 
both non-labelled and labelled with stable isotopes.  
It is anticipated that the stable isotope incorporating methodologies described 
within this thesis will be applicable not only to the synthesis of novel glycopeptide 
antibiotics, but also to other biologically active compounds. The installation of stable 
isotopes affords compounds with highly valuable properties that can be used to study 
drug metabolism, toxicology, pharmacokinetics and reaction mechanisms. 
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Chapter 1. Proteins and amino acids 
1.1. Natural and unnatural amino acids 
Proteins have vital physiological functions: they acts as building blocks (tissue 
construction), enzymes (catalysis of chemical reactions) and antibodies (defence against 
pathogens).1 Each protein consists of a precise sequence of amino acids  that allows it to 
fold up into a particular three-dimensional shape, or conformation. Amino acids that 
constitute proteins are known as proteinogenic amino acids. 
The surface of each protein molecule has a unique chemical reactivity that 
depends not only on which amino acid side chains are exposed, but also on their exact 
orientation relative to one another. For this reason, even two slightly different 
conformations of the same protein molecule may differ greatly in their chemistry. 
Depending on the R-group substituent, amino acids can be divided into three 
subgroups: acidic, basic, neutral.2 Except for glycine, which is not a chiral molecule, 
natural α-amino acids, that are found in proteins, are all L-amino acids, In other words, 
their absolute configurations are related to L-glyceraldehyde (1.1) (Scheme 1.1). 
 
Scheme 1.1. Fischer projections of L-glyceraldehyde (1.1) and L-serine (1.2) 
Following Cahn-Ingold-Prelog's rule, most (except cystein) L-α-amino acids 
have the (S) configuration, because the carbonyl groups in natural α-amino acids take 
priority over the substituent R-groups (Scheme 1.1. L-serine (1.2) example). 
Apart from L-amino acids, naturally occurring D-α-amino acids have been 
discovered as well. Crow et al and Rosenberg et al reported D-serine to be abundant in 
forebrains of mammals and to be very biologically active.3,4 D-aspartic acid was found 
in nerve endings in a mammal (Rattus norvegicus) and a mollusk (Loligo vulgaris).5 D-
alanine was found in frog skin peptide dermorphin. 6  While screening the plasma 
samples of patients with renal diseases, D-serine, D-alanine and D-proline were 
identified by Nagata et al.7 
Additionally a multiple types of non-proteinogenic α-, β-, γ-amino acids have 
been found in nature and they have multiple functions in living organisms. β-alanine 
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and γ-amino butyric acid (GABA) are widely distributed in plants, involved in 
metabolism and neurotransmission respectively.8,9 
There are many unnatural (synthetic) amino acids which are widely used in 
place of natural amino acids during the synthesis of peptides. The peptides (sequence of 
at least two amino acids) bearing uncommon synthetic amino acids may have some 
additional physiological properties, which may be of medical significance and have 
clinical applications.  
1.2. Synthesis of α-amino acids: creating the building blocks 
An efficient synthesis of enantiomerically pure α-amino acids has drawn a 
considerable research interest.10 A diversity of methods has been developed for the 
stereoselective construction of naturally occurring amino acids as well as optically 
active non-proteinogenic amino acids.11  
Unnatural α-amino acids are very valuable tools for modern drug discovery 
research. Due to their unlimited structural diversity and functional versatility, they are 
widely used as chiral building blocks and molecular scaffolds in constructing 
combinatorial libraries. They represent a powerful tool in drug discovery when 
incorporated into peptide analogues. Used as molecular probes they provide a better 
understanding of the function of biological systems. Structural modifications allow the 
design of drug candidates with a perfect match to their biological target, which may 
ultimately lead to improved in vivo stability, enhanced potency, better oral absorption, 
improved tissue distribution, and increased selectivity of biological response.12 
The biological importance of α-amino acids has led to the development of a 
large variety of methods for their synthesis.13  Below there are selected methods of 
asymmetric synthesis of α-amino acids. 
 
Scheme 1.2. Asymmetric synthesis of α-amino acids  
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The Strecker reaction was developed by Adolph Strecker in 1850.14 It is a three-
component reaction between an aldehyde, an amine and hydrogen cyanide to form an α-
amino nitrile. The nitrile can then be hydrolysed resulting in a racemic α-amino acid.15 
The first non-metal catalysed asymmetric Strecker synthesis, reported by Lipton and co-
workers, used a cyclic dipeptide catalyst (Cyclo[(S)-norarginyl-(S)-phenylalanyl])  
(S,S)-(1.4) to achieve high yields and enantiomeric excess (Scheme 1.3.). In particular, 
(S)-phenylglycine salt (S)-(1.6) was synthesised in > 99% e.e. and 92% overall yield in 
3 steps from benzaldehyde (1.3) via the α-amino nitrile intermediate (S)-(1.5).16 
 
Scheme 1.3. (S)-phenylglycine hydrochloride (S)-(1.6) asymmetric Strecker synthesis by Lipton et al  
 
Knowles et al developed asymmetric hydrogenation of dehydroamino acids, 
catalysed by rhodium chiral bisphosphine catalyst.17 To demonstrate the activity and 
selectivity of the catalyst, Knowles synthesised (S)-3,4-dihydroxyphenylalanine (L-
DOPA) (S)-(1.10), a drug used for treating Parkinson's disease (Scheme 1.4.).18 The 
synthesis of L-DOPA (S)-(1.10) employed the asymmetric hydrogenation of (Z)-
2-acetamido-3-(3,4-dihydroxyphenyl)acrylic acid (1.7) using the [Rh(1,5-COD) 
DiPAMP]+ BF4
- catalyst (1.8) followed by deprotection of the amine (S)-(1.9).  
 
Scheme 1.4. L-DOPA (S)-(1.10) synthesis via asymmetric hydrogenation by Knowles et al  
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Optically active α- and β-amino acids can be synthesised via ring opening of 
enantiomerically enriched aziridine-2-carboxylic esters with a variety of 
nucleophiles. 19 , 20  Another method employs chiral α-amino-β-alcohols, oxidation of 
which affords desired α-amino acids. Aziridines and α-amino-β-alcohols are discussed 
in more detail in Chapter 2 and Chapter 3. 
 
1.3. Applications of stable isotopes in protein studies 
In order to fine-tune the protein structure and properties, it is important to study 
the amino acid configuration and interactions. One of the main areas of interest is high-
throughput protein structure determination by nuclear magnetic resonance (NMR) or X-
ray crystallography.21 NMR spectroscopy provides information about the structure and 
dynamic properties of proteins in solution, and offers an approach for determining the 
three-dimensional protein structures of systems that fail to crystallize. However, it is 
difficult to determine the NMR structures of proteins larger than 30 kDa because their 
spectra are complicated by many complex overlapping signals and significant line 
broadening. A common approach for addressing these problems is to label proteins with 
deuterium to simplify the proton spectra. Additionally, the incorporation of  13C, 15N 
and other stable isotopes into proteins, combined with heteronuclear NMR experiments, 
facilitates the assignments of the complex NMR resonances of proteins and thus enables 
the elucidation of their three-dimensional structures. In addition, amino acids labelled 
with stable isotopes are valuable for metabolic studies.22 
Buděšínský et al constructed the Pro-Leu-Gly-NH2 moiety, with 13C and 15N 
fully labelled backbone, which was used as a terminal fragment of neurohypophyseal 
hormone oxytocin. 23  The labeled oxytocin exhibited biological activity identical to 
natural oxytocin. Detailed 1H-, 13C- and 15N-NMR studies confirmed the assigned 
oxytocin conformation containing a β-turn in the cyclic part of the molecule, stabilised 
by hydrogen bonding.  
Apart from naturally occurring amino acids, unnatural acids can provide 
valuable information about binding site distances and interactions of protein analogues. 
Additionally, ligand-protein complexes can be characterised.24 
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Chapter 2. Aziridines and aziridination 
2.1. Definition of aziridines 
Aziridines are classified as three membered heterocycles containing one 
nitrogen atom (Figure 2.1.).25 Structurally aziridines are similar to epoxides, possessing 
nearly identical ring strain energy of 27 kcal mol-1.26  
 
 
Figure 2.1. Generic aziridine, acyclic secondary amine and epoxide 
 
The ring strain of aziridine arises from the bond angles of ~ 60°, which is 
considerably smaller than the ideal tetrahedral angle of 109.5°.27 Bonding within this 
type of compound can be explained by a "banana" bond model (Figure 2.2.).28 As a 
result of bending, the orbitals gain more "s" character, which translates into the 
decreased basicity of the nitrogen lone pair in aziridines.29 Thus, the conjugate acid of 
aziridine has a pKa value of ~ 8, whereas the conjugate acid of an acyclic secondary 
amine has a value of ~ 11.30 
 
 
Figure 2.2. Aziridine "banana" bond model 
 
Due to the ring strain, aziridines readily undergo ring-opening reactions, which 
makes them very useful synthetic precursors to compounds like alkaloids, diamines and 
β-lactam antibiotics.31 Chiral non-racemic trans- and cis-aziridine-2-carboxylates are 
very important compounds, because they serve as useful intermediates to many organic 
molecules, including enantiomerically enriched α- and β-amino acids (Figure 2.3.).  
 
 
Figure 2.3. Generic cis- and trans-aziridine-2-carboxylates 
7 
 
2.2. Synthesis of aziridines 
Synthetic methodologies for the preparation of aziridines can be divided into the 
following categories:32 
1) Nitrene addition to olefins 
2) Carbene or ylide addition to imines  
3) Cyclisation reactions 
 
2.2.1. Nitrene addition to olefins 
Nitrene is a reactive intermediate in which nitrogen atom bears only one 
substituent, one lone pair and two other electrons. The nitrene method of aziridination 
involves addition of nitrenes to the unsaturated partner (Scheme 2.1.).  
 
Scheme 2.1. Aziridination of a generic alkene via the nitrene method 
 
The biggest limitation of this method is the lack of stereoselectivity.33 Nitrenes 
are typically generated by thermal or photochemical decomposition of the 
corresponding azides and therefore exist as mixtures of singlet (more reactive) and 
triplet (more stable) nitrenes (Scheme 2.2.). Only singlet nitrenes react 
stereospecifically with alkenes, because both new C–N bonds are formed in a concerted 
process. Triplet nitrenes react in a two-step process with alkenes, in which a C–N bond 
is formed in each consecutive step. Due to unrestricted C–C bond rotation, the 
stereoselectivity is generally quite low.  
 
Scheme 2.2. Reactions of triplet and singlet nitrenes with a generic alkene 
Jacobsen et al demonstrated that chiral non-racemic (1S,2S)-bis((2,6-
dichlorobenzylidene)diamino)cyclohexane (1S,2S)-(2.4) stabilised a singlet nitrene and 
generated cis-(1R,2S)-N-tosylaziridine (1R,2S)-(2.5) in 70% yield and 87% e.e., which 
8 
 
was determined by chiral HPLC analysis (Scheme 2.3.). 34  This enantioselective 
aziridination of cis-alkene (2.1) was achieved by using copper(I) triflate (2.3) and (N-(p-
toluenesulfonyl)imino)phenyliodinane (2.2) as a nitrene source, that generated a nitrene 
in situ. 
 
Scheme 2.3. Asymmetric synthesis of cis-N-tosylaziridine (1R,2S)-(2.5) by Jacobsen et al 
Evans et al published the enantioselective aziridination of trans-alkene (2.1) 
using copper(I) triflate (2.3) and (N-(p-toluenesulfonyl)imino)phenyliodinane (2.2) as a 
nitrene source. Chiral non-racemic 4,4'-disubstituted (4S,4S')-bis(oxazoline) (4S,4S')- 
(2.7) was used to stabilise a singlet nitrene, affording phenyl trans-(2R,3S)-N-tosyl-
aziridine-2-carboxylate (2R,3S)-(2.8) in 64% yield and 97% e.e., which was determined 
by chiral HPLC analysis (Scheme 2.4.).35 
 
Scheme 2.4. Asymmetric synthesis of phenyl trans-N-tosyl-aziridine-2-carboxylate (2R,3S)-(2.8) by 
Evans et al 
Investigating the mechanism of the reaction, Jacobsen et al performed an 
asymmetric synthesis of (S)-2-phenyl-1-tosylaziridine (S)-(2.12), starting from the same 
styrene (2.11), but using two different nitrene sources: (N-(p-toluenesulfonyl)imino) 
phenyliodinane (2.2) and para-toluenesulfonyl azide (2.9) (Scheme 2.5).36 
 
Scheme 2.5. Synthesis of (S)-2-phenyl-1-tosylaziridine (S)-(2.12) by Jacobsen et al 
 
Under photochemical conditions, para-toluenesulfonyl azide (2.9) was 
converted to the nitrene intermediate (2.10), via nitrogen gas elimination (Scheme 2.5.). 
In the presence of catalytic amounts of the copper(I) hexafluorophosphate and chiral 
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non-racemic (1S,2S)-bis((2,6-dichlorobenzylidene)diamino)cyclohexane (1S,2S)-(2.4) 
ligand, (S)-2-phenyl-1-tosylaziridine (S)-(2.12) was synthesised with the same 
enantioselectivity (41% e.e.) obtained in the catalytic aziridination reaction, that 
employed (N-(p-toluenesulfonyl)imino)phenyliodinane (2.2) as a nitrene source. This 
study was an indication of the common copper-nitrene intermediate (2.13) and allowed 
the mechanism of the reaction to be proposed (Scheme 2.6.). 
 
Scheme 2.6. Proposed mechanism of the synthesis of (S)-2-phenyl-1-tosylaziridine (S)-(2.12) via the 
nitrene method by Jacobsen et al 
 
2.2.2. Carbene or ylid addition to imines 
Carbene and ylid methods of aziridination involve a formation of one C–N bond 
and one C–C bond (Scheme 2.7.). 
 
Scheme 2.7. Aziridination via a metal carbenoid or ylid addition to a generic imine 
 
A plethora of methods employing metal carbenoids or ylids for the synthesis of 
chiral non-racemic aziridines has been reported, outlined in the review by Atkinson.30 
Wulff et al developed a robust catalytic asymmetric aziridination protocol providing 
chiral non-racemic alkyl cis-aziridine-2-carboxylates in high yields (up to 79%) and 
stereoselectivities (up to 99% e.e.). 37  The (S)-VAPOL-Boron complex (S)-(2.15) 
catalyst utilised in asymmetric aziridination reactions of N-substituted imines was 
originally reported to be a Lewis acid and was used previously by Wulff et al in 
asymmetric Diels-Alder reactions (Scheme 2.8.).38  
 
Scheme 2.8. Proposed structure the (S)-VAPOL-Boron complex (S)-(2.15) reported by Wulff et al 
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Although originally a Lewis acid nature of the catalyst was proposed, Wulff et 
al continued an investigation towards the active catalyst structure and succeeded in 
isolation of ion pair (S)-(2.17) and (S)-(2.18) (Scheme 2.9.). The X-ray diffraction 
analysis of these ion pairs allowed the structure of the active catalyst (S)-(2.16) to be 
deduced. These findings led to a conclusion that the boroxinate based (S)-VAPOL 
active catalyst (S)-(2.16) is not a Lewis acid, but in fact is a Brønsted acid of a singular 
structure.39 
 
Scheme 2.9. Active catalyst (S)-(2.16) structure determination via crystallisation of ion pairs (S)-
(2.17) and (S)-(2.18) by Wulff et al 
 
Utilising (S)-VAPOL-Boron complex (S)-(2.16) as a Brønsted acid in an 
asymmetric catalytic aziridination reaction between N-benzhydryl imine (2.19) and 
ethyl diazoacetate (2.20), ethyl (2R,3R)-N-benzhydryl-3-phenylaziridine-2-carboxylate 
(2R,3R)-(2.21) was afforded in 74% yield, after purification by silica gel 
chromatography, and greater than 50:1 cis- over trans-diastereoselectivity, determined 
by 1H-NMR analysis of crude reaction mixture (Scheme 2.10.). The chiral HPLC 
analysis on a Chiralcel OD column displayed 98% e.e. Additionally, the 1H-NMR 
analysis displayed only 4% of the acyclic by-products (2.22) and (2.23), that were 
obtained due to 1,2-hydride or 1,2-aryl shift respectively (Table 2.1. Entry 1). 
 
Scheme 2.10. Asymmetric aziridination of N-benzhydryl imine (2.19) with (S)-VAPOL-Boron 
catalyst (S)-(2.16) carried out by Wulff et al 
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Screening various catalysts, it was established that (S)-VAPOL-borate-complex 
(S)-(2.16) was superior to others listed in Table 2.1.40 It was found that even despite the 
increase of the reaction time from 30 minutes to 16 hours, 1 mol% of the catalyst (S)-
(2.16) was still effective to afford ethyl (2R,3R)-1-benzhydryl-3-phenylaziridine-2-
carboxylate (2R,3R)-(2.21) in 72% yield and 99% e.e. (Table 2.1: Entry 2). 
Entry Catalyst Loading 
(mol%) 
Time 
(h) 
Yield 
(%) cis-
(2.21) 
e.e. (%) 
cis-
(2.21)  
Ratio cis- 
: trans-
(2.21) 
Yield 
(%) 
(2.22) 
Yield 
(%) 
(2.23) 
1 (S)-VAPOL-
borate-complex 
10 0.5 74 98 >50:1 2 2 
2 (S)-VAPOL- 
borate-complex 
1 16 72 99 42:1 4 2.5 
3 (S)-BINOL- 
borate-complex 
10 20 42 17 8:1 8 10 
4 (S)-VAPOL-
BH2Br-complex 
10 20 53 66 >50:1 13 6 
5 (S)-VAPOL-
Et2AlCl-complex 
10 18 41 5 >50:1 17 14 
Table 2.1. Screening of catalysts prepared from vaulted biaryls in the asymmetric aziridination 
reaction by Wulff et al 
 
The absolute configuration of ethyl (2R,3R)-1-benzhydryl-3-phenylaziridine-2-
carboxylate (2R,3R)-(2.21) was confirmed by the reductive ring opening to (R)-
phenylalanine ethyl ester (R)-(2.24) (Scheme 2.11.). The optical rotation of this 
material was found to be [α]D
25
 -23.0 (c 3.2 EtOH), which corresponds well to the 
reported value for (S)-phenylalanine ethyl ester [α]D
25
 +23.8 (c 3.2 EtOH).41 
 
Scheme 2.11. Reductive ring-opening of (2R,3R)-1-benzhydryl-3-phenylaziridine-2-carboxylate cis-
(2.21) by Wulff et al 
 
Chloramphenicol is one of the oldest antibacterial agents, which was first 
isolated from Streptomyces Venezuelae in 1947.42  In 2001 Wulff et al reported an 
asymmetric synthesis of optically pure (-)-(R,R)-chloramphenicol threo-(2.28) via 
asymmetric catalytic aziridination reaction of the corresponding N-benzhydryl imine 
(2.25). The synthesis of enantiomerically pure (-)-(R,R)-chloramphenicol threo-(2.28) 
was achieved in four steps from commercially available starting materials in 38% 
overall yield (Scheme 2.12.). Initially commercially available p-nitrobenzaldehyde was 
converted to the corresponding N-benzhydryl imine (2.25), which was subsequently 
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reacted with ethyl diazoacetate (2.20). This asymmetric aziridination reaction was 
catalysed by 10 mol% (R)-VAPOL-borate-complex (R)-(2.16) and afforded ethyl 
(2S,3S)-1-benzhydryl-3-(4-nitrophenyl)aziridine-2-carboxylate (2S,3S)-(2.26) in 80% 
yield, 96% e.e. and 30:1 cis- over trans-stereoselectivity. Single crystallisation from 
hexane/methylene chloride improved the enantiomeric purity to 99% (84% yield, first 
crop).  
 
Scheme 2.12. Asymmetric synthesis of (-)-(R,R)-chloramphenicol threo-(2.40) by Wulff et al 
Treatment of cis-aziridine-2-carboxylate (2S,3S)-(2.26) with ten equivalents of 
dichloroacetic acid promoted an SN2-like ring-opening with an inversion of 
configuration at the C-3 centre to afford (2S,3R)-ethyl 2-(2,2-dichloroacetamido)-3-
hydroxy-3-(4-nitrophenyl)propanoate threo-(2.27) in 80% yield as a single threo-
diastereoisomer (Scheme 2.13.).  
 
Scheme 2.13. Ring-opening of ethyl (2S,3S)-1-benzhydryl-3-(4-nitrophenyl)aziridine-2-carboxylate 
cis-(2.26) with dichloroacetic acid 
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Reduction of the ethyl ester functionality with sodium borohydride firnished (-)-
(R,R)-chloramphenicol threo-(2.28) in 74% yield and 99% e.e. The optical rotation of 
this material was found to be [α]D
25
 -25.4 (c 1.0 EtOAc), which compares favourably 
with the values [α]D
25
 -24.2 (c 1.1 EtOAc) reported previously by Rao et al.43 
 
2.2.3. Cyclisation reactions 
Cyclisation method of aziridination involves a ring-closure of 1,2-amino 
alcohols or 1,2-amino halides. Wills et al reported a synthesis of chiral non-racemic 
aziridines starting with optically pure 2-amino alcohols derived from the 
enantioselective reduction of N-Boc protected α-amino ketones (Scheme 2.14.).44 The 
enantioselective reduction of 2-(N-tert-butoxycarbonyl-amino)acetophenone (2.29) with 
[(R,R)-Ts-DPEN](para-cymene)ruthenium chloride (R,R)-(2.30) and formic acid 
/triethylamine as the hydrogen source afforded (S)-2-N-tert-butoxycarbonyl-amino-1-
phenylethanol (S)-(2.31) in 86% yield and 99% e.e. as the product. The treatment of N-
Boc protected 2-amino alcohol (S)-(2.31) with diethyl azodicarboxylate (DEAD) (2.32) 
and triphenylphosphine (2.33) in tetrahydrofuran, under Mitsunobu conditions, led to 
the formation of (R)-N-Boc-2-phenylaziridine (R)-(2.34) in 92% yield and 99% e.e. 
 
Scheme 2.14. Aziridination via cyclisation of (S)-2-N-tert-butoxycarbonyl-amino-1-phenylethanol 
(S)-(2.31) by Wills et al 
Mitsunobu reaction is a powerful way to replace an alcohol group by a 
nucleophile with inversion of configuration due to an SN2 type reaction (Scheme 2.15.). 
In the first step, the phosphine (2.33) adds to the N=N bond of DEAD (2.32) to give an 
anion (2.35) stabilised by one of the ester groups. After alcohol (S)-(2.31) 
deprotonation, the anion (2.36) attacks the positively charged phosphorus, due to a very 
strong affinity between oxygen and phosphorus. Finally, DEAD anion (2.37) generates 
the active nucleophile (2.38), that attacks the phosphorus derivative of the alcohol at the 
(S)-carbon centre in a SN2 type reaction with the phosphine oxide (2.39) as the leaving 
group. SN2 reactions lead to inversion of configuration, therefore the product (R)-(2.34) 
is afforded as the (R)-enantiomer. 
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Scheme 2.15. Proposed mechanism of the synthesis of (R)-N-Boc-2-phenylaziridine (R)-(2.34) via 
Mitsunobu reaction by Wills et al 
 
 
Bull et al reported cis-selective synthesis of iodo-aziridines via cyclisation of 
1,2-amino halides by using diiodomethyllithium and in situ generated N-Boc-imines 
(Scheme 2.16.). 45  The reaction proceeds in one-pot via a highly diastereoselective 
cyclisation of an amino gem-diiodide intermediate, analogous to the aza-Darzens 
reaction. 
 
Scheme 2.16. Cyclisation of N-Boc-gem-diiodide intermediate (2.42) affording cis-N-Boc-2-iodo-3-
phenylaziridine cis-(2.43) by Wills et al 
 
N-Boc-protected phenyl(tosyl)methanamine (2.40) was examined, generating 
the corresponding N-Boc-protected imine (2.41) in situ by deprotonation with excess 
base. An addition of diiodomethyllithium to phenyl N-Boc-protected imine at -78 °C 
afforded N-Boc-gem-diiodide intermediate (2.42), which was stable at -78 °C. 
Warming the intermediate to 30 °C, promoted a ring-closure to afford cis-N-Boc-2-
iodo-3-phenylaziridine cis-(2.43) in 83% yield and more than 95:5 cis-selectivity, which 
was detected by 1H-NMR analysis. 
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2.3. Natural products with an aziridine motif 
Apart from being used as precursors to valuable organic entities, aziridines can serve as 
intermediates in the course of the natural product synthesis (see example of (-)-(R,R)-
chloramphenicol threo-(2.28) synthesis, pages 11-13) or be present in the natural 
product itself (vide infra).46 
2.3.1. Mitomycins 
In 1956 mitomycins A (2.44) and B (2.45) were isolated from Streptomyces 
caespitosus by Hata et al in Japan (Figure 2.4.).47 Two years later mitomycin C (2.46) 
was isolated from the same organism by Wakaki and co-workers. 48 Although 
mitomycins A (2.44) and B (2.45) are highly active against tumours (e.g. Ehrlich 
carcinoma), they do possess a very high toxicity (LD50 i.v. in mice: 2 mg/kg and 3 
mg/kg respectively).49  Mitomycin C (2.46) was found to be the least toxic among 
mitomycins (LD50 i.v. in mice: 9 mg/kg), yet potent against a range of tumours as well 
as gram-positive and gram negative bacteria (e.g. Staphylococcus aureus, E. coli).50,51 
 
Figure 2.4. Mitomycins A (2.44) and B (2.45) were isolated by Hata et al. Mitomycin C (2.46) was 
isolated by Wakaki et al  
Tomacz et al reported that mitomycin C (2.46) reacts covalently with DNA, in 
vivo and in vitro, forming cross-links with the complementary strands of guanine 
(Scheme 2.17.).52 Their work has demonstrated that aziridine functionality is directly 
involved into the inhibition of the DNA replication.53 
Investigations towards the mechanism of action of mitomycins revealed that 
mitomycins do not react directly with DNA, but require prior activation (Scheme 2.18.). 
Such activation is initialised via the quinone functionality reduction.54 The reduction 
can be induced by both reductive enzymes and chemical reducing agents. The enzymes 
that can activate mitomycin C (2.46) include: cytochrome P450, cytochrome c 
reductase, DT-diaphorase or xanthine dehydrogenase.55 Chemical reductants that can 
activate mitomycin C (2.46) include: sodium dithionite, catalytic hydrogenation, 
formate radicals or sodium borohydride.56 
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Scheme 2.17. Guanine and mitomycin C (2.46) adducts 
 
Many solid tumours contain less oxygen compared to a normal tissue, resulting 
from an imbalance between oxygen supply and consumption. This imbalance is caused 
by abnormal structure and function of the microvessels supplying the tumour, increased 
diffusion distances between the blood vessels and the tumour cells, and reduced oxygen 
transport capacity of the blood due to the anemia.57 Therefore, reductive activation of 
the mitomycins can proceed in tumours, while it is suppressed by the oxidizing 
environments in normal tissues.  
 
Scheme 2.18. Proposed mechanism of DNA cross-linking by mitomycin C (2.46) by Tomacz et al 
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2.3.2. (2S,3S)-(+)-Aziridine-2,3-dicarboxylic acid (2.50) 
The only known example of naturally occurring 2,3-dicarboxylic acid containing 
aziridine functionality is (2S,3S)-(+)-aziridine-2,3-dicarboxylic acid (2.50), which was 
isolated from a cultured broth of a Streptomyces MD398-A1 by Naganawa and           
co-workers.58 Schirmeister et al evaluated aziridine-2,3-dicarboxylates and N-acylated 
derivatives as potential irreversible inhibitors of the cysteine proteinases.59 Evidence has 
been found for potential therapeutic effects of cysteine protease inhibitors against 
muscular dystrophy, arthritis, myocardial infarct, cancer, Alzheimer's disease, and 
cataracts.60,61 Legters et al reported the asymmetric synthesis of (2S,3S)-(+)-aziridine-
2,3-dicarboxylic acid (2.50) starting from diethyl (2R,3R)-(–)-oxirane-2,3-dicarboxylate 
(2.47) (Scheme 2.19.). 62  Treatment of diethyl (2R,3R)-(–)-oxirane-2,3-dicarboxylate 
(2.47) with trimethylsilyl azide, resulted in a ring-opening of the three-membered ring 
and afforded O-silyl protected anti-vicinal azido alcohol. Addition of ammonium 
chloride cleaved the silyl protecting group and afforded diethyl (2S,3R)-2-azido-3-
hydroxysuccinate (2.48) in 72% yield over two steps. Reaction with triphenylphosphine, 
under Mitsunobu conditions, generated diethyl (2S,3S)-(+)-aziridine dicarboxylate 
(2.49) in 71% yield and 95% e.e., which was determined by a 19F-NMR analysis of its 
Mosher derivative. Hydrolysis of diethyl (2S,3S)-(+)-aziridine dicarboxylate (2.49) with 
lithium hydroxide afforded the dilithio salt, which was subsequently passed through a 
strongly acidic sulfonic acid ion exchange resin (Dowex 50W-X2) to generate (2S,3S)-
aziridine-2,3-dicarboxylic acid (2.50). The impure material was re-crystallised from 
water to afford pure (2S,3S)-aziridine-2,3-dicarboxylic acid (2.50) as a crystalline solid 
in 69% yield. The optical rotation was found to be [α]D
20
 +51.4 (c 0.5 H2O), which is in 
good agreement with that of the natural product [α]D
24
 +54.0 (c 0.5 H2O).
58 
 
Scheme 2.19. Synthesis of (2S,3S)-(+)-aziridine-2,3-dicarboxylic acid (2.50) by Legters et al 
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2.4. Ring opening of aziridines 
Depending on the substituent on the nitrogen atom, aziridines can be classified 
as activated (oxygenated substituent such as carbonyl, sulfonyl or phosphoryl group) or 
non-activated (alkyl, aryl or hydrogen atom as a substituent) (Scheme 2.20.). Non-
activated aziridines undergo ring-opening only after protonation, quaternisation or 
formation of a Lewis acid adduct.63,24  
 
Scheme 2.20. Ring-opening of activated and non-activated aziridines 
Activated aziridines contain a substituent on the nitrogen atom, that can 
conjugatively stabilise the negative charge during a nucleophilic ring-opening (Scheme 
2.21.).24 
 
Scheme 2.21. Negative charge stabilisation by the activating substituent 
As a consequence of the ring-strain present in aziridines, ring-opening reactions 
are a dominant feature of their chemistry, allowing access to α- and β-amino 
derivatives. For example, a nucleophilic attack at C-2 of an aziridine-2-carboxylates 
affords β-amino acid derivatives, whereas a ring-opening at C-3 results in α-amino acid 
derivatives. Although most nucleophiles reported would preferentially attack the less 
hindered site, regioselectivity highly depends on the ring substituents and a nucleophile. 
Some nucleophiles might afford mixtures of α- and β-amino derivatives.  
 
2.4.1. Ring opening of activated aziridines 
Mall and Stamm conducted an investigation towards a mechanism of a 
nucleophilic ring-opening of monocyclic activated aziridines and demonstrated that it 
occurs by an SN2-like mechanism with an inversion of configuration (Scheme 2.22.).
64 
19 
 
Activated cis-(2S,3R)-2,3-diphenyl-1-(phenylsulfonyl)aziridine (2S,3R)-(2.51) and 
trans-(2S,3R)-2,3-diphenyl-1-(phenylsulfonyl)aziridine (2R,3R)-(2.52) were reacted 
with thiophenol to afford corresponing N-((1S,2S)-1,2-diphenyl-2-(phenylthio)ethyl) 
benzenesulfonamide (1S,2S)-(2.53) and N-((1R,2S)-1,2-diphenyl-2-(phenylthio)ethyl) 
benzenesulfonamide (1R,2S)-(2.54) respectively. The sole product from the cis- isomer 
was always observed as a diastereoisomer of the sole product from the trans- isomer, 
therefore, in accordance with complete Walden inversion, these ring-opening reactions 
were interpreted as an SN2 type.  
 
Scheme 2.22. Nucleophilic ring-opening of activated cis- and trans-aziridines via an SN2-like 
mechanism by Mall and Stamm 
 
2.4.2. Ring opening of non-activated aziridines via protonation 
In order to ring-open non-activated aziridines, a prior activation is required. 
Singh et al demonstrated a ring-opening of 1-benzyl-2-phenylaziridine (2.55) with 
aromatic and aliphatic carboxylic acids using a protonation activation mode (Scheme 
2.23.). 65  A nucleophilic attack of the corresponding carboxylate anion at the C-2 
benzylic position of aziridinium species afforded 2-(benzylamino)-1-phenylethyl 
acetate/benzoate (2.56). The direction of opening of aziridines is mainly affected by 
electronic factors because the acetoxy group preferentially attacks the carbon atom best 
able to accommodate some carbocation character.66 
 
Scheme 2.23. A C-2 directed ring-opening of 1-benzyl-2-phenylaziridine (2.55) with carboxylic acids 
by Singh et al 
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2.4.3. Ring opening of non-activated aziridines via quaternisation 
Lee et al treated (2R)-[(1'R)-Phenylethyl]methoxymethylaziridine (1'R,2R)-
(2.57) with methyl trifluoromethanesulfonate, followed by reaction with the 
corresponding nucleophile to yield a single regioisomer (determined by 1H-NMR 
analysis) of C-3 ring-opening product 2-amino-propane (1'R,2R)-(2.58) (Scheme 
2.24.).67 When 2-benzyloxy substituent was introduced, identical regioselectivity was 
observed, with the cleavage of the bond between C-3 and the ring nitrogen. However, 
when the same ring-opening procedure was applied to aziridines containing carboxylate 
and acrylate substituents at C-2, the opposite regioselectivity was observed, with a 
nucleophile attacking the C-2 carbon of an aziridine, affording (1'R,2S)-(2.59). 
 
Entry Substrate/path R Nu Product Yield (%) 
1 (1'R,2R)-
(2.57)  
A 
 
CH2OMe 
 
NaN3  
 
(1'R,2R)-
(2.58) 
89 
2 NaOAc 75 
3 NaCN 80 
4 (1'R,2R)-
(2.57)   
B 
 
CH2OBn 
 
NaN3 76 
5 NaOAc 79 
6 NaCN 81 
7 (1'R,2R)-
(2.57) 
C 
 
CO2Et 
 
NaN3  
 
(1'R,2R)-
(2.59) 
87 
8 NaOAc 72 
9 NaCN 86 
10 (1'R,2R)-
(2.57) 
D 
 
CH=CHCO2Et 
 
NaN3 71 
11 NaOAc 87 
12 NaCN 72 
Scheme 2.24. Aziridine C-2 substituent dependent regioselectivity of ring-opening by Lee et al 
The rationale for the C-2 regioselectivity can be attributed to the fact that when 
acyl or vinyl substituents are present at the C-2 position of an aziridine, the bond 
between the C-2 carbon and the ring nitrogen is activated towards approaching 
nucleophiles, as the π-system of the adjacent double bond stabilises the transition state 
by conjugation.29 
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2.4.4. Ring opening of non-activated aziridines via an adduct formation 
Vessiere et al demonstrated that boron trifluoride activated ring-opening 
reactions of N-alkyl-2-alkoxycarbonylaziridines (2.60) with aliphatic alcohols afford 
corresponding α-amino esters (2.61) (Scheme 2.25.). The reaction proceeded through a 
nucleophilic attack at the less hindered side of the aziridinium moiety.68 
 
Scheme 2.25. A C-3 directed ring-opening of N-alkyl-2-alkoxycarbonylaziridines (2.60) with 
aliphatic alcohols by Vessiere et al 
 
Gotor et al reported a ring-opening of (S)-1-benzyl-aziridine-2-carboxamide S-
(2.62) with methanol under boron trifluoride activation, affording predominantly α-
amino carboxamide S-(2.63) (Scheme 2.26.). 69  The results have matched the ones 
reported previously by Vessiere et al. However, Gotor et al observed a Lewis acid and 
nucleophile dependent regioselectivity, when aluminium trichloride activated (S)-1-
benzyl-aziridine-2-carboxamide S-(2.62) was reacted with sodium azide to afford β-
amino carboxamide R-(2.64) as a major regioisomer. 
 
 
Scheme 2.26. Activation mode and nucleophile dependent regioselectivity of ring-opening of (S)-1-
benzyl-aziridine-2-carboxamide S-(2.62) by Gotor et al 
 
It was postulated that a complexation effect between aluminium trichloride and a 
carbonyl group at the C-2 position directed the incoming nucleophile to the proximal  
C-2 carbon.70 Similar effect has been demonstrated by Tanner et al (see page 22). 
Additional examples of regioselective ring-opening of aziridines are presented 
below that demonstrate that a choice of a substrate, activation mode and reagents can 
control exclusive C-2 or C-3 bond cleavage. 
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2.4.5. Regioselective control of an aziridine ring-opening with halogen nucleophiles 
Ring-opening of aziridine-2-carboxylates with halogen nucleophiles affords α- 
or β-halo-substituted amino acid derivatives. Righi et al demonstrated a ring-opening of 
activated racemic methyl trans-aziridine-2-carboxylates trans-(2.65) with magnesium 
bromide at the C-3 position, affording α-amino acid derivatives anti-(2.66) (Scheme 
2.27.). When the same starting material was reacted with sodium bromide-Amberlyst15 
complex, the bond between the C-2 carbon and ring nitrogen was cleaved affording β-
amino acid derivatives anti-(2.67).71 
 
 
 
 
Scheme 2.27. Regioselective ring-opening of methyl trans-aziridine-2-carboxylates trans-(2.65) with 
magnesium bromide and sodium bromide-Amberlyst15 by Righi et al 
 
When magnesium bromide is used as a reagent, the C-3 regioselectivity can be  
rationalised through a chelated complex between the magnesium metal and the two 
heteroatoms: a ring nitrogen and an oxygen in the C-2 carbonyl group (further 
discussion can be found in 5.17. Ring opening of N-aryl aziridines with magnesium 
bromide diethyl etherate, page 80). 
 
 
2.4.6. Regioselective control of an aziridine ring-opening with carbon nucleophiles 
Tanner et al investigated a nucleophilic ring-opening of trans-aziridino alcohols 
by methyl-transfer reagents such as trimethylaluminium and Gilman cuprate: lithium 
dimethyl cuprate (Scheme 2.28.).72 In general, lithium dimethyl cuprate demonstrated 
excellent C-2 selectivity and the results can be interpreted in terms of directive effects 
exerted by the C-l hydroxyl group, which allows intramolecular methyl transfer.73 On 
the contrary, complete C-3 selectivity was observed in the reactions of trans-(2.68) and 
Substituent (R) Br at C-3:C-2 ratio 
C3H7 > 99:1 
iPr > 99:1 
Cyclohexyl > 99:1 
Ph > 99:1 
Substituent (R) Br at C-2:C-3 ratio 
C3H7 77:23 
iPr 99:1 
Cyclohexyl 99:1 
Ph 50:50 
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trans-(2.68') with trimethylaluminium, indicating a complexation effect of the C-4 
benzyloxy or silyloxy groups in those cases. 
 
Scheme 2.28. Regioselective ring-opening of trans-aziridino alcohols trans-(2.68) and trans-(2.68') 
by Tanner et al 
 
It was proposed that a first equivalent of trimethylaluminium removes the 
hydroxyl proton from trans-(2.68) and trans-(2.68') to form an aluminium alcoholate, 
from which methyl-transfer is expected to be slower than from a trialkylaluminium 
species. A second equivalent of trimethylaluminium then forms a Lewis acid-base 
complex with the C-4 benzyloxy group, thus allowing for intramolecular methyl-
transfer to C-3. The lower C-3 selectivity for trans-(2.68') substrate is expected due to 
steric bulk and the lower Lewis basicity of the tert-butyldimethylsilyloxy group. The 
oxygen basicity decreases upon replacement of alkyl groups by silyl groups because the 
HOMO orbital becomes less localised on an oxygen atom. Consequently, the key 
interaction between the ether HOMO and the LUMO of an electrophile is less 
stabilizing for silyl than for alkyl ethers.74 
 
2.4.7. Reductive ring opening 
Reductive ring opening of non-activated aziridines with C-3 aryl substituents 
usually affords α-amino acid derivatives.75 Hruby et al reported that hydrogenation of 
(2S,3R)-benzyl 3-phenylaziridine-2-carboxylate (2S,3R)-(2.71) with 10 mol% Pd/C in 
methanol afforded (S)-phenylalanine (S)-(2.72) in 90% yield (Scheme 2.29.).76 
 
Scheme 2.29. Synthesis of (S)-phenylalanine (S)-(2.72) via a C-3 ring-opening of  (2S,3R)-benzyl 3-
phenylaziridine-2-carboxylate (2S,3R)-(2.71) by Hruby et al 
Entry Substrate Reagent/conditions Ratio 
(2.69):(2.70) 
Yield 
(%) 
1 trans-(2.68) 3 eq LiMe2Cu, Et2O, -20 °C, 4 h > 99:1 80 
2 trans-(2.68') 3 eq LiMe2Cu, Et2O, -20 °C, 4 h > 99:1 98 
3 trans-(2.68) 6 eq AlMe3, toluene, 75 °C, 12 h < 1:99 71 
4 trans-(2.68') 6 eq AlMe3, toluene, 75 °C, 12 h 15:85 82 
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Davis et al demonstrated a Raney-nickel promoted ring-opening of activated N-
tosyl aziridine (2S,3S)-(2.73) with an aliphatic group present at the C-3 position. 
Hydrogenolysis of the aziridine ring occured at the C-2 carbon, affording the 
corresponding β-amino ester (S)-(2.74) (Scheme 2.30.).77 
 
Scheme 2.30. C-2 ring-opening of  N-tosyl aziridine (2S,3S)-(2.73) by Davis et al 
2.5. Chapter conclusion 
Aziridines are extensively used as ‘core’ heterocycle building blocks, that can be 
readily transformed into alternative structure and function diverse derivatives (e.g. α- 
and β-amino acids).78  Aziridines are used during the synthesis of numerous drugs, 
biologically active natural products and their derivatives. Over 100 biologically active 
aziridine-containing compounds have anticancer and/or antibacterial activity against 
selected cancer cells and/or pathogenic bacteria with the strong indication that aziridine 
functionality is essential for the properties above.79 Additionally, aziridines and their 
derivatives are produced commercially and are employed in plastic, coating, textile and 
other industries.80  
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Chapter 3. Glycopeptide antibiotics 
3.1. Definition of antibiotics 
Antibiotics are natural compounds produced mostly by plant micro-organisms.81 
A term “antibiotic,” was proposed by Selman Waksman, who performed multiple 
screenings of soils for the presence of biologically active compounds.82 The term was 
introduced to describe the compounds that were produced by microbes and could be 
used against other microbes, therefore countering infectious diseases.83 
 
3.2. Classes 
Antibiotics can be classified according to their biochemical target (Table 3.1.).84 
Depending on the mode of action, antibiotics can suspend bacterial cell growth or kill 
the bacterial cells entirely. The majority of these antibiotics were discovered by 
screening bacteria found in soil. 
Antibiotic Class Examples Target Mode of Resistance 
β-lactams Penicillins 
(ampicillin) 
Peptidoglycan 
biosynthesis 
Hydrolysis 
Altered target 
Aminoglycosides Streptomycin Translation Phosphorylation 
Glycopeptides Vancomycin 
Teicoplanin 
Peptidoglycan 
biosynthesis 
Reprogramming of peptidoglycan 
biosynthesis 
Phenicol Chloramphenicol Translation Altered target 
Quinolones Ciprofoxacin DNA 
replication 
Acetylation 
Altered target 
Table 3.1. Antibiotics in clinical use and modes of resistance 
Antibiotics like penicillin and vancomycin are effective against Gram-positive 
bacteria, because they interfere with enzymes required for the bacterial cell wall 
synthesis.85 Structurally penicillin is very similar to the -D-alanyl-D-alanine sequence, 
found in the bacterial cell wall (Scheme 3.1.). Therefore, when the transpeptidase 
enzyme binds penicillin instead of -D-alanyl-D-alanine sequence, the bacterial cell wall 
synthesis is terminated and the bacteria die.86 
 
 
 
Scheme 3.1. Mode of action of penicillin (left) and inactivation by β-lactamase (right) 
       Penicillin binds to transpeptidase,  
terminating bacterial cell wall biosynthesis 
       β-lactamase inactivates penicillin  
    before it can bind to transpeptidase 
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However, not long after penicillin was introduced, some bacteria developed an 
enzyme β-lactamase, that would ring-open penicillin, thus making it inactive. 87 
Although semi-synthetic penicillins, such as methicillin, were developed, the bacterial 
resistance to these antibiotics had emerged as well. With the rising bacterial resistance, 
especially methicillin-resistant Staphylococcus aureus (MRSA), which was resistant to 
the most of the antibiotics in clinical use, it was required to find antibiotics that were 
effective. The vancomycin group of glycopeptide antibiotics was found to be one of the 
very few groups of antibiotics that were effective against MRSA. 
 
3.3. Vancomycin and teicoplanin glycopeptide antibiotics 
Vancomycin (3.1) was isolated in 1956 in the Eli Lilly Research Laboratories 
from Streptomyces orientalis from a soil sample obtained in Indonesia. 88 Vancomycin 
has a low toxicity (LD50 i.v. in mice: 489 mg/kg, in rats: 319 mg/kg) displays potent 
activity against a range of Gram-positive bacteria, with an in vitro minimum inhibitory 
concentration (MIC) of 0.25-1.0 mg/L against MRSA.89,90,91  
Perkins demonstrated that vancomycin disrupts the bacterial cell wall synthesis, 
by terminating the sequence -D-alanyl-D-alanine.92 Williams et al published a proposed 
hydrogen bonding interaction between vancomycin and bacteria (Figure 3.1.). 93 
Teicoplanin (3.2) was isolated in 1978 from Actinoplanes teichomyceticus and belongs 
to the same glycopeptide group of antibiotics as vancomycin.94 Although structurally, 
teicoplanin and vancomycin are very close, teicoplanin possesses additional F-O-G 
arylglycine biaryl subunit and a lipid attachment (Figure 3.1. dotted box) 
     
Figure 3.1. The interactions between vancomycin (3.1) and bacterial cell wall analogue through 
hydrogen bonding represented by the dotted lines (left). Structure of teicoplanin (3.2) (right) 
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3.4. α-Arylglycines 
α-Arylglycine derivatives constitute a very important class of α-amino acids, 
because they are found in a wide range of bioactive compounds (Figure 3.2.): 95,96 
 antiplatelet agents to prevent blood clots such as vicagrel and clopidogrel 
 β-lactam antibiotics such as amoxicillin, cefadroxil and nocardicin A 
 glycopeptide antibiotics such as vancomycin and teicoplanin  
 
Figure 3.2. Bioactive compounds with α-arylglycine motif (highlighted red) 
 
Several substituted phenylglycine derivatives, including 3-
hydroxyphenylglycine, have been described as potent and selective agonists or 
antagonists of glutamate receptors of the central nervous system (CNS).97 Arylglycinols 
constitute a class of α-amino-β-alcohols, which are also valuable structural units in 
synthetic and natural compounds.98  
 
3.5. α-Arylglycine structural motif in glycopeptide antibiotics 
Vancomycin and related glycopeptide antibiotics contain a number of 
arylglycines (3.7) within the heptapeptide backbone. Evans et al reported that any 
attempt to synthesize any member of this family of natural products must incorporate a 
methodology for the construction of these non-proteinogenic arylglycines.99 
Additionally, arylglycines are easily racemised under basic conditions, because 
the alpha proton is benzylic, therefore can be easily abstracted.100  
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3.6. Aminohydroxylation reaction to afford arylglycines via aminoalcohols 
In 1998 Sharpless and Reddy reported the osmium catalysed asymmetric 
aminohydroxylation (AA) reaction, which provided either (R)- or (S)-α-aryl-N-Cbz- or 
N-Boc- protected (R)- or (S)-α-amino-β-alcohols (R)- or (S)-(3.5) from styrene (3.3) 
(Scheme 3.2.).101  The enantioselectivities were generally excellent and a subsequent 
oxidation step yielded the corresponding α-arylglycine derivatives (R)- or (S)-(3.7). 
 
Scheme 3.2. Asymmetric aminohydroxylation reaction of substituted styrenes by Sharpless and 
Reddy 
 
It was observed that the regioselectivity was highly dependent on the nature of 
the styrene (3.3) as well as the choice of ligand, solvent, and ligand-solvent 
combination. Phthalazine ligands (3.4) such as (DHQ)2PHAL or (DHQD)2PHAL in     
n-PrOH strongly favoured the benzylic amine (R)- or (S)-(3.5) over the benzylic alcohol 
(R)- or (S)-(3.6) regioisomer. The optimal experimental conditions employed 4 mol% 
potassium osmate catalyst [K2OsO2(OH)4], 6 mol% alkaloid ligand (DHQ)2PHAL or 
(DHQD)2PHAL, 3.0 equivalents of benzyl carbamate salt [BnOC(O)NNaCl] and         
n-PrOH/H2O solvent mixture (1.5:1) at 25 °C in order to obtain the corresponding        
α-arylglycinol (R)- or (S)-(3.5) product.  
 
3.7. Bacterial resistance and overcoming the problem 
The vancomycin resistant enterococci (VRE) were first reported in 1989.102 It 
appears that these enterococci have been able to obtain genes from other bacteria such 
that the precursor from which their cell wall is built no longer terminates in -D-alanyl-
D-alanine, but rather terminates in -D-alanyl-D-lactate (-D-Ala-D-Lac) (Figure 
3.3.).103,104 As a consequence, the hydrogen bond which is normally made between the 
NH of the terminal D-alanine group and a carbonyl group of the antibiotic can no longer 
29 
 
be made. Instead, it is replaced by a repulsive interaction between the oxygen of the C-
terminal D-lactate group and the carbonyl group of the antibiotic. 
 
   Figure 3.3. The repulsive interaction between 
  vancomycin (3.1) and N-acetyl-D-Ala-D-Lac   
 
 The emergence of bacterial strains, resistant to antibiotics, stimulated the 
synthesis of the individual natural products. In 1998 Evans et al reported the first total 
synthesis of the vancomycin aglycon and the eremomycin aglycon.105 The group of 
Boger succeeded in the total synthesis of vancomycin and subsequent modifications to 
overcome the bacterial resistance with the D-Ala-D-Lac sequence (Figure 3.4.).106 By 
removing the carbonyl group, a repulsive interaction with the oxygen atom of the D-
Ala-D-Lac moiety of resistant bacteria was eliminated, thereby restoring the affinity 
towards the target. 
Scientists at Lilly laboratories demonstrated a different approach of overcoming 
the problem. Instead of modifying the peptide backbone, the periphery was 
functionalised with hydrophobic groups (Figure 3.5.). The new derivatives successfully 
restored activity against resistant bacteria.107,108 
The original rationale behind this modification came from a comparison of 
vancomycin and teicoplanin. Teicoplanin possesses an acyl-linked aliphatic moiety 
(Figure 3.1. dotted box) that is believed to affect pharmacokinetic properties, such as 
longer serum half-life. Additionally, teicoplanin shows greater potency than 
vancomycin against many Gram-positive bacteria.109  
 
  Figure 3.4. Elimination of the repulsive  
interaction between vancomycin analogue  
           and N-acetyl-D-Ala-D-Lac  
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Figure 3.5. Lipid attachments (dotted boxes) promoted membrane anchoring and dimerisation 
 
Williams and co-workers proposed that lipid attachments on glycopeptides were 
acting like anchors to the bacterial cell membrane (Figure 3.6.). 110  Without lipid 
groups, glycopeptides were distributed more broadly in the peptidoglycan layers. Due to 
anchoring, teicoplanin was able to insert itself into the membrane, in a very close 
proximity to D-Ala-D-Lac sequence. The interaction between the two was proposed to 
become  intramolecular, which was more favourable than intermolecular. 
The group of Williams demonstrated that dimerisation of the antibiotics 
enhanced the binding affinities to their cellular targets by preferential location of the 
antibiotic near the site of cell wall biosynthesis. Williams et al hypothesised that the 
binding of a dimer to two cell wall peptides involves only one bimolecular process, 
whereas in the binding of two equivalents of monomeric antibiotic, two bimolecular 
steps are involved, which is less favourable.111 
 
 
Figure 3.6. The binding bacteria and antibiotic monomer (left), dimer (middle) and via the lipid 
anchor (right) adopted from the publication by Williams et al111 
 
3.8. Chapter conclusion 
In 2013 Bauer and Brӧnstrup published a review about industrial drug discovery 
and development based on the natural products.112 They reported that modification of 
glycopeptides with hydrophobic side chains created a sub-class called 
“lipoglycopeptides”. The structural modifications resulted in the improved properties:  
  Monomer Dimer 
Lipid anchor 
     Growing  
     cell wall 
Membrane 
 
 Cytoplasm 
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 Lipid chains promoted the membrane anchoring, positioning the glycopeptide in 
the close proximity to its target. 
 The side chains enhanced the dimerisation of the lipoglycopeptides, which 
resulted in a much tighter binding to the peptidoglycan layer. 
 The increased hydrophobicity also led to higher protein binding compared to 
vancomycin, resulting in longer in vivo half-live of the drug. 
 
In summary, successful total synthesis of the desired antibiotics allowed to 
elucidate their mode of action and study their biological properties. Careful 
modifications of the antibiotics fine-tuned the physicochemical properties, which 
restored efficacy against resistant pathogens and improved pharmacokinetic properties.  
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Chapter 4. Properties and applications of compounds labelled with 
stable isotopes 
4.1. Discovery of isotopes 
Frederick Soddy was one of the pioneering scientists who investigated the 
chemistry of radioactive substances and the nature of isotopes. In 1910, Soddy 
demonstrated that mesothorium, the first product of the thorium disintegration series, 
was chemically inseparable from radium.113 He developed a concept that some atoms 
can be chemically identical and yet have different atomic weights. To describe such a 
phenomenon, the term “isotope” was introduced (Greek for ἴσος [isos] "equal" and 
τόπος [topos] "place"), because these related atoms occupied the same place in the 
periodic table of the elements. 
The discovery of isotopes of stable elements was made by Thomson in 1912.114 
He used positive ray apparatus to determine the atomic weight of the gases in the 
discharge tube. Each atom produced a separate parabola on the photographic plate. 
When analysing the sample of neon, two parabolas corresponding to atomic weights 20 
and 22 were observed. The first one was assigned to neon (atomic weight 20), whereas 
the second could not be assigned as any known gas. Thomson's student Francis Aston 
attempted to separate this unknown gas from neon, but was unsuccessful. Thomson and 
Aston believed that the two gases, although of different atomic weights, had identical 
chemical properties.  
Unfortunately, the "parabola method" had limitations. 115  Aston noticed that 
many rays were lost due to collisions in the narrow canal-ray tube. As a result, Aston 
had to re-design and build a different version of the apparatus, improving the materials, 
vacuum and slit system. The new apparatus was found to work satisfactorily after 
successfully referencing it to the oxygen and carbon mass spectra data. When analysing 
a sample of neon, using the new equipment, similar results were obtained, confirming 
that neon is a mixture of two isotopes of atomic weights 20 and 22. 
 Conversely, Aston did not identify any isotopes of hydrogen, he only reported 
hydrogen itself with atomic weight of one. In 1931, Birge and Menzel noticed a 
difference in the atomic weights of hydrogen when determined chemically and by mass 
spectrometry.116 They made a hypothesis about the existence of an isotope of hydrogen 
with a mass of two. Urey et al performed a concentration experiment in order to obtain 
a sample of heavy isotope of hydrogen.117 The initial experiment involved distillation of 
liquid hydrogen near its triple point and was a success. The isotope of hydrogen of 
atomic weight of two was obtained and named deuterium (Greek for δεύτερος 
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[deuteros] "second").118 Later on, Urey and Washburn developed an electrolytic method 
of separation of the isotopes of hydrogen. 
4.2. Deuterium, kinetic isotope effect 
Compared to the hydrogen nucleus (the proton), with an atomic mass 1.008 
AMU, the deuterium nucleus (the deuteron) contains an additional neutron, which 
results in a near two-fold increase of the atomic mass (2.014 AMU).119 Due to the 
greater atomic mass of deuterium, a carbon-deuterium (C–D) bond has a lower zero-
point energy (vibrational ground state energy) than the corresponding carbon-hydrogen 
(C–H) bond. This results in a higher activation energy for C–D bond cleavage and a 
slower reaction rate (represented by rate constant k). The effect on rate is known as the 
primary deuterium isotope effect (DIE), which is expressed as the ratio of the reaction 
rate constants of C–H versus C–D bond cleavage: DIE = kH/kD.120  
Apart from deuterium, other isotopes can affect the bond energy of a labelled 
compound. The effect of isotopic substitution on a rate constant is referred to as a 
kinetic isotope effect (KIE).121,122 For example, in the reaction:  
A + B → C (k is a rate constant) 
the effect of isotopic substitution in reactant A is expressed as the ratio of rate constants 
kl/kh, where the subscripts "l" and "h" represent reactions in which A contains the light 
and heavy isotopes, respectively. Within the framework of transition state theory the 
reaction can be rewritten as: 
A + B → [TS] → C 
Primary KIE arises from the direct breaking, or formation, of a bond to, or from, 
isotopically substituted atom in the rate-controlling step of a specified reaction. 
Secondary KIE arises when the bond to the isotopically substituted atom is not cleaved 
during the reaction. 
The effect of isotopic substitution on molecular vibration can be understood by 
considering a diatomic model, which can be represented as two masses connected by a 
spring.123 Each mass represents one atom of the molecule and the spring represents a 
chemical bond (Figure 4.1.).  
k 
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Figure 4.1. A diatomic model: two masses connected by a spring 
The vibrational energy in the ground state (zero-point energy, E0) depends on 
the frequency of the bond stretch (𝑣), which in turn is dependent on the reduced mass of 
the two connected atoms (µ) (Figure 4.2.).124 
 
E0 = 1/2 h 𝑣 
𝑣 =
1
2𝜋
√
𝑘𝑓
µ
2
 
µ =  m1 m2 / (m1 + m2) 
(𝑘𝑓 and h are constants) 
 
 
Figure 4.2. Activation energies (Eh and El) required for dissociation of heavy and light atoms 
In summary, due to the higher mass, and thus lower vibrational frequency of the 
molecule that contains the heavy isotope, its ground state energy (also called the zero 
point energy)  is generally lowered. Complete dissociation of a bond with the 
isotopically substituted atom consequently requires more energy (Eh > El) than that for a 
corresponding "lighter" bond in the same environment. 
The increased bond stability to isotopically substituted atom may lead to 
changes of properties of a drug. By altering the metabolic pathways of the compound, 
its biological activity may be enhanced, reduced or prolonged.  By carefully fine-tuning 
the pathway, the formation of an active metabolite may be achieved or the formation of 
a toxic one may be avoided.125 
Initial studies demonstrated that the physical properties of deuterium oxide were 
different to those of normal water (Table 4.1.).45,126  
Property H2O D2O 
Melting point 0 °C 3.8 °C 
Boiling point 100 °C 101.42 °C 
Density 0.9982 1.1056 
Table 4.1. Physical properties of deuterium oxide and hydrogen oxide 
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4.3. Application of isotopes 
In 1969, Jones reported that since 1960 there has been a reawakening of interest 
in stable isotopes. This may be attributed to developments in the analytical equipment 
(MS and NMR in particular) that allow researchers to trace and study desired labelled 
compounds.127  
Non-radioactive isotopes, also known as stable isotopes, are used extensively in 
industry and academia. Compounds labelled with one or multiple stable isotopes (e.g. 
13C, 15N, 2H, etc) combined with analytical techniques (NMR, GS, MS, IR) can provide 
a valuable information in the elucidation of reaction mechanisms and metabolic 
research.128  
The increase in the use of deuterium labelling can be explained by the central 
position which hydrogen holds in chemistry and its role in proton transfer reactions. 
Initial studies of deuterated water, established its low toxicity towards mammalian 
cells.129 Safety is one of the benefits of stable isotopes, which enables their use for in 
vivo human studies.130 Deuteration may change the pathway of drug metabolism, which 
is called metabolic switching. This may lead to increased duration of action and lower 
toxicity.  
The shape of the molecule depends on its atoms and the interactions of their 
electron clouds. Due to the fact that deuterated and non-labelled analogues have the 
same number of electrons, the shapes and sizes of the compounds are very similar 
(Figure 4.3.).131  
 
Figure 4.3. An overlay of the crystal structures of CTP-347 (4.2) hydrochloride hemihydrate 
(purple) and paroxetine (4.1) hydrochloride hemihydrate (green) 
 
Concert Pharmaceuticals developed a compound called CTP-347 (4.2), a 
selectively deuterated analogue of paroxetine (4.1), for the treatment of hot flashes.132 
Modification was required, because paroxetine (4.1) irreversibly inactivates the liver 
enzyme CYP2D6, leading to various side effects when used in combination with other 
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medications. The proposed mechanism (Scheme 4.1.) shows the covalent binding 
between paroxetine metabolite and the active site of CYP2D6, forming irreversible 
complex (4.4).133 On the contraty, CTP-347 (4.2) demonstrated little to no CYP2D6 
inactivation, when the experiments were performed in vitro. It is believed that selective 
deuteration prevents the formation of the undesired carbene metabolite (4.3).  
 
 
Scheme 4.1. Proposed mechanism of CYP2D6 inactivation by the carbene metabolite (4.3) of 
paroxetine (4.1) 
 
CTP-347 (4.2) was subsequently studied in a patient clinical trial. Along with 
CTP-347, dextromethorphan was administered, which acts as a selective probe for 
CYP2D6 activity. Subjects receiving CTP-347 were able to metabolise 
dextromethorphan better than the patients who received paroxetine. This demonstrated 
the benefit of using deuterium over hydrogen in order to overcome undesired drug-drug 
interactions, potentially enabling the broader use of CTP-347 with other drugs. 
Despite the change in the metabolic pathway, CTP-347 has the same inhibition 
and selectivity as paroxetine. In the enzyme assays the two drugs were essentially 
identical. Human assays proved that  CTP-347 did not form any unwanted metabolites 
compared to paroxetine. 
Auspex Pharmaceuticals announced that a deuterated version of venlafaxine 
causes fewer side effects and stays in the bloodstream longer than the non-deuterated 
version, which prolongs the action of the drug.134  
 
4.4. Magnetic properties of atomic nuclei 
 
Many atoms (1H, 13C, 15N, etc) have positively charged nuclei that will resonate 
and spin, when placed in a strong magnetic field (Figure 4.4.).135  Due to angular 
momentum, the nucleus spins in a circular motion called the precession rate: 
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ν = γBo/2π 
ν is the precession rate (frequency) in hertz 
γ is the strength of the nuclear magnet (the 
“magnetogyric ratio”) 
Bo is the strength of the external magnetic field 
Figure 4.4. Model of spinning nucleus in an external magnetic field 
 
Measuring the resonant frequency of an atom gives us detailed information 
about the molecular structure. A selection of some NMR active nuclei is shown below 
(Table 4.2.).136 The magnetogyric ratio is a constant for any particular type of nucleus 
and is directly proportional to the strength of the nuclear magnet and therefore to the 
NMR signal strength (proton NMR has got the strongest signal). 
Nucleus Spin: I Abundance (%) Magnetogyric ratio: γ (106 rad s-1 T-1) 
1H ½ ~100 267.522 
2H 1 0.015 41.066 
13C ½ 1.1 67.283 
15N ½ 0.37 19.338 
19F ½ ~100 251.815 
31P ½ ~100 108.394 
Table 4.2. Properties of some NMR active nuclei 
NMR-active nuclei, located in the bonding network, do interact with each other, 
creating spin-spin splitting. The value of the splitting constant (J) will depend on the 
nuclei involved in the interaction. By labelling a compound with selected isotopes it is 
possible to achieve enhancement of some signals (e.g. 13C label displays strong peak in 
13C-NMR) or masking of others (e.g. replacing 1H with 2H therefore removing proton 
signals). Additionally, specific NMR experiments can provide information about shape 
and configuration of the molecule and the interactions between molecules. 
 
 
4.5. Synthesis of isotopically labelled compounds 
Incorporation of stable isotopes into organic compounds can be achieved by two 
methods: synthetic and exchange.137 
Synthetic method involves a synthesis of 2H-labelled compounds (also 13C, 15N, 
etc) via a series of chemical reactions, starting from commercially available stable 
isotope-labelled precursors. Using this method a highly selective incorporation of the 
isotopic label at the desired position can be achieved. However, long synthetic routes 
and the high costs of some isotopically labelled starting materials (e.g. 13C and 15N) 
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must often be taken into account. Up to date, 13C and 15N-labelled compounds are 
commercially available (> 2000 compounds available from Sigma-Aldrich, May 2015) 
and can be used as synthons during the synthesis of a desired target molecule. 
Exchange method offers a direct exchange of a hydrogen atom (bonded to a 
carbon atom) by a deuterium atom in the desired compound. These exchange reactions 
can be carried out directly on the target molecule using reagents such as D2O or D2 gas 
as the deuterium source. This method is particularly efficient if carried during the final 
stage of the synthetic sequence, because introduction of the isotopes early in the 
synthesis may lead to the loss of the label. However, poor selectivity and incomplete 
deuteration can be among the disadvantages of the above method. Exchange method is 
also applicable to the 18O isotope.138 
 
4.5.1. H/D exchange without the addition of acid or base 
Junk and Catallo demonstrated that H/D exchange can be carried out in 
supercritical media by performing a deuteration of arenes with D2O in autoclaves above 
370 °C.139 Thus, an almost complete incorporation of deuterium was achieved (> 97% 
2H incorporation) of (4.6) in the exchange reaction between 1-methylnaphthalene (4.5) 
and D2O (Scheme 4.2.). 
 
Scheme 4.2. H/D exchange of 1-methylnaphthalene (4.5) under supercritical conditions by Junk and 
Catallo 
 
Shapiro et al reported a method for deuterating cyclopentadienyl (Cp) ligands in 
calcocenes (Scheme 4.3.).140 The four hydrogen atoms of Cp ligands were exchanged 
for deuterium in 2H6-DMSO by heating a closed vessel at 150 °C for 1 hour (> 97% 
2H 
incorporation). Furthermore, it was possible to deuterate substituents on the Cp rings at 
those positions that are π-conjugated with the cyclopentadiene moiety through a fulvene 
tautomer (Scheme 4.4.). 
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Scheme 4.3. H/D exchange of Cp2Ca (4.7) by Shapiro et al 
 
Shapiro et al proposed that H/D exchange proceeded by the coordination of 2H6-
DMSO to the calcium (4.9). Labelling of the 2,5-positions of the cyclopentenyl 
substituents was proposed to occur via a fulvene intermediate (4.10). 
 
Scheme 4.4. Proposed mechanism of H/D exchange of Cp2Ca (4.7) by Shapiro et al 
 
4.5.2. Acid-catalysed H/D exchange 
Aromatic compounds can undergo H/D exchange when treated with acids. 
Ingold et al demonstrated deuteration of benzene to afford 2H6-benzene via D2SO4 
catalysed exchange. 141  Additionally, milder system BF3·D2O was reported to yield 
deuterated aromatic compounds.142  The group of Leis synthesised 2H5-amphetamine 
(4.12) in 89% yield by treating amphetamine (4.11) with 5% DCl in D2O for 15 hours at 
160 °C (Scheme 4.5.).143 
 
Scheme 4.5. H/D exchange of amphetamine (4.11) under acidic conditions by Leis et al 
 
4.5.3. Base-catalysed H/D exchange 
 
Base-catalysed H/D exchange may be useful when the compound is acid-
sensitive. Falardeau et al reported a synthesis of the methyl ester of [8,10,10-2H3]PGF2α 
(4.14) (Scheme 4.6.).144 Prostaglandin E2 (4.13) was treated with deuterium-labeled 
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carbitol in the presence of anhydrous potassium acetate and underwent α-H/D exchange 
via an intermediate enolate. Subsequent reduction afforded the desired deuterated 
product (4.14). 
 
Scheme 4.6. H/D exchange of PGE2 (4.13) under basic conditions by Falardeau et al 
Berthelette et al developed a method of labelling aryl methyl sulfones (4.16) and 
aryl methyl ketones (4.15) with deuterium (Scheme 4.7.).145,146 1,8-Diazabicyclo[5.4.0] 
undec-7-ene (DBU) was found to be the most suitable base in the D2O/THF (1:1) 
solvent system. The desired products (4.17) and (4.18) were afforded with up to 99% 2H 
incorporation. 
 
Scheme 4.7. H/D exchange of (4.15) and (4.16) under basic conditions by Berthelette et al 
Lygo and Humphreys developed a method for the synthesis of deuterium 
labelled L-α-amino acid precursors (4.22) via asymmetric alkylation of a 
benzophenone-derived glycine imine (4.19) (Scheme 4.8.). The key alkylation step 
employs a chiral quaternary ammonium salt (4.21) derived from cinchonidine in 
conjunction with KOD in D2O, enabling both side-chain and isotopic label to be 
incorporated in a single reaction step via the intermediate (4.20).147  
Scheme 4.8. H/D exchange of the glycine derived imine (4.19) under basic conditions by Lygo and 
Humphreys 
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4.5.4. Homogeneous metal catalysts 
Fels et al demonstrated Iridium-catalysed H/D exchange reaction in aromatic 
and non-aromatic double bonds if an electron-donating group was in a 1,4-relation with 
the carbon where the H/D exchange occurred (Scheme 4.9.).148 
 
Scheme 4.9. Iridium-catalysed H/D exchange of (4.23) by Fels et al 
Fels and co-workers demonstrated that cyclooctadiene ligand was replaced by 
solvent molecules, N,N-dimethylacetamide (DMA), to form the real catalytically active 
compound (4.26) (Scheme 4.10.). In the mechanism proposed by Fels et al, 
coordination of the substrate to the iridium catalyst occurs first, forming the complex 
(4.27). This is followed by the oxidative insertion of iridium into the C–H bond (4.28). 
Subsequently, coordination of D2O promoted H/D exchange (4.29). The reductive 
elimination afforded a regeneration of the catalyst (4.26) and the labelled product 
(4.25). This proposed mechanism reflects the preferred square-planar coordination 
sphere for Ir(I) and the octahedral coordination for Ir(III).  
 
Scheme 4.10. Proposed mechanism for Iridium-catalysed H/D exchange of (4.23) by Fels et al 
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4.5.5. Heterogeneous catalysts 
An important technical advantage of heterogeneous catalysis over homogeneous 
is the possibility to remove the catalyst by simple filtration at the end of the reaction. 
High activity for H/D exchange has been found with palladium, platinum, rhodium, 
nickel, and cobalt catalysts.149 
In 1964 Garnett and co-workers postulated that a π-complex mechanism had to 
be involved in heterogeneously catalysed H/D exchange. 150  Kinetic investigations 
indicated that, in addition to an associative mechanism, a competing dissociative π-
complex mechanism was also involved (Scheme 4.11.). In the associative mechanism 
(I), direct substitution of a hydrogen atom by a deuterium atom bound to the metal 
centre takes place (4.30). In the dissociative mechanism (II), a proton of the initially 
formed π-complex is substituted by the metal atom to form a carbon-metal σ-bond 
(4.31). In the second step (4.32) a substitution of the metal atom by a deuterium atom 
takes place to form the product (4.33). 
 
Scheme 4.11. Proposed associative (I) and dissociative mechanism (II) of the heterogeneous H/D 
exchange of aromatic substrates by Garnett et al 
It has been demonstrated by comparative studies of Sajiki and co-workers that 
palladium catalysts were able to promote the H/D exchange reactions in inactive alkyl 
chains, while platinum catalysts were superior at deuteration of aromatic positions. 
Sajiki et al reported excellent deuterium incorporation (min 96%) of ibuprofen (4.34), 
an anti-inflammatory drug (Scheme 4.12.).151 The non-labelled compound (4.34) was 
subjected to the deuteration procedure catalysed by 5 mol% Pt/C, which resulted in the 
high levels of the deuterium incorporation at the aromatic and benzylic positions (4.35). 
Subsequent 10 mol% Pd/C-catalysed H/D exchange afforded excellent deuterium 
incorporation in the non-activated alkyl chains (4.36). 
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Scheme 4.12. Sequential deuteration of ibuprofen (4.34) by Sajiki et al 
Sajiki et al extended the methodology to overcome the low levels of deuteration 
at sterically hindered positions. Attempted deuteration of 2-n-propylphenol (4.37) with 
either palladium or platinum afforded only moderate deuterium incorporation at the C-4 
position of (4.38) which has steric hindrance of the alkyl chain (Scheme 4.13. Entry 1 
and 2).152 However, when combined palladium and platinum complexes were used as a 
catalyst, fully deuterated 2H11-2-n-propylphenol (4.38) was obtained (Scheme 4.13. 
Entry 3). This result indicates that a more dispersed catalyst has a higher activity in the 
H/D exchange reaction and demonstrates the presence of a synergistic effect between 
the platinum and palladium complexes. 
 
Entry Catalyst (wt%) 2H Content [%] Yield 
[%] C1 C2 C3 C4 C5 C6 C7 
1 10% Pd/C (10%) 99 98 99 48 98 97 97 84 
2 5% Pt/C (20%) 98 98 98 38 72 42 28 62 
3 5% Pd/C (20%) + 5% Pt/C (20%) 99 99 98 97 98 98 98 84 
Scheme 4.13. Synergistic effect of palladium and platinum in H/D exchange of (XX) by Sajiki et al 
 
Sajiki et al demonstrated a selective deuteration of the β-position of L-
phenylalanine (4.39) by using Pd/C-H2/D2O system (Scheme 4.14.).
153 The deuterated 
analogue (4.40) was afforded in 99% yield, 96% 2H incorporation and more importantly 
without any racemisation. 
 
Scheme 4.14. Palladium-catalysed H/D exchange of (4.39) by Sajiki et al 
 
Cioffi and co-workers developed a deuteration of carbohydrates with Raney-
nickel catalyst, which proceeded with a retention of configuration (Scheme 4.15.).154 
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Methyl-β-D-galactopyranoside (4.41) was subjected to ultrasonication conditions, that 
afforded the desired product (4.42) in quantitative yield and more than 74% 2H 
incorporation.155 
 
 
Scheme 4.15. Raney-nickel-catalysed H/D exchange of (4.41) by Cioffi et al 
 
4.6. Chapter conclusion 
Non-radioactive isotopes, also known as stable isotopes, are used extensively in 
industry and academia in the research areas such as: drug metabolism, toxicology, 
pharmacokinetics and reaction mechanisms.156,157,158,159 Compounds labelled with one 
or multiple stable isotopes can provide a valuable information, which would be 
unavailable if only non-labelled compounds are studied. With the advent of peptides 
and proteins, it is important to study them rigorously to understand and improve drug 
treatment. 
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Chapter 5. Synthesis and applications of chiral non-racemic aziridines 
labelled with stable isotopes 
5.1. Chapter introduction 
Up to date numerous methods have been reported for the synthesis of 2H-, 13C-, 
15N- and 18O-labelled proteinogenic and non-proteinogenic α-amino acids covered in the 
review by Kelly et al and publications by Veglia et al and Geierstanger et al.160,161,162 
However, some methods suffer from harsh reaction conditions (high temperatures, 
strong acids or bases), toxic and environmentally unfriendly metal salts, multi-step 
inefficient protocols or formation of inseparable by-products.163 Furthermore, relatively 
low yields and/or reduced levels of 2H incorporation are among common drawbacks.  
Optically active aziridines are well-known precursors for chiral α- and β-amino 
acids. Thus, we were looking to develop an atom-efficient, multi-component, 
organocatalytic protocol to access structurally diverse optically active aziridines 
labelled with stable isotopes. Employing readily generated isotopically labelled 
aldehydes, amines and alkyl diazoacetates as building blocks, we aimed to maximise the 
number and type of isotope nuclei embedded within an aziridine, without additional 
reaction optimisation.  
Initially, we performed model organocatalytic aziridination reactions to generate 
non-labelled racemic and chiral non-racemic cis-aziridines. By establishing optimal 
reaction conditions, we aimed to synthesise chiral non-racemic cis-aziridines, labelled 
with stable isotopes, via an organocatalytic asymmetric aziridination reaction. 
 
5.2. Studies towards a racemic aziridination protocol 
The work that was previously carried out within the Bew group, focused on 
developing novel aziridination reaction protocols. This work demonstrated that a 
Brønsted acid, pyridinium triflate (5.5), catalysed a reaction between ethyl or tert-butyl 
diazoacetate and N-alkyl or N-arylimine.164 Using this simple organocatalyst, racemic 
(±) N-aryl-, N-alkyl- and NH-C2,3-disubstituted aziridines were generated in good yields 
(up to 92%) and diastereoselectivities (cis- predominantly over trans-). The selection of 
the catalyst (5.5) was based on the work of Johnston et al, who employed various 
Brønsted acids (e.g. acetic acid [pKa 4.75], trifluoroacetic acid [pKa 0.5], triflic acid 
[pKa -14]) as catalysts for ethyl cis-aziridine-2-carboxylates formation.
165 He reported 
that lower pKa resulted in a better catalytic activity in terms of a shorter reaction time 
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and higher product yields. However, triflic acid is extremely hygroscopic, making it 
difficult to handle and store. Furthermore, the use of such strong acid prevents 
chemistry on substrates that have acid-sensitive functional and/or protecting groups. 
Additionally, good yields (53-89%) and diastereoselectivities (>95:5 cis:trans) were 
achieved only when reactions were performed at -78 °C and reasonably high 25 mol% 
loading of triflic acid catalyst. Using pyridinium triflate as a catalyst in aziridination 
reactions has got several advantages over triflic acid. As a stable solid, pyridinium 
triflate is easily weighed and handled, inexpensive, non-hygroscopic, requires no drying 
or crystallisation and its mildly acidic nature allows incorporation of acid-sensitive 
groups. 
As part of our preliminary investigation towards the synthesis of (±)-cis-
aziridines, a one-pot procedure was attempted, with the desired imine (5.3) pre-formed 
in situ (Scheme 5.1.).  
Scheme 5.1. Synthesis of (±)-cis-(5.6) via a one-pot aziridination reaction with the intermediate 
imine (5.3) 
 
 
A slight excess (10%) of 4-nitrobenzaldehyde (5.1) ensured that all of the 2-tert-
butoxyaniline (5.2) was consumed and the corresponding imine (5.3) was formed. If any 
of the unreacted amine is present, it will react with the catalyst (5.5), competing with the 
imine. This reactivity can be rationalised by considering the molecular orbital effect on 
acidity/basicity. The more "s" character the orbital possesses, the closer the electrons are 
held to the nucleus and therefore the acidity of a bond increases.166 If the lone pair is in 
an sp2 or sp orbital, it is held closer to the nucleus and is more difficult to protonate than 
if it is in an sp3 orbital. For example, cyclohexanimine has pKa of 9.2 (nitrogen lone pair 
is in sp2 orbital) and is less basic (thus more acidic) than cyclohexylamine, which has 
pKa of 10.6 (nitrogen lone pair is in sp
3 orbital). 
Activated (flame dried) 4 Å molecular sieves were used to trap the generated 
water in the condensation reaction between 4-nitrobenzaldehyde (5.1) and 2-tert-
butoxyaniline (5.2) and shift the reaction equilibrium towards the imine (5.3) formation. 
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After three hours stirring at room temperature, an aliquot was taken out and submitted 
to 1H-NMR analysis; this confirmed the imine (5.3) formation (Figure 5.1.). New 
singlet was observed at δ 8.58 ppm, which was assigned to the proton on the α-carbon 
of the imine (5.3). Residual, due to 10% excess, aldehyde (5.1) singlet was observed at 
δ 10.15 ppm (17% detected by 1H-NMR analysis).  
 
Figure 5.1. 1H-NMR (500 MHz, CDCl3) spectrum of imine (5.3)  
Imine (5.3) was not isolated and was directly submitted to the aziridination 
reaction. After addition of 10 mol% pyridinium triflate (5.5) catalyst and tert-butyl 
diazoacetate (5.4) a rapid gas evolution was observed in the vial, which was 
hypothesised to be molecular nitrogen elimination, during the aziridine ring closing step 
(5.7) (see Scheme 5.2., page 50). After 6 hours at room temperature, 1H-NMR (500 
MHz, CDCl3) analysis of an aliquot indicated a complete disappearance of the 
characteristic imine singlet at δ 8.58 ppm (Figure 5.2.).  
 
Figure 5.2. 1H-NMR (500 MHz, CDCl3) spectrum of (±)-cis-(5.6) 
Purification by flash chromatography on silica gel, eluting with 20% diethyl 
ether in 40-60 petroleum ether, afforded (±)-cis-(5.6) as an orange oil in a 81% yield. 
The cis-configuration of the product was assigned on the basis of the vicinal proton-
proton coupling constants (J2,3 6.8 Hz) of the doublets, corresponding to the protons at 
C2-H 
J2,3 6.8 Hz 
C3-H 
J2,3 6.8 Hz 
(α) 
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C-3 (δ 3.53 ppm) and C-2 (δ 3.14 ppm).167,168 Our results were in good agreement with 
the work of Templeton et al, who reported cis-aziridine formation over trans- in the 
reactions between N-substituted aryl imines with ethyl diazoacetate, catalysed by Lewis 
acids.169  
The observed magnitude of the coupling constants in cis-aziridines can be 
rationalised using the research by Martin Karplus, who established a relationship 
between the dihedral angle and vicinal coupling constant applicable to the structural 
analysis of organic molecules (Figure 5.3.).170 In the trans-aziridines, the dihedral angle 
ϕ is ~ 120 degrees, thus a coupling constant 3J is ~ 2 - 5 Hz. In the cis-configuration of 
aziridines, the dihedral angle ϕ is close to 0 (zero) degrees, therefore affording 3J in the 
range of ~ 5 - 9 Hz.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Aziridine coupling constant (3J) dependence on the dihedral angle (ϕ)  
A literature search on the aziridination reaction mechanism afforded several 
publications by Wulff et al, who proposed that the diazo- group should be in 
antiperiplanar conformation to the nitrogen that ends up in the aziridine ring for the 
elimination of the dinitrogen leaving group to occur in the ring closing step (5.7) 
(Scheme 5.2.).171 Based on this research, we proposed a mechanism of the reaction 
generating (±)-cis-(5.6), which is racemic, because using achiral catalyst such as 
pyridinium triflate (5.5), allows tert-butyl diazoacetate (5.4) to attack imine (5.3) 
equally from both faces. Cis- selectivity was rationalised considering the fact that bulky 
tert-butyl group of the diazoacetate occupies the least sterically hindered position 
relative to the aromatic groups of the imine, setting the stereochemistry in the first 
irreversible step. 
ϕ 
ϕ 
  trans- 
ϕ ~ 120°  
 
  cis- 
ϕ ~ 0°  
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Scheme 5.2. Proposed mechanism of the reaction yielding (±)-cis-(5.6) 
At this point it was considered important to confirm the cis-character of the 
aziridines synthesised via the methodology discussed previously. Up to this point, cis-
character of the aziridines had only been proven by the characteristic coupling constants 
of in the range 5 - 9 Hz of the C-2-H and C-3-H peaks within 1H-NMR spectra of the 
products. After much experimentation, a further confirmation of the cis-relationship at 
the C-2 and C-3 positions was achieved via single-crystal structure analysis of (±)-cis-
(5.8) (Figure 5.4.). Compound (±)-cis-(5.8) was generated using identical procedure 
utilised in the synthesis of (±)-cis-(5.6) and it was indentified that (±)-cis-(5.8) 
possessed the doublets at δ 3.59 ppm and δ 3.19 ppm with J2,3 being 6.8 Hz. A 
successful crystallisation of (±)-cis-(5.8) was achieved from pentane/diethyl ether 2:1 
mixture, with the crystals obtained as pale yellow needles. The X-ray crystal structure 
confirmed the cis-relationship at the C-2 and C-3 positions (see below the conformation 
of the carbon sequence C15-C14-C7-C8 ). 
                  
Figure 5.4. Oak Ridge Thermal Ellipsoid Plot (ORTEP) representation of the X-ray crystal 
structure of (±)-cis-(5.8) displaying cis-stereochemistry at the C-2 and C-3 positions 
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Obtaining the confirmation of cis-configuration of aziridines synthesised, we 
attempted to rationalise the diastereoselectivity by considering steric effects during the 
ring-closing step (Scheme 5.3.). Additionally to this argument, Wulff  et al conducted 
an extensive research into the stereoselectivity of the asymmetric aziridination reaction, 
by using a combination of experimental kinetic isotope effects and theoretical 
calculations.172 A comparison of theoretical Gibbs free energies in the transition state 
for the SN2-like ring closure led to the conclusion that the cis-aziridination pathway 
(21.3 kcal/mol) has lower energy than trans- (22.6 kcal/mol) and is therefore more 
energetically favourable. This is in reasonable agreement with the experimental > 50:1 
cis-/trans- ratio observed by Wulff et al for this reaction and our data, which suggest 
predominantly cis-aziridine formation over trans-. 
 
Scheme 5.3. Newman projections to justify the cis-stereoselectivity of (±)-cis-(5.6) 
Our preliminary investigations into a racemic aziridination protocol resulted in a  
successful synthesis of (±)-cis-(5.6) and (±)-cis-(5.8). A cis-configuration of the 
generated aziridines was confirmed on a basis of crystal structure and aziridine ring 
coupling constants. Using the results obtains, we proceeded with an investigation 
towards asymmetric aziridination reactions. 
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5.3. Studies towards an asymmetric aziridination protocol 
Within the work of Pesce, it was demonstrated that chiral non-racemic Brønsted 
acid catalysts derived from (S)-1,1′-binaphthyl-2,2′-diol (BINOL) proved effective in 
providing excellent asymmetric inductions in aziridination reactions (Figure 5.5.).173 
The catalyst of choice was (S)-BINOL derived phosphoryl N-trifluoromethane 
sulfonamide functionalised with two 9-anthryl substituents (S)-(5.9) at the 3- and 3'- 
positions. The selection was based on the work of Yamamoto et al, who utilised (S)-
BINOL-based chiral N-triflyl phosphoramide as a catalyst in a highly enantioselective 
Diels-Alder reaction of an α,β-unsaturated ketone with silyloxydienes.174 
Using Molecular Mechanics 2 (MM2) software, Pesce demonstrated that two 9-
anthryl substituents of the catalyst (S)-(5.9) create a "box" cavity with the phosphoryl 
N-trifluoromethane sulfonamide group in the centre. The activation of an imine occurs 
via protonation by the acidic proton NH of the catalyst. Additionally the transition state 
is stabilised by phosphoryl oxygen via bonding to the hydrogen atom on the α-carbon of 
the N-aryl imine. Similar transition state was observed by Gridnev et al between (S)-
BINOL derived phosphoric acid and N-Boc imine and a crystal structure was obtained 
as the evidence.175 
        
Figure 5.5. Proposed model of the transition state between the catalyst (S)-(5.9) and a generic imine  
Following the procedure reported by Pesce, our initial attempt towards a one-pot 
asymmetric aziridination reaction utilised 10 mol% (S)-3,3’-bis(anthracen-9-yl)-[1,1’]-
binaphthalen-2,2’-yl N-triflyl phosphoramide catalyst (S)-(5.9), tert-butyl diazoacetate 
(5.4) and N-substituted imine, generated in situ from 4-nitrobenzaldehyde (5.1) and 2-
tert-butoxyaniline (5.2) (Scheme 5.4.).  
Deuterated chloroform/deuterated dichloromethane (8:2) solvent system allowed 
reaction monitoring directly by 1H-NMR analysis, without obscuring the spectrum by 
any additional solvent peaks. Additionally, this system was one of the cheapest 
deuterated solvent combinations, that allowed reactions to be carried at -78 °C, without 
freezing. The freezing point of chloroform is -63.5 °C, dichloromethane is -97 °C.176  
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Scheme 5.4. Asymmetric synthesis of chiral non-racemic cis-(5.6) 
The reaction was kept at -78 °C and monitored by thin layer chromatography 
and 1H-NMR analysis. After circa 24 hours, the characteristic imine peak at δ 8.58 ppm 
was no longer observed. Two new doublets were observed at δ 3.53 (J2,3 6.8 Hz) and 
3.14 ppm (J2,3 6.8 Hz), matching with the racemic sample (±)-cis-(5.6). To determine 
the enantiopurity of cis-(5.6), a chiral HPLC analysis was performed. The chiral non-
racemic sample was run against the corresponding racemic aziridine and e.e. was 
calculated to be 96% (Table 5.1.). 
Compound Chiral HPLC spectrum 
 
 
 
 
Rt = 6.27, 10.41 min 
racemic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rt = 6.25, 10.38 min 
96% e.e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: Chiralpak AD-H HPLC column, 95% iso-hexane : 5% iso-propanol, flow 
rate: 1 mL / min 
Table 5.1. Chiral HPLC spectra of (±)-cis-(5.6) and cis-(5.6) 
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With the synthesis of chiral non-racemic cis-(5.6), accomplished, chiral non-
racemic cis-(5.8) was generated via the asymmetric aziridination protocol described 
above, utilising aniline instead of 2-tert-butoxyaniline. This reaction was designed to 
test the differences in yield and, most importantly, e.e., which occur upon changing the 
amine substituent within the one-pot reaction asymmetric aziridination reaction. It was 
observed that without 2-tert-butoxy group e.e. decreased from 96% to 92% (Table 5.2.). 
This can be attributed to the fact that bulky 2-tert-butoxy group provides additional 
steric influence, blocking one face of the imine during tert-butyl diazoacetate approach. 
Compound Chiral HPLC spectrum 
 
 
 
 
Rt = 17.93, 26.52 min 
racemic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rt = 18.53, 26.95 min 
92% e.e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: Phenomenex Lux Cellulose-1 HPLC column, 99% iso-hexane : 1% iso-
propanol, flow rate: 1 mL / min 
Table 5.2. Chiral HPLC spectra of (±)-cis-(5.8) and cis-(5.8) 
Although chiral HPLC analysis allowed the enantiopurity of aziridines to be 
established, no confirmation of the absolute stereochemistry was obtained. 
Unfortunately, no similar examples were found within the literature in order to compare 
the specific rotation values. Thus, the stereochemistry of enantiomerically enriched 
aziridines throughout this thesis should be considered as the relative stereochemistry. 
However, Freedman et al reported that chiro-optical methods, such as vibrational 
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circular dichroism (VCD) can be used to determine the absolute configuration of the 
molecule.177  VCD utilises the differential interaction of a chiral molecule with left 
versus right circularly polarized light. Felippe et al demonstrated that absolute 
configuration of several natural products was assigned using VCD spectroscopy. 178 
Therefore, the subject of our future investigations will be the measurement of VCD 
spectra of enantiomerically enriched aziridines and elucidation of their absolute 
configuration.                         
By synthesising non-labelled racemic aziridines (±)-cis-(5.6) and (±)-cis-(5.8) 
and non-labelled enantiomerically enriched cis-(5.6) and cis-(5.8) the aziridination 
protocols (racemic and asymmetric) have been established. Thus, it was necessary to 
generate a suite of starting materials, such as aldehydes, amines, diazoacetates, labelled 
with stable isotopes so we could investigate the synthesis of the corresponding labelled 
optically active aziridines.  
A literature search on the synthesis of isotopically labelled aziridines was, 
surprisingly, rather limited. Beresford and Young reported synthesis of labelled 
aziridine-2-carboxylates, which were subsequently used as synthons for preparation of 
L-amino acids, labelled at the β-carbon atom.179 Davies et al used 2H- or 13C-formyl 
labelled aromatic aldehydes to generate corresponding C-3 labelled N-tosyl-3-aryl-2-
alkynyl aziridines, that were subsequently converted into 2,4-disubstituted pyrroles via 
gold-catalysed 1,2-aryl shift.180 Although reaxys and scifinder searches afforded several 
hits on 15N-labelled aziridines, these compounds were mainly generated for 
spectroscopic studies.181,182 
We envisaged the introduction of stable isotopes into an aziridine ring and its 
subsequent ring-opening, generating high-value compounds such as optically active α- 
and β-amino acid derivatives, labelled with stable isotopes. An aziridine ring itself is a 
desirable target for labelling, because protons and carbons within the ring display very 
specific NMR signals, in the region, not obstructed by other signals. This allows 
straightforward identification and characterisation of the changes induced by the 
isotopic incorporation, such as loss of a signal if a proton has been substituted with a 
deuteron or enhancement of a signal when 13C is used instead of 12C. 
 Although this chapter is dedicated to the production of chiral non-racemic 
aziridines labelled with stable isotopes, the author feels that the background 
development of isotopically labelled starting materials is worthy of note. Detection and 
analysis of isotopic splitting patterns in starting materials provides valuable information 
during product characterisation.  
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5.4. Synthesis of α-2H-aldehydes 
A literature search on the aldehyde deuteration at the formyl group afforded a 
publication by Kirby et al, who published a procedure of introducing deuterium or 
tritium labels at the formyl group of aromatic aldehydes, via the readily accessible 
morpholino-acetonitrile intermediates, such as (5.10).183  
Following the method published by Kirby et al, 4-nitrobenzaldehyde (5.1) was 
treated with perchloric acid and potassium cyanide in morpholine as a solvent to afford 
2-morpholino-2-(4-nitrophenyl)acetonitrile (5.10) (Scheme 5.5.). 
 
Scheme 5.5. Synthesis of 2H-formyl 4-nitrobenzaldehyde (5.11) 
The 1H-NMR (500 MHz, CDCl3) analysis of (5.10) revealed a complete absence 
of aldehyde peak (~ δ 10 ppm) and a new singlet at δ 4.90 ppm related to the proton on 
the α-carbon of (5.10), as well as the multiplets at δ 3.75 ppm and δ 2.61 ppm 
corresponding to the protons on the morpholino-group (Figure 5.6.). FT-IR analysis 
indicated the absence of the carbonyl group at 1705 cm-1 and the presence of the new 
peak at 2226 cm-1, corresponding to the cyano group. 
 
 
Figure 5.6. 1H-NMR (500 MHz, CDCl3) spectrum of morpholino-acetonitrile derivative (5.10) 
 
Hanson reported that in the morpholino-acetonitrile derivatives the presence of 
the nitrile group, increases the acidic character of the proton attached to the α-carbon.184 
Following the procedure by Kirby et al, a deprotonation of (5.10) with sodium hydride 
was performed, followed by subsequent quenching of the resulting anion with 
deuterium oxide to install the deuterium atom on the α-carbon of (5.10). Sodium 
hydride was selected, because of its ability to remove the desired proton irreversibly, 
generating hydrogen gas, which is the driving force of the reaction. The 2H-labelled 
morpholino-acetonitrile derivative (not shown) was hydrolysed under the mildly acidic 
(α) 
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conditions (1% DCl in D2O) under a reflux to afford 
2H-formyl 4-nitrobenzaldehyde 
(5.11) without any loss of the deuterium label (2H incorporation remained > 95%). 
Deuterium incorporation level was determined by analysing the 1H-NMR spectra of 
(5.1) and (5.11) and comparing the integration of the formyl proton (Figure 5.7.). 
Deuterium incorporation in all subsequent examples discussed throughout this 
dissertation was established using this procedure: direct comparison of the integration 
values between the proton in a non-labelled sample and a residual proton in a deuterated 
material. 
 
Figure 5.7. Stacked 1H-NMR (500 MHz, CDCl3) spectra of α-2H-4-nitrobenzaldehyde (5.11) (top) 
and 4-nitrobenzaldehyde (5.1) (bottom) 
 
2H-NMR (500 MHz, DCM) analysis of (5.11) displayed a broad singlet at δ 
10.11 ppm, which corresponded to the signal of the deuterium atom (Figure 5.8.). All 
2H-NMR experiments were performed in the "unlocked" mode in a non-deuterated 
solvent (e.g. DCM) with a drop of CDCl3 and/or CD2Cl2 as a chemical shift reference. 
 
Figure 5.8. 2H-NMR (77 MHz, DCM) spectrum of α-2H-4-nitrobenzaldehyde (5.11) 
CDCl3 
reference 
Ar-H 
δ 8.38 ppm 
and 
δ 8.07 ppm 
doublets 
J 8.8 Hz 
Formyl-H 
δ 10.15 ppm 
residual 
singlet 
 
1.00 (1H) 
2.00 (1H) 0.01 (1H) 2.00 (1H) 
2.00 (1H) 2.00 (1H) 
Formyl-H 
δ 10.16 ppm 
singlet 
 
Ar-H 
δ 8.40 ppm 
and 
δ 8.08 ppm 
doublets 
J 8.8 Hz 
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Furthermore, within the 13C-NMR (126 MHz, CDCl3) spectrum of (5.11), the 
carbonyl signal was observed as a triplet at δ 190.2 ppm with JC-D 27.4 Hz (Figure 
5.9.). This splitting pattern was accounted for the fact that the 13C-NMR spectrum was 
not deuterium decoupled. Deuterium has a spin of 1, with three spin states possible: spin 
1, 0, and -1.135 A 2H nucleus splits the 13C signal into three equally spaced peaks (1:1:1 
ratio due to the nearly equal populations of the three 2H spin states) and this results in 
lower intensities of the peaks. In addition, the reduced carbonyl signal intensity was 
observed, because carbons are much slower to relax when bound to 2H (relative to 1H), 
due to the smaller nuclear magnet (magnetogyric ratio) of deuterium (see page 37). The 
ipso-carbon was observed at δ 140.1 ppm as a triplet as well, however with a smaller 
magnitude of the coupling constant (2JC-D 3.5 Hz). 
 
Figure 5.9. 13C-NMR (126 MHz, CDCl3) spectrum of α-2H-4-nitrobenzaldehyde (5.11)  
Using the method outlined above, a library of deuterated aldehydes has been 
generated, including 2H-formyl 4-nitrobenzaldehyde (5.11), 2H-formyl 4-
cyanobenzaldehyde (5.12), 2H-formyl 4-fluorobenzaldehyde (5.13), 2H-formyl 4-
bromobenzaldehyde (5.14) and 2H-formyl 2-naphthaldehyde (5.15) (Table 5.3.). Their 
synthesis proceeded exceptionally well on a multi-gram scale and, more importantly, 
with excellent deuterium incorporation levels (> 95% 2H incorporation). Reactions were 
cost effective, due to commercially available inexpensive starting materials. 
Furthermore, morpholino-acetonitrile intermediates are highly crystalline solids, which 
is convenient for their handling and storage. The functional groups were chosen on a 
basis of electronic character and utilisation in any subsequent transformations. Nitro and 
cyano groups are strongly deactivating substituents towards electrophilic aromatic 
substitution, fluoro and bromo substituents are weakly deactivating and 2-naphthyl 
group is weakly activating. Nitro and cyano groups can be reduced to the corresponding 
amines, that can be used in peptide coupling or transformed into other groups via 
diazonium salts.185 Additionally, the cyano group can be hydrolysed to an amide or a 
δ 190.2 ppm 
JC-D 27.4 Hz 
δ 140.1 ppm 
2JC-D 3.5 Hz 
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carboxylic acid derivative. Bromo substituent can be used in cross-coupling reactions 
and fluorine nucleus is an excellent NMR probe, often used for studies of chemical and 
biological systems (see example of cis-(5.37) page 72).186 
 
 
 
 
 
 
  
 
 
 
 
Table 5.3. Generated library of α-2H-aldehydes  
 
With isotopically labelled starting materials in hand, we attempted to introduce 
stable isotope labels into the corresponding aziridines, following the asymmetric 
protocol discussed previously. 
 
5.5. Asymmetric synthesis of 1-15N-3-2H-tert-butyl 3-(4-nitrophenyl)-1-phenyl 
aziridine-2-carboxylate cis-(5.18)  
 
The first isotope incorporating aziridination reaction, utilising the asymmetric 
protocol discussed previously employed α-2H-4-nitrobenzaldehyde (5.11) and 
commercially available 15N-aniline (5.16). Imine (5.17) was pre-formed in situ at room 
temperature, which was confirmed by 1H- and 2H-NMR spectroscopy (Scheme 5.6). 
(S)-3,3’-Bis(anthracen-9-yl)-[1,1’]-binaphthalen-2,2’-yl N-triflyl phosphoramide (10 
mol%) catalyst (S)-(5.9) was added and the reaction vessel was cooled to -80 °C. tert-
Butyl diazoacetate (5.4) was syringed through the septum of the reaction vessel and the 
reaction mixture was stirred at -80 °C, monitoring by 1H-NMR and TLC until the 
reaction was deemed complete (~ 72 hours). 
 
Scheme 5.6. Asymmetric synthesis of cis-(5.18) 
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The rate of the above reaction was observed to be significantly slower (72 h vs 
24 h) compared to the aziridination to form chiral non-racemic cis-(5.8), when no 
isotopes were incorporated. The decrease of the reaction rate to form cis-(5.18) can be 
attributed to a kinetic isotope effect (KIE). 187  A primary KIE arises from bond 
breaking/making to the 15N atom. When isotopes are remote from the reaction centre, a 
secondary KIE may be observed. In the compound cis-(5.18), deuterium was not 
involved directly in the bond breaking/making, however, it was attached to the carbon 
participating in the bond formation, potentially contributing to the secondary KIE.  
A literature search of the comparison of the reaction rates between labelled and 
non-labelled compounds afforded a publication by Chupakhin et al, who reported a 
reaction between 7-15N-1H-1,2,4-triazole-5-diazonium chloride (5.20) and α-formyl-α-
phenylacetonitrile (5.19) affording 2-15N-3-phenyl-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-
amine (5.22).188 The first step involved a nucleophilic addition to the sp hybridised 15N 
affording hybridisation change to sp2.189 Second step proceeded via cyclisation of six-
membered ring of (5.21), without any 15N-hybridisation changes, but with a 
rearrangement of bonds connected to 15N. During both steps, the reaction with 15N-
labelled compound proceeded with a much slower rate, compared to the non-labelled 
equivalent (5.23).190 
 
 
Scheme 5.7. Direct comparison of the reaction rates during formation of 2-15N-3-phenyl-
[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-amine (5.22) and 3-phenyl-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-
amine (5.23) by Chupakhin et al 
 
 
Purification by flash chromatography on silica gel afforded cis-(5.18) as a 
yellow solid in 59% yield and 86% e.e. (determined by chiral HPLC). Subsequent 1H-
NMR (500 MHz, CDCl3) analysis of cis-(5.18) revealed the absence of the signal from 
the proton at the C-3 position, because it had been replaced with deuterium           
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(Figure 5.10.). The proton at the C-2 position was expected to be observed as a triplet 
due to a spin coupling with an adjacent deuterium atom at the C-3 position. However, 
the actual signal was observed at δ 3.19 ppm as a singlet. This fact is attributed to the 
differences in the magnetogyric ratios of a proton and a deuteron (see Table 4.2. 
Properties of some NMR active nuclei, page 37). The coupling constants for 1H–2H 
couplings are proportional to those of 1H–1H coupling and are reduced by a factor of ~ 
7. Thus, a cis-coupling constant of the proton at C-2 is expected to be less than 1.0 Hz. 
Couplings this small are sometimes not observed within 1H-NMR and the triplet 
appears as a singlet, which is slightly broad near the baseline. In the 2H-NMR (77 MHz, 
DCM) spectrum of cis-(5.18) a broad singlet was observed at δ 3.54 ppm corresponding 
to the deuterium atom installed at C-3.  
 
 
Figure 5.10. 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.18) with 2H-NMR (77 MHz, DCM) 
insert 
 
 
Although no crystal structure was obtained for cis-(5.18), 1H-NMR analysis was 
used to confirm deuterium incorporation and a cis-configuration (Figure 5.11.). 1H-
NMR (500 MHz, CDCl3) analysis of cis-(5.18) revealed a signal at δ 3.59 ppm from the 
residual proton at the C-3 position with the integration of 0.01, therefore deuterium 
incorporation was recorded above 95%. The coupling constant of this proton was 
recorded as J2,3 6.8 Hz. Chemical shift and the coupling constant (J2,3) of the C3-
residual proton have matched the ones obtained from the racemic sample (±)-cis-(5.8), 
therefore a cis-configuration of  cis-(5.18) was confirmed. 
CD2Cl2 
reference 
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Figure 5.11. 1H-NMR (500 MHz, CDCl3) spectra of (±)-cis-(5.8) (top) and cis-(5.18) (bottom) 
 
While examining the 13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.18), a 
complex splitting pattern was observed, mainly arising from the fact that a 15N nucleus 
is NMR-active. (Figure 5.12.). Signal from the C-2 position appeared at δ 46.6 ppm as 
a doublet (JC-N 6.8 Hz), which was attributed to the coupling to the 
15N nucleus. 
Likewise, carbon at the C-3 position was split by both 2H and 15N, therefore a triplet of 
doublets splitting pattern was observed at δ 45.7 ppm (JC-D 25.5 Hz, JC-N 6.8 Hz). The 
strength of the NMR magnet and the concentration of the sample allowed to observe 
other carbons to be split by 15N as well. Carbonyl peak at δ 166.1 (JC-N 4.8 Hz) ppm 
appeared as a doublet, as well as aromatic carbons at δ 151.8 (JC-N 2.6 Hz), δ 142.5 (JC-N 
4.1 Hz), δ 128.9 (JC-N 1.8 Hz) and δ 120.0 ppm (JC-N 3.3 Hz). The coupling constants of 
similar magnitude were reported by Beller et al, who characterised 15N-labelled N-
benzylaniline.191  
 
Figure 5.12. 13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.18) 
C2-H 
JC-N 6.8 Hz 
 
C3-D 
JC-N 6.8 Hz 
JC-D 25.5 Hz 
 
 
C3-H 
δ 3.59 ppm 
doublet 
J2,3 6.8 Hz 
C2-H 
δ 3.19 ppm 
doublet 
J2,3 6.8 Hz 
C2-H 
δ 3.19 ppm 
singlet 
 
C3-H 
δ 3.59 ppm 
residual 
doublet 
J2,3 6.8 Hz 
1.00 (1H) 1.00 (1H) 
1.00 (1H) 0.01 (1H) 
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The HRMS analysis provided a confirmation of the synthesis of cis-(5.18) with 
[M+H]+ ions found at the required m/z (found: 343.1526, required: 343.1529) (Figure 
5.13.). No peaks was detected corresponding to the 342.1529 fragment (M+-1) or 
342.1529 fragment (M+-2) which confirms no 2H or 15N "loss" occurred, suggesting the 
deuterium and 15N incorporation level to be above 95%. 
 
Figure 5.13. HRMS (HASP) spectrum of cis-(5.18) 
 
With accomplished synthesis of cis-(5.18), we wanted to extend the scope of our 
investigation by introducing additional isotopic labels into aziridines and examine 
subsequent impact on enantiomeric excess, yield and isotopic incorporation levels. 
 
5.6. Synthesis of α-2H-tert-butyl diazoacetate (5.24) 
Diazo compounds are remarkably versatile building blocks in organic synthesis, 
that are utilised in reactions such as: aziridination, cyclopropanation and formation of 
lactams.192 Previously, within the Bew group, a methodology has been developed, that 
employs a one-pot-one-cycle procedure to obtain aryl and alkyl diazoacetates with 
deuterium installed at the α-position (Scheme 5.8.).193  
                   
Scheme 5.8. Synthesis and a proposed mechanism of a formation of α-2H-tert-butyl diazoacetate 
(5.24) 
(α) (α) 
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The high levels of deuterium incorporation (> 95%) were achieved employing 
commercially available, inexpensive starting materials and very mild conditions. 
Treating tert-butyl diazoacetate with 10 mol% of potassium carbonate in homogenous 
acetonitrile-deuterium oxide 1:1 mixture at ambient temperature afforded the desired α-
2H-tert-butyl diazoacetate. 1H-NMR (500 MHz, CDCl3) analysis revealed the absence 
of the alpha proton singlet at δ 4.59 ppm (determined from the starting material), 
whereas a signal of the tert-butyl group remained intact (Figure 5.14.). 
                     
Figure 5.14. 1H-NMR (500 MHz, CDCl3) spectra of tert-butyl diazoacetate (5.4) (left) and α-2H-tert-
butyl diazoacetate (5.24) (right) 
Within the 13C-NMR (126 MHz, CDCl3) spectrum of tert-butyl diazoacetate 
(5.4) the signal from the α-carbon was observed as a singlet at δ 46.7 ppm, because the 
13C-NMR spectrum was proton decoupled (Figure 5.15.). However, in the 13C-NMR 
(126 MHz, CDCl3) spectrum of α-2H-tert-butyl diazoacetate (5.24) the signal of the α-
carbon was observed as a triplet (JC-D 29.9 Hz).
 This was attributed to the deuterium 
nucleus splitting the carbon, its attached to, into three peaks of equal intensity. Identical 
pattern was observed when a deuterium label was incorporated into the formyl group of 
aromatic aldehydes (see 5.4. Synthesis of α-2H-aldehydes, page 56).  
 
 
Figure 5.15. 13C-NMR (126 MHz, CDCl3) spectrum of tert-butyl diazoacetate (5.4) (top) α-2H-tert-
butyl diazoacetate (5.24) (bottom) 
 
(α) 
(α) 
Cα-D 
JC-D 29.9 Hz 
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Following a successful synthesis of cis-(5.18) with a deuterium label at the C-3 
position, we attempted incorporation of a 2H-label at the C-2 position as well, using α-
2H-tert-butyl diazoacetate (5.24). 
 
 
5.7. Asymmetric synthesis of 1-15N-2,3-2H-tert-butyl 3-(4-nitrophenyl)-1-phenyl 
aziridine-2-carboxylate cis-(5.25)  
With 2H-tert-butyl diazoacetate (5.24) in hand, the synthesis of cis-(5.25) was 
attempted, incorporating 2H-labels at both C-3 and C-2 positions as well as 15N-ring 
nitrogen, utilising the same method as described in the synthesis of cis-(5.18). 
Purification by flash chromatography on silica gel afforded cis-(5.25) as a yellow solid 
in 44% yield and 66% e.e. (determined by chiral HPLC) (Scheme 5.9.). 
 
Scheme 5.9. Asymmetric synthesis of cis-(5.25) 
Subsequent 1H-NMR (500 MHz, CDCl3) analysis of cis-(5.25) revealed the 
absence of the aziridine proton signals, that were expected in the δ 3 - 4 ppm range by 
comparison with the non-labelled sample (Figure 5.16.). The 2H-NMR (77 MHz, 
DCM) spectrum of cis-(5.25) displayed broad singlets at δ 3.54 and δ 3.14 ppm 
corresponding to the deuterium atoms installed at C-3 and C-2 positions (> 95% 2H 
incorporation). 
 
Figure 5.16. 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.25) with 2H-NMR (77 MHz, DCM) 
insert 
 
CD2Cl2 
reference 
CDCl3 
reference 
2H-NMR insert 
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As expected, the 13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.25) revealed 
the carbon signals from C-2 and C-3 to be very close to the baseline due to deuterium 
splitting and the effect of relaxation. Unfortunately, due to low intensity, the peaks were 
not resolved and appeared as multiplets at δ 46.4 and 45.7 ppm.  
15N-NMR (51 MHz, CDCl3) spectra of cis-(5.18) and cis-(5.25) correlated well 
with each other (Figure 5.17.). Signals were observed as singlets at δ 66.41 ppm and     
δ 66.22 ppm respectively. 
       
Figure 5.17. 15N-NMR (51 MHz, CDCl3) spectrum of cis-(5.18) (left) and cis-(5.25) (right) 
 
Overall, both cis-(5.18) and cis-(5.25) were obtained successfully following a 
one-pot asymmetric aziridination protocol. Predominantly cis-aziridines were observed 
with little or no trans-. The yields of the aziridination reactions were moderate, 
however, mainly due to problems with purification. Most importantly, isotope 
incorporation levels above 95% were achieved, without any loss of label. Encouraged 
by the results of the aziridination reactions described above, incorporation of 13C-stable 
isotope was attempted. 
 
5.8. Synthesis of α-13C-3-nitrobenzaldehyde (5.29) 
The natural abundance of the NMR active 13C-isotope is 1.1%, with remaining 
98.9% being 12C-isotope, which is NMR inactive. Therefore, NMR sensitivity of the 13C 
nucleus is very low. However, when enriched above natural abundance, the 13C-isotope 
displays a very strong signal, which can provide a valuable information from the 
specific sites of a labelled compound. The chemical shift of the 13C-isotope is sensitive 
to an isotope that is attached to it. Thus, a chemical shift of a 13C–2H or a 13C–18O signal 
appears at a slightly different position from the corresponding 13C–1H or 13C–16O 
signal.184 Coupling with other NMR active nuclei has proved to be a valuable tool in the 
structure elucidation of chemical compounds. At natural abundance the statistical 
chance of having two 13C-nuclei adjacent to each other is too low for the 13C–13C 
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coupling to be observed. However, if enriched, two or more adjacent 13C-nuclei will 
reveal a coupling pattern. If the 13C–13C bond has been broken, the coupling is no longer 
present. 
Hutton et al demonstrated a powerful technique called Triple-Resonance 
Isotope-Edited (TRIED) NMR for studying metabolism.194 TRIED NMR uses through-
bond (scalar) coupling between spins to select NMR signals from molecules having 1H–
13C–15N atom sequence. Natural-abundance background signals from molecules not 
containing such labelled atoms are effectively suppressed, with a suppression ratio of 
approximately 104:1. This filtering allows labelled species to be detected and 
characterised without requiring extensive, time-consuming sample purification. Stark et 
al published a method to selectively detect 1H–13C–13C fragments, that were 
biosynthetically introduced into the active site of  heme  proteins. 195  This method 
utilised nearly identical pulse sequence, described by Hutton et al. The only difference 
was the third atom in a fragment: 13C instead of 15N. The proton connected to 13C–13C 
atoms was pulsed and a transfer of a magnetisation back to the 1H nucleus allowed an 
enhanced proton signal to be observed. 
α-13C-Benzoic acid (99 atom%) (5.26) was chosen as the starting material for 
generating a series of 13C-labelled aldehydes, due to the combination of its price, 
commercial availability and straightforward transformation to the desired α-13C-labelled 
aldehydes. During the first stage of the synthesis, α-13C-benzoic acid (5.26) was 
converted to ethyl α-13C-benzoate (5.27) (Scheme 5.10.). Following the procedure 
reported by Baker and Hey, attempted nitration occurred at the meta-position of the 
aromatic ring, affording ethyl α-13C-3-nitrobenzoate (5.28), because the ester functional 
group is a strongly deactivating substituent and is meta-directing.196 Reduction of the 
ester functional group of ethyl α-13C-3-nitrobenzoate (5.28) using diisobutylaluminium 
hydride (DIBAL-H) resulted in α-13C-3-nitrobenzaldehyde (5.29). 197  DIBAL-H is a 
reducing agent, commonly used for the reduction of esters to aldehydes.198 DIBAL-H 
acts as an “electrophilic” reductant, coordinating a lone pair from the carbonyl oxygen 
(a nucleophile) to the aluminium (electrophile). After hydride transfer, a neutral 
hemiacetal intermediate is formed, that is stable at low temperatures (-78 °C). Aqueous 
workup protonates the hemiacetal, releasing the desired aldehyde as the product. The 
by-products of the reaction are corresponding alcohol and aluminium salts. The 
temperature must be kept below -70 °C to prevent over-reduction of the aldehyde to the 
alcohol. The overall yield of the transformation of (5.26) to (5.29) was 61% over the 
three steps. 
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Scheme 5.10. Synthesis of α-13C-3-nitrobenzaldehyde (5.29) 
 
Within the 1H-NMR (500 MHz, CDCl3) spectrum of (5.29), the formyl proton 
was observed at δ 10.13 ppm as a doublet with a very large coupling constant (JC-H = 
179.1 Hz) (Figure 5.18.). This was attributed to the fact that the sample of (5.29) was 
enriched in 13C-isotope (99 atom%), which is NMR active and therefore splits the 
attached proton into a doublet. An example of 1H–13C coupling was found within the 
literature, reported by Jones et al, who observed coupling constant values for 13C-
labelled benzaldehyde derivatives of ~ 160 Hz magnitude.199 The 13C-NMR (126 MHz, 
CDCl3) analysis of (5.29) afforded a signal from the α-carbon at δ 189.8 ppm as a 
singlet, as the 13C-NMR spectrum was proton decoupled. The intensity of the carbonyl 
signal was greatly enhanced compared to the aromatic non-labelled carbons due to the 
99% enrichment of 13C-isotope.  
         
Figure 5.18. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (126 MHz, CDCl3) spectra of (5.29) 
 
 
 
 
5.9. Asymmetric synthesis of 1-15N-3-13C-tert-butyl 3-(3-nitrophenyl)-1-phenyl 
aziridine-2-carboxylate cis-(5.31) and 1-15N-2-2H-3-13C-tert-butyl 3-(3-nitrophenyl)-
1-phenylaziridine-2-carboxylate cis-(5.32) 
 
Employing the asymmetric aziridination protocol discussed previously, α-13C-3-
nitrobenzaldehyde (5.29) was mixed with 15N-aniline (5.16), generating corresponding 
15N-aryl α-13C-imine (5.30) intermediate, that was reacted with the corresponding tert-
butyl diazoacetates (5.4) and (5.24) affording aziridines cis-(5.31) and cis-(5.32) 
(Scheme 5.11.). 
JC-H 179.1 Hz 
 
 
 CDCl3   
 solvent   
  peak 
 CDCl3   
 solvent   
  peak 
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Scheme 5.11. Synthesis of cis-(5.31) and cis-(5.32) 
Analysing the 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.31), it was noted 
that the proton at the C-3 position at δ 3.59 ppm was split by both the 13C-labelled 
carbon and the neighbouring proton at the C-2 carbon (dd, J13C-H = 169.0 Hz;  J2,3 = 6.7 
Hz) (Table 5.4.). The proton at the C-2 carbon at δ 3.17 ppm was split by the 15N, 13C 
and the proton at the C-3 position (ddd, J2,3 = 6.7 Hz; 
2J13C-H = 2.5 Hz; JN-H = 0.7 Hz). 
Within the 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.32), no signal was observed 
from the proton at the C-2 carbon, as it had been replaced with a deuterium atom           
(> 95% 2H incorporation). The absence of the C-2 proton affected the splitting pattern 
of the C-3 proton, which was observed as a doublet (J13C-H = 169.0 Hz), due to the 
splitting by the 13C-nucleus.    
Both aziridines had 13C-labelled C-3 carbon, therefore the signal was greatly 
enhanced, suppressing the rest of the spectrum. The 13C-NMR (126 MHz, CDCl3) 
spectrum of cis-(5.31) revealed the C-3 carbon at δ 45.9 ppm as a doublet due to 15N 
splitting (J13C-N = 7.0 Hz). Similar splitting was observed within the 
15N-NMR (51 MHz, 
CDCl3) spectrum of cis-(5.31), where 
15N signal was observed at δ 66.15 ppm as a 
doublet due to 13C splitting (J13C-N = 6.8 Hz). Nearly identical results were observed 
within the 13C-NMR (126 MHz, CDCl3) and the 
15N-NMR (51 MHz, CDCl3) spectra of       
cis-(5.32). The C-3 carbon was identified at δ 45.7 ppm as a doublet (J13C-N = 7.0 Hz) 
and the 15N signal was observed at δ 65.98 ppm as a doublet (J13C-N = 6.8 Hz). 
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1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.31) 
 
1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.32) 
 
13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.31) 
 
13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.32) 
 
15N-NMR (51 MHz, CDCl3) spectrum of cis-(5.31) 
 
15N-NMR (51 MHz, CDCl3) spectrum of cis-(5.32) 
Table 5.4. Comparison of the 1H-, 13C- and 15N-NMR data between cis-(5.31) and cis-(5.32) 
 
Results obtained above demonstrate that, if enriched, 13C-isotope can be used as 
an excellent NMR probe. The appearance of strongly enhanced 13C-resonances permits 
assignment of the labelled positions. Additionally, coupling to other NMR active nuclei 
results in specific splitting patterns with unique coupling constants that can be used to 
gather information about a molecule as a whole or its fragments. 
 
5.10. Synthesis of 15N-2,4-dimethoxyaniline (5.35)  
In order to obtain the desired NH-amino acid derivatives from the optically 
active aziridines synthesised, the nitrogen atom must contain a cleavable protecting 
J2,3 6.7 Hz 
JC-H 2.5 Hz 
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group. A search within the literature revealed a publication by Mayer et al, who 
demonstrated a deprotection of the N-para-methoxyphenyl (PMP) aziridine, using a 
readily available oxidant: ammonium cerium(IV) nitrate (CAN).200 Two equivalents of 
CAN cleaved the N-PMP group under mild conditions affording the corresponding NH-
aziridine in a 82% yield. 
Structurally, apart from an additional methoxy group at the 2-position, 2,4-
dimethoxyphenyl is identical to PMP. Thus, we considered 2,4-dimethoxy phenyl to be 
a suitable nitrogen protecting group, that can be introduced in the form of 2,4-
dimethoxyaniline. 
15N-2,4-dimethoxyaniline (5.35) was synthesised in two steps from 
commercially available 1,3-dimethoxybenzene (5.33) (Scheme 5.12.).  
 
Scheme 5.12. Synthesis of 15N-2,4-dimethoxyaniline (5.35) 
 
The procedure reported by Iskra et al was utilised to achieve a selective and 
efficient aerobic oxidative iodination of 1,3-dimethoxybenzene (5.33), using molecular 
iodine, air as the terminal oxidant, sodium nitrite as a catalyst and sulfuric acid as an 
activator of the overall catalytic process.201 1-Iodo-2,4-dimethoxybenzene (5.34) was 
afforded as a yellow liquid in a 74% yield after purification by flash chromatography on 
silica gel, eluting with 20% diethyl ether in 40-60 petroleum ether. Exploiting an 
Ullmann coupling, reported by Kim and Chang, 15N-2,4-dimethoxyaniline (5.35) was 
afforded in a 45% yield via a copper(I) iodide catalysed N-arylation of 1-iodo-2,4-
dimethoxybenzene (5.34).202 Ullmann coupling is discussed in more detail on page 93. 
 
5.11. Asymmetric synthesis of 1-15N-3-2H-tert-butyl 1-(2,4-dimethoxy phenyl)-3-(4-
fluorophenyl)aziridine-2-carboxylate cis-(5.37) with cleavable N-2,4-dimethoxy 
phenylprotecting group 
 
Apart from cleavable N-protecting group, an installation of a 19F-nucleus was 
attempted, which is often used as an NMR probe for investigating the interactions of 
biological molecules, due to its NMR characteristics, small size, and near total absence 
from biology.203 Fluorine is often considered as isosteric with hydrogen because the van 
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der Waals radius of fluorine is 1.35 Å, similar to that of hydrogen, 1.2 Å, although a 
C−F bond is actually significantly longer (~ 1.4 Å) than a C−H bond (~ 1.0 Å). 
Nevertheless, fluorine can often replace hydrogen in small molecules with minimal 
effect on their binding to enzymes and proteins. The 19F-nucleus has a spin of ½ and 
exists in 100% natural abundance. Its NMR properties are very close to that of proton 
NMR: the large magnetogyric ratio translates into high sensitivity in NMR spectroscopy 
(83% sensitivity compared to 1H). The chemical shift of 19F-nucleus is very sensitive to 
changes in the local chemical environment. 19F-chemical shift has a range of ~ 400 ppm, 
whereas 1H chemical shift covers only ~ 15 ppm. Therefore, a wide range of changes 
affecting the local environment of a peptide or protein can be detected using simple 19F-
NMR techniques by incorporating suitably labelled residues at appropriate positions 
within the protein. Protein conformational changes, ligand binding, interactions with 
other proteins, nucleic acids or lipid membranes, solvent isotope effects can be detected 
via 19F-NMR chemical shift changes. 
With 15N-2,4-dimethoxyaniline (5.35) prepared, a synthesis of cis-(5.37) was 
attempted, following the aziridination protocol developed previously, via the 
intermediate (5.36) starting from 2H-formyl 4-fluorobenzaldehyde (5.13)  (Scheme 
5.13.). Purification by flash chromatography on silica gel afforded cis-(5.37) as a dark 
orange solid in 48% yield and 61% e.e. 
 
Scheme 5.13. Asymmetric synthesis of cis-(5.37) 
Subsequent 1H-NMR (500 MHz, CDCl3) analysis of cis-(5.37) revealed the 
absence of the signal from the proton at the C-3 position, because it had been replaced 
with deuterium (> 95% 2H incorporation) (Figure 5.19.). Signal from the proton at the 
C-2 position was observed at δ 2.91 ppm as a singlet, due to the absence of the 
neighbouring proton at the C-3 position. 
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Figure 5.19. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (126 MHz, CDCl3) spectra of cis-(5.37) 
 
Because the 13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.37) was not 
19F 
decoupled, fluorine-carbon couplings were observed. The para-carbon, with the fluorine 
atom directly attached to it, was observed at δ 162.4 ppm as a doublet with a large 
splitting constant 1JC-F = 245.2 Hz. The meta-carbon was observed at δ 114.7 ppm (d, 
2JC-F = 21.5 Hz). The ortho-carbon was observed at δ 129.8 ppm as a doublet of 
doublets as it was split by both 19F and 15N nuclei (3JC-F = 8.1, 
3JC-N = 1.7 Hz). The ipso-
carbon was observed at δ 131.2 ppm (dd, 4JC-F = 3.9, 2JC-N = 3.2 Hz), displaying four 
bond carbon-fluorine coupling and two bond carbon-15N coupling. The data matched 
favourably to the studies of Lichter and Wasylishen, who recorded the JC-F coupling 
constants of fluorobenzene to be 245 (1J), 21 (2J), 8 (3J), and 3 (4J) Hz.204 Carbonyl 
carbon was observed as a doublet at δ 167.4  (2JC-N = 4.6 Hz). The signal at δ 46.7 ppm 
(d, 1JC-N = 7.0 Hz) was assigned to the carbon on the C-2 position. Unfortunately, the 
carbon on the C-3 position was not observed, possibly due to the low concentration of 
the sample and insufficient number of the scans. The remaining signals were recorded at 
δ 153.1 ppm (d, 2JC-N = 2.6 Hz), 135.0 ppm (d, 1JC-N = 3.0 Hz) and 119.8 ppm (d, 3JC-N 
= 1.8 Hz) and assigned to the carbons from the dimethoxyphenyl aromatic ring. 19F 
NMR (471 MHz, CDCl3) spectrum of cis-(5.37) displayed a strong singlet at δ -115.24 
ppm. 
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5.12. Synthesis of α-13C-3-azidobenzaldehyde (5.40) 
Organic azides possess diverse chemical reactivities.205  They undergo [3+2] 
cycloaddition with unsaturated bonds, such as those in alkynes and alkenes as well as 
carbonitriles to afford triazoles, triazolines and tetrazoles respectively. Organic azides 
can also be regarded as nitrene equivalents, that are capable of forming a new bond with 
the internal azido nitrogen and releasing molecular nitrogen as a leaving group. The 
azido group can also be used as a protecting group for primary amines in metathesis 
reactions, because primary amines displace the phosphine ligands in the first and second 
generation Grubbs catalysts.206 
Due to high versatility of the azido functional group, a synthesis of α-13C-3-
azidobenzaldehyde (5.40) was attempted starting from ethyl α-13C-3-nitrobenzoate 
(5.28), with the desired product achieved in 71% overall yield over three steps (Scheme 
5.14.). 
Scheme 5.14. Synthesis of α-13C-3-azidobenzaldehyde (5.40) 
Following the procedure reported by Try et al, ethyl α-13C-3-nitrobenzoate 
(5.28) was converted to the corresponding ethyl α-13C-3-aminobenzoate (5.38) via nitro 
group reduction.207 Employing the conditions reported by Yao et al, the amine group 
was subjected to a nitrosation reaction using the nitrosyl cation (+NO) (5.41), which was 
generated in situ from nitrous acid (HNO2) (Scheme 5.15.).
208  The diazonium 
intermediate (5.42) was reacted with sodium azide, affording ethyl α-13C-3-
azidobenzoate (5.39).209 In the final step, the ester group of ethyl α-13C-3-azidobenzoate 
(5.39) was reduced with DIBAL-H (see synthesis of (5.29), page 67-68) affording α-
13C-3-azidobenzaldehyde (5.40). 
 
Scheme 5.15. Proposed mechanism of the nitrosation of the primary amine (5.38) and subsequent 
conversion to azide derivative (5.39) 
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Subsequent 1H-NMR (500 MHz, CDCl3) analysis of (5.40) revealed the proton 
at the α-carbon at δ 9.99 ppm to be a doublet with the coupling constant of 176.2 Hz 
(Figure 5.20.), similar to that of α-13C-3-nitrobenzaldehyde (5.29), which displayed the 
proton at the α-carbon at δ 10.13 ppm (d, J13C-H = 179.1 Hz) (see Figure 5.18., page 68).   
 
Figure 5.20. 1H-NMR (500 MHz, CDCl3) spectrum of (5.40) 
The presence of the azide group was indicated by the FT-IR analysis with a 
strong peak at 2114 cm-1. The HRMS analysis provided a final confirmation of the 
synthesis of (5.40) with [M+H]+ ions found at the required m/z (found: 149.0535, 
requires: 149.0539). Synthesis of (5.40) allowed us to generate compounds such as 
chiral non-racemic aziridine cis-(5.52) and β-bromo-α-amino ester (5.68), suitable for 
further transformations such as "click" reaction or Staudinger reduction.210  
5.13. Synthesis of α-13C,2H-3-nitrobenzaldehyde (5.44) 
It has been discussed previously that a chemical shift of a 13C-isotope is 
sensitive to an isotope that is attached to it. To explore this property, and with α-13C-3-
nitrobenzaldehyde (5.29) already generated, we attempted a synthesis of α-13C,2H-3-
nitrobenzaldehyde (5.44) with a deuteron instead of a proton directly attached to a 13C-
nucleus. 
α-13C,2H-3-nitrobenzaldehyde (5.44) was synthesised in two steps from ethyl α-
13C-3-nitrobenzoate (5.28) (Scheme 5.16.). The first step involved a reduction of 13C-3-
nitrobenzoate (5.28) with lithium aluminium deuteride, affording α-di-2H,13C-3-
nitrobenzyl alcohol (5.43). Subsequent oxidation of this alcohol with pyridinium 
chlorochromate afforded α-13C,2H-3-nitrobenzaldehyde (5.44) in a 83% overall yield. 
The experimental procedure utilised was originally reported by Goss et al, who 
synthesised a α-2H-labelled benzaldehyde from ethyl benzoate in a 80% overall yield.211  
JC-H 176.2 Hz 
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Scheme 5.16. Synthesis of α-13C,2H-3-nitrobenzaldehyde (5.44) 
Within the 1H-NMR (500 MHz, CDCl3) spectrum of α-2H,13C-3-
nitrobenzaldehyde (5.44) no signal for the formyl proton was observed, as it had been 
replaced with deuterium (> 95% 2H incorporation) (Figure 5.21.). The 2H-NMR (77 
MHz, CDCl3) spectrum of (5.44) displayed the deuterium signal at δ 10.09 ppm as a 
doublet (J13C-D = 27.5 Hz), due to the splitting by the NMR active 
13C-nucleus. 
 
 
Figure 5.21. 1H-NMR (500 MHz, CDCl3) spectrum of (5.44) with 2H-NMR (77 MHz, DCM)  insert 
13C-NMR (126 MHz, CDCl3) analysis of (5.44) afforded a signal from the α-
carbon at δ 189.5 ppm as a triplet (J13C-D = 27.4 Hz), due to 2H–13C coupling (Figure 
5.22.). The effect of deuteration was also observed in the intensity of the peak, which 
was not as enhanced as the peak in the proteo-equivalent compound: α-13C-3-
nitrobenzaldehyde (5.29), possessing a carbonyl peak at 189.8 ppm (see page 68). The 
chemical shift difference was attributed to the sensitivity of a 13C-nucleus to a directly 
attached isotope, known as an isotope shift effect. 
 
 
Figure 5.22. 13C-NMR (126 MHz, CDCl3) spectrum of (5.44) 
JC-D 27.5 Hz 
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5.14. Synthesis of 1-15N-3-13C,2H-tert-butyl 1-(2,4-dimethoxyphenyl)-3-(3-nitro 
phenyl)aziridine-2-carboxylate cis-(5.46)  
 
With α-2H,13C-3-nitrobenzaldehyde (5.44) prepared, a synthesis of cis-(5.46) 
was attempted, following the asymmetric aziridination protocol developed earlier via 
the intermediate (5.45) (Scheme 5.17.). Purification by flash chromatography on silica 
gel, afforded cis-(5.46) as a yellow oil in a 53% yield and 82% e.e. 
 
Scheme 5.17. Asymmetric synthesis of cis-(5.46) 
Analysing the 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.46), it was noted 
that the proton at the C-2 carbon at δ 3.02 ppm was split by the 13C-nucleus, which 
resulted in a doublet (2J13C-H = 2.1 Hz) (Figure 5.23.). Similar coupling was observed in 
the compound cis-(5.31). 
 
Figure 5.23. 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.46) 
The 13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.46) displayed a signal from 
the α-carbon at δ 46.4 ppm as a triplet of doublets (J13C-D = 25.5 Hz, J13C-N = 7.0 Hz), as 
it has been split not only by the 2H-nucleus [as observed in the starting material (5.44)], 
but also by 15N (Figure 5.24.). The peak possessed low intensity and was not fully 
resolved due to the effect of the deuteration. 
JC-H 2.1 Hz 
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Figure 5.24. 13C-NMR (126 MHz, CDCl3) spectrum of cis-(5.46) 
 
5.15. Summary table of enantiomerically enriched N-aryl aziridine-2-carboxylates 
labelled with stable isotopes 
 
   
   
   
   
Table 5.5. Chiral non-racemic aziridine library 
 
To summarise, during the course of this project a library of novel optically active 
aziridines has been generated (Table 5.5.). The aziridines were generated in 44 - 67% 
yield, 61 - 87% e.e. and were 2H, 15N and/or 13C isotopically enriched. It was 
established that incorporation of stable isotopic labels led to increased reaction time, 
which could be attributed to the time required to break a stronger, isotopically 
JC-D 25.5 Hz 
JC-N 7.0 Hz 
 
 
 
 CDCl3   
 solvent   
  peak 
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substituted bond, thus suggesting that the rate determining step is the addition of a 
diazoacetate derivative to an 15N-labelled imine. Additionally, the energy difference 
between light and heavy atoms influences the approach of the diazoacetate derivative to 
an imine, which is reflected in the decreasing e.e. trend observed, thus making C-C 
bond formation a step where the stereochemistry is set. Furthermore, we wanted to 
investigate if any subsequent transformations of isotopically labelled aziridines such as 
ring-opening, N-terminus deprotection would result in a loss of label, decrease of e.e., 
lack of reactivity. 
 
5.16. Oxidative cleavage of N-2,4-dimethoxyphenyl protecting group from 1-15N-
2,3-2H-tert-butyl 3-(4-bromophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-
carboxylate cis-(5.46)  
 
As discussed previously, a literature search afforded a publication by Mayer et 
al, who demonstrated a deprotection of the N-PMP group, using CAN, affording the 
corresponding NH-aziridine in a 82% yield (see page 71). Following this procedure we 
were able to demonstrate that N-2,4-dimethoxyphenyl group can be removed from cis-
(5.51) under oxidative conditions, using CAN (Scheme 5.18.). Gratifyingly, cis-(5.53) 
was obtained in 58% yield and 82% enantiomeric excess, which confirmed that no 
racemisation occurred during the oxidative deprotection of the N-terminus. 
 
Scheme 5.18. Synthesis of cis-(5.53) 
Investigating a mechanism of the side-chain oxidation of alkylated aromatic 
hydrocarbons with CAN, Baciocchi et al established that the first step of the reaction 
was a formation of a radical cation. 212 Jarrahpour and Zarei reported successful 
deprotection of PMP from the substituted β-lactams using CAN. 213  Their study 
indicated that a successful deprotection occurred only when at least two equivalents of 
CAN were present. By analogy with their results, we proposed a reaction of 1,4-
dimethoxybenzene group of cis-(5.51) with CAN initially afforded a radical cation 
intermediate cis-(5.54), stabilised by electron donating substituents (Scheme 5.19.).214 
An aqueous media was required to promote a successful dissociation of CAN into 
[Ce(NO3)6]
2- and NH4
+, as well as to allow the attack of a water molecule at the para-
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position of cis-(5.54). Second equivalent of CAN promoted a water attack at the ipso-
carbon of 1,4-dimethoxybenzene group. Elimination of methanol from cis-(5.55) and 
subsequent formation of 2-methoxy-1,4-benzoquinone generated tert-butyl 1-15NH-2,3-
2H-3-(4-bromophenyl)aziridine-2-carboxylate cis-(5.53). 
 
Scheme 5.19. Proposed mechanism of 2,4-dimethoxyphenyl group cleavage via CAN 
 
The 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.53) displayed the signals 
from the para-bromophenyl group at δ 7.44 ppm (d, JH-H = 7.9 Hz) and δ 7.22 ppm (d, 
JH-H = 7.9 Hz) and a signal from the tert-butoxy group at δ 1.22 ppm as a singlet 
(Figure 5.25.). Compared to the 1H-NMR spectrum of starting material cis-(5.51) which 
displayed aromatic protons from the bromo-phenyl substituent at δ 7.49 - 7.38  ppm as a 
multiplet, a clear difference in chemical shift and a splitting pattern was observed. 
Additionally it was confirmed that the oxidative deprotection did not affect 
neither e.e., which remained at 82% (determined by chiral HPLC), nor the deuterium 
incorporation level, which remained above 95% (determined from the non-labelled 
sample). 
 
 
Figure 5.25. 1H-NMR (500 MHz, CDCl3) spectrum of cis-(5.53) with 2H-NMR (77 MHz, DCM) insert 
5.17. Ring opening of N-aryl aziridines with magnesium bromide diethyl etherate 
Molinaro et al reported an enantio- and diastereoselective route to novel non-
symmetrically substituted N-protected β,β-diaryl-α-amino esters (5.59), through the 
CD2Cl2 
reference 
2H-NMR insert 
CDCl3 
reference 
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asymmetric hydrogenation of tetrasubstituted olefins (5.58) (Scheme 5.20). 215  The 
corresponding β-bromo-β-substituted dehydroamino esters (5.57) were prepared in 88% 
yield as a 1.5:1 mixture of E-and Z-isomers. The isomers were separable by flash 
chromatography and were individually coupled under Suzuki-Miyaura conditions with 
commercially available arylboronic acids. A catalytic complex of Pd(OAc)2 and 
DavePhos provided alkenes (5.58) in 45-89% yields. The reaction conditions used 
bis(norbornadiene)rhodium(I) tetrafluoroborate [Rh(NBD)2BF4] and (S,RP)- or (R,SP)-
Josiphos ligands and allowed outstanding control over the two vicinal stereogenic 
centers providing excellent enantioselectivities (88-99%) during the synthesis of (5.59). 
 
Scheme 5.20. Synthesis of N-protected β,β-diaryl-α-amino esters (5.59) by Molinaro et al 
 
The β,β-diarylalanine structural motif is an important pharmacophore in molecular 
agents that target many diseases, including atherosclerosis, cancer, diabetes, HIV and 
thrombosis (Figure 5.26). Fex et al synthesised a set of compounds such as (5.60) 
designed to bind to thrombin, a serine protease that is critically involved in blood 
coagulation by converting soluble fibrinogen into insoluble fibrin.216 Additionally, this 
structural class appears in synthetic intermediates in natural product synthesis such as 
the intermediate of podophyllotoxin (5.61).217  
 
Figure 5.26. Bioactive compounds with β,β-diaryl-α-amino acid motif 
 
Employing the procedure reported by Righi et al (see Scheme 2.22, page 22), 
we wanted to ring-open our optically active labelled aziridines in order to generate 
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corresponding β-bromo-α-amino esters, that are suitable for cross-coupling reactions, 
ultimately affording optically active β,β-diarylalanine derivatives, labelled with stable 
isotopes.  
To test this methodology, racemic non-labelled aziridines were subjected to the 
ring-opening with magnesium bromide diethyl etherate (Table 5.6.). Gratifyingly, the 
ring-opened products were generated in 61 - 80% yield, were easily purified by flash 
column chromatography on silica gel and were reasonably stable (no decomposition 
was observed after being left at room temperature for more than two months).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.6. Generated library of racemic aziridines ring-opened with magnesium bromide 
 
Subsequent publications by the group of Righi included ring opening of 
epoxides using metal halides and elucidation of the ring-opening chelation control 
mechanism.218,219,220 Based on the mechanism, it was proposed that the magnesium 
metal coordinates to the nitrogen of the aziridine and one of the oxygens of the carbonyl 
group (Scheme 5.21.). This blocks the approach of the bromine nucleophile to the C-2 
position and ring-opens the aziridines at the C-3, affording β-bromo-α-amino acid 
derivatives. 
 
Scheme 5.21. Proposed mechanism of aziridine ring-opening under MgBr2 chelation control by 
Righi et al 
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At this point it was still unconfirmed whether the bromine atom occupied β-
position affording the desired α-amino acid derivatives (5.62) - (5.67) or ring-opened 
aziridines at the C-2, yielding α-bromo-β-amino acid precursors. To establish the 
configuration of the ring-opened compounds, it was desired to obtain a crystal suitable 
for an x-ray analysis. After much experimentation, a further confirmation of the 
bromine atom at the β-position was achieved via single-crystal structure analysis 
(Figure 5.27.). A successful crystallisation of (5.63) was achieved from pentane/diethyl 
ether (2:1), with the crystal obtained as a colourless cube. The X-ray crystal structure 
confirmed the formation of the desired β-bromo-α-amino acid derivative. 
 
Figure 5.27. Oak Ridge Thermal Ellipsoid Plot (ORTEP) representation of the X-ray crystal 
structure of (5.63) 
 
Encouraged by these results, we performed a ring-opening of chiral non-racemic 
aziridine cis-(5.52), investigating any possible negative impacts such as loss of e.e., 
label scrambling or loss. Following the procedure described above, cis-(5.52), which 
had 72% e.e. determined, was subjected to the ring opening with the magnesium 
bromide diethyl etherate (Scheme 5.22.). Purification by flash chromatography on silica 
gel afforded (5.68) in 83% yield and 70% e.e., which confirmed that the product did not 
fully racemise during the ring-opening step. A slight e.e. loss from 72% to 70% might 
be attributed to a very minor racemisation or an experimental error. 
 
Scheme 5.22. Synthesis of (5.68) via the ring-opening of cis-(5.52) 
Analysing the 1H-NMR (500 MHz, CDCl3) spectrum of (5.68), it was noted that 
the proton at the β-carbon at δ 5.32 ppm was split into a double of doublets (Figure 
5.28.). It was split by the 13C-nucleus, which resulted in a coupling constant, JC-H to be 
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153.8 Hz. It was also split by a proton on the 15N-atom, and the coupling constant was 
recorded as 3.2 Hz. 
 
Figure 5.28. 1H-NMR (500 MHz, CDCl3) spectrum of (5.68) with 2H-NMR (77 MHz, DCM) insert 
Analysing the starting material of the above reaction, aziridine cis-(5.52), it was 
noticed that one bond 13C–15N coupling constant was recorded to be ~ 7.0 Hz 
magnitude. After the ring-opening of cis-(5.52) and purification of the product (5.68), 
13C-NMR (126 MHz, CDCl3) and 
15N-NMR (51 MHz, CDCl3) spectra displayed the 
13C–15N coupling constant to be ~ 2.0 Hz (Figure 5.29.). A decrease of the magnitude 
suggests that 13C and 15N atoms are no longer bonded together and are separated by at 
least one atom. Conclusively, it was proposed that the ring opening resulted in the β-
bromo-α-amino ester derivative (5.68). 
           
Figure 5.29. 13C-NMR (126 MHz, CDCl3) (left) and 15N-NMR (51 MHz, CDCl3) (right) spectra of 
(5.68) 
 
The presence of the azide group was indicated by the FT-IR analysis with a 
strong peak at 2113 cm-1. The HRMS analysis provided a final confirmation of the 
synthesis of (5.68) with [M+H]+ ions found at the required m/z (found: 480.1187, 
required: 480.1199). 
Although no cross-coupling reactions have been attempted and will be the 
subject of future investigations, optically active β-bromo-α-amino esters, labelled with 
<= CDCl3       
CD2Cl2 => 
2H-NMR insert 
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stable isotopes can provide a direct route towards corresponding β,β-diarylalanine 
derivatives. 
5.18. Triple-Resonance Isotope-Edited (TRIED) NMR1 
With several compounds possessing the desired atom sequence for TRIED NMR 
analysis, we wanted to apply this method to achieve a signal enhancement. Recently, 
Sando et al demonstrated that in situ analysis of 8-13C-7-15N-theophylline (5.69) was 
achieved using a TRIED NMR experiment, which utilises through-bond (scalar) 
coupling between three NMR-active nuclei with different frequencies (Figure 5.30.).221 
Theophylline is a pharmaceutical agent for treatment of respiratory diseases, such as 
chronic obstructive pulmonary disease and asthma. 222  The conventional 1H-NMR 
spectrum of a 200 µM sample of [8-13C-7-15N]-theophylline (5.69) in D2O, containing 
excess amino acids (42.875 mM), displayed a barely visible proton signal in the 
sequence 1H–13C–15N, due to strong background signals derived from the amino acids. 
However, when performing a 1H–{13C–15N} TRIED NMR experiment, an enhanced 
singlet was observed around 8.0 ppm corresponding to proton connected to the 13C–15N 
atom sequence. This result suggests a high selectivity of the double-labelled probe 
under the triple resonance NMR conditions and allows a detection of the labelled 
compound in a crude biological sample. Most importantly, the labelled theophylline 
displayed identical biological properties of the non-labelled analogue, allowing the 
investigation towards its behaviour as a pharmaceutical agent. 
 
 
Figure 5.30. Conventional 1H-NMR (top) and 1H–{13C–15N} triple resonance NMR (bottom) spectra 
of [8-13C-7-15N]-labelled theophylline (5.69) (200 µM) in D2O containing excess amino acids (42.875 
mM) recorded by Sando et al 
 
 
                                                          
1 All TRIED data collection and processing for compounds cis-(5.31) and (±)-cis-(5.64) carried 
out by Dr Colin Macdonald, UEA, Norwich, UK 
1H-NMR 
 
1H–{13C–15N}-NMR 
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With a previously synthesised aziridine cis-(5.31) having desired atom sequence, 
it was decided to apply the TRIED analysis to determine if it can be used as a probe for 
the pharmacokinetic analysis (Figure 5.31.). The conventional 1H-NMR spectrum of 
cis-(5.31) revealed a signal (doublet, J2,3 6.7 Hz; J13C-H 169.0 Hz) at δ 3.59 ppm 
corresponding to the proton in the 1H–13C–15N sequence. The intensity was recorded as 
~ 500 units (2.9 mM in CDCl3). Performing the 
1H–{13C–15N} triple resonance NMR 
experiment, a single peak was observed at δ 3.64 ppm, which corresponded to the 
proton at the C-3 position, connected to the 13C–15N atom sequence. The intensity of the 
peak was recorded to be ~ 250000 units (2.9 mM concentration in CDCl3), which was 
500 times higher than the intensity of the proton peak in the conventional 1H-NMR 
spectrum. This result confirmed that the signal of the proton in the 1H–13C–15N 
sequence was greatly enhanced, while the rest of the signals were suppressed.  
 
 
Figure 5.31. Conventional 1H-NMR (top) and 1H–{13C–15N} triple resonance NMR (bottom) spectra 
of cis-(5.31) (2.9 mM) in CDCl3 
 
 
After successful testing of the 1H–{13C–15N} triple resonance technique, it was 
hypothesised that 2H–{13C–15N}experiment would enhance a deuterium signal. After 
much experimentation a successful result was obtained using compound (±)-cis-(5.64).  
The conventional 2H-NMR spectrum of (±)-cis-(5.64) revealed a signal (doublet, 
JC-D 25.1 Hz) at δ 3.47 ppm, which was assigned to the deuterium atom in the 2H–13C–
15N sequence (Figure 5.32.). The intensity was recorded to be ~ 7 units (3.3 mM in 
1H-NMR 
 
1H–{13C–15N} -NMR 
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CH2Cl2). Analysing the 
2H–{13C–15N} triple resonance NMR experiment, a single peak 
was observed at δ 3.47 ppm. This signal was assigned to the deuterium atom at the C-3 
position, which was connected to the 13C–15N atom sequence. The intensity of the peak 
was recorded to be ~ 350 units (3.3 mM in CH2Cl2), which was 50 times higher than the 
intensity of the deuterium peak in the conventional 2H-NMR spectrum. 
 
 
Figure 5.32. Conventional 2H-NMR (top) and 2H–{13C–15N} triple resonance NMR (bottom) spectra 
of (±)-cis-(5.64) (3.3 mM) in CH2Cl2 
 
Although, the enhancement of the deuterium signal had 10 fold decrease in 
magnitude compared the proton signal enhancement, it was demonstrated that 
deuterium could act as a probe for selective NMR detection by triple resonance analysis. 
Attaching a proton or deuteron to the 13C–15N sequence greatly improves the signal of 
the pulsed atom: proton - up to 500 times and deuteron - up to 50 times.  
In conclusion the TRIED NMR technique discussed above provides a powerful 
approach for a detection of organic molecules containing 1H–13C–15N atom sequence 
and their analysis without any purification. With H–C–N atom sequence being very 
common in amino acids, TRIED NMR technique can be used as a tool in protein 
characterisation. Within this chapter, only proton and deuterium enhancement has been 
explored so far, with plenty of other potential candidate molecules to be investigated in 
the future. It well may be the case that other NMR active nuclei can provide even better 
signal enhancement. 
 
 
 
2H-NMR 
 
2H–{13C–15N} -NMR 
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5.19. Chapter conclusion 
Aziridines are extensively used as ‘core’ heterocycle building blocks that can be 
readily transformed into a plethora of alternative entities: α- and β-amino acids, 
diamines, oxazolidinones, etc. Within this chapter we reported a multi-component, 
asymmetric Brønsted acid organocatalytic method that mediated  incorporation of stable 
isotopes  (2H, 13C, 15N) into structure and function diverse optically active aziridines. 
The levels of isotope incorporation were recorded above 95%, with no evidence of 
isotope scrambling and aziridines were generated with good levels of diastereo and 
enantioselectivity (up to 87% e.e.). Our isotope incorporating methodology will be of 
significant utility in academia, medicinal, pharmaceutical, agrochemical and biological 
industries. 
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Chapter 6. Synthetic efforts towards a model fragment of teicoplanin 
glycopeptide antibiotic 
6.1. Introduction 
Glycopeptide antibiotics form a crucial part of human defence against the deadly 
threat of bacterial infections.223 The emergence of antibiotic resistant bacteria requires 
the discovery of new compounds or the modification of existing antibiotics, that would 
be more potent. For these processes to be successful it is crucial to study antibacterial 
drugs more rigorously and to develop new methodologies that can afford target 
structures more efficiently.  
First total synthesis of teicoplanin aglycon was reported by Boger et al, who 
utilised an introduction of the E-F-O-G ring system onto the preformed A-B-C-D ring 
system (Scheme 6.1.).224 A special attraction of this approach was the recognition of the 
common A-B-C-D ring system of vancomycin (3.1) and teicoplanin (3.2) and its 
utilisation as a key synthetic intermediate providing access to both classes of natural 
products. Because of concerns over the C2
3 centre epimerisation observed within the F 
ring system, Boger et al chosen to form the F-O-G biaryl ether by an intermolecular 
aromatic nucleophilic substitution reaction using acyclic substrates which are incapable 
of epimerisation. 225  Thus, both the F ring and G ring amino acid precursors were 
utilised as the reduced α-arylglycinols (6.1) and (6.2) to avoid α-centre racemisation 
during the synthesis and oxidised to the corresponding carboxylic acids immediately 
prior to use in an amide coupling. Oxidation step proceeded exceptionally well, as the 
reaction conditions had been established by the group during the synthesis of 
vancomycin.226After the successful coupling of the F and G ring derivatives, affording 
biaryl ether (6.3), the nitro group on the G ring was converted to the methoxy group in 
76% total yield over two steps, affording (6.4).227  After removal of trifluoroacetate 
protecting group from the F ring, resulting in (6.5), amide coupling with the E ring 
derivative (6.6) was attempted. Oxidation of the primary alcohol on the G ring of (6.7) 
to the carboxylic acid derivative (6.8) and trimethylsilylethoxycarbonyl (Teoc) N-
protecting group deprotection afforded (6.9). Subsequent amide coupling with amine 
functionality of the E ring furnished E-F-O-G fragment (6.10). NOE experiments 
confirmed the fragment had correct space orientation identical to that found in 
teicoplanin (3.2). 
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Scheme 6.1. Synthesis of E-F-O-G fragment (6.10) of teicoplanin (3.2) by Boger et al 
 
This chapter outlines our synthetic route towards the synthesis of E-F-O-G 
model fragment (6.17) of teicoplanin (3.2) employing aziridination methodology 
developed within the Bew group (Scheme 6.2.). We wanted to construct the F-O-G 
fragment (blue) of teicoplanin (3.2) and append it to the E ring (red) via an aziridination 
reaction. The C-3 ring opening of the aziridine with various nucleophiles (X) would 
afford teicoplanin derivatives (6.17) with a modified benzylic carbon at the E ring. 
Initiating this process, we proposed a strategy to construct the F-O-G fragment via an 
Ullmann ether synthesis, that employed commercially available inexpensive starting 
materials such as 3-hydroxybenzaldehyde (6.11) and 3-bromobenzaldehyde (6.23). As 
this method might suffer from poor yield and harsh conditions (100 - 300 °C, 
stoichiometric copper catalyst), which are detrimental for compounds containing 
delicate functionalities and sensitive stereocenters, we opted to perform the biaryl ether 
coupling at the first stage of the synthesis.228 A key reaction was the installation of a 
chiral non-racemic centre creating optically active α-amino-β-alcohol derivative from 
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aldehyde (6.12) via the asymmetric aminohydroxylation (AA) reaction developed by 
Sharpless et al. Subsequent oxidation of an alcohol functional group was anticipated to 
afford the corresponding α-amino acid (6.13), which was hoped to be converted into the 
diazoacetamide derivative (6.14). Reaction between a suitable imine and the 
diazoacetamide derivative (6.14) was expected to afford a key fragment (6.15), which 
could be subjected to an aziridine ring-opening.  
 
 
 
Scheme 6.2. Retrosynthetic route towards the model fragment (6.17) of teicoplanin (3.2) 
Although not discussed within this thesis and will be a subject of future 
investigations, a nucleophilic C-3 ring-opening of (6.15) would afford a library of 
precursors (6.16) to teicoplanin derivatives. Removal of the protecting group (R') would 
allow the installation of the second α-amino acid subunit on the biaryl ether and 
subsequently furnish the model fragment (6.17) via an amide coupling. 
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6.2. Synthesis of 3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenol (6.19) 
Prior to the Ullmann biaryl ether coupling, commercially available                      
3-hydroxybenzaldehyde (6.11) was converted into the corresponding 1,3-dioxolane 
(6.19). Acetals offer robust protection of a carbonyl functional group against 
nucleophiles such as aqueous and non-aqueous bases, organometallic reagents or 
hydride reduction. However acetals can be cleaved using aqueous acid in wet solvents 
or when strong oxidizing agents are present.229 Cyclic acetals are generally more stable 
towards hydrolysis compared to acyclic acetals. Additionally, more substituted cyclic 
acetals possess additional resistance to nucleophilic attack due to steric hindrance. 
Acyclic acetals are prone to hydrolysis during aqueous reaction work-ups and can be 
challenging to purify using flash column chromatography due to the slightly acidic 
nature of silica gel.230 
Following a procedure reported by Ovaa et al, 3-hydroxybenzaldehyde (6.11) 
was treated with pinacol (6.18) in refluxing toluene with 10 mol% para-toluenesulfonic 
acid as a catalyst (Scheme 6.3.).231  
 
Scheme 6.3. Synthesis and the proposed mechanism of 1,3-dioxolane (6.19) formation 
A Dean-Stark apparatus allowed the continuous removal of water from the 
reaction mixture, driving the equilibrium towards the protected compound. FT-IR 
analysis displayed the absence of the carbonyl group signal at 1672 cm-1, suggesting, 
along with full physicochemical analysis, 3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenol (6.19) had been generated in an excellent 98% yield as a white powder with 
sufficient purity for further synthesis without any chromatographic purification. 
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6.3. Synthesis of 3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenoxy)benzaldehyde 
(6.24) 
 
A search of the literature revealed a number of methods reported for biaryl ether 
synthesis.232 Buchwald and Hartwig reported the palladium(II) acetate catalysed cross 
coupling reaction to afford biaryl ether (6.22) (Scheme 6.4.). 233  The reaction was 
accomplished in the presence of the mild base tripotassium phosphate and a catalytic 
quantity of DPPF ligand. 
 
Scheme 6.4. Synthesis of biaryl ether (6.22), catalysed by palladium(II) acetate 
Buchwald et al reported that a catalytic amount of copper(I) iodide in 
conjunction with 1,10-phenanthroline ligand facilitated carbon-oxygen bond formation 
between aryl bromides or iodides and aromatic or aliphatic alcohols.234 Thus, employing 
the procedure reported by Buchwald et al, 3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenol (6.19) was reacted with 3-bromobenzaldehyde (6.23) (Scheme 6.5.). The 
reaction was catalysed by the copper metal chelated with 1,10-phenanthroline ligand, 
using the reaction conditions outlined in the scheme below. Aqueous work up and flash 
chromatography on silica gel afforded 3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenoxy)benzaldehyde (6.24) as an orange oil in a 67% yield.  
 
Scheme 6.5. Synthesis of biaryl ether (6.24), catalysed by copper(I) iodide (Ullmann coupling) 
A proposed mechanism for biaryl ether (6.24) formation via a copper(I) 
catalysed procedure is outlined below (Scheme 6.6.).235 The catalytic cycle begins with 
the chelation of 1,10-phenanthroline ligand (L) to the copper(I) halide. The complex 
(6.25) subsequently reacts with the phenol derivative (6.19) and undergoes an oxidative 
addition with the aryl halide (6.23), generating a copper(III) adduct. Subsequent 
reductive elimination affords the desired biaryl ether (6.24) and regenerates the original 
copper-ligand catalyst (6.25), which re-enters this catalytic cycle.236 
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Scheme 6.6. Proposed mechanism for the biaryl ether synthesis of (6.24) catalysed by copper(I) 
iodide  
 
In the 1H-NMR (500 MHz, CDCl3) spectrum of (6.24) a singlet was observed at 
δ 9.95 ppm, which was assigned to the proton of the aldehyde functional group (Figure 
6.1.).  Eight aromatic protons were clearly detected in the aromatic region from δ 7.60 
to 6.99 ppm. The proton at the α-carbon of the dioxolane was recorded as a singlet at δ 
5.95 ppm. Mass spectrometry afforded a strong ion at m/z 365.2 [M+K]+, suggesting the 
product (6.24) had been generated. FT-IR analysis displayed a strong carbonyl peak at 
1703 cm-1, confirming the presence of an intact aldehyde functional group.  
 
Figure 6.1. 1H-NMR (500 MHz, CDCl3) spectrum of biaryl ether (6.24) 
 
 
6.4. Synthesis of 4,4,5,5-tetramethyl-2-(3-(3-vinylphenoxy)phenyl)-1,3-dioxolane 
(6.27) 
 
The Wittig reaction is routinely employed in the preparation of an alkene by the 
reaction of an aldehyde or ketone with the phosphonium salt ylide.237  
Following the procedure, originally reported by Osakada et al, 
methyltriphenylphosphonium bromide (6.26) was deprotonated irreversibly with 
sodium hydride and subsequently reacted with the aldehyde derivative (6.24) (Scheme 
6.7.).238 After 30 minutes, TLC analysis indicated a complete absence of the starting 
material. Subsequent flash chromatography on silica gel allowed the isolation of the 
(α) 
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desired product 4,4,5,5-tetramethyl-2-(3-(3-vinylphenoxy)phenyl)-1,3-dioxolane (6.27) 
as a yellow oil in a 95% yield. 
 
Scheme 6.7. Synthesis of styrene derivative (6.27) from the corresponding aromatic aldehyde (6.24) 
(Wittig reaction) 
A proposed mechanism of the styrene formation, proceeds via a four-membered 
oxaphosphetane intermediate (6.28), which is formed after the deprotonated ylid attacks 
the aldehyde (6.24) (Scheme 6.8.). 239  The affinity of phosphorus towards oxygen, 
results in the collapse of oxaphosphetane (6.28), generating triphenylphosphine oxide 
(6.29) and styrene derivative (6.27). The P=O bond is one of the strongest double bonds 
in chemistry with its bond energy of 540 kJ mol–1.240  Thus the Wittig reaction is 
irreversible and is driven forward by the formation of this P=O bond. 
 
Scheme 6.8. Proposed mechanism of the conversion of aldehyde functionality of (6.24) into vinyl 
functionality of (6.27)  
 
 
A complete consumption of the starting material (6.24) was confirmed by FT-IR 
analysis (no carbonyl peak at 1702 cm-1) and 13C-NMR analysis (no carbonyl peak at 
191.7 ppm). Additionally, the 1H-NMR (500 MHz, CDCl3) analysis of (6.27) indicated 
an absence of a formyl proton at 9.95 ppm and a presence of a new signal at δ 6.66 ppm 
(dd, JH-H 17.6, 10.9 Hz), which was assigned to the proton Ha of the vinyl group (Figure 
6.2.). Signals associated with Hb and Hx were observed as doublets at δ 5.71 ppm and δ 
5.25 ppm respectively. Proton-proton coupling constants were recorded as  Ja-b 17.6 Hz 
and Ja-x 10.9 Hz. The data correlated well with the research published by Reynolds et al, 
who performed experiments using substituted styrenes and established relative chemical 
shifts and coupling constants of the vinyl protons.241  
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Figure 6.2. 1H-NMR (500 MHz, CDCl3) spectrum of styrene derivative (6.27) 
 
 
6.5. Synthesis of chiral non-racemic benzyl (R)-(2-hydroxy-1-(3-(3-(4,4,5,5-
tetramethyl-1,3-dioxolan-2-yl)phenoxy)phenyl)ethyl)carbamate (R)-(6.32) 
 
α-Arylglycinols constitute an important class of α-amino-β-alcohols that are 
often found as structural motifs themselves (antitumour agents cyanocycline A and 
ecteinascidin 743) or serve as precursors for other valuable functionalities (α-
arylglycine motif in glycopeptide antibiotics) (Figure 6.3.).242,243 
 
Figure 6.3. α-Arylglycinol motif (highlighted red) in the antitumor agents 
  
Sharpless et al reported the conversion of styrenes to the corresponding (R)- or 
(S)-α-aryl-N-Cbz- or N-Boc-protected α-amino-β-alcohols via the catalytic asymmetric 
aminohydroxylation (AA) reaction on the alkene.101 The mechanism of the AA reaction 
has been closely based on mechanistic studies of its forerunner, the asymmetric 
dihydroxylation (AD) reaction.244 Ligand structure-activity studies have shed light on 
the origin of the enantioselectivity in the AD reaction and demonstrated the importance 
of an enzyme-like binding pocket present in the "dimeric" cinchona alkaloid ligands 
such as phthalazine ligands.245 Sharpless et al demonstrated that the cinchona alkaloid 
backbone is ideally suited for providing high ligand acceleration as well as 
enantioselectivity. 246 The relationship between ligand structure and its activity is 
summarised in Figure 6.4.  
JH-H 17.6 Hz JH-H 10.9 Hz 
JH-H 17.6, 10.9 Hz 
(α) 
 
(β) 
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Figure 6.4. Structure-activity relations of DHQD ligand participating in AD reaction 
 
The investigations have further shown the reaction rates were influenced chiefly 
by the nature of the O9 substituent of the cinchona alkaloid, with certain aromatic 
appendages giving especially large rate accelerations for aromatic olefins.247 Further 
evidence from binding data suggested that a stabilisation of the transition state was due 
to aromatic stacking interactions and a presence of a binding pocket or cleft. Thus, 
nearly perfect match between the phthalazine ligands and aromatic olefins with respect 
to rates and enantioselectivities was explained by an especially good transition-state 
stabilisation resulting from offset-parallel interactions between the aromatic substituent 
of the olefin and the phthalazine floor of the ligand, as well as favourable edge-to-face 
interactions with the "bystander" methoxyquinoline ring (Figure 6.5.). 
 
                            
Figure 6.5. Rationalisation of enantiofacial selectivity of AD reaction 
 
Sharpless et al designed a mnemonic model for predicting the enantiofacial 
selectivity in the AD reaction.248 Based on steric barriers, the "southwest quadrant" is 
relatively open for olefin substituents, which makes it suitable to accommodate flat, 
aromatic substituents or, in their absence, “large” aliphatic groups. An olefin positioned 
according to these constraints is attacked either from the top face (i.e., the β-face), in the 
case of dihydroquinidine (DHQD) derivatives, or from the bottom face (i.e., the α-face), 
in the case of dihydroquinine (DHQ) derived ligands. 
β-face 
α-face 
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Following the AA procedure reported by Sharpless et al, a synthesis of benzyl 
(R)-(2-hydroxy-1-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenoxy)phenyl)ethyl)-
carbamate (R)-(6.32) was attempted (Scheme 6.9.). 
Scheme 6.9. Synthesis of α-amino-β-alcohol (R)-(6.32) via asymmetric aminohydroxylation reaction 
 To generate the desired α-amino-β-alcohol (R)-(6.32), osmium catalyst was 
incorporated into the reaction in the form of potassium osmate dihydrate (6.31), a non-
volatile powder, convenient for handling and storage (Scheme 6.10.). Benzyl carbamate 
was reacted with sodium hydroxide and tert-butyl hypochlorite to afford the carbamate 
salt (6.34), which reacted with osmium(VI) to form an osmium(VIII) complex (6.35). 
Chiral alkaloid ligand hydroquinidine 1,4-phthalazinediyl diether [(DHQD)2PHAL] 
(6.30) was used to introduce an (R)-chiral centre in (R)-(6.32). Sharpless et al 
demonstrated that switching to the hydroquinine based ligand, (DHQ)2PHAL, reversed 
the enantioselectivity to (S). Aqueous work up and flash chromatography on silica gel 
afforded the desired product (R)-(6.32) as a pale yellow oil in a 65% yield and 96% e.e. 
 
Scheme 6.10. Proposed mechanism of the asymmetric aminohydroxylation reaction 
The moderate yield (65%) of the desired product (R)-(6.32) can be explained by 
the formation of the regioisomer, the secondary benzylic alcohol (R)-(6.33), which was 
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also isolated and characterised. Crude 1H-NMR analysis displayed ~ 15% of (R)-(6.33) 
present in the reaction mixture. Sharpless et al reported that the regioselectivity of AA 
reaction depended on the styrene substituents, choice of a chiral ligand, solvent, and a 
ligand-solvent combination. It was also reported that the regioisomers possess several 
characteristic peaks with NMR, therefore can be distinguished. Additionally, oxidation 
of regioisomers affords completely different products: a carboxylic acid or a ketone. 1H-
NMR spectra of α-amino-β-alcohol (R)-(6.32) and β-amino-α-alcohol (R)-(6.33) are 
compared in Figure 6.6. and Figure 6.7. MALDI-TOF analysis afforded a strong ion at 
m/z 514.4 [M+Na]+, suggesting that the product (R)-6.32 had been generated. The 1H-
NMR (500 MHz, CDCl3) spectrum of (R)-(6.32) displayed a characteristic AB system 
of two distorted doublets at δ 5.12 and 5.07 ppm (2JH-H 12.2 Hz), corresponding to the 
two aliphatic protons at the benzyl carbamate group (Figure 6.6.). Two protons on the 
β-carbon appended with the hydroxyl group were observed at δ 3.81 as a multiplet. 
               
Figure 6.6. 1H-NMR (500 MHz, CDCl3) and MALDI-TOF spectra of (R)-(6.32) 
In the 1H-NMR (500 MHz, CDCl3) spectrum of benzylic alcohol (R)-6.33 [the 
minor regioisomer of (R)-6.32], the two aliphatic protons of benzyl carbamate group 
were observed as a singlet at δ 5.11 ppm [compared to two doublets of the AB system in 
the spectrum of (R)-6.32] (Figure 6.7.). Additionally, the two protons on the β-carbon 
were observed as separate multiplets at δ 3.55 ppm and δ 3.29 ppm. 
 
Figure 6.7. 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(6.33) 
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To determine the enantiopurity of (R)-6.32, a chiral HPLC analysis was 
performed. The chiral non-racemic sample was run against the corresponding racemic 
α-amino-β-alcohol derivative (±)-(6.32). Enantiomeric excess was calculated to be 96% 
(Table 6.1.). Although the synthesis of the racemic sample (±)-(6.32) is not discussed 
here, it was prepared via the same AA procedure outlined in the synthesis of (R)-6.32, 
but using a mixture of [(DHQD)2PHAL] and [(DHQ)2PHAL] (1:1) at the 6 mol% total 
loading. 
Compound Chiral HPLC spectrum 
 
 
 
 
Rt = 8.87, 16.76 min 
racemic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rt = 8.85, 17.31 min 
96% e.e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: Phenomenex Lux Cellulose-1 HPLC column, 85% iso-hexane : 15% 
iso-propanol, flow rate: 1 mL / min 
Table 6.1. Chiral HPLC spectra of (±)-(6.32) and (R)-(6.32) 
 
6.6. Synthesis of (R)-2-(((benzyloxy)carbonyl)amino)-2-(3-(3-(4,4,5,5-tetramethyl-
1,3-dioxolan-2-yl)phenoxy)phenyl)acetic acid (R)-(6.39) and methyl (R)-2-
(((benzyloxy)carbonyl)amino)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenoxy)phenyl)acetate (R)-(6.40) 
 
The procedure reported by Boger et al was followed to convert the primary 
alcohol (R)-(6.32) directly to the desired carboxylic acid (R)-(6.39), using 
stoichiometric oxidants: sodium hypochlorite (6.37) and 2,2,6,6-tetramethyl-1-
piperidine-1-oxyl (TEMPO) (6.36), a free radical (Scheme 6.11.). 249  Boger et al 
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proposed that TEMPO scavenged unreacted chlorine, therefore 1.1 equivalent of 
TEMPO was required to prevent an unwanted chlorination of the starting material. 
Scheme 6.11. Oxidation of α-amino-β-alcohol into corresponding amino acid (R)-(6.39) and 
subsequent esterification, affording (R)-(6.40) 
During the work-up of (R)-(6.39), the addition of saturated aqueous sodium 
hydrogen carbonate (5 equivalents) to the impure reaction promoted the formation of the 
corresponding sodium salt of the acid. The aqueous phase was washed with diethyl 
ether, which helped to remove organic impurities such as TEMPO (6.36). The washed 
salt was then suspended in ethyl acetate/distilled water (2:1), and the aqueous phase was 
acidified to pH ~ 4 with 1 M hydrochloric acid. The two phases were separated, and the 
aqueous phase was re-extracted with ethyl acetate twice. The combined organic phases 
were washed with saturated brine, dried over anhydrous magnesium sulfate and 
concentrated to afford the pure acid (R)-(6.39) as a colourless oil in a 87% yield. 
The reaction mechanism is outlined below (Scheme 6.12.). Reaction between 
potassium bromide (6.38) and sodium hypochlorite (6.37) afforded hypobromous acid 
(6.41), which transformed TEMPO (6.36) into the oxoammonium salt (6.42) that 
operated as the primary oxidant, converting the primary alcohol (R)-(6.32) into the 
corresponding aldehyde (6.43). This resulted in the formation of the hydroxylamine 
(6.44) that was oxidised back to TEMPO (6.36), thus completing the catalytic cycle. 
The aqueous conditions allowed the formation of the corresponding dihydrate of the 
aldehyde, which was then oxidised to the corresponding carboxylic acid (R)-(6.39).   
 
Scheme 6.12. Proposed mechanism of the primary alcohol (R)-(6.32) oxidation into carboxylic acid 
(R)-(6.39)  
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Anelli et al observed a significant reaction rate acceleration when hypobromous 
acid (6.41) was used as a secondary oxidant instead of hypochlorous acid (HOCl).250 
Similar results were observed by Petrônio et al and were explained by the fact that due 
to lower electronegativity and larger atomic radius, bromine radicals are more easily 
formed compared to chlorine radicals.251 
The carboxylic acid (R)-(6.39) was subsequently reacted with methyl iodide to 
afford the corresponding ester (R)-(6.40) as an orange oil in a 92% yield. In the 1H-
NMR (500 MHz, CDCl3) spectrum of the ester (R)-(6.40), the methoxy group was 
observed as a singlet at δ 3.73 ppm (Figure 6.8.). The HRMS analysis provided a final 
confirmation of the synthesis of (R)-(6.40) with [M+NH4]
+ ions identified at the 
required m/z (found: 537.2601, required: 537.2595). 
 
Figure 6.8. 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(6.40) 
 
6.7. Synthesis of methyl (R)-2-(2-bromoacetamido)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-
dioxolan-2-yl)phenoxy)phenyl)acetate (R)-(6.47) 
 
The N-benzyl carbamate protecting group on (R)-(6.40) was removed via 
hydrogenation in the presence of 10 mol% palladium on carbon and a balloon filled 
with hydrogen gas, affording primary amine (R)-(6.45) in a 88% yield (Scheme 6.13.). 
1H-NMR analysis confirmed the disappearance of the characteristic AB system at          
δ 5.13-5.08 ppm associated with the aliphatic protons of the benzyl carbamate group, as 
well as the absence of the corresponding aromatic protons. The FT-IR analysis of (R)-
(6.45) also confirmed the benzyl carbamate group had been removed, as the carbonyl 
peak at 1724 cm-1 was no longer observed. The ester carbonyl peak at 1741 cm-1 was 
however still detected. 
 
Scheme 6.13. Synthesis of (R)-(6.47) 
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The generated primary amine (R)-(6.45) was subsequently reacted with 
bromoacetyl bromide (6.46) and triethylamine to afford the corresponding 
bromoacetamide (R)-(6.47). Aqueous work up and flash chromatography on silica gel 
afforded the desired product (R)-(6.47) as a yellow oil in a 72% yield. The 1H-NMR 
(500 MHz, CDCl3) spectrum of the bromoacetamide (R)-(6.47) revealed two doublets 
of the AB system at δ 3.91 and 3.87 ppm (2JH-H 13.7 Hz), which was associated with the 
two protons of the bromoacetamide group (Figure 6.9.). The signal from the amide 
proton was observed as a doublet at δ 7.42 ppm (JH-H 7.1 Hz), which was presumably 
coupled to the proton on the α-carbon at δ 5.51 ppm (d, JH-H 7.0 Hz). In the FT-IR 
spectrum two carbonyl peaks were identified at 1747 cm-1 and 1662 cm-1 corresponding 
to ester and acetamide functional groups respectively. 
 
 
Figure 6.9. 1H-NMR (500 MHz, CDCl3) spectrum of bromoacetamide derivative (R)-(6.47) 
 
6.8. Synthesis of (R)-methyl 2-(2-diazoacetamido)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-
dioxolan-2-yl)phenoxy)phenyl)acetate (R)-(6.49) 
 
In 2007 Fukuyama et al published a novel synthetic method for the preparation 
of alkyl diazoacetates from the corresponding bromoacetates by treating the latter with 
N,N′-ditosylhydrazine (6.48) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).252  
Following the procedure reported by Fukuyama et al, N,N′-ditosylhydrazine 
(6.48) was deprotonated with DBU and reacted with bromoacetamide derivative (R)-
(6.47) (Scheme 6.14.), generating (R)-methyl 2-(2-diazoacetamido)-2-(3-(3-(4,4,5,5-
tetramethyl-1,3-dioxolan-2-yl)phenoxy)phenyl)acetate (R)-(6.49). 
 
Scheme 6.14. Synthesis of diazoacetamide derivative (R)-(6.49) 
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A proposed mechanism involves an elimination of two equivalents of para-
toluenesulfinic acid (6.50), which furnishes the desired diazoacetamide derivative (R)-
(6.49) (Scheme 6.15.). Flash chromatography on silica gel afforded the desired product 
(R)-(6.49) as a pale yellow oil in a 76% yield. 
 
Scheme 6.15. Proposed mechanism of diazoacetamide derivative (R)-(6.49) synthesis 
Within the 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(6.49), a new singlet 
was observed at δ 4.82 ppm, which was assigned to the proton on the carbon with the 
diazo group (Figure 6.10.). The FT-IR analysis supported the formation of (R)-(6.49), 
with a strong peak observed at 2105 cm-1, corresponding to the diazo functional 
group.253 
 
                      
Figure 6.10. 1H-NMR (500 MHz, CDCl3) and FT-IR spectra of (R)-(6.49) 
 
At this point it was very important to determine the enantiomeric excess of (R)-
(6.49) in order to establish if any racemisation of α-carbon had occurred. 
To determine the enantiopurity of (R)-(6.49), a chiral HPLC analysis was 
performed. The chiral non-racemic sample was run against the corresponding 
diazoacetamide derivative (±)-(6.49). Enantiomeric excess was calculated to be 94% 
(Table 6.2.) 
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Compound Chiral HPLC spectrum 
 
 
 
 
Rt = 8.88, 13.00 min 
racemic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rt = 8.82, 12.94 min 
94% e.e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: Phenomenex Lux Cellulose-1 HPLC column, 80% iso-hexane : 20% 
iso-propanol, flow rate: 1 mL / min 
Table 6.2. Chiral HPLC spectra of (±)-(6.49) and (R)-(6.49) 
 
 
6.9. Synthesis of a key E-F-O-G fragment derivative cis-(6.55) via aziridination 
reaction 
With the required diazoacetamide derivative (R)-(6.49) in hand we attempted a 
synthesis of a key E-F-O-G fragment (6.15), which subsequently could be subjected to 
an aziridine ring-opening, affording a library of precursors to teicoplanin derivatives 
(Scheme 6.16.).  
 
Scheme 6.16. Proposed synthesis of a model E-F-O-G fragment (6.15) via aziridination reaction 
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We have chosen 4-benzyloxybenzaldehyde (6.51) to mimic the E ring of teicoplanin 
and two amines to introduce various protecting groups at the N-terminus of aziridine 
derivatives. 2,4-Dimethoxyaniline (6.53) was ultimately chosen due to the fact it can be 
cleaved under oxidative conditions affording NH-aziridine. Methyl 2-amino-2-
methylpropanoate (6.52) was selected to investigate the reactivity of aliphatic amines 
compared to aromatic. Unfortunately, an attempt to purify a reaction that has utilised 
2,4-dimethoxyalinine (6.53) has failed, mainly due to the small scale of the reaction. On 
the contrary, the synthesis and purification of aziridine derived from methyl 2-amino-2-
methylpropanoate (6.52) was successful and is discussed below. 
Amine selected 
for the 
aziridination 
reaction 
 
methyl 2-amino-2-
methylpropanoate (6.52)  
 
2,4-dimethoxyalinine (6.53) 
Crude 
aziridination 
product observed 
  
Aziridination 
product purified 
  
Table 6.3. Synthesis of a model E-F-O-G fragment (6.15) via aziridination reaction, utilising 
aromatic and aliphatic amines 
 
The synthesis of cis-(6.55) was attempted utilising our standard racemic 
aziridination protocol outlined earlier (See 5.2. Studies towards a racemic 
aziridination protocol) (Scheme 6.17.).  
Scheme 6.17. Synthesis of cis-(6.55) 
 
 
A slight excess (10%) of 4-benzyloxybenzaldehyde (6.51) ensured that all of the 
methyl 2-amino-2-methylpropanoate (6.52) was consumed and the corresponding imine 
107 
 
(6.54) was formed. Activated (flame dried) 4 Å molecular sieves were used to trap the 
generated water in the condensation reaction between 4-benzyloxybenzaldehyde (6.51) 
and methyl 2-amino-2-methylpropanoate (6.52) and shift the reaction equilibrium 
towards the imine (6.54) formation. After three hours stirring at room temperature, an 
aliquot was taken out and submitted to 1H-NMR analysis; this confirmed the imine 
(6.54) formation, which was not isolated and was directly submitted to the aziridination 
reaction outlined in Scheme 6.17. Pyridinium triflate (5.5) was added at 10 mol% 
loading and the reaction flask was cooled to 0 °C. Diazoacetamide derivative (R)-(6.49) 
was added via syringe through the seal. The reaction was stirred at 0 °C and monitored 
by the 1H-NMR analysis every hour. After circa 5 hours, the characteristic imine peak at 
δ 8.58 ppm was no longer observed. An aqueous work up and flash chromatography on 
silica gel afforded a colourless oil in a 52% yield. 
The desired product cis-(6.55) was identified via 1H-NMR (500 MHz, CDCl3) 
analysis, which displayed two new doublets at δ 3.30 (J2,3 6.8 Hz) and δ 2.84 ppm (J2,3 
6.8 Hz), that were assigned to the aziridine protons on carbons C-3 and C-2 respectively 
(Figure 6.11.). The use of vicinal proton-proton coupling constants (JH-H 6.8 Hz 
confirmed the cis-configuration of the product. 
 
Figure 6.11. 1H-NMR (500 MHz, CDCl3) spectrum of cis-(6.55) 
The HRMS analysis provided a final confirmation of the synthesis of cis-(6.55) 
with [M+H]+ ions found at the required m/z (found: 737.3435, required: 737.3433). 
An interesting chromatogram was obtained when the chiral HPLC analysis of 
cis-(6.55) was performed. Various conditions (columns and solvent systems) were 
applied, but in every case one strong peak was observed (Table 6.4.), suggesting that 
  J2,3  
6.8 Hz 
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non-racemic compound is obtained. Thus, we postulated the idea that the (R) chiral 
centre of the "F ring" controls the stereochemistry of the aziridine formed. 
 
 
 
 
 
 
 
 
Conditions: Chiralpak AD-H  HPLC column, 90% iso-hexane :  
10% iso-propanol, flow rate: 1 mL / min 
 
 
 
 
 
 
Conditions: Phenomenex Lux Cellulose-1 HPLC column, 85% iso-hexane : 
15% iso-propanol, flow rate: 1 mL / min 
Table 6.4. Chiral HPLC spectrum of cis-(6.55) 
A search of the literature uncovered several reports on remote asymmetric 
induction. Rapoport et al reported the synthesis of (+)-vincamine (6.58) from L-aspartic 
acid (6.56) (Scheme 6.18.).254 The chiral non-racemic α-centre of the starting amino 
Peak area % 
97 : 3 
Peak area % 
95.5 : 4.5 
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acid was utilised as the sole source of chiral information in the construction of the three 
chiral centres in the target molecule.  
 
Scheme 6.18. Synthesis of (+)-vincamine (6.58) using L-aspartic acid (6.56) as the source of chiral 
induction by Rapoport et al 
The high diastereoselectivity obtained in the alkylation of six membered ring 
with ethyl iodide to yield primarily (6.57) was rationalised using the fact that the 
electrophile, ethyl iodide, had approached the less-hindered face opposite the axial C-2 
methoxycarbonyl group (Scheme 6.19.). The stereochemistry of (6.57) was rigorously 
established by COSY and NOESY experiments.  
 
Scheme 6.19. Rationalisation of stereochemistry of the key intermediate (6.57) in the synthesis of 
(+)-vincamine (6.58) by Rapoport et al 
 
To obtain additional evidence of the remote stereocontrol during an aziridination 
reaction, a model aziridine cis-(6.60) was synthesised utilising identical imine (6.54) 
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and the diazoacetamide derived from (R)-phenyl glycine methyl ester (R)-(6.59), 
mimicking the biaryl ether diazoacetamide derivative (R)-(6.49) 
 
Scheme 6.20. Synthesis of (R)-(6.60) 
 
A sample of cis-(6.60) was submitted to the chiral HPLC analysis and a nearly 
identical chromatogram was obtained to the one observed when analysing cis-(6.55) 
(Figure 6.12). This study indicated that amino acid chiral α-centre provides a 
stereocontrol in the formation of aziridine.  
 
Figure 6.12. HPLC spectrum of cis-(6.60) 
In order to obtain a conclusive evidence, chiral chromatography spectra obtained 
during the analysis of cis-(6.55) and cis-(6.60) must be matched with the racemic 
counterparts. Aziridine (±)-cis-(6.61) will be synthesised as a racemic sample, 
separately from the F-O-G fragment (±)-(6.45) and joined via an amide coupling, 
affording (±)-cis-(6.65) as outlined in Scheme 6.21. However the synthesis of (±)-cis-
(6.65) has not been attempted yet and will be the subject of future investigations. 
Peak area % 
97 : 3 
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Scheme 6.21. Synthesis of (±)-cis-(6.65) 
6.10. Chapter conclusion 
A successful synthesis of the key intermediate fragment of teicoplanin was 
performed, employing aziridination protocol developed previously. Ring-opening of the 
aziridine functionality would afford analogues of the antibiotic. 
A further examination of the aziridine stereochemistry is required, to support a 
remote asymmetric induction hypothesis. Racemic and chiral systems will be 
investigated separately and crystallisation for a single crystal diffraction will be 
attempted. 
By combining our studies towards teicoplanin and isotope incorporating 
methodologies, analogues of glycopeptide antibiotics can be generated and utilised in 
academia and industry. 
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Chapter 7. Synthesis and applications of chiral non-racemic α-aryl 
glycinols labelled with stable isotopes 
7.1. Introduction 
Chiral non-racemic α-aryl glycinols can be accessed via the asymmetric 
aminohydroxylation (AA) reaction developed by Sharpless et al, which utilises styrenes 
as starting materials. We have demonstrated that the AA methodology can be used to 
generate a model F-O-G fragment of Teicoplanin [see compound (R)-(6.22)]. To 
expand the scope of the reaction, we wanted to incorporate isotope labels into optically 
active α-amino-β-alcohols. The applications of this chemistry can be extended to 
mechanistic studies and metabolic research. 
With isotopically labelled aldehydes, already generated for the aziridination 
studies, incorporation of stable isotopes (2H and 13C) into optically active α-aryl 
glycinols was attempted. 
 
7.2. Synthesis of benzyl α-2H-(R)-(1-(4-bromophenyl)-2-hydroxyethyl)carbamate 
(R)-(7.3)  
 
α-2H-4-bromobenzaldehyde (7.1) was converted into the corresponding styrene 
(7.2) utilising the experimental procedure reported by Delmas et al (Scheme 7.1.). A 
similar procedure was utilised previously to synthesise compound (6.17) (See Chapter 
6). Utilising the AA protocol [used during the synthesis of compound (R)-(6.32)], 
styrene (7.2) was converted into the desired α-amino-β-alcohol (R)-(7.3) with the 2H-
label at the α-carbon. Although the synthesis is not shown here, non-labelled samples 
i.e. 4-bromostyrene (7.4) and racemic α-amino-β-alcohol (±)-(7.5) were generated to 
allow determination of deuterium incorporation and e.e. of α-amino-β-alcohol (R)-(7.3). 
 
Scheme 7.1. Synthesis of α-amino-β-alcohol (R)-(7.3) via AA and Wittig reactions from α-2H-4-
bromobenzaldehyde (7.1) 
The 1H-NMR (500 MHz, CDCl3) spectrum of (7.2) displayed two singlets at δ 
5.75 ppm and δ 5.29 ppm, that were assigned to Hb and Hx protons respectively (Table 
7.1.). No signal was observed in the δ 6.0 - 7.0 ppm region, which confirmed the 
(β) 
 (α) 
 
(β) 
 (α) 
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successful installation of deuterium at the α-carbon. Deuteration level was determined 
by comparing 1H-NMR spectra of labelled sample (7.2) and non-labelled (7.4). 
Deuterium incorporation was recorded above 95%. Analysing the 1H-NMR (500 MHz, 
CDCl3) spectrum of non-labelled sample (7.4), the signal at δ 6.66 ppm (dd, JH-H 17.6, 
10.9 Hz) was observed, which was assigned to proton Ha of styrene (7.4). Signals 
associated with Hb and Hx were observed as a doublet of doublets at δ 5.74 ppm and δ 
5.28 ppm respectively. Proton-proton coupling constants were recorded as Ja-b 17.6 Hz 
and Jb-x 0.7 Hz for Hb and Ja-x 10.9 Hz and Jb-x 0.7 Hz for Hx.  
Examining the 13C-NMR (126 MHz, CDCl3) spectrum of (7.2) the signal arising 
from the α-carbon was observed as a triplet at δ 135.5 ppm, resulting from splitting by 
the deuterium atom (Table 7.1.). A carbon-deuterium coupling constant (JC-D) was 
recorded as 23.7 Hz. The 13C-NMR (126 MHz, CDCl3) spectrum of (7.4) displayed a 
signal from α-carbon as a singlet at δ 135.9 ppm. The difference between δ 135.5 ppm 
and δ 135.9 ppm was attributed to the isotope shift effect. 
Structure 1H-NMR 13C-NMR 
 
 
 
 
 
 
 
  
 
Table 7.1. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (126 MHz, CDCl3) spectra of (7.4) and (7.2) 
 
The 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(7.3) displayed characteristic 
two doublets of the AB system at δ 5.12 and 5.07 ppm (2JH-H 12.2 Hz), which 
corresponded to the two aliphatic protons associated with the benzyl carbamate group 
(Table 7.2.). Furthermore the two protons on the β-carbon with the hydroxyl group 
were located at δ 3.80 as a multiplet. No signal was observed at the 4.5 - 5.0 ppm 
region. This could be explained by the fact that the proton at the α-carbon had been 
replaced with the deuterium atom. The 1H-NMR (500 MHz, CDCl3) spectrum of 
racemic non-labelled sample (±)-(7.5) displayed a singlet at 4.79 ppm, corresponding to 
 Ja-b 17.6 Hz 
  Jb-x 0.7 Hz 
 
δ 135.5 ppm 
JC-D 23.7 Hz 
 Ja-x 10.9 Hz 
  Jb-x 0.7 Hz 
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the proton at the α-carbon. Within the 13C-NMR (126 MHz, CDCl3) spectrum of (R)-
(7.3) a signal from the α-carbon was observed as a triplet at δ 56.2 ppm as a result of 
splitting by deuterium. Carbon-deuterium coupling constant was recorded as JC-D 19.3 
Hz. The signal from the α-carbon in the racemic non-labelled sample (±)-(7.5) was 
observed as a singlet at δ 56.6 ppm due to the isotope shift effect. 
Structure 1H-NMR 13C-NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.2. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (126 MHz, CDCl3) spectra of (R)-(7.3) and  
(±)-(7.5) 
The HRMS analysis provided a confirmation of the synthesis of (±)-(7.5) with 
[M+H]+ ions found at the required m/z (found: 350.0390, required: 350.0386) and (R)-
(7.3) with [M+H]+ ions found at the required m/z (found: 351.0452, required: 
351.0449). To determine the enantiopurity of the labelled α-amino-β-alcohol (R)-(7.3) 
synthesised, a chiral HPLC analysis was performed. The optically active sample was 
run against the corresponding racemic non-labelled α-amino-β-alcohol sample (±)-(7.5). 
Enantiomeric excess was calculated to be 94% (Table 7.3.). 
Compound Chiral HPLC spectrum 
 
 
 
 
Rt = 24.93, 28.97 min 
racemic 
 
 
 
 
 
 
 
 
 
 
 
 
 
δ 56.2 ppm 
JC-D 19.3 Hz 
 
115 
 
 
 
 
 
Rt = 25.88, 28.36 min 
94% e.e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: Phenomenex Lux Cellulose-3 HPLC column, 90% iso-hexane : 10% 
iso-propanol, flow rate: 1 mL / min 
Table 7.3. Chiral HPLC spectra of (±)-(7.5) and (R)-(7.3) 
 
7.3. Synthesis of benzyl α-13C-(R)-(2-hydroxy-1-(3-nitrophenyl)ethyl)carbamate 
(R)-(7.7)  
α-13C-3-nitrobenzaldehyde (5.29) was converted to the corresponding styrene 
(7.6), that was subsequently submitted to the AA reaction to afford the desired α-amino-
β-alcohol (R)-(7.7) with the 13C-label on the α-carbon (Scheme 7.2.). 
Scheme 7.2. Synthesis of (R)-(7.7) 
Examining the 1H-NMR (500 MHz, CDCl3) spectrum of styrene (7.6), the signal 
at δ 6.77 ppm (ddd, JH-H 17.5, 10.9 Hz; J13C-H 156.8 Hz), was observed and assigned to 
the α-proton Ha (Figure 7.1.). Typically a one-bond coupling between 13C and 1H is 
expected to be in the range of 150 Hz.135 Protons Hb and Hx were observed as doublet of 
doublets at δ 5.90 ppm and δ 5.44 ppm respectively with proton-proton coupling 
constants of Ja-b 17.5 Hz and Ja-x 10.9 Hz. Two-bond 
1H–13C coupling constants were 
also identified at 2J13C-H 3.2 Hz and 
2J13C-H 4.3 Hz. The long-range couplings between 
13C and 1H (2J13C-H and 
3J13C-H) have magnitude in the range of 0 - 10 Hz. 
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Figure 7.1. 1H-NMR (500 MHz, CDCl3) spectrum of (7.6)                 
 
The 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(7.7) displayed a doublet at δ 
4.92 ppm (partially obscured by the signal from Cbz- group at δ 5.13 ppm) with a large 
coupling constant (JC-H 136.1 Hz), corresponding to the proton at the α-13C (Figure 
7.2.). 
Within the 13C-NMR (126 MHz, CDCl3) spectra of (7.6) and (R)-(7.7) signals 
from α-carbon were observed as enhanced singlets at δ 134.9 ppm and δ 56.3 ppm 
respectively, as a result of 13C isotope enrichment (Figure 7.3.). The signal intensity of 
non-labelled carbons was greatly reduced.  
        
Figure 7.3. 13C-NMR (126 MHz, CDCl3) spectra of (7.6) and (R)-(7.7) 
The HRMS analysis provided a confirmation of the synthesis of (7.6) with 
[M+H]+ ions found at the required m/z (found: 151.0580, required: 151.0583) and (R)-
(7.7) with [M+H]+ ions found at the required m/z (found: 318.1165, required: 
318.1166). 
 
7.4. Synthesis of benzyl β-13C-(R)-(2-hydroxy-1-(4-nitrophenyl)ethyl)carbamate 
(R)-(7.10)  
After the successful installation of 2H and 13C labels at the α-positions of 
compounds (R)-(7.3) and (R)-(7.7), it was considered important to investigate a 
    13C-H 
JC-H 136.1 Hz 
 
 Ja-b 17.5 Hz 
2JC-H 3.2 Hz 
 
 Ja-x 10.9 Hz 
2JC-H 4.3 Hz 
 
 Ja-b 17.5 Hz 
Ja-x 10.9 Hz 
JC-H 156.8 Hz 
 
CDCl3 
reference 
CDCl3 
reference 
Figure 7.2. 1H-NMR (500 MHz,    
CDCl3) spectrum of (R)-(7.7) 
 
117 
 
functionalisation of a β-carbon of optically active α-amino-β-alcohols. To achieve this, 
an isotope incorporating synthesis of the phosphonium salt was required. In order to 
generate 13C-labelled phosphonium salt (7.8), the procedure reported by Takeuchi and 
Osakada was utilised.255  
Equimolar amounts of triphenylphosphine and 13C-labelled iodomethane were 
reacted as outlined below, generating 13CH3-methyltriphenyl phosphonium iodide (7.8) 
in a quantitative yield (Scheme 7.3.). The resulting salt (7.8) was reacted with 4-
nitrobenzaldehyde (5.1) to afford the corresponding styrene (7.9) with the 13C label at 
the β-position, which was subsequently converted to (R)-(7.10). 
 
Scheme 7.3. Synthesis of (R)-(7.10) 
 
The 1H-NMR (500 MHz, CDCl3) spectrum of (7.9) displayed a signal at δ 6.78 
ppm (dd, JH-H 17.6, 10.9 Hz), which was assigned to the proton Ha of the styrene 
(Figure 7.4.). Signals of Hb and Hx were observed as doublet of doublets at δ 5.93 ppm 
and δ 5.50 ppm respectively. Proton-proton coupling constants were recorded as Ja-b 
17.6 Hz and Ja-x 10.9 Hz. Proton-
13C coupling constants were recorded as J13C-H 155.2 
Hz and J13C-H 161.8 Hz. 
 
Figure 7.4. 1H-NMR (500 MHz, CDCl3) spectrum of (7.9) 
 Ja-b 17.6 Hz 
JC-H 155.2 Hz 
 
 Ja-x 10.9 Hz 
JC-H 161.8 Hz 
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The 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(7.10) displayed two doublet 
of doublets at δ 3.96 and 3.85 ppm (J13C-H 147.0 Hz; JH-H 12.5 Hz and J13C-H 143.4 Hz; 
JH-H 9.5 Hz), corresponding to the protons at the β-13C (Figure 7.5.). 
 
Figure 7.5. 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(7.10) 
 
7.5. Synthesis of benzyl β-2H, 2H-(R)-(2-hydroxy-1-(4-nitrophenyl)ethyl)carbamate 
(R)-(7.13) 
To install the 2H-labels at the β-carbon, a suitable phosphonium salt was 
required. In order to synthesise 2H-labelled phosphonium salt (7.11), the procedure 
reported by Yin et al was utilised.256 Methyltriphenylphosphonium bromide (6.26) was 
suspended in deuterated methanol and treated with catalytic amount of sodium 
methoxide base (Scheme 7.4.). After the mixture was stirred for 30 min, the solvent was 
removed under reduced pressure to afford 2H-labelled methyltriphenylphosphonium 
bromide (7.11) (> 95% 2H incorporation) in a quantitative yield. The resulting salt was 
reacted with 4-nitrobenzaldehyde (5.1) to afford the corresponding styrene (7.12) with 
two deuterium atoms installed at the β-position. Unfortunately, any attempt to purify 
and characterise the above styrene (7.12) was unsuccessful. Thus (7.12) was subjected 
to the aminohydroxylation reaction straight after simple filtration and concentration in 
vacuo. Gratifyingly, the desired amino alcohol (R)-(7.13) was afforded in a 60% yield. 
Scheme 7.4. Synthesis of (R)-(7.13) 
 JH-H 12.5 Hz 
JC-H 147.0 Hz 
 
  JH-H 9.5 Hz 
JC-H 143.4 Hz 
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The 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(7.13) displayed the absence 
of the signals in the δ 3.5 - 4.5 ppm region, which suggested successful deuteration at 
the β-carbon (> 95% 2H incorporation) (Figure 7.6.). Further evidence was obtained 
from the 2H-NMR (77 MHz, DCM) spectrum, where deuterium signals were observed 
at δ 3.87 and 3.76 ppm. 
 
Figure 7.6. 1H-NMR (500 MHz, CDCl3) spectrum of (R)-(7.13) with 2H-NMR (77 MHz, DCM) 
insert 
 
 
7.6. Chapter conclusion  
 
To summarise, during the course of this project a library of optically active α-
arylglycinols has been generated. The α-amino-β-alcohols were generated in 61 - 73% 
yield, 93 - 98% e.e. and were 2H or 13C isotopically enriched. Isotope incorporation 
levels were above 95%. 
It has been demonstrated, that the catalytic asymmetric aminohydroxylation 
reaction proves to be a powerful tool for the enantioselective one-step synthesis of N-
Cbz-protected α-arylglycinols from styrenes, in good yields and excellent 
enantioselectivities.  
α-Arylglycinols are very valuable structural units in synthetic and natural 
compounds.  If oxidised, α-arylglycinols can be converted to the corresponding α-
arylglycines, an important class of amino acids found in a wide range of bioactive 
compounds such as glycopeptide antibiotics. 
  
  CDCl3 
reference 
  2H-NMR insert 
120 
 
 
Styrene α-amino-β-alcohol Yield and e.e. of α-amino-β-alcohol 
  
 
 
68% yield 
95% e.e. 
  
 
 
73% yield 
93% e.e. 
  
 
 
61% yield 
98% e.e. 
  
 
65% yield 
93% e.e. 
  
 
 
70% yield 
96% e.e. 
Table 7.4. Generated library of α- or β-labelled styrenes and corresponding optically active α-
amino-β-alcohols 
 
Additionally, aminohydroxylation methodology can be further extended to 
convert α,β-unsaturated esters to the corresponding β-hydroxyamides.257 Sharpless et al 
reported a synthesis of protected (2R,3S)-3-phenylisoserine (2R,3S)-(7.17), a precursor 
for the side chains of the anticancer drugs Taxol and Taxotere.258 Furthermore, isotopic 
labelling can be extended into the dihydroxylation reaction. 
 
Scheme 7.5. Synthesis of (2R,3S)-(7.17) 
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Section 3. 
Experimental 
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8.1. General Directions  
 
Reactions described as under an argon or nitrogen atmosphere were conducted in flame 
dried apparatus. Reactions carried out at 0 °C were conducted using a water / ice bath, 
those at -78 °C were conducted in an acetone / solid carbon dioxide bath. 
Tetrahydrofuran (THF) and diethyl ether were freshly distilled from sodium wire and 
benzophenone under argon. Dichloromethane (DCM), propionitrile, acetonitrile and 
triethylamine were freshly distilled from calcium hydride under argon. Toluene was 
freshly distilled from sodium under argon. Petroleum ether (PET) refers to the fraction 
that boils between 40 and 60 °C. Chloroform and deuterated chloroform were filtered 
through basic aluminium oxide and stored over activated 4Å molecular sieves in 
darkened glass bottles. All commercially available reagents were used as supplied. 
However, the following reagents were treated as follows before use: phosphorus 
oxychloride was distilled from sodium under reduced pressure and stored under an 
argon atmosphere; trimethyl borate was freshly distilled from sodium  and stored under 
an argon atmosphere. 
 
8.2. Characterisation  
Flash column chromatography was carried out on silica gel (Fluka Silica gel 60, 70-230 
mesh). Analytical thin-layer chromatography (TLC) was performed on Merck plates 
(aluminium coated with 0.2 mm silica gel 60 F254), with visualization by UV light 
and/or potassium permanganate stain followed by heating. Melting points were recorded 
using open capillary tubes on melting point a Stuart Scientific SMP1 apparatus and are 
uncorrected. 1H and 13C-NMR spectra were recorded in Fourier transform mode on a 
Bruker Ascend 500 MHz spectrometer at the field strength indicated and unless 
otherwise stated deuterated chloroform was used as solvent. 15N and 2H-NMR were run, 
unlocked, on a Bruker Ascend 500 MHz. The 1H-spectra were recorded in ppm and 
referenced to the residual CHCl3 signal located at δ 7.26 ppm. 13C-NMR spectra were 
recorded in ppm and referenced to the residual CHCl3 signal found at δ 77.16 ppm. 
Multiplicities in the NMR spectra are described as: s = singlet, d = doublet, t = triplet, 
q= quartet, m = multiplet, br = broad; coupling constants are reported in Hz. Ion 
mass/charge (m/z) ratios are reported as values in atomic mass units and carried out on a 
Shimadzu Kratos MALDI-TOF. Optical rotation values were measured on a Perkin 
Elmer 241 polarimeter with a 1 mL cell (path length 1 dm) and are reported as follows: 
[α]D
T(ºC)
 concentration (c = g / 100 mL, solvent). FT-IR spectra were recorded on a 
123 
 
Perkin-Elmer 298 spectrometer either as a thin film or neat sample and are reported in 
wavenumbers (cm-1). HRMS was carried out by the EPSRC at the National Mass 
Spectrometry Service, University of Wales, Swansea. Chiral analytical HPLC analysis 
was performed using Hewlett Packard Agilent 1100 HPLC system and the conditions 
are given as following: column, solvents, solvent ratio (%), flow rate (mL / min),  
retention time (min), e.e. (%).  
 
8.3. Preparation of the Cooling Bath for Asymmetric Aziridination Reactions 
 
As the asymmetric aziridination reactions require sustained low temperature conditions 
in order to induce the desired level of enantiomeric excess, the use of an immersion 
chiller is recommended. The bath was prepared by the addition of iso-propanol or 
acetone to a dewar flask of the appropriate size, within which the chiller arm was 
submerged. Care was taken to ensure the arm was settled firmly into the bottom of the 
flask, leaving the central space free for a large magnetic stirrer. The arm was clamped 
securely above the bath to ensure no movement during the reaction, and the apparatus 
was placed upon a magnetic stirrer plate. Efficient stirring of the bath was essential in 
order to achieve uniform cooling, and also in preventing build up of ice. A thermometer 
was suspended within the bath in order to check the correlation between the temperature 
of the bath and the set temperature of the chiller. Any required offset could then be 
implemented. At -80 °C, the bath was reasonably expected to last around two weeks 
before requiring defrosting and change of the solvent. However, depending upon the 
strength of the chiller used, some heating of the bath may be observed before this point, 
and thus the bath may require more regular maintenance. 
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8.4. Synthesis of stable isotope labelled optically active aziridines 
 
tert-butyl cis-1-15N-3-2H-3-(4-nitrophenyl)-1-phenylaziridine-2-carboxylate cis-
(5.18) 
 
α-2H-4-Nitrobenzaldehyde (5.11) (30.0 mg, 0.20 mmol) and 15N-aniline (5.16) (17.6 
mg, 0.19 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (16.4 mg, 0.02 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, tert-butyl diazoacetate (5.4) (30 μL, 0.21 mmol) 
was added via syringe, and the reaction mixture was stirred at -80 °C (~ 72 hours). At 
this point the reaction mixture was quenched with triethylamine (0.5 mL), passed 
through a short plug of silica, eluted with diethyl ether and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography on 
silica gel (3% ethyl acetate in 40-60 PET, Rf = 0.22) to afford a bright yellow solid. 
Subsequent physicochemical analysis confirmed this to be the title compound cis-(5.18)  
(39.0 mg, 0.11 mmol, 59% yield). A sample was submitted to chiral analytical HPLC 
analysis [Cellulose 1, iso-hexane / iso-propanol : 99 / 01, 1 mL / min,  18.5 min (1st 
peak),  26.2 min (2nd peak), 86% e.e.].  
1H NMR (500 MHz, CDCl3) δ 8.22 (d, J 8.9 Hz, 2H, ArH), 7.71 (d, J 8.9 Hz, 2H, ArH), 
7.29 (t, J 7.5 Hz, 2H, ArH), 7.07 (t, J 7.5 Hz, 1H, ArH), 7.04 (dd, J 7.5, 1.4 Hz, 2H, 
ArH), 3.19 (s, 1H, C2-H), 1.23 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.1 
(d, JC-N 4.8 Hz), 151.8 (d, JC-N 2.6 Hz), 147.6, 142.5 (d, JC-N 4.1 Hz), 129.4, 128.9 (d, 
JC-N 1.8 Hz), 123.9, 123.3, 120.0 (d, JC-N 3.3 Hz), 82.4, 46.6 (d, JC-N 6.8 Hz), 45.74 (dt, 
JC-D 25.5, JC-N 6.8 Hz), 28.0; 
2H NMR (77 MHz, CH2Cl2) δ 5.26 (CD2Cl2 ref), 3.54 (br 
s); 15N NMR (51 MHz, CDCl3) δ 66.41; M.p. 124 - 126 °C (from diethyl ether / n-
pentane); [α]D
23
 -213 (c 2.0 CHCl3); FT-IR (thin film) 2977 (C-H), 1739 (C=O), 
1599/1519/1495 (C=C aromatic), 1345 (NO2), 1227/1158 (C(O)C), 1047 (C-N), 904 
(C-H bend) cm-1; MS (MALDI) 343.2 [M+H]+; HRMS (HASP) exact mass calculated 
for [C19H20D1
15N1N1O4] requires m/z 343.1529, found m/z 343.1526 [M+H]
+. 
125 
 
tert-butyl cis-1-15N-2,3-2H-3-(4-nitrophenyl)-1-phenylaziridine-2-carboxylate cis-
(5.25) 
 
α-2H-4-Nitrobenzaldehyde (5.11) (30.0 mg, 0.20 mmol) and 15N-aniline (5.16) (17.6 
mg, 0.19 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (16.4 mg, 0.02 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl diazoacetate (5.24) (30 
μL, 0.21 mmol) was added via syringe, and the reaction mixture was stirred at -80 °C (~ 
72 hours). At this point the reaction mixture was quenched with triethylamine (0.5 mL), 
passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (3% ethyl acetate in 40-60 PET, Rf = 0.22) to afford a 
bright yellow solid. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(5.25) (30.1 mg, 0.09 mmol, 44% yield). A sample was submitted to 
chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 99 / 01, 1 mL / 
min,  18.3 min (1st peak),  27.6 min (2nd peak), 66% e.e.].  
1H NMR (500 MHz, CDCl3) δ 8.22 (d, J 8.9 Hz, 2H, ArH), 7.71 (d, J 8.9 Hz, 2H, ArH), 
7.29 (t, J 7.8 Hz, 2H, ArH), 7.14 – 6.97 (m, 3H, ArH), 1.23 (s, 9H, C(CH3)3); 13C NMR 
(126 MHz, CDCl3) δ 166.1 (d, JC-N 4.7 Hz), 151.8 (d, JC-N 2.6 Hz), 147.7, 142.5 (d, JC-N 
4.1 Hz), 129.5, 128.9 (d, JC-N 1.8 Hz), 123.9, 123.3, 120.0 (d, JC-N 3.2 Hz), 82.4 (s), 46.4 
(m), 45.7 (m), 28.0; 2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 5.26 (CD2Cl2 ref), 
3.54 (br s), 3.14 (br s); 15N NMR (51 MHz, CDCl3) δ 66.22; M.p. 123 - 125 °C (from 
diethyl ether / n-pentane); [α]D
23
 -161 (c 2.0 CHCl3); FT-IR (thin film) 2979 (C-H), 1742 
(C=O), 1599/1520/1491 (C=C aromatic), 1345 (NO2), 1266/1154 (C(O)C), 1047 (C-N), 
904 (C-H bend) cm-1; MS (MALDI) 344.2 [M+H]+; HRMS (HNESP) exact mass 
calculated for [C19H19D2
15N1N1O4] requires m/z 344.1592, found m/z 344.1592 [M+H]
+. 
 
 
 
126 
 
 tert-butyl cis-1-15N-3-2H-3-(4-cyanophenyl)-1-phenylaziridine-2-carboxylate cis-
(5.47) 
 
α-2H-4-Cyanobenzaldehyde (5.12) (15.0 mg, 0.12 mmol) and 15N-aniline (5.16) (10.1 
mg, 0.11 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (9.6 mg, 0.01 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, tert-butyl diazoacetate (5.4) (17 μL, 0.12 mmol) 
was added via syringe, and the reaction mixture was stirred at -80 °C (~ 72 hours). At 
this point the reaction mixture was quenched with triethylamine (0.5 mL), passed 
through a short plug of silica, eluted with diethyl ether and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography on 
silica gel (10% diethyl ether in 40-60 PET, Rf = 0.30) to afford an orange solid. 
Subsequent physicochemical analysis confirmed this to be the title compound cis-(5.47) 
(24.5 mg, 0.07 mmol, 67% yield). A sample was submitted to chiral analytical HPLC 
analysis [Cellulose 1, iso-hexane / iso-propanol : 99 / 01, 1 mL / min,  17.7 min (1st 
peak),  22.8 min (2nd peak), 85% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.65 (s, 4H, ArH), 7.29 (t, J 7.8 Hz, 2H, ArH), 7.11 – 
7.00 (m, 3H, ArH), 3.16 (s, 1H, C2-H), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, 
CDCl3) δ 166.2 (d, JC-N 4.7 Hz), 151.9 (d, JC-N 2.6 Hz), 140.5 (d, JC-N 4.1 Hz), 131.9, 
129.4, 128.8 (d, JC-N 1.8 Hz), 123.8, 120.0 (d, JC-N 3.2 Hz), 118.9, 111.6, 82.3, 46.5 (d, 
JC-N 6.8 Hz), 45.9 (m), 27.9; 
2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 5.26 
(CD2Cl2 ref), 3.50 (br s); 
15N NMR (51 MHz, CDCl3) δ 65.81;  M.p. 87 - 89 °C (from 
diethyl ether / n-pentane); [α]D
23
 -40 (c 1.0 CHCl3); FT-IR (thin film) 2977 (C-H), 2226 
(C=N), 1740 (C=O), 1593/1504 (C=C aromatic),  1205/1155 (C(O)C), 1032 (C-N), 820 
(C-H bend) cm-1; MS (MALDI) 361.1 [M+K]+; HRMS (HASP) exact mass calculated 
for [C20H20D1
15N1N1O2] requires m/z 323.1631, found m/z 323.1634 [M+H]
+. 
 
 
127 
 
tert-butyl cis-1-15N-2,3-2H-3-(4-cyanophenyl)-1-phenylaziridine-2-carboxylate cis-
(5.48) 
 
α-2H-4-Cyanobenzaldehyde (5.12) (12.0 mg, 0.09 mmol) and 15N-aniline (5.16) (8.1 
mg, 0.08 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (7.5 mg, 0.01 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl diazoacetate (5.24) (14 
μL, 0.10 mmol) was added via syringe, and the reaction mixture was stirred at -80 °C (~ 
72 hours). At this point the reaction mixture was quenched with triethylamine (0.5 mL), 
passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (10% diethyl ether in 40-60 PET, Rf = 0.30) to afford an 
orange solid. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(5.48) (15.0 mg, 0.05 mmol, 49% yield). A sample was submitted to 
chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 99 / 01, 1 mL / 
min,  17.9 min (1st peak),  23.4 min (2nd peak), 75% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.65 (s, 4H, ArH), 7.29 (t, J 7.8 Hz, 2H, ArH), 7.09 – 
7.01 (m, 3H, ArH), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.2 (d, JC-N 
4.8 Hz), 151.9 (d, JC-N 2.6 Hz), 140.5 (d, JC-N 4.0 Hz), 131.9, 129.4 (d, JC-N 1.0 Hz), 
128.8 (d, JC-N 1.9 Hz), 123.8, 120.0 (d, JC-N 3.3 Hz), 118.9, 111.6, 82.3, 46.5 (m), 46.0 
(m), 27.9; 2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 5.26 (CD2Cl2 ref), 3.50 (br 
s), 3.11 (br s); 15N NMR (51 MHz, CDCl3) δ 65.60; M.p. 88 - 90 °C (from diethyl ether 
/ n-pentane); [α]D
23
 -30 (c 1.0 CHCl3); FT-IR (thin film) 2977 (C-H), 2226 (C=N), 1738 
(C=O), 1596/1490 (C=C aromatic), 1277/1152 (C(O)C), 1052 (C-N), 817 (C-H bend) 
cm-1; MS (MALDI) 362.1 [M+K]+; HRMS (HASP) exact mass calculated for 
[C20H19D2
15N1N1O2] requires m/z 324.1693, found m/z 324.1697 [M+H]
+. 
 
128 
 
tert-butyl cis-1-15N-3-13C-3-(3-nitrophenyl)-1-phenylaziridine-2-carboxylate cis-
(5.31) 
 
α-13C-3-Nitrobenzaldehyde (5.29) (22.0 mg, 0.14 mmol) and 15N-aniline (5.16) (12.2 
mg, 0.13 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (12.0 mg, 0.01 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, tert-butyl diazoacetate (5.4) (22 μL, 0.16 mmol) 
was added via syringe, and the reaction mixture was stirred at -80 °C (~ 72 hours). At 
this point the reaction mixture was quenched with triethylamine (0.5 mL), passed 
through a short plug of silica, eluted with diethyl ether and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography on 
silica gel (3% diethyl ether in 40-60 PET, Rf = 0.20) to afford a yellow solid. 
Subsequent physicochemical analysis confirmed this to be the title compound cis-(5.31) 
(30.0 mg, 0.09 mmol, 61% yield). A sample was submitted to chiral analytical HPLC 
analysis [Cellulose 1, iso-hexane / iso-propanol : 95 / 05, 1 mL / min, 9.6 min (1st peak), 
13.0 min (2nd peak), 87% e.e.].  
1H NMR (500 MHz, CDCl3) δ 8.42 – 8.36 (m, 1H, ArH), 8.17 (ddd, J 8.2, 2.3, 1.0 Hz, 
1H, ArH), 7.92 – 7.85 (m, 1H, ArH), 7.54 (t, J 7.8 Hz, 1H, ArH), 7.30 (t, J 7.8 Hz, 2H, 
ArH), 7.11 – 7.02 (m, 3H, ArH), 3.59 (dd, J13C-H 169.0, J2,3 6.7 Hz, 1H, C3-H), 3.17 
(ddd, J2,3 6.7, J13C-H 2.5, JN-H 0.7 Hz, 1H, C2-H), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 
MHz, CDCl3) δ 166.3 (dd, JC-N 4.6, JC-13C 1.9 Hz), 151.9 (t, JC-N 2.4 Hz), 148.2 (d, JC-13C 
5.5 Hz), 137.4 (dd, JC-13C 60.9, JC-N 4.1 Hz), 134.2 (dd, JC-13C 2.9, JC-N 2.1 Hz), 129.4, 
129.1 (d, JC-13C 4.7 Hz), 123.9, 123.1 (dd, JC-N 4.1, JC-13C 1.9 Hz), 122.9, 120.0 (t, JC-N 
2.9 Hz), 82.3, 45.8 (d, JC-N 7.0 Hz), 44.6 (d, JC-N 6.8 Hz), 27.9; 
15N NMR (51 MHz, 
CDCl3) δ 66.15 (d, JC-N 6.8 Hz); M.p. 118 - 120 °C (from diethyl ether / n-pentane); 
[α]D
23
 -170 (c 2.0 CHCl3); FT-IR (thin film) 2985 (C-H), 1738 (C=O), 1714, 1527/1489 
(C=C aromatic), 1346 (NO2), 1253/1150 (C(O)C), 1034 (C-N), 909/844/758 (C-H 
bend) cm-1; MS (MALDI) 343.2 [M+H]+; HRMS (HNESP) Exact mass calculated for 
[13C1C18H21
15N1N1O4]
+ requires 343.1500, found 343.1499 [M+H]+. 
129 
 
tert-butyl cis-1-15N-2-2H-3-13C-3-(3-nitrophenyl)-1-phenylaziridine-2-carboxylate 
cis-(5.32) 
 
α-13C-3-Nitrobenzaldehyde (5.29) (20.0 mg, 0.13 mmol) and 15N-aniline (5.16) (11.4 
mg, 0.11 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (11.0 mg, 0.01 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl diazoacetate (5.24) (20 
μL, 0.14 mmol) was added via syringe, and the reaction mixture was stirred at -80 °C (~ 
72 hours). At this point the reaction mixture was quenched with triethylamine (0.5 mL), 
passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (3% diethyl ether in 40-60 PET, Rf = 0.20) to afford a 
yellow solid. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(5.32) (25.0 mg, 0.07 mmol, 55% yield). A sample was submitted to 
chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 95 / 05, 1 mL / 
min, 9.6 min (1st peak), 13.0 min (2nd peak), 70% e.e.].  
1H NMR (500 MHz, CDCl3) δ 8.41 – 8.37 (m, 1H, ArH), 8.17 (dd, J 8.1, 1.6 Hz, 1H, 
ArH), 7.91 – 7.87 (m, 1H, ArH), 7.54 (t, J 7.8 Hz, 1H, ArH), 7.29 (t, J 7.8 Hz, 2H, 
ArH), 7.10 – 7.03 (m, 3H, ArH), 3.60 (d, J13C-H 169.0 Hz, 1H, C3-H), 1.22 (s, 9H, 
C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.3 (dd, JC-N 4.6, JC-13C 2.0 Hz), 151.8 (t, JC-
N 2.4 Hz), 148.1 (d, JC-13C 5.5 Hz), 137.4 (dd, JC-13C 61.0, JC-N 4.2 Hz), 134.2 (dd, JC-13C 
2.8, JC-N 1.9 Hz), 129.4, 129.1 (d, JC-13C 4.7 Hz), 123.8, 123.1 (dd, JC-N 4.1, JC-13C 1.9 
Hz), 122.9, 120.0 (t, JC-N 2.9 Hz), 82.3, 45.8 (d, JC-N 7.0 Hz), 44.6 (m), 27.9; 
2H NMR 
(77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 5.26 (CD2Cl2 ref), 3.12 (br s); 15N NMR (51 
MHz, CDCl3) δ 65.98 (d,  JC-N 6.8 Hz); M.p. 118 - 120 °C (from diethyl ether / n-
pentane); [α]D
23
 -110 (c 1.0 CHCl3); FT-IR (thin film) 2991 (C-H), 1735 (C=O), 
1598/1526/1490 (C=C aromatic), 1345 (NO2), 1251/1147 (C(O)C), 1081 (C-N), 
903/815 (C-H bend) cm-1; MS (MALDI) 344.2 [M+H]+;  HRMS (HNESP) Exact mass 
calculated for [13C1C18H20D1
15N1N1O4]
+ requires 344.1563, found 344.1558 [M+H]+. 
130 
 
tert-butyl cis-1-15N-2,3-2H-1-(2,4-dimethoxyphenyl)-3-(naphthalen-2-yl)aziridine-2-
carboxylate cis-(5.50) 
 
α-2H-2-Naphthaldehyde (5.15) (54.0 mg, 0.34 mmol) and 15N-2,4-dimethoxyaniline 
(5.35) (47.7 mg, 0.31 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (28.6 mg, 0.03 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl diazoacetate (54 μL, 
0.38 mmol) was added via syringe, and the reaction mixture was stirred at -80 °C (~ 72 
hours). At this point the reaction mixture was quenched with triethylamine (0.5 mL), 
passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (15% diethyl ether in 40-60 PET, Rf = 0.18) to afford a 
white solid. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(5.50) (79.0 mg, 0.19 mmol, 56% yield). A sample was submitted to 
chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 85 / 15, 1 mL / 
min, 7.6 min (1st peak), 9.0 min (2nd peak), 66% e.e.].  
1H NMR (500 MHz, CDCl3) δ 8.04 (s, 1H, ArH), 7.86 – 7.77 (m, 3H, ArH), 7.65 (dd, J 
8.4, 1.7 Hz, 1H, ArH), 7.50 – 7.42 (m, 2H, ArH), 6.89 (dd, J 8.4, 1.7 Hz, 1H, ArH), 
6.48 (d, J 2.4 Hz, 1H, ArH), 6.40 (dd, J 8.5, 2.4 Hz, 1H, ArH), 3.79 (s, 3H, OCH3), 3.78 
(s, 3H, OCH3), 1.12 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.5, 156.7, 
153.2, 135.2, 133.2, 133.1, 133.0, 128.0, 127.8, 127.4, 127.2, 126.1, 126.0, 125.8, 
120.0, 103.7, 99.8, 81.4, 55.8, 55.7, 47.8 (m), 46.3 (m), 27.9;  2H NMR (77 MHz, 
CH2Cl2) δ 7.26 (CDCl3 ref), 5.27 (CD2Cl2 ref), 3.50 (br s), 2.91 (br s); 15N NMR (51 
MHz, CDCl3) δ 55.50; M.p. 83 - 85 °C (from diethyl ether / n-pentane); [α]D
26
 -26 (c 1.0 
CHCl3); FT-IR (thin film) 2933 (C-H), 1743 (C=O), 1712, 1506 (C=C aromatic), 
1243/1208 (C(O)C), 1037 (C-N), 840/760 (C-H bend) cm-1; MS (MALDI) 409.0 
[M+H]+; HRMS (HNESP) Exact mass calculated for [C25H26D2
15N1O4]
+ requires 
409.2109, found 409.2109 [M+H]+. 
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tert-butyl cis-1-15N-2,3-2H-3-(4-bromophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-
carboxylate cis-(5.51) 
 
α-2H-4-Bromobenzaldehyde (5.14) (21.0 mg, 0.11 mmol) and 15N-2,4-dimethoxyaniline 
(5.35) (15.6 mg, 0.10 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (9.4 mg, 0.01 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl diazoacetate (5.24) (18 
μL, 0.12 mmol) was added via syringe, and the reaction mixture was stirred at -80 °C (~ 
72 hours). At this point the reaction mixture was quenched with triethylamine (0.5 mL), 
passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (20% diethyl ether in 40-60 PET, Rf = 0.27) to afford a 
brown solid. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(5.51) (25.0 mg, 0.06 mmol, 50% yield). A sample was submitted to 
chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 85 / 15, 1 mL / 
min, 6.3 min (1st peak), 6.9 min (2nd peak), 79% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.49 – 7.38 (m, 4H, ArH), 6.81 (dd, J 8.5, 1.6 Hz, 1H, 
ArH), 6.45 (d, J 2.5 Hz, 1H, ArH), 6.37 (dd, J 8.5, 2.5 Hz, 1H, ArH), 3.77 (s, 3H, 
OCH3), 3.77 (s, 3H, OCH3), 1.24 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 
167.2 (d, JC-N 4.6 Hz), 156.7, 153.1 (d, JC-N 2.6 Hz), 134.8 (d, JC-N 3.1 Hz), 134.6 (d, JC-
N 4.1 Hz), 131.0, 129.9 (d, JC-N 1.8 Hz), 121.4, 119.8 (d, JC-N 1.8 Hz), 103.7, 99.8, 81.6, 
55.8, 55.7, 47.0 (m), 46.7 (m), 28.0; 2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 
5.27 (CD2Cl2 ref), 3.28 (br s), 2.87 (br s); 
15N NMR (51 MHz, CDCl3) δ 55.35; M.p. 
115 - 118 °C (from diethyl ether / n-pentane); [α]D
26
 -18 (c 1.0 CHCl3); FT-IR (thin film) 
2931 (C-H), 1742 (C=O), 1711, 1507 (C=C aromatic), 1229/1208/1157 (C(O)C), 1036 
(C-N), 835 (C-H bend)  cm-1; MS (MALDI) 477.5 [M+K]+; HRMS (HNESP) Exact 
mass calculated for [C21H23D2
79Br1
15N1O4]
+ requires 437.1057, found 437.1052 
[M+H]+. 
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tert-butyl cis-1-15N-3-2H-1-(2,4-dimethoxyphenyl)-3-(4-fluorophenyl)aziridine-2-
carboxylate cis-(5.37) 
 
α-2H-4-Fluorobenzaldehyde (5.13) (20.0 mg, 0.16 mmol) and 15N-2,4-dimethoxyaniline 
(5.35) (22.2 mg, 0.14 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (13.0 mg, 0.02 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, tert-butyl diazoacetate (5.4) (24 μL, 0.18 mmol) 
was added via syringe, and the reaction mixture was stirred at -80 °C (~ 72 hours). At 
this point the reaction mixture was quenched with triethylamine (0.5 mL), passed 
through a short plug of silica, eluted with diethyl ether and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography on 
silica gel (5% diethyl ether in 40-60 PET, Rf = 0.26) to afford a yellow solid. 
Subsequent physicochemical analysis confirmed this to be the title compound cis-(5.37) 
(29.0 mg, 0.08 mmol, 48% yield). A sample was submitted to chiral analytical HPLC 
analysis [Cellulose 1, iso-hexane / iso-propanol : 90 / 10, 1 mL / min, 7.7 min (1st peak), 
8.9 min (2nd peak), 60% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.48 (m, 2H, ArH), 7.05 – 6.98 (m, 2H, ArH), 
6.82 (dd, J 8.5, 1.6 Hz, 1H, ArH), 6.46 (d, J 2.4 Hz, 1H, ArH), 6.37 (dd, J 8.5, 2.4 Hz, 
1H, ArH), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 2.91 (s, 1H, C2-H), 1.23 (s, 9H, 
C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.4 (d, JC-N 4.6 Hz), 162.4 (d, JC-F 245.2 
Hz), 156.7, 153.1 (d, JC-N 2.6 Hz), 134.9 (d, JC-N 3.0 Hz), 131.2 (dd, JC-N 3.9, JC-F 3.2 
Hz), 129.8 (dd, JC-F 8.1, JC-N 1.7 Hz), 119.8 (d, JC-N 1.8 Hz), 114.7 (d, JC-F 21.5 Hz), 
103.7, 99.8, 81.5, 55.8, 55.7, 47.0 (m), 46.7 (d, JC-N 7.0 Hz), 28.0; 
2H NMR (77 MHz, 
CH2Cl2) 7.26 (CDCl3 ref), 5.27 (CD2Cl2 ref), 3.30 (br s); 15N NMR (51 MHz, CDCl3) δ 
55.60; 19F NMR (471 MHz, CDCl3) δ -115.24; M.p. 73 - 75 °C (from diethyl ether / n-
pentane); [α]D
25
 -11.7 (c 0.5 CHCl3); FT-IR (thin film) 2964 (C-H), 1743 (C=O), 
1508/1465 (C=C aromatic), 1209/1158 (C(O)C), 1036 (C-N) cm-1; MS (MALDI) 414.0 
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[M+K]+; HRMS (HASP) Exact mass calculated for [C21H24D1F1
15N1O4]
+ requires 
376.1795, found 376.1793 [M+H]+. 
 
tert-butyl cis-1-15N-2-2H-1-(2,4-dimethoxyphenyl)-3-(4-fluorophenyl)aziridine-2-
carboxylate cis-(5.49) 
 
4-Fluorobenzaldehyde (8.1) (25.0 mg, 0.20 mmol) and 15N-2,4-dimethoxyaniline (5.35) 
(28.0 mg, 0.18 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (17.0 mg, 0.02 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl diazoacetate (5.24) (31 
μL, 0.22 mmol) was added via syringe, and the reaction mixture was stirred at -80 °C (~ 
72 hours). At this point the reaction mixture was quenched with triethylamine (0.5 mL), 
passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (5% diethyl ether in 40-60 PET, Rf = 0.26) to afford a 
yellow solid. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(5.49) (39.0 mg, 0.10 mmol, 51% yield). A sample was submitted to 
chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 90 / 10, 1 mL / 
min, 7.8 min (1st peak), 9.0 min (2nd peak), 70% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.55 – 7.48 (m, 2H, ArH), 7.05 – 6.98 (m, 2H, ArH), 
6.82 (dd, J 8.5, 1.6 Hz, 1H, ArH), 6.46 (d, J 2.4 Hz, 1H, ArH), 6.37 (dd, J 8.5, 2.4 Hz, 
1H, ArH), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.38 (s, 1H, C3-H), 1.23 (s, 9H, 
C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.4 (d, JC-N 4.6 Hz), 162.4 (d, JC-F 245.2 
Hz), 156.7, 153.1 (d, JC-N 2.6 Hz), 134.9 (d, JC-N 3.1 Hz), 131.3 (dd, JC-N 3.9, JC-F 3.1 
Hz), 129.8 (dd, JC-F 8.1, JC-N 1.8 Hz), 119.8 (d, JC-N 1.8 Hz), 114.7 (d, JC-F 21.5 Hz), 
103.7, 99.8, 81.5, 55.8, 55.7, 47.0 (d, JC-N 7.4 Hz), 46.7 (m), 28.0; 
2H NMR (77 MHz, 
CH2Cl2) 7.26 (CDCl3 ref), 5.27 (CD2Cl2 ref), 2.85 (br s); 
15N NMR (51 MHz, CDCl3) δ 
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55.62; 19F NMR (471 MHz, CDCl3) δ -115.29; M.p. 73 - 75 °C (from diethyl ether / n-
pentane); [α]D
26
 -21.3 (c 1.0 CHCl3); FT-IR (thin film) 2977 (C-H), 1743 (C=O), 
1506/1455 (C=C aromatic), 1209/1156 (C(O)C), 1091 (C-N), 839 (C-H bend) cm-1; MS 
(MALDI) 376.5 [M+H]+; HRMS (HASP) Exact mass calculated for 
[C21H24D1F1
15N1O4]
+ requires 376.1795, found 376.1790 [M+H]+. 
 
 
tert-butyl cis-1-15N-2-2H-3-13C-3-(3-azidophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-
carboxylate cis-(5.52) 
 
α-13C-3-Azidobenzaldehyde (5.40) (25.0 mg, 0.17 mmol) and 15N-2,4-dimethoxyaniline 
(5.35) (23.4 mg, 0.15 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (14.0 mg, 0.02 mmol, 10 mol%) was added and the vial was 
cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl diazoacetate (5.24) (27 
μL, 0.19 mmol) was added via syringe, and the reaction mixture was stirred at -80 °C (~ 
72 hours). At this point the reaction mixture was quenched with triethylamine (0.5 mL), 
passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (10% diethyl ether in 40-60 PET, Rf = 0.21) to afford an 
orange solid. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(5.52) (29.5 mg, 0.07 mmol, 44% yield). A sample was submitted to 
chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 90 / 10, 1 mL / 
min, 12.6 min (1st peak), 16.9 min (2nd peak), 70% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 3H, ArH), 6.96 – 6.91 (m, 1H, ArH), 
6.83 (dd, J 8.5, 1.6 Hz, 1H, ArH), 6.46 (d, J 2.5 Hz, 1H, ArH), 6.38 (dd, J 8.5, 2.5 Hz, 
1H, ArH), 3.79 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.38 (d, J13C-H 168.2 Hz, 1H, C3-H), 
1.24 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.3 (d, JC-N 2.8 Hz), 156.7, 
153.1, 139.8 (d, JC-13C 5.3 Hz), 137.8 (dd, JC-13C 60.5, JC-N 3.7 Hz), 134.8, 129.3 (d, JC-13C 
4.9 Hz), 124.8, 119.9, 118.9, 118.2, 103.7, 99.8, 81.6, 55.8, 55.7, 47.3 (d, JC-N 7.3 Hz), 
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46.5 (m), 27.9; 2H NMR (77 MHz, CH2Cl2) 5.26 (CD2Cl2 ref), 2.87 (br s); 
15N NMR 
(51 MHz, CDCl3) δ 55.52 (d, JC-N 7.5 Hz); M.p. 91 - 93 °C (from diethyl ether / n-
pentane); [α]D
25
 -52.7 (c 2.0 CHCl3); FT-IR (thin film) 2977 (C-H), 2115 (N3), 1749 
(C=O), 1590/1505 (C=C aromatic), 1208/1157 (C(O)C), 1035 (C-N) cm-1; MS 
(MALDI) 344.2 [M+H]+; HRMS (HNESP) Exact mass calculated for 
[13C1C20H24D1
15N1N3O4]
+ requires 400.1937, found 400.1937 [M+H]+. 
 
tert-butyl cis-1-15N-2-2H-3-13C-1-(2,4-dimethoxyphenyl)-3-(3-nitrophenyl)aziridine-2-
carboxylate cis-(7.2) 
 
α-13C-3-Nitrobenzaldehyde (5.31) (15.0 mg, 0.10 mmol) and 15N-2,4-dimethoxyaniline 
(5.35) (13.7 mg, 0.09 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. An aliquot was submitted to 1H-NMR analysis, which confirmed the formation 
of the imine intermediate. Catalyst (S)-(5.9) (8.2 mg, 0.01 mmol, 10 mol%) was added 
and the vial was cooled to -80 °C. After 30 minutes, > 95% deuterated tert-butyl 
diazoacetate (5.24) (15 μL, 0.11 mmol) was added via syringe, and the reaction mixture 
was stirred at -80 °C, monitoring by 1H-NMR until the reaction was deemed complete 
(~ 72 hours). At this point the reaction mixture was quenched with triethylamine (0.5 
mL), passed through a short plug of silica, eluted with diethyl ether and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (5% diethyl ether in 40-60 PET, Rf = 0.15) to afford a 
yellow oil. Subsequent physicochemical analysis confirmed this to be the title 
compound cis-(8.2) (23.4 mg, 0.06 mmol, 58% yield). A sample was submitted to chiral 
analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 90 / 10, 1 mL / min, 
12.1 min (1st peak), 15.0 min (2nd peak), 80% e.e.].  
1H NMR (500 MHz, CDCl3) δ 8.47 – 8.42 (m, 1H, ArH), 8.15 (ddd, J 8.0, 2.4, 0.9 Hz, 
1H, ArH), 7.95 – 7.89 (m, 1H, ArH), 7.51 (t, J 8.0 Hz, 1H, ArH), 6.84 (dd, J 8.5, 1.9 
Hz, 1H, ArH), 6.47 (d, J 1.9 Hz, 1H, ArH), 6.39 (dd, J 8.5, 2.4 Hz, 1H, ArH), 3.79 (s, 
3H, OCH3), 3.78 (s, 3H, OCH3), 3.45 (d, J13C-H 169.3 Hz, 1H, C3-H), 1.22 (s, 9H, 
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C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 166.9, 156.9, 153.1, 148.1, 137.7, 134.5, 
134.2, 128.8, 123.5, 122.6, 119.8, 103.7, 99.8, 82.0, 55.8, 55.7, 46.7 (broad), 27.9; 2H 
NMR (77 MHz, CH2Cl2) 7.26 (CD3Cl ref), 5.27 (CD2Cl2 ref), 2.99 (br s); 
15N NMR (51 
MHz, CDCl3) δ 56.00 (d, JC-N 7.5 Hz); [α]D
24
 -12.1 (c 0.5 CHCl3); FT-IR (thin film) 2982 
(C-H), 1746 (C=O), 1530/1505 (C=C aromatic), 1349 (NO2), 1208/1156 (C(O)C), 1038 
(C-N), 820 (C-H bend) cm-1; MS (MALDI) 404.0 [M+H]+; HRMS (HNESP) Exact 
mass calculated for [13C1C20H24D1
15N1N1O6]
+ requires 404.1774, found 404.1777 
[M+H]+. 
 
tert-butyl cis-1-15N-3-13C,2H-1-(2,4-dimethoxyphenyl)-3-(3-nitrophenyl)aziridine-2-
carboxylate cis-(5.46) 
 
α-2H,13C-3-Nitrobenzaldehyde (5.44) (15.0 mg, 0.10 mmol) and 15N-2,4-dimethoxy 
aniline (5.35) (13.6 mg, 0.09 mmol) were added to a flame dried Biotage 5 mL 
microwave vial, containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. 
Deuterated chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the 
vial was sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 
°C for 2 hours. An aliquot was submitted to 1H-NMR analysis, which confirmed the 
formation of the imine intermediate. Catalyst (S)-(5.9) (8.0 mg, 0.01 mmol, 10 mol%) 
was added and the vial was cooled to -80 °C. After 30 minutes, tert-butyl diazoacetate 
(5.4) (16 μL, 0.11 mmol) was added via syringe, and the reaction mixture was stirred at 
-80 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 72 hours). 
At this point the reaction mixture was quenched with triethylamine (0.5 mL), passed 
through a short plug of silica, eluted with diethyl ether and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography on 
silica gel (5% diethyl ether in 40-60 PET, Rf = 0.15) to afford a yellow oil. Subsequent 
physicochemical analysis confirmed this to be the title compound cis-(5.46) (21.2 mg, 
0.05 mmol, 53% yield). A sample was submitted to chiral analytical HPLC analysis 
[Cellulose 1, iso-hexane / iso-propanol : 90 / 10, 1 mL / min, 12.1 min (1st peak), 15.1 
min (2nd peak), 82% e.e.]. 
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1H NMR (500 MHz, CDCl3) δ 8.56 – 8.39 (m, 1H, ArH), 8.15 (d, J 8.1 Hz, 1H, ArH), 
7.95 – 7.86 (m, 1H, ArH), 7.51 (t, J 7.9 Hz, 1H, ArH), 6.84 (dd, J 8.5, 1.4 Hz, 1H, 
ArH), 6.47 (d, J 2.3 Hz, 1H, ArH), 6.39 (dd, J 8.5, 2.5 Hz, 1H, ArH), 3.79 (s, 3H, 
OCH3), 3.78 (s, 3H, OCH3), 3.02 (d, J13C-H 2.1 Hz, 1H, C2-H), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.9, 156.9, 153.1, 148.1, 137.7, 134.5, 134.2, 128.8, 
123.5, 122.6, 119.8, 103.7, 99.8, 82.0, 55.8, 55.7, 46.4 (t, JC-D 25.4 Hz), 27.9; 
2H NMR 
(77 MHz, CH2Cl2) 7.26 (CD3Cl ref), 5.27 (CD2Cl2 ref), 3.48 (br d, JC-D 26.0 Hz); 15N 
NMR (51 MHz, CDCl3) δ 56.04 (d, JC-N 8.0 Hz); [α]D
24
 -9.2 (c 0.4 CHCl3); FT-IR (thin 
film) 2938 (C-H), 1740 (C=O), 1530/1507 (C=C aromatic), 1349 (NO2), 1208/1157 
(C(O)C), 1035 (C-N), 815 (C-H bend) cm-1; MS (MALDI) 404.0 [M+H]+; HRMS 
(HNESP) Exact mass calculated for [13C1C20H24D1
15N1N1O6]
+ requires 404.1774, found 
404.1781 [M+H]+. 
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8.5. Synthesis of racemic non-labelled aziridines 
 
tert-butyl cis-1-(2,4-dimethoxyphenyl)-3-(4-nitrophenyl)aziridine-2-carboxylate 
(±)-cis-(8.4) 
 
4-Nitrobenzaldehyde (5.1) (200.0 mg, 1.32 mmol), and 2,4-dimethoxyaniline (8.3) 
(193.0 mg, 1.26 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform (2 mL) was added, the vial was sealed with a PTFE crimp cap and the 
reaction mixture was left stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-
NMR analysis, which confirmed the formation of the imine intermediate. Pyridinium 
triflate (5.5) (30.3 mg, 0.13 mmol, 10 mol%) was added. After 5 minutes, tert-butyl 
diazoacetate (5.4) (183 μL, 1.32 mmol) was added via syringe, and the reaction mixture 
was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 
12 hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether and the solvent was removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (15% ethyl acetate in 
40-60 PET, Rf = 0.35) to afford an orange solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (±)-cis-(8.4) (327.4 mg, 0.82 mmol, 62% yield).  
1H NMR (500 MHz, CDCl3) δ 8.20 (d, J 8.6 Hz, 2H, ArH), 7.73 (d, J 8.6 Hz, 2H, ArH), 
6.83 (d, J 8.6 Hz, 1H, ArH), 6.47 (d, J 2.6 Hz, 1H, ArH), 6.39 (dd, J 8.6, 2.6 Hz, 1H, 
ArH), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.44 (d, J 6.7 Hz, 1H, C3-H), 3.04 (d, J 
6.7 Hz, 1H, C2-H), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.7, 156.9, 
153.1, 147.4, 143.2, 134.1, 129.2, 123.1, 119.8, 103.6, 99.7, 82.0, 55.8, 55.7, 47.02, 
46.98, 28.0; M.p. 98 - 100 °C (from diethyl ether / n-pentane); FT-IR (KBr (neat), cm-1) 
2966.4 (C-H), 1735.2 (C=O), 1591.8/1505.0 (C=C aromatic), 1341.7 (NO2), 
1267.0/1206.1/1132.3 (C(O)C), 1032.7 (C-N), 819.4/743.7 (C-H bend); HRMS (HASP) 
exact mass calculated for [C21H25N2O6] requires m/z 401.1707, found m/z 401.1702 
[M+H]+. 
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tert-butyl cis-3-(4-bromophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-carboxylate 
(±)-cis-(8.6) 
 
4-Bromobenzaldehyde (8.5) (150.0 mg, 0.81 mmol), and 2,4-dimethoxyaniline (8.3) 
(118.0 mg, 0.77 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform (2 mL) was added, the vial was sealed with a PTFE crimp cap and the 
reaction mixture was left stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-
NMR analysis, which confirmed the formation of the imine intermediate. Pyridinium 
triflate (5.5) (18.6 mg, 0.08 mmol, 10 mol%) was added. After 5 minutes, tert-butyl 
diazoacetate (5.4) (112 μL, 0.81 mmol) was added via syringe, and the reaction mixture 
was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 
12 hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether and the solvent was removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% ethyl acetate in 
40-60 PET, Rf = 0.31) to afford a white solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (±)-cis-(8.6) (239.3 mg, 0.55 mmol, 68% yield).  
1H NMR (500 MHz, CDCl3) δ 7.48 – 7.41 (m, 4H, ArH), 6.82 (d, J 8.5 Hz, 1H, ArH), 
6.45 (d, J 2.6 Hz, 1H, ArH), 6.37 (dd, J 8.5, 2.6 Hz, 1H, ArH), 3.77 (s, 3H, OCH3), 3.77 
(s, 3H, OCH3), 3.35 (d, J 6.7 Hz, 1H, C3-H), 2.93 (d, J 6.7 Hz, 1H, C2-H), 1.23 (s, 9H, 
C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.2, 156.7, 153.1, 134.7, 134.6, 131.0, 
129.9, 121.4, 119.8, 103.6, 99.7, 81.7, 55.8, 55.7, 47.2, 46.8, 28.0; M.p. 122 - 124 °C 
(from diethyl ether / n-pentane); FT-IR (KBr (neat), cm-1) 2977.3 (C-H), 1739.2 (C=O), 
1591.8/1505.4 (C=C aromatic), 1266.9/1205.6/1132.6(C(O)C), 1032.5 (C-N), 
820.8/748.2 (C-H bend); HRMS (HNESP) exact mass calculated for [C21H25
79BrNO4] 
requires m/z 434.0961, found m/z 434.0959 [M+H]+. 
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tert-butyl cis-1-(2,4-dimethoxyphenyl)-3-(4-fluorophenyl)aziridine-2-carboxylate 
(±)-cis-(8.7) 
 
4-Fluorobenzaldehyde (8.1) (100.0 mg, 0.80 mmol), and 2,4-dimethoxyaniline (8.3) 
(117.0 mg, 0.76 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform (2 mL) was added, the vial was sealed with a PTFE crimp cap and the 
reaction mixture was left stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-
NMR analysis, which confirmed the formation of the imine intermediate. Pyridinium 
triflate (5.5) (18.5 mg, 0.08 mmol, 10 mol%) was added. After 5 minutes, tert-butyl 
diazoacetate (5.4) (111 μL, 0.80 mmol) was added via syringe, and the reaction mixture 
was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 
12 hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether and the solvent was removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% ethyl acetate in 
40-60 PET, Rf = 0.39) to afford a white solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (±)-cis-(8.7) (213.8 mg, 0.57 mmol, 71% yield).  
1H NMR (500 MHz, CDCl3) δ 7.52 (dd, J 8.5, 5.6 Hz, 2H, ArH), 7.01 (t, J 8.5 Hz, 2H, 
ArH), 6.83 (d, J 8.5 Hz, 1H, ArH), 6.45 (d, J 2.5 Hz, 1H, ArH), 6.37 (dd, J 8.5, 2.5 Hz, 
1H, ArH), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.38 (d, J 6.7 Hz, 1H, C3-H), 2.91 
(d, J 6.7 Hz, 1H, C2-H), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.4, 
162.4 (d, JC-F 245.2 Hz), 156.7, 153.1, 134.9, 131.2 (d, JC-F 3.0 Hz), 129.8 (d, JC-F 8.1 
Hz), 119.8, 114.7 (d, JC-F 21.5 Hz), 103.6, 99.7, 81.5, 55.8, 55.7, 47.1, 46.8, 27.9; 19F 
NMR (471 MHz, CDCl3) δ -115.25; M.p. 71 - 73 °C (from diethyl ether / n-pentane); 
FT-IR (KBr (neat), cm-1) 2971.9 (C-H), 1741.0 (C=O), 1592.4/1504.8 (C=C aromatic), 
1205.4/1133.6(C(O)C), 1032.3 (C-N), 821.9 (C-H bend); HRMS (HASP) exact mass 
calculated for [C21H25FNO4] requires m/z 374.1762, found m/z 374.1758 [M+H]
+. 
 
141 
 
tert-butyl cis-3-(4-cyanophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-carboxylate 
(±)-cis-(8.9) 
 
4-Cyanobenzaldehyde (8.8) (40.0 mg, 0.30 mmol), and 2,4-dimethoxyaniline (8.3) (44.5 
mg, 0.29 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated chloroform (2 
mL) was added, the vial was sealed with a PTFE crimp cap and the reaction mixture 
was left stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-NMR analysis, 
which confirmed the formation of the imine intermediate. Pyridinium triflate (5.5) (7.0 
mg, 0.03 mmol, 10 mol%) was added. After 5 minutes, tert-butyl diazoacetate (5.4) (42 
μL, 0.30 mmol) was added via syringe, and the reaction mixture was stirred at 25 °C, 
monitoring by 1H-NMR until the reaction was deemed complete (~ 12 hours). At this 
point the reaction mixture was passed through a short plug of silica, eluted with diethyl 
ether and the solvent was removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (30% diethyl ether in 40-60 PET, Rf = 
0.30) to afford a yellow solid. Subsequent physicochemical analysis confirmed this to 
be the title compound (±)-cis-(8.9) (65.2 mg, 0.17 mmol, 56% yield).  
1H NMR (500 MHz, CDCl3) δ 7.67 (d, 8.3 Hz, 2H, ArH), 7.63 (d, 8.3 Hz, 2H, ArH), 
6.82 (d, J 8.5 Hz, 1H, ArH), 6.46 (d, J 2.5 Hz, 1H, ArH), 6.38 (dd, J 8.5, 2.5 Hz, 1H, 
ArH), 3.77 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.41 (d, J 6.7 Hz, 1H, C3-H), 3.01 (d, J 
6.7 Hz, 1H, C2-H), 1.21 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.8, 156.9, 
153.1, 141.2, 134.2, 131.7, 129.0, 119.8, 119.1, 111.2, 103.6, 99.7, 81.9, 55.8, 55.7, 
47.1, 46.9, 27.9; M.p. 91 - 93 °C (from diethyl ether / n-pentane); FT-IR (KBr (neat), 
cm-1) 2978.0 (C-H), 2227.5 (C=N), 1714.8 (C=O), 1592.5/1507.7 (C=C aromatic), 
1279.4/1208.8/1159.8 (C(O)C), 1032.7 (C-N), 848.2/745.9 (C-H bend); HRMS 
(HNESP) exact mass calculated for [C22H24N2O4Na] requires m/z 403.1628, found m/z 
403.1627 [M+Na]+. 
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tert-butyl cis-1-(2,4-dimethoxyphenyl)-3-(naphthalen-2-yl)aziridine-2-carboxylate 
(±)-cis-(8.11) 
 
2-Naphthabenzaldehyde (8.10) (50.0 mg, 0.32 mmol), and 2,4-dimethoxyaniline (8.3) 
(46.5 mg, 0.30 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform (2 mL) was added, the vial was sealed with a PTFE crimp cap and the 
reaction mixture was left stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-
NMR analysis, which confirmed the formation of the imine intermediate. Pyridinium 
triflate (5.5) (7.3 mg, 0.03 mmol, 10 mol%) was added. After 5 minutes, tert-butyl 
diazoacetate (5.4) (44 μL, 0.32 mmol) was added via syringe, and the reaction mixture 
was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 
12 hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether and the solvent was removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% ethyl acetate in 
40-60 PET, Rf = 0.28) to afford a brown solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (±)-cis-(8.11) (87.4 mg, 0.21 mmol, 67% yield).  
1H NMR (500 MHz, CDCl3) δ 8.06 (s, 1H, ArH), 7.87 – 7.79 (m, 3H, ArH), 7.66 (dd, J 
8.5, 1.3 Hz, 1H, ArH), 7.49 – 7.42 (m, 2H, ArH), 6.90 (d, J 8.5 Hz, 1H, ArH), 6.49 (d, J 
2.5 Hz, 1H, ArH), 6.40 (dd, J 8.5, 2.5 Hz, 1H, ArH), 3.80 (s, 3H, OCH3), 3.78 (s, 3H, 
OCH3), 3.60 (d, J 6.8 Hz, 1H, C3-H), 3.01 (d, J 6.8 Hz, 1H, C2-H), 1.13 (s, 9H, 
C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 167.5, 156.6, 153.2, 135.1, 133.2, 133.03, 
133.01, 128.0, 127.7, 127.4, 127.1, 126.1, 126.0, 125.7, 119.9, 103.6, 99.7, 81.4, 55.7, 
55.6, 48.0, 47.2, 27.8; M.p. 85 - 87 °C (from diethyl ether / n-pentane); FT-IR (KBr 
(neat), cm-1) 2976.3 (C-H), 1713.1 (C=O), 1592.0/1507.3 (C=C aromatic), 
1278.9/1208.3/1158.4(C(O)C), 1034.0 (C-N), 824.8/750.0 (C-H bend); HRMS 
(HNESP) exact mass calculated for [C25H28NO4] requires m/z 406.2013, found m/z 
406.2009 [M+H]+. 
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di-tert-butyl cis-3,3'-(1,4-phenylene)bis(1-(2,4-dimethoxyphenyl)aziridine-2-
carboxylate) (±)-cis-(8.13) 
 
1,4-Terephthaldehyde (8.12) (80.0 mg, 0.60 mmol), and 2,4-dimethoxyaniline (8.3) 
(174.0 mg, 1.13 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 200 mg) under nitrogen. Deuterated 
chloroform (4 mL) was added, the vial was sealed with a PTFE crimp cap and the 
reaction mixture was left stirring at 25 °C for 3 hours. An aliquot was submitted to 1H-
NMR analysis, which confirmed the formation of the imine intermediate. Pyridinium 
triflate (5.5) (27.3 mg, 0.11 mmol, 20 mol%) was added. After 5 minutes, tert-butyl 
diazoacetate (5.4) (165 μL, 1.20 mmol) was added via syringe, and the reaction mixture 
was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 
12 hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether and the solvent was removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (30% diethyl ether in 
40-60 PET, Rf = 0.24) to afford a brown solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (±)-cis-(8.13) (218.0 mg, 0.34 mmol, 57% 
yield).  
1H NMR (500 MHz, CDCl3) δ 7.50 (d, J 1.8 Hz, 4H, ArH), 6.82 (d, J 8.5 Hz, 2H, ArH), 
6.44 (d, J 1.8 Hz, 2H, ArH), 6.37 (dd, J 8.5, 2.6 Hz, 2H, ArH), 3.76 (d, J 4.5 Hz, 12H, 
4xOCH3), 3.40 (d, J 6.8 Hz, 2H, 2xC3-H), 2.91 (dd, J 6.8, 4.5 Hz, 2H, 2xC2-H), 1.26 
(d, J 1.5 Hz, 18H, 2xC(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.5, 167.4, 156.59, 
156.58, 153.2, 135.29, 135.28, 134.6, 134.5, 127.62, 127.60, 119.9, 103.59, 103.57, 
99.74, 99.70, 81.4, 55.74, 55.69, 47.89, 47.85, 47.1, 46.7, 28.0; M.p. 45 - 47 °C (from 
diethyl ether / n-pentane); FT-IR (KBr (neat), cm-1) 2977.1 (C-H), 1745.9 (C=O), 
1592.1/1506.4 (C=C aromatic), 1278.9/1159.2(C(O)C), 1034.1 (C-N), 847.2/736.8 (C-
H bend); HRMS (HNESP) exact mass calculated for [C36H45N2O8] requires m/z 
633.3170, found m/z 633.3168 [M+H]+. 
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tert-butyl cis-3-(3-azidophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-carboxylate 
(±)-cis-(8.15) 
 
3-Azidobenzaldehyde (8.14) (20.0 mg, 0.13 mmol), and 2,4-dimethoxyaniline (8.3) 
(18.7 mg, 0.12 mmol) were added to a flame dried Biotage 5 mL microwave vial, 
containing activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform (2 mL) was added, the vial was sealed with a PTFE crimp cap and the 
reaction mixture was left stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-
NMR analysis, which confirmed the formation of the imine intermediate. Pyridinium 
triflate (5.5) (3.1 mg, 0.01 mmol, 10 mol%) was added. After 5 minutes, tert-butyl 
diazoacetate (5.4) (19 μL, 0.13 mmol) was added via syringe, and the reaction mixture 
was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 
12 hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether and the solvent was removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% diethyl ether in 
pentane, Rf = 0.22) to afford a brown solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (±)-cis-(8.15) (25.1 mg, 0.06 mmol, 46% yield).  
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 1H, ArH), 6.96 – 6.91 (m, 1H, ArH), 
6.83 (d, J 8.5 Hz, 1H, ArH), 6.46 (d, J 2.6 Hz, 1H, ArH), 6.38 (dd, J 8.5, 2.6 Hz, 1H, 
ArH), 3.79 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.39 (d, J 6.7 Hz, 1H, C3-H), 2.95 (d, J 
6.7 Hz, 1H, C2-H), 1.24 (s, 9H, C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 167.3, 156.7, 
153.1, 139.8, 137.8, 134.8, 129.3, 124.8, 119.9, 118.9, 118.2, 103.7, 99.8, 81.6, 55.8, 
55.7, 47.4, 46.7, 27.9; M.p. 87 - 89 °C (from diethyl ether / n-pentane); FT-IR (KBr 
(neat), cm-1) 2934.4 (C-H), 2107.3 (N3), 1744.0 (C=O), 1589.2/1509.1 (C=C aromatic), 
1293.1/1207.9/1158.3 (C(O)C), 1032.4 (C-N), 834.4/799.9 (C-H bend); HRMS 
(HNESP) exact mass calculated for [C21H25N4O4] requires m/z 397.1870, found m/z 
397.1871 [M+H]+. 
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tert-butyl cis-1-(2,4-dimethoxyphenyl)-3-(3-iodophenyl)aziridine-2-carboxylate (±)-
cis-(8.17) 
 
3-Iodobenzaldehyde (8.16) (20.0 mg, 0.09 mmol), and 2,4-dimethoxyaniline (8.3) (11.9 
mg, 0.08 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated chloroform (2 
mL) was added, the vial was sealed with a PTFE crimp cap and the reaction mixture 
was left stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-NMR analysis, 
which confirmed the formation of the imine intermediate. Pyridinium triflate (5.5) (2.0 
mg, 0.01 mmol, 10 mol%) was added. After 5 minutes, tert-butyl diazoacetate (5.4) (12 
μL, 0.09 mmol) was added via syringe, and the reaction mixture was stirred at 25 °C, 
monitoring by 1H-NMR until the reaction was deemed complete (~ 12 hours). At this 
point the reaction mixture was passed through a short plug of silica, eluted with diethyl 
ether and the solvent was removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (30% diethyl ether in pentane, Rf = 0.29) 
to afford a white solid. Subsequent physicochemical analysis confirmed this to be the 
title compound (±)-cis-(8.17) (18.3 mg, 0.04 mmol, 44% yield).  
1H NMR (500 MHz, CDCl3) δ 7.93 (s, 1H, ArH), 7.64 – 7.58 (m, 1H, ArH), 7.49 (d, J 
7.7 Hz, 1H, ArH), 7.06 (t, J 7.7 Hz, 1H, ArH), 6.82 (d, J 8.5 Hz, 1H, ArH), 6.46 (d, J 
2.6 Hz, 1H, ArH), 6.38 (dd, J 8.5, 2.6 Hz, 1H, ArH), 3.79 (s, 3H, OCH3), 3.77 (s, 3H, 
OCH3), 3.35 (d, J 6.7 Hz, 1H, C3-H), 2.92 (d, J 6.7 Hz, 1H, C2-H), 1.24 (s, 9H, 
C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 167.3, 156.8, 153.1, 138.1, 137.1, 136.6, 
134.7, 129.7, 127.5, 119.8, 103.7, 99.8, 93.8, 81.8, 55.8, 55.7, 46.8, 28.0; M.p. 104 - 
107 °C (from diethyl ether / n-pentane); FT-IR (KBr (neat), cm-1) 2976.5 (C-H), 1715.6 
(C=O), 1592.1/1506.1 (C=C aromatic), 1280.0/1208.7/1160.3 (C(O)C), 1049.3 (C-N), 
803.4/736.1 (C-H bend); HRMS (HNESP) exact mass calculated for [C21H26INO4
35Cl] 
requires m/z 518.0590, found m/z 518.0583 [M+HCl+H]+. 
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8.6. Synthesis of ring-opened aziridines 
 
tert-butyl 3-bromo-3-(4-bromophenyl)-2-(2,4-dimethoxyphenylamino)propanoate 
(5.63) 
 
tert-Butyl cis-3-(4-bromophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-carboxylate   (±)-
cis-(8.6) (20.0 mg, 0.05 mmol), and magnesium bromide diethyl etherate (17.8 mg, 0.07 
mmol) were added to a flame dried 5 mL round bottom flask under nitrogen. Anhydrous 
diethyl ether (2 mL) was added via syringe, and the reaction mixture was stirred at      
25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 12 hours). At 
this point the reaction mixture was passed through a short plug of silica, eluted with 
diethyl ether (10 mL), transferred into a 25 mL separating funnel and washed with 
saturated brine (10 mL). Organic phase was separated, dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (10% diethyl ether in n-pentane,            
Rf = 0.15) to afford a yellow solid. Subsequent physicochemical analysis confirmed this 
to be the title compound (5.63) (15.0 mg, 0.03 mmol, 64% yield). 
1H NMR (500 MHz, CDCl3) δ 7.44 (s, 4H, ArH), 6.45 (d, J 2.6 Hz, 1H, ArH), 6.27 (dd, 
J 8.6, 2.6 Hz, 1H, ArH), 6.21 (d, J 8.6 Hz, 1H, ArH), 5.33 (d, J 5.2 Hz, 1H, CHBr), 4.85 
(s, 1H, NH), 4.26 (d, J 5.2 Hz, 1H, Cα-H), 3.85 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 1.33 
(s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 169.6, 153.1, 148.8, 137.9, 131.7, 
130.8, 130.5, 122.9, 111.9, 103.7, 99.5, 82.8, 64.9, 55.8, 55.8, 54.8, 27.9; M.p. 104 - 
106 °C (from diethyl ether / n-pentane); FT-IR (KBr (neat), cm-1) 3388.2 (N-H), 2925.3 
(C-H), 1698.1 (C=O), 1591.6/1518.6 (C=C aromatic), 1259.1 (C(O)C), 1208.0/1153.1 
(CH2Br), 1034.5 (C-N), 797.6 (C-H bend); HRMS (HASP) exact mass calculated for 
[C21H26
79Br2NO4] requires m/z 514.0214, found m/z 514.0223 [M+H]
+. 
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tert-butyl 3-bromo-2-(2,4-dimethoxyphenylamino)-3-(4-fluorophenyl)propanoate 
(5.62) 
 
tert-Butyl cis-1-(2,4-dimethoxyphenyl)-3-(4-fluorophenyl)aziridine-2-carboxylate (±)-
cis-(8.7) (40.0 mg, 0.11 mmol), and magnesium bromide diethyl etherate (41.5 mg, 0.16 
mmol) were added to a flame dried 5 mL round bottom flask under nitrogen. Anhydrous 
diethyl ether (2 mL) was added via syringe, and the reaction mixture was stirred at          
25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 12 hours). At 
this point the reaction mixture was passed through a short plug of silica, eluted with 
diethyl ether (10 mL), transferred into a 25 mL separating funnel and washed with 
saturated brine (10 mL). Organic phase was separated, dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (25% diethyl ether in n-pentane,            
Rf = 0.35) to afford a orange solid. Subsequent physicochemical analysis confirmed this 
to be the title compound (5.62) (35.0 mg, 0.08 mmol, 72% yield). 
1H NMR (500 MHz, CDCl3) δ 7.54 (dd, J 8.8, 5.3 Hz, 2H, ArH), 7.00 (t, J 8.8 Hz, 2H, 
ArH), 6.46 (d, J 2.5 Hz, 1H, ArH), 6.29 – 6.21 (m, 2H, ArH), 5.36 (d, J 5.5 Hz, 1H, 
CHBr), 4.87 (s, 1H, NH), 4.26 (d, J 5.5 Hz, 1H, Cα-H), 3.86 (s, 3H, OCH3), 3.73 (s, 3H, 
OCH3), 1.32 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 169.7, 162.9 (d, JC-F 
248.5 Hz), 153.1, 148.8, 134.8 (d, JC-F 3.3 Hz), 130.9, 130.6 (d, JC-F 8.4 Hz), 115.5 (d, 
JC-F 21.7 Hz), 112.0, 103.8, 99.5, 82.7, 65.3, 55.85, 55.84, 54.9, 27.9; M.p. 68 - 70 °C 
(from diethyl ether / n-pentane); FT-IR (KBr (neat), cm-1) 3376.7 (N-H), 2934.1 (C-H), 
1717.8 (C=O), 1604.5/1515.0 (C=C aromatic), 1259.5 (C(O)C), 1223.2/1155.8 
(CH2Br), 1035.9 (C-N), 802.6 (C-H bend); HRMS (HASP) exact mass calculated for 
[C21H26
79BrFNO4] requires m/z 454.1024, found m/z 454.1020 [M+H]
+. 
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tert-butyl 3-bromo-2-(2,4-dimethoxyphenylamino)-3-(naphthalen-2-yl)propanoate 
(5.64) 
 
tert-Butyl cis-1-(2,4-dimethoxyphenyl)-3-(naphthalen-2-yl)aziridine-2-carboxylate (±)-
cis-(8.11) (25.0 mg, 0.06 mmol), and magnesium bromide diethyl etherate (24.0 mg, 
0.09 mmol) were added to a flame dried 5 mL round bottom flask under nitrogen. 
Anhydrous diethyl ether (2 mL) was added via syringe, and the reaction mixture was 
stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 12 
hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether (10 mL), transferred into a 25 mL separating funnel and 
washed with saturated brine (10 mL). Organic phase was separated, dried with 
magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (25% diethyl ether in 
n-pentane, Rf = 0.34) to afford a brown solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (5.64) (18.3 mg, 0.04 mmol, 61% yield). 
1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H, ArH), 7.83 – 7.78 (m, 3H, ArH), 7.73 (dd, J 
8.6, 1.8 Hz, 1H, ArH), 7.50 – 7.46 (m, 2H, ArH), 6.46 (d, J 2.6 Hz, 1H, ArH), 6.32 (d, J 
8.6 Hz, 1H, ArH), 6.25 (dd, J 8.6, 2.6 Hz, 1H, ArH), 5.52 (d, J 6.4 Hz, 1H, CHBr), 4.94 
(d, J 8.6 Hz, 1H, NH), 4.42 (t, J 6.4 Hz, 1H, Cα-H), 3.86 (s, 3H, OCH3), 3.72 (s, 3H, 
OCH3), 1.23 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 169.9, 153.0, 148.8, 
136.1, 133.48, 132.9, 131.0, 128.5, 128.3, 127.8, 127.6, 126.8, 126.5, 126.5, 112.1, 
103.7, 99.5, 82.6, 65.3, 56.3, 55.9, 55.8, 27.8; M.p. 79 - 82 °C (from diethyl ether / n-
pentane); FT-IR (KBr (neat), cm-1) 3395.5 (N-H), 2974.5 (C-H), 1731.0 (C=O), 
1693.1/1599.1/1518.2 (C=C aromatic), 1259.8 (C(O)C), 1207.2/1154.4 (CH2Br), 1034.6 
(C-N), 820.8/751.2 (C-H bend); HRMS (HNESP) exact mass calculated for 
[C25H29
79BrNO4] requires: m/z 486.1274, found m/z [M+H]
+ 486.1271. 
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tert-butyl 3-bromo-2-((2,4-dimethoxyphenyl)amino)-3-(3-iodophenyl)propanoate 
(5.65) 
 
tert-Butyl cis-1-(2,4-dimethoxyphenyl)-3-(3-iodophenyl)aziridine-2-carboxylate (±)-
cis-(8.17) (15.0 mg, 0.03 mmol), and magnesium bromide diethyl etherate (12.0 mg, 
0.05 mmol) were added to a flame dried 5 mL round bottom flask under nitrogen. 
Anhydrous diethyl ether (2 mL) was added via syringe, and the reaction mixture was 
stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 12 
hours). At this point the reaction mixture was passed through a short plug of silica, 
eluted with diethyl ether (10 mL), transferred into a 25 mL separating funnel and 
washed with saturated brine (10 mL). Organic phase was separated, dried with 
magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (30% diethyl ether in 
n-pentane, Rf = 0.35) to afford a white solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (5.65) (13.0 mg, 0.02 mmol, 73% yield). 
1H NMR (500 MHz, CDCl3) δ 7.84 (t, J 1.7 Hz, 1H, ArH), 7.66 – 7.60 (m, 1H, ArH), 
7.53 (d, J 7.8 Hz, 1H, ArH), 7.04 (t, J 7.8 Hz, 1H, ArH), 6.45 (t, J 1.4 Hz, 1H, ArH), 
6.28 (d, J 1.4 Hz, 2H, ArH), 5.23 (d, J 5.7 Hz, 1H, CHBr), 4.28 (d, J 5.7 Hz, 1H, Cα-H), 
3.86 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 1.32 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, 
CDCl3) δ 169.5, 153.1, 148.8, 140.9, 137.9, 137.5, 130.7, 130.3, 128.3, 112.1, 103.7, 
99.5, 93.9, 82.8, 65.0, 55.9, 55.8, 54.2, 27.9; M.p. 88 - 90 °C (from diethyl ether / n-
pentane); FT-IR (KBr (neat), cm-1) 3391.6 (N-H), 2963.9 (C-H),  1732.2 (C=O), 1519.8 
(C=C aromatic), 1260.1 (C(O)C), 1207.6/1151.4 (CH2Br), 1035.1 (C-N), 797.8 (C-H 
bend); HRMS (HNESP) exact mass calculated for [C21H26
79BrINO4] requires: m/z 
562.0084, found m/z [M+H]+ 562.0081. 
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tert-butyl 3-(3-azidophenyl)-3-bromo-2-((2,4-dimethoxyphenyl)amino)propanoate 
(5.66) 
 
tert-Butyl 3-(3-azidophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-carboxylate (±)-cis-
(8.15) (10.0 mg, 0.02 mmol), and magnesium bromide diethyl etherate (10.0 mg, 0.04 
mmol) were added to a flame dried 5 mL round bottom flask under nitrogen. Anhydrous 
diethyl ether (2 mL) was added via syringe, and the reaction mixture was stirred at            
25 °C, monitoring by 1H-NMR until the reaction was deemed complete (~ 12 hours). At 
this point the reaction mixture was passed through a short plug of silica, eluted with 
diethyl ether (10 mL), transferred into a 25 mL separating funnel and washed with 
saturated brine (10 mL). Organic phase was separated, dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (30% diethyl ether in n-pentane,             
Rf = 0.33) to afford a yellow solid. Subsequent physicochemical analysis confirmed this 
to be the title compound (5.66) (10.0 mg, 0.02 mmol, 80% yield). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.28 (m, 2H, ArH), 7.21 (s, 1H, ArH), 6.96 (dt, J 
7.2, 1.9 Hz, 1H, ArH), 6.45 (d, J 2.4 Hz, 1H, ArH), 6.30 – 6.20 (m, 2H, ArH), 5.33 (d, J 
5.4 Hz, 1H, CHBr), 4.86 (s, 1H, NH), 4.29 (d, J 5.4 Hz, 1H, Cα-H), 3.85 (s, 3H, OCH3), 
3.73 (s, 3H, OCH3), 1.33 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 169.5, 153.0, 
148.7, 140.7, 140.3, 130.7, 129.9, 125.3, 119.5, 119.4, 111.9, 103.7, 99.5, 82.8, 64.8, 
55.8, 54.8, 27.9; M.p. 61 - 63 °C (from diethyl ether / n-pentane); FT-IR (KBr (neat), 
cm-1) 3397.3 (N-H), 2963.5 (C-H),  2113.8 (N3), 1732.4 (C=O), 1519.8 (C=C aromatic), 
1260.5 (C(O)C), 1208.0/1151.1 (CH2Br), 1030.6 (C-N), 798.5 (C-H bend); HRMS 
(HNESP) exact mass calculated for [C21H25
79BrN4O4H] requires: m/z 477.1132, found 
m/z [M+H]+ 477.1126. 
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di-tert-butyl 3,3'-(1,4-phenylene)bis(3-bromo-2-((2,4-
dimethoxyphenyl)amino)propanoate) (5.67) 
 
di-tert-Butyl cis-3,3'-(1,4-phenylene)bis(1-(2,4-dimethoxyphenyl)aziridine-2-
carboxylate) (±)-cis-(8.13) (10.0 mg, 0.02 mmol), and magnesium bromide diethyl 
etherate (12.0 mg, 0.05 mmol) were added to a flame dried 5 mL round bottom flask 
under nitrogen. Anhydrous diethyl ether (2 mL) was added via syringe, and the reaction 
mixture was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed 
complete (~ 12 hours). At this point the reaction mixture was passed through a short 
plug of silica, eluted with diethyl ether (10 mL), transferred into a 25 mL separating 
funnel and washed with saturated brine (10 mL). Organic phase was separated, dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (30% diethyl ether in 
n-pentane, Rf = 0.28) to afford an orange oil. Subsequent physicochemical analysis 
confirmed this to be the title compound (5.67) (8.5 mg, 0.01 mmol, 68% yield). 
1H NMR (500 MHz, CDCl3) δ 7.49 (d, J 1.6 Hz, 4H, ArH), 6.44 (t, J 2.5 Hz, 2H, ArH), 
6.30 – 6.18 (m, 4H, ArH), 5.34 (t, J 5.5 Hz, 2H, 2xCHBr), 4.87 (s, 2H, 2xNH), 4.26 (d, 
J 3.7 Hz, 2H, 2xCα-H), 3.84 (d, J 1.6 Hz, 6H, 2xOCH3), 3.72 (s, 6H, 2xOCH3), 1.29 (s, 
18H, 2xC(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 168.6, 151.8, 147.6, 138.3, 129.7, 
127.7, 110.8, 102.5, 98.3, 81.6, 63.7, 63.6, 54.6, 54.0, 26.7; FT-IR (KBr (neat), cm-1) 
3398.9 (N-H), 2976.5/2941.7 (C-H),  1730.9 (C=O), 1599.5/1518.8 (C=C aromatic), 
1258.3 (C(O)C), 1207.6/1153.2 (CH2Br), 1035.0 (C-N), 835.1/732.9 (C-H bend); 
HRMS (HNESP) exact mass calculated for [C36H46
79Br2N2O8H] requires: m/z 793.1694, 
found m/z [M+H]+ 793.1698. 
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tert-butyl 2-15N-2,3-2H-3-bromo-2-(2,4-dimethoxyphenylamino)-3-(naphthalen-2-
yl)propanoate (8.18) 
 
 
tert-Butyl cis-1-15N-2,3-2H-1-(2,4-dimethoxyphenyl)-3-(naphthalen-2-yl)aziridine-2-
carboxylate cis-(5.50) (5.0 mg, 0.01 mmol), and magnesium bromide diethyl etherate 
(4.8 mg, 0.02 mmol) were added to a flame dried 10 mL round bottom flask under 
nitrogen. Anhydrous diethyl ether (2 mL) was added via syringe, and the reaction 
mixture was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed 
complete (~ 12 hours). At this point the reaction mixture was passed through a short 
plug of silica, eluted with diethyl ether (10 mL), transferred into a 25 mL separating 
funnel and washed with saturated brine (10 mL). Organic phase was separated, dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (25% diethyl ether in 
n-pentane, Rf = 0.34) to afford a brown solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (8.18) (4.5 mg, 0.01 mmol, 77% yield). A 
sample was submitted to chiral analytical HPLC analysis [Cellulose 3, iso-hexane / iso-
propanol : 95 / 05, 1 mL / min,  24.3 min (1st peak),  42.9 min (2nd peak), 78% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.91 (d, J 1.6 Hz, 1H, ArH), 7.84 – 7.77 (m, 3H, ArH), 
7.72 (dd, J 8.5, 1.6 Hz, 1H, ArH), 7.51 – 7.46 (m, 2H, ArH), 6.46 (d, J 2.5 Hz, 1H, 
ArH), 6.37 (d, J 8.5 Hz, 1H, ArH), 6.26 (dd, J 8.5, 2.5 Hz, 1H, ArH), 3.86 (s, 3H, 
OCH3), 3.72 (s, 3H, OCH3), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 
169.7, 153.4, 148.9, 135.9, 133.5, 132.9, 131.1, 128.5, 128.3, 127.8, 127.6, 126.8, 
126.6, 126.4, 112.5, 103.8, 99.5, 82.7, 55.9, 55.8, 27.8; 2H NMR (77 MHz, CH2Cl2) δ 
7.26 (CDCl3 ref), 5.51 (br s), 5.26 (CD2Cl2 ref), 4.42 (br s); M.p. 84 - 86 °C (from 
diethyl ether / n-pentane); [α]D
23
 +5.3 (c 0.3 CHCl3); FT-IR (KBr (neat), cm
-1) 3389.0 
(N-H), 2928.8 (C-H), 1731.9 (C=O), 1599.5/1515.0 (C=C aromatic), 1259.1 (C(O)C), 
1207.5/1156.5 (CH2Br), 1035.2 (C-N), 818.2/748.7 (C-H bend); MS (MALDI) 490.2 
[M+H]+; HRMS (HNESP) exact mass calculated for [C25H27D2
79Br1
15N1O4] requires 
m/z 489.1370, found m/z 489.1362 [M+H]+. 
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tert-butyl 2-15N-2-2H-3-13C-3-(3-azidophenyl)-3-bromo-2-((2,4-dimethoxyphenyl) 
amino)propanoate (5.68) 
 
tert-Butyl cis-1-15N-2-2H-3-13C-3-(3-azidophenyl)-1-(2,4-dimethoxyphenyl)aziridine-2-
carboxylate cis-(5.52) (20.0 mg, 0.05 mmol), and magnesium bromide diethyl etherate 
(19.4 mg, 0.08 mmol) were added to a flame dried 10 mL round bottom flask under 
nitrogen. Anhydrous diethyl ether (2 mL) was added via syringe, and the reaction 
mixture was stirred at 25 °C, monitoring by 1H-NMR until the reaction was deemed 
complete (~ 12 hours). At this point the reaction mixture was passed through a short 
plug of silica, eluted with diethyl ether (10 mL), transferred into a 25 mL separating 
funnel and washed with saturated brine (10 mL). Organic phase was separated, dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (30% diethyl ether in 
n-pentane, Rf = 0.33) to afford a yellow solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (5.68) (20.0 mg, 0.04 mmol, 83% yield). A 
sample was submitted to chiral analytical HPLC analysis [Cellulose 3, iso-hexane / iso-
propanol : 97 / 03, 1 mL / min,  12.1 min (1st peak),  15.8 min (2nd peak), 70% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 2H, ArH), 7.24 – 7.18 (m, 1H, ArH), 
6.99 – 6.93 (m, 1H, ArH), 6.45 (s, 1H, ArH), 6.27 (s, 2H, ArH), 5.32 (dd, J13C-H 153.8, J 
3.2 Hz, 1H, 13CHBr), 3.85 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 1.33 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 169.5, 153.1, 148.8, 142.9 (d, JC-13C 5.9 Hz), 140.6 (d, 
JC-13C 48.0 Hz), 140.3 (d, JC-13C 4.9 Hz), 129.9 (d, JC-N 4.5 Hz), 125.3 (d, JC-N 3.4 Hz), 
119.5 (d, JC-N 3.5 Hz), 119.4, 112.1, 103.8, 99.5, 82.8, 55.85, 54.6 (d, JC-N 1.7 Hz), 27.9; 
2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 5.27 (CD2Cl2 ref), 4.24 (br s); 15N 
NMR (51 MHz, CDCl3) δ 54.27 (d, JC-N 2.0 Hz); M.p. 60 - 63 °C (from diethyl ether / 
n-pentane); [α]D
23
 +11.6 (c 1.0 CHCl3); FT-IR (KBr (neat), cm
-1) 3382.3 (N-H), 2963.5 
(C-H),  2113.4 (N3), 1732.5 (C=O), 1601.7/1515.0 (C=C aromatic), 1290.9/1259.0 
(C(O)C), 1208.0/1157.9 (CH2Br), 1035.2 (C-N), 794.7 (C-H bend); MS (MALDI) 
481.0 [M+H]+; HRMS (HNESP) exact mass calculated for 
[C20
13C1H25D1
79Br1N3
15N1O4] requires m/z 480.1199, found m/z 480.1187 [M+H]
+. 
154 
 
8.7. Synthesis of deprotected NH-aziridines 
 
tert-butyl cis-1-15NH-2,3-2H-3-(4-bromophenyl)aziridine-2-carboxylate cis-(5.53) 
 
A 25 mL RBF was charged with tert-butyl cis-1-15N-2,3-2H-3-(4-bromophenyl)-1-(2,4-
dimethoxyphenyl)aziridine-2-carboxylate cis-(5.51) (20.0 mg, 0.05 mmol) in 
acetonitrile (1 mL) and the solution was cooled to 0 °C using an ice bath.  Ammonium 
cerium(IV) nitrate (150 mg, 0.30 mmol) was dissolved in water (0.5 mL) and added to 
the flask at 0 °C. After 30 min stirring at 0 °C, no starting material was detected by TLC 
analysis. Saturated aqueous sodium hydrogen carbonate (10 mL) was added and the 
mixture was extracted with ethyl acetate (3 x 30 mL), dried with magnesium sulfate and 
filtered. The solvents were removed under reduced pressure, and the residue was 
purified by flash chromatography on basic aluminium oxide (30% diethyl ether in 40-60 
PET, Rf = 0.21) to afford a yellow solid. Subsequent physicochemical analysis 
confirmed this to be the title compound cis-(5.53) (8.0 mg, 0.03 mmol, 58% yield). A 
sample was submitted to chiral analytical HPLC analysis [Cellulose 3, iso-hexane / iso-
propanol : 97 / 03, 1 mL / min, 10.2 min (1st peak), 14.0 min (2nd peak), 82% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.44 (d, J 7.9 Hz, 2H, ArH), 7.22 (d, J 7.9 Hz, 2H, ArH), 
1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 168.0, 134.3, 131.2, 129.6, 121.6, 
82.2, 27.9; 2H NMR (77 MHz, DCM) δ 7.26 (CDCl3 ref), 5.27 (CD2Cl2 ref), 3.29 (br s), 
2.83 (br s); M.p. 132 - 134 °C (from diethyl ether / n-pentane); [α]D
25
 -9.3 (c 0.5 CHCl3); 
FT-IR (thin film) 3240 (N-H), 2970 (C-H), 1726 (C=O), 1588 (C=C aromatic), 
1232//1154 (C(O)C), 1069 (C-N), 847 (C-H bend)  cm-1; MS (MALDI) 340.9 [M+K]+; 
HRMS (HNESP) Exact mass calculated for [C13H14D2
79Br1
15N1O2Na1]
+ requires 
323.0353, found 323.0354 [M+Na]+. 
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tert-butyl cis-3-(4-bromophenyl)aziridine-2-carboxylate (±)-cis-(8.19) 
 
A 25 mL RBF was charged with tert-butyl cis-3-(4-bromophenyl)-1-(2,4-
dimethoxyphenyl)aziridine-2-carboxylate (±)-cis-(8.6) (40.0 mg, 0.10 mmol) in 
acetonitrile (1 mL) and the solution was cooled to 0 °C using an ice bath.  Ammonium 
cerium(IV) nitrate (300 mg, 0.60 mmol) was dissolved in water (0.5 mL) and added to 
the flask at  0 °C. After 30 min stirring at 0 °C, no starting material was detected by 
TLC analysis. Saturated aqueous sodium hydrogen carbonate (10 mL) was added and 
the mixture was extracted with ethyl acetate (3 x 30 mL), dried with magnesium sulfate 
and filtered. The solvents were removed under reduced pressure, and the residue was 
purified by flash chromatography on basic aluminium oxide (30% diethyl ether in 40-60 
PET, Rf = 0.21) to afford a yellow solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (±)-cis-(8.19) (17.5 mg, 0.06 mmol, 65% yield). 
1H NMR (500 MHz, CDCl3) δ 7.43 (d, J 8.5 Hz, 2H, ArH), 7.21 (d, J 8.5 Hz, 2H, ArH), 
3.37 (s, 1H, C3-H), 2.92 (s, 1H, C2-H), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, 
CDCl3) δ 168.0, 134.4, 131.2, 129.5, 121.6, 82.1, 37.9, 27.9; M.p. 134 - 136 °C (from 
diethyl ether / n-pentane); FT-IR (thin film) 3310 (N-H), 2978 (C-H), 1728 (C=O), 
1489 (C=C aromatic), 1231/1153 (C(O)C), 1070 (C-N), 840 (C-H bend)  cm-1; MS 
(MALDI) 337.9 [M+K]+; HRMS (HNESP) Exact mass calculated for 
[C13H16
79Br1N1O2Na1]
+ requires 320.0257, found 320.0259 [M+Na]+. 
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8.8. Synthesis of Teicoplanin fragment analogue 
 
3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenol (6.19) 
 
To a 50 mL flame dried round bottom flask, equipped with a Dean-Stark trap and a 
magnetic stirrer bar, under nitrogen was added 3-hydroxybenzaldehyde (6.11) (1.0 g, 
8.19 mmol), pinacol (6.18) (1.5 g, 12.28 mmol) and para-toluenesulfonic acid 
monohydrate (156.0 mg, 0.82 mmol). Anhydrous toluene (20 mL) was added via 
syringe and the reaction was refluxed at 120 °C for 4 hours. The reaction mixture was 
cooled down to room temperature, diluted with toluene (30 mL), transferred into a 100 
mL separating funnel, washed with saturated aqueous sodium hydrogen carbonate (40 
mL), saturated brine (40 mL), dried with magnesium sulphate, filtered and the solvent 
removed under reduced pressure to afford a pale yellow solid. Recrystallisation from 
hot toluene afforded white solid, which was dried in the vacuum oven for 2 hours to 
afford a fine white powder. Subsequent physicochemical analysis confirmed this to be 
the title compound (6.19) (1.78 g, 8.0 mmol, 98% yield). 
1H NMR (500 MHz, CDCl3) δ 7.17 (t, J 7.7 Hz, 1H, ArH), 7.03 (d, J 7.7 Hz, 1H, ArH), 
6.96 (d, J 2.5 Hz, 1H, ArH), 6.72 (dd, J 7.7, 2.5 Hz, 1H, ArH), 6.55 (br s, 1H, OH), 5.94 
(s, 1H, O-CH-O), 1.33 (s, 6H, 2 x CH3), 1.28 (s, 6H, 2 x CH3); 
13C NMR (126 MHz, 
CDCl3) δ 155.9, 140.8, 129.7, 118.5, 116.1, 113.4, 99.7, 83.1, 24.3, 22.2; M.p. 137 - 
139 °C (from toluene); FT-IR (thin film) 3377 (OH), 2984 (C-H), 1583/1495 (C=C 
aromatic), 1234/1152 (C(O)C), 865/780 (C-H bend) cm-1; MS (MALDI) 221.1 [M-H]+; 
HRMS (HNESP) exact mass calculated for [C13H18O3H] requires m/z 223.1301, found 
m/z 223.1329 [M+H]+. 
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3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenoxy)benzaldehyde (6.24) 
 
 
3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenol (6.19) (1.0 g, 4.50 mmol), 3-
bromobenzaldehyde (6.23) (0.5 mL, 4.50 mmol), potassium carbonate (0.9 g, 6.75 
mmol), 1,10-phenathroline (162.0 mg, 0.90 mmol) and copper (I) iodide (86.0 mg, 0.45 
mmol) were added to a flame dried Biotage 25 mL microwave vial under nitrogen. 
Anhydrous pyridine (15 mL) was added via syringe, the vial sealed with a PTFE crimp 
cap and heated via microwave irradiation at 190 °C for 5 hours. The reaction mixture 
was cooled down to room temperature, diluted with dichloromethane (100 mL), 
transferred into a 250 mL separating funnel, washed with saturated aqueous copper (II) 
sulfate (100 mL), aqueous 1M hydrochloric acid (100 mL), saturated brine (40 mL), 
dried with magnesium sulphate, filtered and the solvent removed under reduced 
pressure. The crude material was purified by flash chromatography on silica gel (5% 
ethyl acetate in 40-60 PET, Rf = 0.22) to afford a yellow oil. Subsequent 
physicochemical analysis confirmed this to be the title compound (6.24) (0.98 g, 3.0 
mmol, 67% yield). 
1H NMR (500 MHz, CDCl3) δ 9.95 (s, 1H, CHO), 7.60 (d, J 7.7 Hz, 1H, ArH), 7.51 – 
7.46 (m, 2H, ArH), 7.37 (t, J 7.7 Hz, 1H, ArH), 7.31 – 7.26 (m, 2H, ArH), 7.21 – 7.18 
(m, 1H, ArH), 6.99 (dd, J 7.7, 2.1 Hz, 1H, ArH), 5.95 (s, 1H, O-CH-O), 1.31 (s, 6H, 2 x 
CH3), 1.24 (s, 6H, 2 x CH3); 13C NMR (126 MHz, CDCl3) δ 191.7, 158.4, 156.3, 142.5, 
138.2, 130.5, 130.1, 124.8, 124.6, 122.3, 119.6, 118.7, 117.4, 99.4, 83.0, 24.4, 22.3; FT-
IR (thin film) 2979 (C-H), 1703 (C=O), 1584/1481 (C=C aromatic), 1253/1153 
(C(O)C), 1086/789 (C-H bend) cm-1; MS (MALDI) 365.2 [M+K]+; HRMS (HNESP) 
exact mass calculated for [C20H22O4H] requires m/z 327.1598, found m/z 
327.1595[M+H]+. 
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4,4,5,5-tetramethyl-2-(3-(3-vinylphenoxy)phenyl)-1,3-dioxolane (6.27) 
 
To a 50 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyltriphenylphosphonium bromide (6.26) (2.2 g, 6.13 mmol) in 
anhydrous tetrahydrofuran (30 mL) and the flask was cooled to 0 °C. Then sodium 
hydride (60% w/w in mineral oil [235.0 mg, 6.13 mmol]) was added and the mixture 
was stirred at 0 °C for 10 minutes. Then 3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenoxy)benzaldehyde (6.24) (1.0 g, 3.06 mmol) was added and the mixture was 
stirred at 0 °C for an additional 30 minutes. The reaction mixture was diluted with ethyl 
acetate (100 mL), transferred into a 250 mL separating funnel, washed with saturated 
brine (100 mL), dried with magnesium sulphate, filtered and the solvent removed under 
reduced pressure. The crude material was purified by flash chromatography on silica gel 
(20% diethyl ether in 40-60 PET, Rf = 0.35) to afford a yellow oil. Subsequent 
physicochemical analysis confirmed this to be the title compound (6.27) (0.87 g, 2.7 
mmol, 88% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32 (t, J 7.7 Hz, 1H, ArH), 7.30 – 7.27 (m, 1H, ArH), 
7.23 (d, J 7.7 Hz, 1H, ArH), 7.19 – 7.18 (m, 1H, ArH), 7.14 (d, J 7.7 Hz, 1H, ArH), 
7.07 (t, J 2.0 Hz, 1H, ArH), 6.96 (ddd, J 8.1, 2.5, 0.9 Hz, 1H, ArH), 6.90 (dd, J 8.1, 1.8 
Hz, 1H, ArH), 6.66 (dd, J 17.6, 10.9 Hz, 1H, CHCH2), 5.94 (s, 1H, O-CH-O), 5.71 (d, J 
17.6 Hz, 1H, CHCH2), 5.25 (d, J 10.9 Hz, 1H, CHCH2), 1.31 (s, 6H, 2 x CH3), 1.24 (s, 
6H, 2 x CH3); 
13C NMR (126 MHz, CDCl3) δ 157.5, 157.3, 142.1, 139.6, 136.4, 129.9, 
129.8, 121.5, 121.4, 119.1, 118.5, 116.9, 116.7, 114.7, 99.6, 82.9, 24.4, 22.3; FT-IR 
(thin film) 2977 (C-H), 2929 (H2C=C-H), 1574/1485 (C=C aromatic), 1253/1156 
(C(O)C), 1086/792 (C-H bend) cm-1; MS (MALDI) 323.2 [M-H]+; HRMS (HNESP) 
exact mass calculated for [C21H24O3H] requires m/z 325.1798, found m/z 
325.1801[M+H]+. 
 
 
159 
 
benzyl (R)-2-hydroxy-1-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl) 
phenoxy)phenyl)ethylcarbamate (R)-(6.32) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (489.0 mg, 3.24 mmol) and sodium hydroxide (129.0 mg, 
3.24 mmol). 1-propanol (4 mL) and distilled water (5 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.37 mL, 3.24 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of 
(DHQD)2PHAL (6.30) (50.4 mg, 0.06 mmol) in 1-propanol (2 mL) was added, 
followed by a solution of 4,4,5,5-tetramethyl-2-(3-(3-vinylphenoxy)phenyl)-1,3-
dioxolane (6.27) (350.0 mg, 1.08 mmol) in 1-propanol (4 mL).  Potassium osmate 
dihydrate (6.31) (15.9 mg, 0.04 mmol) added at 0 °C and the reaction was stirred for     
3 hours changing the colour from dark green to deep yellow. The mixture was quenched 
with saturated aqueous sodium sulfite solution (30 mL) at 0 °C, diluted with ethyl 
acetate (50 mL) and transferred into a 100 mL separating funnel. The organic layer was 
separated and washed with saturated brine (40 mL), dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (30% ethyl acetate in 40-60 PET,          
Rf = 0.26) to afford a pale yellow oil. Subsequent physicochemical analysis confirmed 
this to be the title compound (R)-(6.32) (0.35 g, 0.7 mmol, 65% yield). A sample was 
submitted to chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 
85 /15, 1 mL / min,  8.85 min (1st peak),  17.31 min (2nd peak), 96% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.22 (m, 8H, ArH), 7.18 – 7.15 (m, 1H, ArH), 
7.01 (d, J 7.7 Hz, 1H, ArH), 7.00 – 6.91 (m, 2H, ArH), 6.89 (d, J 7.7 Hz, 1H, ArH), 
5.93 (s, 1H, O-CH-O), 5.57 (s, 1H, NH), 5.12 (d, J 12.2 Hz, 1H, O-CHH-Ph), 5.07 (d, J 
12.2 Hz, 1H, O-CHH-Ph), 4.81 (s, 1H, Cα-H), 3.81 (m, 2H, CH2OH), 2.14 (s, 1H, OH), 
1.30 (s, 6H, 2 x CH3), 1.25 (s, 6H, 2 x CH3); 
13C NMR (126 MHz, CDCl3) δ 157.8, 
156.9, 156.4, 142.1, 141.4, 141.4, 136.3, 130.2, 129.9, 128.7, 128.3, 121.7, 121.4, 
119.3, 117.9, 117.1, 117.1, 99.5, 82.9, 67.2, 66.4, 56.9, 24.4, 22.3; [α]D
25
 -15.1 (c 1.0 
CHCl3); FT-IR (thin film) 3406 (NH), 3333 (OH), 2977 (C-H), 1704 (C=O), 1584/1486 
(C=C aromatic), 1255/1159 (C(O)C), 1086/736 (C-H bend) cm-1; MS (MALDI) 514.4 
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[M+Na]+; HRMS (HNESP) exact mass calculated for [C29H33N1O6NH4] requires m/z 
509.2646, found m/z 509.2655[M+NH4]
+. 
 
methyl (R)-2-(benzyloxycarbonylamino)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-
2-yl)phenoxy)phenyl)acetate (R)-(6.40) 
 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl (R)-2-hydroxy-1-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl) 
phenoxy)phenyl)ethylcarbamate (R)-(6.32) (0.3 g, 0.61 mmol). Acetone (10 mL) and 
aqueous sodium hydrogen carbonate solution (5 mL) were added and the mixture was 
cooled to 0 °C. To this solution was added sequentially potassium bromide (6.38) (8.0 
mg, 0.07 mmol) and TEMPO (6.36) (2,2,6,6-tetramethyl piperidinyloxy, free radical) 
(105.0 mg, 0.67 mmol). Sodium hypochlorite (6.37) (11% chlorine) (1.03 mL, 1.83 
mmol) was added dropwise via syringe over a period of 10 min, while the mixture was 
vigorously stirred and maintained at 0 °C. After 3 hours, acetone was removed under 
reduced pressure, the residue was diluted with distilled water (10 mL), transferred into a 
50 mL separating funnel and washed with diethyl ether (2 x 20 mL). The aqueous phase 
was acidified to pH 4 and extracted with ethyl acetate (2 x 20 mL). The combined 
organic layers were washed with saturated brine (10 mL), dried with magnesium 
sulphate, filtered and the solvent removed under reduced pressure to yield crude 
carboxylic acid derivative (R)-(6.39) (0.27 g, 0.53 mmol, 87% yield) as colourless oil, 
which was used in the next step without purification. To a 50 mL flame dried round 
bottom flask, equipped with a magnetic stirrer bar, under nitrogen was added crude 
carboxylic acid derivative (R)-(6.39) (200.0 mg, 0.40 mmol) and potassium carbonate 
(109.0 mg, 0.80 mmol). Anhydrous N,N-dimethylformamide (3 mL) was added via 
syringe, followed by iodomethane (0.05 mL, 0.80 mmol). After 2 hours, the reaction 
was diluted with ethyl acetate (50 mL) and transferred into a 100 mL separating funnel. 
The organic layer was washed with distilled water (5 x 25 mL), saturated brine (30 mL), 
dried with magnesium sulphate, filtered and the solvent removed under reduced 
pressure. The crude material was purified by flash chromatography on silica gel (30% 
diethyl ether in 40-60 PET, Rf = 0.31) to afford an orange oil. Subsequent 
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physicochemical analysis confirmed this to be the title compound (R)-(6.40)  (190.0 mg, 
0.37 mmol, 92% yield). 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.26 (m, 8H, ArH), 7.18 – 7.16 (m, 1H, ArH), 
7.09 (d, J 7.3 Hz, 1H, ArH), 7.04 (s, 1H, ArH), 6.97 – 6.90 (m, 2H, ArH), 5.94 (s, 1H, 
O-CH-O), 5.81 (d, J 7.3 Hz, 1H, NH), 5.36 (d, J 7.3 Hz, 1H, Cα-H), 5.13 (d, J 12.2 Hz, 
1H, O-CHH-Ph), 5.08 (d, J 12.2 Hz, 1H, O-CHH-Ph), 3.73 (s, 3H, OCH3), 1.30 (s, 6H, 
2 x CH3), 1.24 (s, 6H, 2 x CH3); 
13C NMR (126 MHz, CDCl3) δ 171.1, 157.9, 156.7, 
155.4, 142.2, 138.6, 136.2, 130.3, 129.9, 128.7, 128.4, 128.3, 121.9, 121.8, 119.3, 
118.6, 117.6, 117.2, 99.5, 82.9, 67.3, 57.7, 53.0, 24.4, 22.3; [α]D
23
 -14.8 (c 1.0 CHCl3); 
FT-IR (thin film) 3326 (NH), 2977 (C-H), 1727 (C=O), 1724 (C=O), 1585/1486 (C=C 
aromatic), 1251/1159 (C(O)C), 1058/697 (C-H bend) cm-1; MS (MALDI) 542.4 
[M+Na]+; HRMS (HNESP) exact mass calculated for [C30H33N1O7 NH4] requires m/z 
537.2595, found m/z 537.2601 [M+NH4]
+. 
 
methyl (R)-2-amino-2-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl) 
phenoxy)phenyl)acetate (R)-(6.45) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added methyl (R)-2-(benzyloxycarbonylamino)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-
dioxolan-2-yl)phenoxy)phenyl)acetate (R)-(6.40) (0.2 g, 0.39 mmol) and palladium on 
carbon (10% w/w) (41.0 mg, 0.04 mmol). Ethyl acetate (5 mL) was added via syringe 
and the flask was sealed with suba-seal rubber septum. Then, hydrogen gas atmosphere 
was introduced through the septum and the reaction was stirred at 25 °C for 2 hours. At 
this point the reaction mixture was passed through a short plug of celite and eluted with 
ethyl acetate (10 mL). The solvent was removed under reduced pressure to afford a 
colourless oil. Subsequent physicochemical analysis confirmed this to be the title 
compound (R)-(6.45) (130.0 mg, 0.34 mmol, 88% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.27 (m, 2H, ArH), 7.24 (d, J 7.7 Hz, 1H, ArH), 
7.19 – 7.16 (m, 1H, ArH), 7.11 (d, J 7.7 Hz, 1H, ArH), 7.07 – 7.03 (m, 1H, ArH), 6.96 
(ddd, J 8.1, 2.4, 0.9 Hz, 1H, ArH), 6.91 (dd, J 8.2, 1.6 Hz, 1H, ArH), 5.94 (s, 1H, O-
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CH-O), 4.59 (s, 1H, Cα-H), 3.71 (s, 3H, OCH3), 1.30 (s, 6H, 2 x CH3), 1.24 (s, 6H, 2 x 
CH3); 
13C NMR (126 MHz, CDCl3) δ 174.2, 157.7, 156.9, 142.2, 130.2, 129.9, 121.7, 
121.5, 119.3, 118.3, 117.5, 117.1, 99.6, 82.9, 58.6, 52.6, 29.8, 24.4, 22.3; [α]D
25
 -17.3 (c 
1.0 CHCl3); FT-IR (thin film) 3389 (NH2), 2978 (C-H), 1740 (C=O), 1585/1484 (C=C 
aromatic), 1253/1157 (C(O)C), 1063/800 (C-H bend) cm-1; MS (MALDI) 424.3 
[M+K]+; HRMS (HNESP) exact mass calculated for [C22H27N1O5H] requires m/z 
386.1962, found m/z 386.1964 [M+H]+. 
 
methyl (R)-2-(2-bromoacetamido)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl) 
phenoxy)phenyl)acetate (R)-(6.47) 
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyl (R)-2-amino-2-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenoxy)phenyl)acetate (R)-(6.45) (0.1 g, 0.26 mmol). Anhydrous dichloromethane 
(5 mL) was added via syringe and the reaction was cooled to 0 °C. Then triethylamine 
(0.07 mL, 0.52 mmol) was added, followed by bromoacetyl bromide (6.46) (0.03 mL, 
0.39 mmol) and the mixture was stirred at 0 °C for 1 hour. The reaction mixture was 
diluted with dichloromethane (5 mL), transferred into a 25 mL separating funnel, 
washed with aqueous 1M hydrochloric acid (10 mL), saturated aqueous sodium 
hydrogen carbonate (10 mL), saturated brine (10 mL), dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (40% diethyl ether in pentane, Rf = 0.41) 
to afford a yellow oil. Subsequent physicochemical analysis confirmed this to be the 
title compound (R)-(6.47) (94.0 mg, 0.18 mmol, 72% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.42 (d, J 6.9 Hz, 1H, NH), 7.36 – 7.26 (m, 3H, ArH), 
7.19 – 7.16 (m, 1H, ArH), 7.10 (d, J 7.7 Hz, 1H, ArH), 7.03 (t, J 2.0 Hz, 1H, ArH), 6.98 
– 6.91 (m, 2H, ArH), 5.94 (s, 1H, O-CH-O), 5.51 (d, J 6.9 Hz, 1H, Cα-H), 3.89           
(d, J 13.7 Hz, 1H, CHHBr), 3.89 (d, J 13.7 Hz, 1H, CHHBr), 3.75 (s, 3H, OCH3), 1.30 
(s, 6H, 2 x CH3), 1.24 (s, 6H, 2 x CH3); 13C NMR (126 MHz, CDCl3) δ 170.5, 165.1, 
158.0, 156.6, 142.3, 137.7, 130.4, 129.9, 121.9, 121.8, 119.4, 118.7, 117.4, 117.3, 99.5, 
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82.9, 56.7, 53.2, 28.6, 24.4, 22.3; [α]D
26
 -24.1 (c 1.0 CHCl3); FT-IR (thin film) 3298 
(NH), 2978 (C-H), 1746 (C=O), 1662 (C=O), 1585/1485 (C=C aromatic), 1252/1157 
(C(O)C), 1087 (C-H bend), 663 (C-Br) cm-1; MS (MALDI) 546.4 [M+K]+; HRMS 
(HNESP) exact mass calculated for [C24H28
79Br1N1O6Na] requires m/z 528.0992, found 
m/z 528.0982 [M+Na]+. 
 
methyl (R)-2-(2-diazoacetamido)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenoxy)phenyl)acetate (R)-(6.49) 
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyl (R)-2-(2-bromoacetamido)-2-(3-(3-(4,4,5,5-tetramethyl-1,3-
dioxolan-2-yl)phenoxy)phenyl)acetate (R)-(6.47) (0.1 g, 0.20 mmol). Anhydrous 
tetrahydofuran (5 mL) was added via syringe and the reaction was cooled to 0 °C. Then 
N,N'-ditosylhydrazine (6.48) (0.1 g, 0.30 mmol) was added, followed by 1,8-
diazabicyclo[5.4.0]undec-7-ene (0.09 mL, 0.6 mmol) and the mixture was stirred at        
0 °C for 2 hours. Then the solvent was removed under reduced pressure, the residue was 
re-dissolved in diethyl ether, passed through a short plug of silica and eluted with 
diethyl ether. The solvent removed under reduced pressure and the crude material was 
purified by flash chromatography on silica gel (40% diethyl ether in pentane, Rf = 0.33) 
to afford a pale yellow oil. Subsequent physicochemical analysis confirmed this to be 
the title compound (R)-(6.49) (68.0 mg, 0.15 mmol, 76% yield). A sample was 
submitted to chiral analytical HPLC analysis [Cellulose 1, iso-hexane / iso-propanol : 
80 / 20, 1 mL / min,  8.82 min (1st peak),  12.94 min (2nd peak), 94% e.e.].  
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.27 (m, 2H, ArH), 7.24 (s, 1H, ArH), 7.17 – 7.15 
(m, 1H, ArH), 7.09 (d, J 7.7 Hz, 1H, ArH), 7.01 (t, J 2.0 Hz, 1H, ArH), 6.95 (ddd, J 8.1, 
2.5, 1.0 Hz, 1H, ArH), 6.91 (ddd, J 8.2, 2.4, 0.8 Hz, 1H, ArH), 6.13 (d, J 6.9 Hz, 1H, 
NH), 5.93 (s, 1H, O-CH-O), 5.61 (d, J 5.5 Hz, 1H, Cα-H), 4.82 (s, 1H, CHN2), 3.73 (s, 
3H, OCH3), 1.30 (s, 6H, 2 x CH3), 1.24 (s, 6H, 2 x CH3); 13C NMR (126 MHz, CDCl3) 
δ 171.4, 165.0, 157.9, 156.7, 142.2, 138.6, 130.4, 129.9, 122.1, 121.8, 119.4, 118.6, 
117.5, 117.2, 99.5, 82.9, 56.5, 53.1, 47.7, 24.4, 22.3; [α]D
25
 -19.8 (c 1.0 CHCl3); FT-IR 
164 
 
(thin film) 3353 (NH), 2977 (C-H), 2105 (N2), 1746 (C=O), 1585/1485 (C=C aromatic), 
1248/1156 (C(O)C), 1087/966 (C-H bend) cm-1; HRMS (HNESP) exact mass calculated 
for [C24H27N3O6Na] requires m/z 476.1792, found m/z 476.1784 [M+Na]
+. 
 
methyl cis-2-(4-(benzyloxy)phenyl)-3-(((R)-2-methoxy-2-oxo-1-(3-(3-(4,4,5,5-tetramethyl-
1,3-dioxolan-2-yl)phenoxy)phenyl)ethyl)carbamoyl)aziridin-1-yl)-2-methylpropanoate    
cis-(6.55) 
 
A flame dried Biotage 2 mL microwave vial was charged with, methyl 2-amino-2-
methylpropanoate (6.52) (11.2 mg, 0.09 mmol), 4-benzyloxybenzaldehyde (6.51) (19.8 
mg, 0.10 mmol) and activated 4Å molecular sieves (~ 100 mg) in anhydrous 
dichloromethane (0.5 mL) under nitrogen. After the formation of the corresponding 
imine was confirmed by 1H-NMR analysis, pyridinium triflate (5.5) (2.2 mg, 0.01 
mmol, 10 mol%) was added, the vial was sealed with a PTFE crimp cap and the 
reaction mixture was cooled to 0 °C. Then methyl (R)-2-(2-diazoacetamido)-2-(3-(3-
(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenoxy)phenyl)acetate (R)-(6.49) (39.3 mg, 
0.09 mmol) in dichloromethane (0.5 mL) was added via syringe and the reaction 
mixture was stirred at 0 °C, monitoring by 1H-NMR until the reaction was deemed 
complete. At this point the reaction mixture was passed through a short plug of silica 
and eluted with dichloromethane. The solvent removed under reduced pressure and the 
crude material was purified by flash chromatography on silica gel (15% diethyl ether in 
pentane, Rf = 0.2) to afford a colourless oil. Subsequent physicochemical analysis 
confirmed this to be the title compound cis-(6.55)  (37.4 mg, 0.05 mmol, 52% yield). 
1H NMR (500 MHz, CDCl3) δ 7.63 (d, J 7.7 Hz, 1H, NH), 7.42 – 7.36 (m, 4H, ArH), 
7.34 – 7.29 (m, 4H, ArH), 7.24 (d, J 8.0 Hz, 2H, ArH), 7.16 (s, 1H, ArH), 7.03 (d, J 7.6 
Hz, 1H, ArH), 6.99 (d, J 1.8 Hz, 1H, ArH), 6.94 – 6.85 (m, 4H, ArH), 5.93 (s, 1H, O-
CH-O), 5.23 (d, J 7.7 Hz, 1H, Cα-H), 5.03 (s, 2H, OCH2Ph), 3.66 (s, 3H, OCH3), 3.55 
(s, 3H, OCH3), 3.30 (d, J 6.8 Hz, 1H, C3-H), 2.84 (d, J 6.8 Hz, 1H, C2-H), 1.42 (s, 3H, 
CH3), 1.30 (s, 6H, 2 x CH3), 1.29 (s, 3H, CH3), 1.24 (s, 6H, 2 x CH3); 13C NMR (126 
MHz, CDCl3) δ 174.3, 170.3, 167.3, 158.4, 157.7, 156.9, 142.2, 138.9, 137.1, 130.1, 
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129.8, 129.0, 128.7, 128.1, 127.6, 127.5, 121.7, 121.6, 119.2, 118.3, 117.4, 117.2, 
114.6, 99.5, 82.9, 70.2, 61.4, 55.3, 52.7, 52.3, 41.9, 41.1, 24.5, 24.4, 22.3, 21.5; [α]D
25
 -
9.8 (c 0.4 CHCl3); FT-IR (thin film) 3380 (NH), 2979 (C-H), 1739 (C=O), 1682 (C=O), 
1585/1514 (C=C aromatic), 1249/1150 (C(O)C), 1086/1010 (C-H bend) cm-1; HRMS 
(HNESP) exact mass calculated for [C43H48N2O9H] requires m/z 737.3433, found m/z 
737.3435 [M+H]+. 
 
methyl cis-2-(4-(benzyloxy)phenyl)-3-(((R)-2-methoxy-2-oxo-1-phenylethyl) 
carbamoyl)aziridin-1-yl)-2-methylpropanoate cis-(6.60) 
 
A flame dried Biotage 2 mL microwave vial was charged with, methyl 2-amino-2-
methylpropanoate (6.52) (11.2 mg, 0.09 mmol), 4-benzyloxybenzaldehyde (6.51) (19.8 
mg, 0.10 mmol) and activated 4Å molecular sieves (~ 100 mg) in anhydrous 
dichloromethane (0.5 mL) under nitrogen. After the formation of the corresponding 
imine was confirmed by 1H-NMR analysis, pyridinium triflate (5.5) (2.2 mg, 0.01 
mmol, 10 mol%) was added, the vial was sealed with a PTFE crimp cap and cooled to 0 
°C. Then methyl (R)-2-(2-diazoacetamido)-2-phenylacetate (R)-(6.59) (22.3 mg, 0.09 
mmol) in dichloromethane (0.5 mL) was added via syringe and the reaction mixture was 
stirred at 0 °C, monitoring by 1H-NMR until the reaction was deemed complete. At this 
point the reaction mixture was passed through a short plug of silica and eluted with 
dichloromethane. The solvent removed under reduced pressure and the crude material 
was purified by flash chromatography on silica gel (15% diethyl ether in pentane, Rf = 
0.24) to afford a colourless oil. Subsequent physicochemical analysis confirmed this to 
be the title compound cis-(6.60) (26.7 mg, 0.05 mmol, 55% yield). 
1H NMR (500 MHz, CDCl3) δ 7.63 (d, J 7.7 Hz, 1H, NH), 7.45 – 7.36 (m, 4H, ArH), 
7.35 – 7.27 (m, 8H, ArH), 6.90 (d, J 8.7 Hz, 2H, ArH), 5.26 (d, J 7.8 Hz, 1H, Cα-H), 
5.04 (s, 2H, OCH2Ph), 3.66 (s, 3H, OCH3), 3.54 (s, 3H, OCH3), 3.31 (d, J 6.8 Hz, 1H, 
C3-H), 2.83 (d, J 6.8 Hz, 1H, C2-H), 1.44 (s, 3H, CH3), 1.30 (s, 3H, CH3); 
13C NMR 
(126 MHz, CDCl3) δ 174.3, 170.6, 167.2, 158.4, 137.1, 137.0, 129.0, 128.9, 128.7, 
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128.4, 128.1, 127.6, 127.5, 127.0, 114.7, 70.2, 61.4, 55.6, 52.6, 52.3, 41.9, 41.2, 24.4, 
21.5; [α]D
25
 -32.1 (c 1.0 CHCl3); FT-IR (thin film) 3382 (NH), 2952 (C-H), 1739 (C=O), 
1678 (C=O), 1514 (C=C aromatic), 1242/1145 (C(O)C), 1018 (C-H bend) cm-1; MS 
(MALDI) 555.0 [M+K]+; HRMS (HNESP) exact mass calculated for [C30H32N2O6H] 
requires m/z 517.2333, found m/z 517.2318 [M+H]+. 
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8.9. Synthesis of α-arylglycinols 
 
benzyl (2-hydroxy-1-(3-nitrophenyl)ethyl)carbamate (±)-(8.22) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (365.0 mg, 2.41 mmol) and sodium hydroxide (97.0 mg, 
2.41 mmol). 1-Propanol (2 mL) and distilled water (3 mL) were added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.27 mL, 2.41 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of 
(DHQ)2PHAL (8.21) (18.8 mg, 0.02 mmol) and (DHQD)2PHAL (6.30) (18.8 mg, 0.02 
mmol) in 1-propanol (1 mL) was added, followed by a solution of 1-nitro-3-
vinylbenzene (8.20) (120.0 mg, 0.80 mmol) in 1-propanol (3 mL).  Potassium osmate 
dihydrate (6.31) (11.8 mg, 0.03 mmol) added at 0 °C and the reaction was stirred for      
3 hours changing the colour from dark green to deep yellow. The mixture was quenched 
with saturated aqueous sodium sulfite solution (30 mL) at 0 °C, diluted with ethyl 
acetate (50 mL) and transferred into a 100 mL separating funnel. The organic layer was 
separated and washed with saturated brine (40 mL), dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (30% ethyl acetate in 40-60 PET,           
Rf = 0.29) to afford a white solid. Subsequent physicochemical analysis confirmed this 
to be the title compound (±)-(8.22) (210.0 mg, 0.66 mmol, 83% yield).  
1H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H, ArH), 8.10 (d, J 7.9 Hz, 1H, ArH), 7.61 (d, J 
6.8 Hz, 1H, ArH), 7.47 (t, J 7.9 Hz, 1H, ArH), 7.32 (br s, 5H, ArH), 6.00 (br s, 1H, 
NH), 5.11 – 5.02 (m, 2H, BnOCH2), 4.89 (br s, 1H, Cα-H), 3.86 (s, 1H, CH2OH), 3.77 
(s, 1H, CH2OH), 2.70 (br s, 1H, OH); 13C NMR (126 MHz, CDCl3) δ 156.5, 148.5, 
142.1, 136.0, 133.2, 129.7, 128.6, 128.4, 128.2, 122.8, 121.7, 67.4, 65.4, 56.4; M.p. 84 - 
86 °C (from diethyl ether) [lit. 85 - 86 °C]; FT-IR (thin film) 3396 (NH), 3317 (OH), 
2945 (C-H), 1695 (C=O), 1531/1351 (NO2), 1255 (C(O)C), 1056/902 (C-H bend) cm
-1. 
The spectroscopic data is consistent with that reported in the literature.101 
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benzyl (R)-(α-13C-2-hydroxy-1-(3-nitrophenyl)ethyl)carbamate (R)-(7.7) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (91.0 mg, 0.60 mmol) and sodium hydroxide (24.0 mg, 
0.60 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.07 mL, 0.60 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of  
(DHQD)2PHAL (6.30) (9.4 mg, 0.01 mmol) in 1-propanol (1 mL) was added, followed 
by a solution of α-13C-1-nitro-3-vinylbenzene (7.6) (30.0 mg, 0.20 mmol) in 1-propanol 
(3 mL).  Potassium osmate dihydrate (6.31) (3.0 mg, 8.0 µmol) added at 0 °C and the 
reaction was stirred for 3 hours changing the colour from dark green to deep yellow. 
The mixture was quenched with saturated aqueous sodium sulfite solution (10 mL) at     
0 °C, diluted with ethyl acetate (20 mL) and transferred into a 50 mL separating funnel. 
The organic layer was separated and washed with saturated brine (10 mL), dried with 
magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (30% ethyl acetate in 
40-60 PET, Rf = 0.29) to afford a white solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (R)-(7.7) (41.0 mg, 0.13 mmol, 65% yield). A 
sample was submitted to chiral analytical HPLC analysis [Cellulose 3, iso-hexane / iso-
propanol : 90 / 10, 1 mL / min,  51.6 min (1st peak),  65.0 min (2nd peak), 93% e.e.]. 
1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H, ArH), 8.15 (d, J 7.9 Hz, 1H, ArH), 7.65 (s, 
1H, ArH), 7.52 (t, J 7.9 Hz, 1H, ArH), 7.36 (s, 5H, ArH), 5.78 (s, 1H, NH), 5.22 – 4.97 
(m, 2H, BnOCH2), 4.92 (d, J13C-H 136.1 Hz, 1H, 
13Cα-H), 4.03 – 3.70 (m, 2H, CH2OH); 
13C NMR (126 MHz, CDCl3) δ 156.3, 148.6 (d, JC-13C 4.3 Hz), 142.2, 136.1, 133.2, 
129.8 (d, JC-13C 3.9 Hz), 128.7, 128.5, 128.4, 122.9, 121.8 (d, JC-13C 3.0 Hz), 67.4, 65.7 
(d, JC-13C 37.6 Hz), 56.3; M.p. 83 - 85 °C (from diethyl ether) [lit. 85 - 86 °C]; [α]D
24
 -
25.6 (c 0.5 CHCl3); FT-IR (thin film) 3386 (OH), 2937 (C-H), 1698 (C=O), 1533/1350 
(NO2), 1254 (C(O)C), 1054/738 (C-H bend) cm
-1; MS (MALDI) 341.8 [M+Na]+; 
HRMS (HNESP) exact mass calculated for [C15
13C1H16N2O5H] requires m/z 318.1166, 
found m/z 318.1165 [M+H]+. 
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benzyl (2-hydroxy-1-(4-nitrophenyl)ethyl)carbamate (±)-(8.24) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (304.0 mg, 2.01 mmol) and sodium hydroxide (80.0 mg, 
2.01 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.23 mL, 2.01 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of 
(DHQ)2PHAL (8.21) (15.7 mg, 0.02 mmol) and (DHQD)2PHAL (6.30) (15.7 mg, 0.02 
mmol) in 1-propanol (1 mL) was added, followed by a solution of 1-nitro-3-
vinylbenzene (8.23) (100.0 mg, 0.67 mmol) in 1-propanol (3 mL).  Potassium osmate 
dihydrate (6.31) (9.9 mg, 0.03 mmol) added at 0 °C and the reaction was stirred for 3 
hours changing the colour from dark green to deep yellow. The mixture was quenched 
with saturated aqueous sodium sulfite solution (30 mL) at 0 °C, diluted with ethyl 
acetate (50 mL) and transferred into a 100 mL separating funnel. The organic layer was 
separated and washed with saturated brine (40 mL), dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (30% ethyl acetate in 40-60 PET, Rf = 
0.31) to afford a white solid. Subsequent physicochemical analysis confirmed this to be 
the title compound (±)-(8.24) (167.0 mg, 0.53 mmol, 79% yield). 
1H NMR (500 MHz, CDCl3) δ 8.16 (d, J 7.7 Hz, 2H, ArH), 7.46 (d, J 6.8 Hz, 2H, ArH), 
7.34 (br s, 5H, ArH), 5.84 (s, 1H, NH), 5.10 (d, J 11.4 Hz, 1H, BnOCHH), 5.06 (d, J 
11.4 Hz, 1H, BnOCHH), 4.89 (s, 1H, Cα-H), 3.97 – 3.74 (m, 2H, CH2OH), 2.30 (br s, 
OH); 13C NMR (126 MHz, CDCl3) δ 156.4, 147.5, 147.2, 136.1, 128.7, 128.5, 128.3, 
127.7, 123.9, 67.4, 65.5, 56.5; M.p. 114 - 116 °C (from diethyl ether) [lit. 110 - 111 °C]; 
FT-IR (thin film) 3396 (NH), 3319 (OH), 3068 (C-H), 1965 (C=O), 1520/1349 (NO2), 
1258 (C(O)C), 1056/854 (C-H bend) cm-1. 
 
 
The spectroscopic data is consistent with that reported in the literature.101 
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benzyl (R)-(2,2-di-2H-2-hydroxy-1-(4-nitrophenyl)ethyl)carbamate (R)-(7.13) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (90.0 mg, 0.60 mmol) and sodium hydroxide (23.8 mg, 
0.60 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.07 mL, 0.60 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of  
(DHQD)2PHAL (6.30) (9.3 mg, 0.01 mmol) in 1-propanol (1 mL) was added, followed 
by a solution of 1-(β-di-2H-vinyl)-4-nitrobenzene (7.12) (30.0 mg, 0.20 mmol) in 1-
propanol (3 mL).  Potassium osmate dihydrate (6.31) (2.9 mg, 7.9 µmol) added at 0 °C 
and the reaction was stirred for 3 hours changing the colour from dark green to deep 
yellow. The mixture was quenched with saturated aqueous sodium sulfite solution (10 
mL) at 0 °C, diluted with ethyl acetate (20 mL) and transferred into a 50 mL separating 
funnel. The organic layer was separated and washed with saturated brine (10 mL), dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (30% ethyl acetate in 
40-60 PET, Rf = 0.31) to afford a white solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (R)-(7.13) (38.0 mg, 0.12 mmol, 60% yield). A 
sample was submitted to chiral analytical HPLC analysis [Cellulose 3, iso-hexane / iso-
propanol : 90 / 10, 1 mL / min,  51.2 min (1st peak),  55.0 min (2nd peak), 98% e.e.]. 
1H NMR (500 MHz, CDCl3) δ 8.20 (d, J 7.4 Hz, 2H, ArH), 7.49 (d, J 7.4 Hz, 2H, ArH), 
7.35 (br s, 5H, ArH), 5.70 (d, J 6.4 Hz, 1H, NH), 5.12 (d, J 11.3 Hz, 1H, BnOCHH), 
5.07 (d, J 11.3 Hz, 1H, BnOCHH), 4.91 (s, 1H, Cα-H), 1.85 (br s, 1H, OH); 13C NMR 
(126 MHz, CDCl3) δ 156.3, 147.5, 147.2, 136.1, 128.7, 128.5, 128.4, 127.7, 124.0, 67.4, 
64.9 (t, JC-D 22.1 Hz), 56.4; 
2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 3.87 (br s), 
3.76 (br s); M.p. 119 - 121 °C (from diethyl ether); [α]D
25
 -26.3 (c 0.5 CHCl3); FT-IR 
(thin film) 3334 (OH), 2951 (C-H), 1695 (C=O), 1520/1349 (NO2), 1270 (C(O)C), 
1061/854 (C-H bend) cm-1; MS (MALDI) 342.0 [M+Na]+; HRMS (HASP) exact mass 
calculated for [C16H14
2H2N2O5H] requires m/z 319.1258, found m/z 319.1259 [M+H]
+. 
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 benzyl (R)-(2-13C-2-hydroxy-1-(4-nitrophenyl)ethyl)carbamate (R)-(7.10) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (151.0 mg, 1.00 mmol) and sodium hydroxide (40.0 mg, 
1.00 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.11 mL, 1.00 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of  
(DHQD)2PHAL (6.30) (15.6 mg, 0.02 mmol) in 1-propanol (1 mL) was added, 
followed by a solution of 1-(β-13C-vinyl)-4-nitrobenzene (7.9)  (50.0 mg, 0.33 mmol) in 
1-propanol (3 mL).  Potassium osmate dihydrate (6.31) (4.9 mg, 13.0 µmol) added at 0 
°C and the reaction was stirred for 3 hours changing the colour from dark green to deep 
yellow. The mixture was quenched with saturated aqueous sodium sulfite solution (10 
mL) at 0 °C, diluted with ethyl acetate (20 mL) and transferred into a 50 mL separating 
funnel. The organic layer was separated and washed with saturated brine (10 mL), dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (30% ethyl acetate in 
40-60 PET, Rf = 0.31) to afford a white solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (R)-(7.10) (77.0 mg, 0.24 mmol, 73% yield). A 
sample was submitted to chiral analytical HPLC analysis [Cellulose 3, iso-hexane / iso-
propanol : 90 / 10, 1 mL / min,  51.7 min (1st peak),  55.0 min (2nd peak), 96% e.e.]. 
1H NMR (500 MHz, CDCl3) δ 8.20 (d, J 7.8 Hz, 2H, ArH), 7.49 (d, J 7.8 Hz, 2H, ArH), 
7.36 (s, 5H, ArH), 5.73 (s, 1H, NH), 5.12 (d, J 12.1 Hz, 1H, BnOCHH), 5.07 (d, J 12.1 
Hz, 1H, BnOCHH), 4.92 (br s, 1H, Cα-H), 3.96 (dd, J13C-H 147.0, J 12.5 Hz, 1H, 
13CH2OH), 3.85 (dd, J13C-H 143.4, J 9.5 Hz, 1H, 
13CH2OH); 13C NMR (126 MHz, 
CDCl3) δ 156.2, 147.6, 147.2, 136.1, 128.7, 128.5, 128.4, 127.7, 124.1, 67.4, 65.7, 48.7; 
M.p. 115 - 117 °C (from diethyl ether); [α]D
25
 -28.9 (c 0.5 CHCl3); FT-IR (thin film) 
3396 (OH), 2935 (C-H), 1695 (C=O), 1520/1348 (NO2), 1258 (C(O)C), 1045/853 (C-H 
bend) cm-1; MS (MALDI) 358.7 [M+K]+; HRMS (HASP) exact mass calculated for 
[C15
13C1H16N2O5H] requires m/z 318.1166, found m/z 318.1168 [M+H]
+. 
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benzyl (1-(4-bromophenyl)-2-hydroxyethyl)carbamate (±)-(7.5) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (248.0 mg, 1.64 mmol) and sodium hydroxide (65.6 mg, 
1.64 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.19 mL, 1.64 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of 
(DHQ)2PHAL (8.21) (10.6 mg, 14 µmol) and (DHQD)2PHAL (6.30) (10.6 mg, 14 
µmol) in 1-propanol (1 mL) was added, followed by a solution of 1-bromo-4-
vinylbenzene (7.4) (100.0 mg, 0.55 mmol) in 1-propanol (3 mL).  Potassium osmate 
dihydrate (6.31) (8.0 mg, 0.02 mmol) added at 0 °C and the reaction was stirred for 3 
hours changing the colour from dark green to deep yellow. The mixture was quenched 
with saturated aqueous sodium sulfite solution (30 mL) at 0 °C, diluted with ethyl 
acetate (50 mL) and transferred into a 100 mL separating funnel. The organic layer was 
separated and washed with saturated brine (40 mL), dried with magnesium sulphate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (20% ethyl acetate in 40-60 PET,          
Rf = 0.25) to afford a white solid. Subsequent physicochemical analysis confirmed this 
to be the title compound (±)-(7.5) (179.0 mg, 0.51 mmol, 94% yield). 
1H NMR (500 MHz, CDCl3) δ 7.47 (d, J 8.2 Hz, 2H, ArH), 7.35 (s, 5H, ArH), 7.18 (d, J 
8.2 Hz, 2H, ArH), 5.55 (d, J 4.7 Hz, 1H, NH), 5.09 (m, 2H, BnOCH2), 4.79 (s, 1H, Cα-
H), 3.85 (m, 2H, CH2OH); 
13C NMR (126 MHz, CDCl3) δ 156.4, 138.5, 136.2, 132.0, 
128.7, 128.5, 128.4, 121.9, 67.3, 66.1, 56.6; M.p. 128 - 130 °C (from diethyl ether) [lit. 
133 - 134 °C]; FT-IR (thin film) 3318 (OH), 1695 (C=O), 1541/1490 (C=C aromatic), 
1270 (C(O)C), 1055/698 (C-H bend) cm-1; HRMS (HNESP) exact mass calculated for 
[C16H16
79Br1N1O3H] requires m/z 350.0386, found m/z 350.0390 [M+H]
+. 
The spectroscopic data is consistent with that reported in the literature.101 
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benzyl (R)-(1-2H-1-(4-bromophenyl)-2-hydroxyethyl)carbamate (R)-(7.3) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (246.0 mg, 1.63 mmol) and sodium hydroxide (65.0 mg, 
1.63 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.18 mL, 1.63 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of  
(DHQD)2PHAL (6.30) (25.4 mg, 0.03 mmol) in 1-propanol (1 mL) was added, 
followed by a solution of α-2H-1-bromo-4-vinylbenzene (7.2) (100.0 mg, 0.54 mmol) in 
1-propanol (3 mL).  Potassium osmate dihydrate (6.31) (8.0 mg, 0.02 mmol) added at 0 
°C and the reaction was stirred for 3 hours changing the colour from dark green to deep 
yellow. The mixture was quenched with saturated aqueous sodium sulfite solution (10 
mL) at 0 °C, diluted with ethyl acetate (20 mL) and transferred into a 50 mL separating 
funnel. The organic layer was separated and washed with saturated brine (10 mL), dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% ethyl acetate in 
40-60 PET, Rf = 0.25) to afford a white solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (R)-(7.3) (129.0 mg, 0.37 mmol, 67% yield). A 
sample was submitted to chiral analytical HPLC analysis [Cellulose 3, iso-hexane / iso-
propanol : 90 / 10, 1 mL / min,  25.9 min (1st peak),  28.3 min (2nd peak), 94% e.e.]. 
1H NMR (500 MHz, CDCl3) δ 7.46 (d, J 7.9 Hz, 2H, ArH), 7.34 (m, 5H, ArH), 7.16 (d, 
J 7.9 Hz, 2H, ArH), 5.63 (s, 1H, NH), 5.10 (d, J 11.9 Hz, 1H, BnOCHH), 5.06 (d, J 
11.9 Hz, 1H, BnOCHH), 3.80 (m, 2H, CH2OH); 
13C NMR (126 MHz, CDCl3) δ 156.4, 
138.4, 136.2, 132.0, 131.8, 128.7, 128.5, 127.7, 121.8, 67.2, 66.0, 56.2 (m); 2H NMR 
(77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 4.69 (br s); M.p. 125 - 127 °C (from diethyl 
ether); [α]D
25
 -21.1 (c 0.5 CHCl3); FT-IR (thin film) 3318 (OH), 2942 (C-H), 1688 
(C=O), 1532 (C=C aromatic), 1270 (C(O)C), 1047/824 (C-H bend) cm-1; HRMS 
(HNESP) exact mass calculated for [C16H15
2H1
79Br1N1O3H] requires m/z 351.0449, 
found m/z 351.0452 [M+H]+. 
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benzyl (2-hydroxy-1-(naphthalen-2-yl)ethyl)carbamate (±)-(8.26) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (294.0 mg, 1.95 mmol) and sodium hydroxide (78.0 mg, 
1.95 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.22 mL, 1.95 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of 
(DHQ)2PHAL (8.21) (15.1 mg, 19 µmol) and (DHQD)2PHAL (6.30) (15.1 mg, 19 
µmol) in 1-propanol (1 mL) was added, followed by a solution of 2-vinylnaphthalene 
(8.25) (100.0 mg, 0.55 mmol) in 1-propanol (3 mL).  Potassium osmate dihydrate (6.31) 
(9.6 mg, 26 µmol) added at 0 °C and the reaction was stirred for 3 hours changing the 
colour from dark green to deep yellow. The mixture was quenched with saturated 
aqueous sodium sulfite solution (30 mL) at 0 °C, diluted with ethyl acetate (50 mL) and 
transferred into a 100 mL separating funnel. The organic layer was separated and 
washed with saturated brine (40 mL), dried with magnesium sulphate, filtered and the 
solvent removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (25% ethyl acetate in 40-60 PET, Rf = 0.24) to afford a 
white solid. Subsequent physicochemical analysis confirmed this to be the title 
compound (±)-(8.26) (181.0 mg, 0.56 mmol, 87% yield).  
1H NMR (500 MHz, CDCl3) δ 7.84 – 7.77 (m, 3H, ArH), 7.73 (s, 1H, ArH), 7.50 – 7.46 
(m, 2H, ArH), 7.46 – 7.26 (m, 6H, ArH), 5.82 (s, 1H, NH), 5.10 (m, 2H, BnOCH2), 4.99 
(s, 1H, Cα-H), 3.87 (m, 2H, CH2OH), 2.61 (s, 1H, OH); 13C NMR (126 MHz, CDCl3) δ 
156.6, 136.7, 136.3, 133.4, 133.0, 128.7, 128.6, 128.3, 128.0, 127.7, 126.4, 126.2, 
125.5, 124.6, 67.1, 66.2, 57.3; M.p. 141 - 143 °C (from diethyl ether) [lit. 146 - 147 °C]; 
FT-IR (thin film) 3397 (NH), 3322 (OH), 2947 (C-H), 1695 (C=O), 1532 (C=C 
aromatic), 1260 (C(O)C), 1055/745 (C-H bend) cm-1; HRMS (HNESP) exact mass 
calculated for [C20H19N1O3H] requires m/z 322.1438, found m/z 322.1441 [M+H]
+. 
The spectroscopic data is consistent with that reported in the literature.101 
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benzyl (R)-(1-2H-2-hydroxy-1-(naphthalen-2-yl)ethyl)carbamate (R)-(7.15) 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added benzyl carbamate (467.0 mg, 3.10 mmol) and sodium hydroxide (124.0 mg, 
3.10 mmol). 1-propanol (2 mL) and distilled water (3 mL) was added via syringe and 
the mixture was cooled to 0 °C. Then tert-butyl hypochlorite (0.35 mL, 3.10 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then a solution of  
(DHQD)2PHAL (6.30) (48.2 mg, 0.06 mmol) in 1-propanol (1 mL) was added, 
followed by a solution of α-2H-2-vinylnaphthalene (7.14) (160.0 mg, 1.03 mmol) in 1-
propanol (3 mL).  Potassium osmate dihydrate (6.31) (15.2 mg, 0.04 mmol) added at       
0 °C and the reaction was stirred for 3 hours changing the colour from dark green to 
deep yellow. The mixture was quenched with saturated aqueous sodium sulfite solution 
(10 mL) at 0 °C, diluted with ethyl acetate (20 mL) and transferred into a 50 mL 
separating funnel. The organic layer was separated and washed with saturated brine (10 
mL), dried with magnesium sulphate, filtered and the solvent removed under reduced 
pressure. The crude material was purified by flash chromatography on silica gel (20% 
ethyl acetate in 40-60 PET, Rf = 0.25) to afford a white solid. Subsequent 
physicochemical analysis confirmed this to be the title compound (R)-(7.15) (228.0 mg, 
0.70 mmol, 69% yield). A sample was submitted to chiral analytical HPLC analysis 
[Cellulose 3, iso-hexane / iso-propanol : 85 / 15, 1 mL / min,  36.0 min (1st peak),  45.6 
min (2nd peak), 93% e.e.]. 
1H NMR (500 MHz, CDCl3) δ 7.80 (q, J 7.0 Hz, 3H, ArH), 7.73 (s, 1H, ArH), 7.57 – 
7.46 (m, 2H, ArH), 7.48 – 7.24 (m, 6H, ArH), 5.81 (s, 1H, NH), 5.12 (d, J 12.0 Hz, 1H, 
BnOCHH), 5.08 (d, J 12.0 Hz, 1H, BnOCHH), 3.87 (m, 2H, CH2OH), 2.62 (s, 1H, OH), 
13C NMR (126 MHz, CDCl3) δ 156.6, 136.6, 136.3, 133.4, 133.0, 128.7, 128.6, 128.3, 
128.0, 127.7, 126.5, 126.2, 125.5, 124.6, 67.2, 66.2, 56.9 (m); 2H NMR (77 MHz, 
CH2Cl2) δ 7.26 (CDCl3 ref), 4.89 (br s); M.p. 139 - 141 °C (from diethyl ether); [α]D
25
 -
7.9 (c 0.5 CHCl3); FT-IR (thin film) 3332 (OH), 3058 (C-H), 1687 (C=O), 1531 (C=C 
aromatic), 1264 (C(O)C), 1085/748 (C-H bend) cm-1; HRMS (HNESP) exact mass 
calculated for [C20H18
2H1N1O3H] requires m/z 323.1500, found m/z 323.1504 [M+H]
+. 
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8.10. Synthesis of styrenes 
1-bromo-4-vinylbenzene (7.4) 
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyltriphenylphosphonium bromide (6.26) (772.0 mg, 2.16 
mmol). Anhydrous tetrahydrofuran (10 mL) was added via syringe and the reaction was 
cooled to 0 °C. Then sodium hydride (60% w/w in mineral oil) (83.0 mg, 2.16 mmol) 
was added and the mixture was stirred at 0 °C for 10 minutes. Then 4-
bromobenzaldehyde (8.27) (0.2 g, 1.08 mmol) was added and the mixture was stirred at 
0 °C for 30 minutes. The reaction mixture was diluted with ethyl acetate (30 mL), 
transferred into a 50 mL separating funnel, washed with saturated brine (10 mL), dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% diethyl ether in 
40-60 PET, Rf = 0.40) to afford a colourless oil. Subsequent physiochemical analysis 
confirmed this to be the title compound (7.4) (137.0 mg, 0.75 mmol, 69% yield). 
1H NMR (500 MHz, CDCl3) δ 7.48 – 7.42 (m, 2H, ArH), 7.30 – 7.26 (m, 2H, ArH), 
6.66 (dd, J 17.6, 10.9 Hz, 1H, Cα-H), 5.74 (dd, J 17.6, 0.6 Hz, 1H, Cβ-H), 5.28 (dd, J 
10.9, 0.6 Hz, 1H, Cβ-H); 
13C NMR (126 MHz, CDCl3) δ 136.6, 135.9, 131.7, 127.9, 
121.7, 114.7. 
The spectroscopic data is  consistent with that reported in the literature.259 
 
α-2H-1-bromo-4-vinylbenzene (7.2) 
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyltriphenylphosphonium bromide (6.26) (960.0 mg, 2.70 
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mmol). Anhydrous tetrahydrofuran (10 mL) was added via syringe and the reaction was 
cooled to 0 °C. Then sodium hydride (60% w/w in mineral oil) (103.0 mg, 2.70 mmol) 
was added and the mixture was stirred at 0 °C for 10 minutes. Then α-2H-4-
bromobenzaldehyde (5.14) (250.0 mg, 1.35 mmol) was added and the mixture was 
stirred at 0 °C for 30 minutes. The reaction mixture was diluted with ethyl acetate (30 
mL), transferred into a 50 mL separating funnel, washed with saturated brine (10 mL), 
dried with magnesium sulphate, filtered and the solvent removed under reduced 
pressure. The crude material was purified by flash chromatography on silica gel (20% 
diethyl ether in 40-60 PET, Rf = 0.40) to afford a colourless oil. Subsequent 
physiochemical analysis confirmed this to be the title compound (7.2) (213.0 mg, 1.16 
mmol, 86% yield). 
1H NMR (500 MHz, CDCl3) δ 7.46 (d, J 8.4 Hz, 2H, ArH), 7.28 (d, J 8.4 Hz, 2H, ArH), 
5.75 (s, 1H, Cβ-H), 5.29 (s, 1H, Cβ-H); 
13C NMR (126 MHz, CDCl3) δ 136.5, 135.5 (t, 
JC-D 23.7 Hz), 131.7, 127.8, 121.7, 114.6; 
2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 
ref), 6.67 (br s); IR (thin film) 2954 (C-H), 2925 (H2C=C-H), 1615/1464 (C=C 
aromatic), 1070/831 (C-H bend) cm-1; HRMS (HNESP) exact mass calculated for 
[C8H6
2H1
79Br1H] requires m/z 185.9846, found m/z 185.9861 [M+H]
+. 
 
2-vinylnaphthalene (8.25) 
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyltriphenylphosphonium bromide (6.26) (915.0 mg, 2.56 
mmol). Anhydrous tetrahydrofuran (10 mL) was added via syringe and the reaction was 
cooled to 0 °C. Then sodium hydride (60% w/w in mineral oil) (98.0 mg, 2.56 mmol) 
was added and the mixture was stirred at 0 °C for 10 minutes. Then 2-
naphthabenzaldehyde (8.28) (0.2 g, 1.28 mmol) was added and the mixture was stirred 
at 0 °C for 30 minutes. The reaction mixture was diluted with ethyl acetate (30 mL), 
transferred into a 50 mL separating funnel, washed with saturated brine (10 mL), dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
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crude material was purified by flash chromatography on silica gel (15% diethyl ether in 
40-60 PET, Rf = 0.35) to afford a colourless oil. Subsequent physiochemical analysis 
confirmed this to be the title compound (8.25) (154.0 mg, 1.00 mmol, 78% yield). 
1H NMR (500 MHz, CDCl3) δ 7.83 (t, J 8.4, 3H, ArH), 7.80 (s, 1H, ArH), 7.69 (d, J 8.4 
Hz, 1H, ArH), 7.50 (m, 2H, ArH), 6.94 (dd, J 18.3, 11.5 Hz, 1H, Cα-H), 5.93 (dd, J 
17.5, 3.1 Hz, 1H, Cβ-H), 5.39 (dd, J 10.7, 3.1 Hz, 1H, Cβ-H); 13C NMR (126 MHz, 
CDCl3) δ 137.1, 135.1, 133.7, 133.3, 128.3, 128.2, 127.8, 126.5, 126.3, 126.0, 123.3, 
114.3. 
The spectroscopic data is consistent with that reported in the literature.260 
 
 
α-2H-2-vinylnaphthalene (7.14) 
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyltriphenylphosphonium bromide (6.26) (1.1 g, 3.18 mmol). 
Anhydrous tetrahydrofuran (10 mL) was added via syringe and the reaction was cooled 
to 0 °C. Then sodium hydride (60% w/w in mineral oil) (122.0 mg, 3.18 mmol) was 
added and the mixture was stirred at 0 °C for 10 minutes. Then α-2H-2-naphthaldehyde 
(5.15) (250.0 mg, 1.59 mmol) was added and the mixture was stirred at 0 °C for 30 
minutes. The reaction mixture was diluted with ethyl acetate (30 mL), transferred into a 
50 mL separating funnel, washed with saturated brine (10 mL), dried with magnesium 
sulphate, filtered and the solvent removed under reduced pressure. The crude material 
was purified by flash chromatography on silica gel (15% diethyl ether in 40-60 PET,         
Rf = 0.35) to afford a colourless oil. Subsequent physiochemical analysis confirmed this 
to be the title compound (7.14) (181.0 mg, 1.16 mmol, 73% yield). 
1H NMR (500 MHz, CDCl3) δ 7.94 (t, J 8.5 Hz, 3H, ArH), 7.89 (s, 1H, ArH), 7.80 (d, J 
8.5 Hz, 1H, ArH), 7.69 – 7.51 (m, 2H, ArH), 6.04 (s, 1H, Cβ-H), 5.50 (s, 1H, Cβ-H); 13C 
NMR (126 MHz, CDCl3) δ 136.7 (t, JC-D 23.6 Hz), 135.0, 133.6, 133.2, 128.2, 128.1, 
127.7, 126.5, 126.3, 126.0, 123.2, 114.0; 2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 
ref), 6.98 (br s); IR (thin film) 3054 (C-H), 2951 (H2C=C-H), 1615/1506 (C=C 
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aromatic), 1264/895 (C-H bend) cm-1; HRMS (HASP) exact mass calculated for 
[C12H9
2H1H] requires m/z 156.0918, found m/z 156.0917 [M+H]
+. 
 
 
α-13C-1-nitro-3-vinylbenzene (7.6)  
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added methyltriphenylphosphonium bromide (6.26) (282.0 mg, 0.79 
mmol). Anhydrous tetrahydrofuran (10 mL) was added via syringe and the reaction was 
cooled to 0 °C. Then sodium hydride (60 % w/w in mineral oil) (30.2 mg, 0.79 mmol) 
was added and the mixture was stirred at 0 °C for 10 minutes. Then α-13C-3-
nitrobenzaldehyde (5.29) (60.0 mg, 0.39 mmol) was added and the mixture was stirred 
at 0 °C for 30 minutes. The reaction mixture was diluted with ethyl acetate (30 mL), 
transferred into a 50 mL separating funnel, washed with saturated brine (10 mL), dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% diethyl ether in 
40-60 PET, Rf = 0.5) to afford a pale yellow oil. Subsequent physiochemical analysis 
confirmed this to be the title compound (7.6) (45.0 mg, 0.30 mmol, 76% yield). 
1H NMR (500 MHz, CDCl3) δ 8.30 – 8.19 (m, 1H, ArH), 8.17 – 8.04 (m, 1H, ArH), 
7.76 – 7.65 (m, 1H, ArH), 7.56 – 7.44 (m, 1H, ArH), 6.77 (ddd, J13C-H 156.8, J 17.5, 
10.9 Hz, 1H, Cα-H), 5.90 (dd, J 17.5, 3.2 Hz, 1H, Cβ-H), 5.44 (dd, J 10.9, 4.3 Hz, 1H, 
Cβ-H);
 13C NMR (126 MHz, CDCl3) δ 148.7, 139.4 (d, JC-13C 55.6 Hz), 134.8, 132.2, 
129.6 (d, JC-13C 4.5 Hz), 122.5, 121.0, 117.2 (d, JC-13C 70.2 Hz); IR (thin film) 3091 (C-
H), 2925 (H2C=C-H), 1532/1350 (NO2), 1097/920 (C-H bend) cm
-1; HRMS (HASP) 
exact mass calculated for [C7
13C1H7N1O2H] requires m/z 151.0583, found m/z 151.0580 
[M+H]+. 
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β-13C-1-nitro-3-vinylbenzene (7.9)  
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added 13C-labelled methyltriphenylphosphonium iodide (7.8) (375.0 mg, 
0.92 mmol). Anhydrous tetrahydrofuran (10 mL) was added via syringe and the reaction 
was cooled to 0 °C. Then sodium hydride (60 % w/w in mineral oil) (35.5 mg, 0.92 
mmol) was added and the mixture was stirred at 0 °C for 10 minutes. Then                   
4-nitrobenzaldehyde (5.1) (70.0 mg, 0.46 mmol) was added and the mixture was stirred 
at 0 °C for 30 minutes. The reaction mixture was diluted with ethyl acetate (30 mL), 
transferred into a 50 mL separating funnel, washed with saturated brine (10 mL), dried 
with magnesium sulphate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (20% diethyl ether in 
40-60 PET, Rf = 0.45) to afford a yellow oil. Subsequent physiochemical analysis 
confirmed this to be the title compound (7.9) (52.0 mg, 0.35 mmol, 75% yield). 
1H NMR (500 MHz, CDCl3) δ 8.22 – 8.17 (m, 2H, ArH), 7.56 – 7.52 (m, 2H, ArH), 
6.78 (dd, J 17.6, 10.9 Hz, 1H, Cα-H), 5.93 (dd, J13C-H 155.2, 17.6 Hz, 1H, Cβ-H), 5.50 
(dd, J13C-H 161.8, 10.9 Hz, 1H, Cβ-H); 13C NMR (126 MHz, CDCl3) δ 143.9, 135.1 (d, 
JC-13C 69.5 Hz), 132.7, 126.9 (d, JC-13C 4.3 Hz), 124.1, 118.7; IR (thin film) 3079 (C-H), 
2931 (H2C=C-H), 1515/1345 (NO2), 1110/858 (C-H bend) cm
-1; HRMS (HASP) exact 
mass calculated for [C7
13C1H7N1O2H] requires m/z 151.0583, found m/z 151.0581 
[M+H]+. 
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8.11. Synthesis of isotopically labelled aldehydes 
 
The procedures reported below for the synthesis of (5.10) and (5.11) are representative 
and were used to create a library of deuterated aldehydes (5.12), (5.13), (5.14) and  
(5.15). 
 
 
2-morpholino-2-(4-nitrophenyl)acetonitrile (5.10) 
 
To a 150 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, 
under nitrogen was added morpholine (5 mL), followed by a dropwise addition of 
perchloric acid (1.3 mL, 21.84 mmol) over 5 minutes. 4-nitrobenzaldehyde (5.1) (3.0 g, 
19.85 mmol) in morpholine (25 mL) was added dropwise with care and the resulting 
solution was stirred at 70 °C for 2 hours. Sodium cyanide (1.07 g, 21.84 mmol) in water  
(10 mL) was added dropwise and the reaction was heated at 90 °C for 1 hour. Then, the 
reaction was allowed to cool slightly before pouring onto crushed ice. The resulting 
precipitate was collected by vacuum filtration and recrystallised from hot ethanol to 
afford orange crystals. Subsequent physiochemical analysis confirmed this to be the title 
compound (5.10) (4.16 g, 16.83 mmol, 85% yield). 
 
 
1H NMR (500 MHz, CDCl3) δ 8.29 (d, J 8.6 Hz, 2H, ArH), 7.78 (d, J 8.6 Hz, 2H, ArH), 
4.90 (s, 1H, CH), 3.82 – 3.67 (m, 4H, CH2OCH2), 2.68 – 2.52 (m, 4H, CH2NCH2); 13C 
NMR (126 MHz, CDCl3) δ 148.6, 139.7, 129.1, 124.2, 114.2, 66.7, 62.0, 50.2. 
 
The spectroscopic data is consistent with that reported in the literature.183 
 
  
182 
 
α-2H-4-nitrobenzaldehyde (5.11) 
 
To a 50 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added 2-morpholino-2-(4-nitrophenyl)acetonitrile (5.10) (4.0 g, 16.18 
mmol) and anhydrous N,N-dimethylformamide (20 mL). The reaction was cooled to 0 
°C with an ice bath and sodium hydride (60% w/w in mineral oil [1.94 g, 48.54 mmol]) 
was added to the reaction. The resulting slurry was stirred vigorously at 0 °C for 1 hour. 
At this point, deuterium oxide (1.8 mL, 97.08 mmol) was added via syringe and the 
reaction was allowed to warm to room temperature over 1 hour. Then the reaction was 
cooled to 0 °C and thionyl chloride was added slowly via syringe until pH ~ 3. After 10 
minutes stirring, the reaction was allowed to warm to room temperature, at which point 
it was diluted with diethyl ether (100 mL), transferred into a 250 mL separating funnel, 
washed with saturated brine (100 mL), dried with magnesium sulphate, filtered and the 
solvent removed under reduced pressure to afford a solid. At this point, deuterium oxide 
(10 mL) was added via syringe, followed by deuterium chloride (0.1 mL) and the 
solution was refluxed at 100 °C for 2 hours. The reaction was allowed to cool to room 
temperature, at which point it was diluted with diethyl ether (100 mL), transferred into a 
250 mL separating funnel, washed with saturated aqueous sodium hydrogen carbonate 
(50 mL), saturated brine (100 mL), dried with magnesium sulfate, filtered and the 
solvent removed under reduced pressure. The crude material was purified by flash 
chromatography on silica gel (10% diethyl ether in 40-60 PET, Rf = 0.31) to afford a 
yellow solid. Subsequent physicochemical analysis confirmed this to be the title 
compound (5.11) (1.6 g, 10.45 mmol, 65% yield). 
 
1H NMR (500 MHz, CDCl3) δ 8.38 (d, J 8.8 Hz, 2H), 8.07 (d, J 8.8 Hz, 2H); 13C NMR 
(126 MHz, CDCl3) δ 190.2 (t, JC-D 27.4 Hz), 151.2, 140.1 (t, JC-D 3.5 Hz), 130.6, 124.4; 
2H NMR (77 MHz, CH2Cl2) δ 10.11 (br s), 7.26 (CDCl3 ref). 
 
 The spectroscopic data is consistent with that reported in the literature.261 
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α-2H-4-cyanobenzaldehyde (5.12) 
 
 
The procedure used for the synthesis of (5.11) was utilised to obtain (5.12) as a white 
solid after flash chromatography on silica gel (10% diethyl ether in 40-60 PET, Rf = 
0.35). Subsequent physicochemical analysis confirmed this to be the title compound 
(5.12) (1.0 g, 7.58 mmol, 67% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.95 (d, J 8.3 Hz, 2H), 7.88 (d, J 8.3 Hz, 2H); 13C NMR 
(126 MHz, CDCl3) δ 190.8 (t, JC-D 28.1 Hz), 141.7, 133.8 (t, JC-D 3.3 Hz), 129.4, 118.3, 
117.1; 2H NMR (77 MHz, CH2Cl2) δ 10.03 (br s), 7.26 (CDCl3 ref). 
 
The spectroscopic data is consistent with that reported in the literature.262 
 
 
 
α-2H-4-fluorobenzaldehyde (5.13) 
 
 
The procedure used for the synthesis of (5.11) was utilised to obtain (5.13) as a white 
solid after flash chromatography on silica gel (5% diethyl ether in 40-60 PET, Rf = 
0.26). Subsequent physicochemical analysis confirmed this to be the title compound 
(5.13) (1.9 g, 15.18 mmol, 71% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.90 (m, 2H), 7.32 (m, 2H); 13C NMR (126 MHz, 
CDCl3) δ 190.0 (t, JC-D 26.2 Hz), 169.2 (d, JC-F 245.9 Hz), 133.1 (dt, JC-D 3.3, JC-F 3.1 
Hz Hz), 132.4 (d, JC-F 7.9 Hz), 116.9 (d, JC-F 21.4 Hz); 
2H NMR (77 MHz, CH2Cl2) δ 
9.91 (br s), 7.26 (CDCl3 ref). 
 
 The spectroscopic data is consistent with that reported in the literature.263 
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α-2H-4-bromobenzaldehyde (5.14) 
 
 
The procedure used for the synthesis of (5.11) was utilised to obtain (5.14) as a white 
solid after flash chromatography on silica gel (10% diethyl ether in 40-60 PET, Rf = 
0.32). Subsequent physicochemical analysis confirmed this to be the title compound 
(5.14) (2.1 g, 11.29 mmol, 58% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.74 (d, J 8.6 Hz, 2H), 7.66 (d, J 8.6 Hz, 2H); 13C NMR 
(126 MHz, CDCl3) δ 188.3 (t, JC-D 25.8 Hz), 136.1, 133.7 (t, JC-D 3.2 Hz), 131.4, 128.6; 
2H NMR (77 MHz, CH2Cl2) δ 9.96 (br s), 7.26 (CDCl3 ref). 
 
 The spectroscopic data is consistent with that reported in the literature.262 
 
 
 
α-2H-4-napthaldehyde (5.15) 
 
 
The procedure used for the synthesis of (5.11) was utilised to obtain (5.15) as a white 
solid after flash chromatography on silica gel (15% diethyl ether in 40-60 PET, Rf = 
0.39). Subsequent physicochemical analysis confirmed this to be the title compound 
(5.15) (1.7 g, 10.81 mmol, 63% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.85 (t, J 8.1 Hz, 3H, ArH), 7.71 (s, 1H, ArH), 7.63 (d, J 
8.1 Hz, 1H, ArH), 7.51 (m, 2H, ArH); 13C NMR (126 MHz, CDCl3) δ 192.4 (t, JC-D 26.6 
Hz), 137.2, 134.9, 134.1 (t, JC-D 2.4 Hz), 132.6, 130.6, 129.3, 128.7, 127.9, 127.2, 
124.4; 2H NMR (77 MHz, CH2Cl2) δ 10.15 (br s), 7.26 (CDCl3 ref). 
 
The spectroscopic data is consistent with that reported in the literature.263 
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ethyl α-13C-3-nitrobenzoate (5.28) 
 
 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added α-13C-benzoic acid (5.26) (0.5 g, 4.06 mmol) and concentrated sulfuric acid 
(0.2 mL, 4.06 mmol) in ethanol (5 mL). The reaction was refluxed for 2 hours, cooled to 
room temperature and the solvent was removed under reduced pressure to afford ethyl 
α-13C-3-nitrobenzoate (5.27) (0.6 g, 3.97 mmol, 98% yield), as an orange oil, which was 
used in the subsequent step without any further purification. To a 25 mL round bottom 
flask, equipped with a magnetic stirrer bar, under nitrogen was added ethyl α-13C-3-
nitrobenzoate (5.27) (120.0 mg, 0.79 mmol) and concentrated sulfuric acid (4 mL). The 
reaction was cooled to 0 °C and concentrated nitric acid (0.03 mL, 0.79 mmol) was 
syringed slowly with vigorous stirring. After 30 minutes stirring at 0 °C, the reaction 
was poured carefully onto cold saturated aqueous sodium hydrogen carbonate (20 mL) 
and extracted with diethyl ether (3 x 20 mL). The combined organic layers were dried 
over magnesium sulfate and evaporated. The crude material was purified by flash 
chromatography on silica gel (10% diethyl ether in 40-60 PET, Rf = 0.26) to afford a 
white solid. Subsequent physicochemical analysis confirmed this to be the title 
compound (5.28) (116.0 g, 0.59 mmol, 75% yield). 
 
 
 
1H NMR (500 MHz, CDCl3) δ 8.84 – 8.79 (m, 1H), 8.40 – 8.32 (m, 2H), 7.63 (t, J 8.0 
Hz, 1H), 4.45 – 4.39 (m, 2H), 1.41 (td, J 7.1, 2.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
δ 164.5, 148.3 (d, JC-13C 5.5 Hz), 135.3 (d, JC-13C 2.5 Hz), 132.3 (d, JC-13C 75.8 Hz), 129.7 
(d, JC-13C 4.8 Hz), 127.3, 124.6 (d, JC-13C 2.9 Hz), 62.0 (d, JC-13C 2.3 Hz), 14.3 (d, JC-13C 
2.0 Hz); M.p. 43 - 45 °C (from diethyl ether / 40-60 PET); IR (thin film) 2981 (C-H), 
1695 (C=O), 1534/1351 (NO2), 1288/1244 (C(O)C), 1082 (C-H bend) cm
-1; HRMS 
(HASP) exact mass calculated for [C8
13C1H9N1O4H] requires m/z 196.0682, found m/z 
196.0676 [M+H]+. 
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α-13C-3-nitrobenzaldehyde (5.29) 
 
 
To a 50 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added ethyl α-13C-3-nitrobenzoate (5.28) (200.0 mg, 1.02 mmol) and 
anhydrous toluene (10 mL). The flask was cooled to -78 °C and DIBAL-H (0.8 mL of a 
1.2 M solution in toluene) was added dropwise over 20 minutes. The reaction was 
stirred for a further 2 hours at -78 °C, before being quenched by the dropwise addition 
of dry methanol (2 mL). The reaction was allowed to warm to about -20 °C internal 
temperature, and then poured into a vigorously stirred solution of Rochelle's salt (1.2 M 
aqueous potassium sodium tartrate, 20 mL). The viscous solution was stirred vigorously 
for 1 hour, after which time it settled to two clear phases. The organic layer was 
separated, and the aqueous layer extracted with diethyl ether (3 x 20 mL). The 
combined organic layers were dried over magnesium sulfate and evaporated. The crude 
material was purified by flash chromatography on silica gel (3% diethyl ether in 40-60 
PET, Rf = 0.28) to afford a pale yellow solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (5.29) (0.13 g, 0.85 mmol, 83% yield). 
 
 
1H NMR (500 MHz, CDCl3) δ 10.13 (d, J13C-H 179.1 Hz, 1H), 8.75 – 8.70 (m, 1H), 8.50 
(ddd, J 8.2, 2.2, 0.9 Hz, 1H), 8.26 – 8.22 (m, 1H), 7.77 (t, J 8.0 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 189.8, 134.7 (d, JC-13C 3.7 Hz), 130.5 (d, JC-13C 4.9 Hz), 128.7, 124.7 (d, 
JC-13C 4.8 Hz); M.p. 59 - 61 °C (from diethyl ether / 40-60 PET); IR (thin film) 2972 (C-
H), 1706 (C=O), 1535/1351 (NO2), 1084/785 (C-H bend) cm
-1; HRMS (HASP) exact 
mass calculated for [C6
13C1H5N1O3H] requires m/z 153.0373, found m/z 153.0376 
[M+H]+. 
 
Due to 13C enrichment, the reduced intensity of some signals was observed in the 13C-
NMR spectrum.  
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α-13C,2H-3-nitrobenzaldehyde (5.44) 
 
 
To a 25 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added a suspension of lithium aluminium deuteride (77.0 mg, 2.04 mmol) 
in anhydrous diethyl ether (10 mL).  The flask was cooled to 0 °C and a solution of         
ethyl α-13C-3-nitrobenzoate (5.28) (200.0 mg, 1.02 mmol) in anhydrous diethyl ether 
(1 mL) was added. After addition, the reaction mixture was warmed to 35 °C and stirred 
for 5 h. The reaction mixture was cooled 0 °C again, and distilled water (2 mL) was 
added. The precipitated inorganic salt was filtered off and washed with diethyl ether. 
Organic phase was washed with dried over magnesium sulfate, and evaporated to afford 
α-di-2H,13C-3-nitrobenzyl alcohol (5.43) (152.0 mg, 0.97 mmol, 95% yield) as a white 
solid. The crude product was used in the subsequent step without any further 
purification. To a 25 mL flame dried round bottom flask, equipped with a magnetic 
stirrer bar, under nitrogen was added a solution of benzyl alcohol derivative (5.43) 
(150.0 mg, 0.96 mmol) in anhydrous dichloromethane (5 mL). The flask was cooled to 
0 °C and PCC (207.0 mg, 0.96 mmol) in dichloromethane (15 mL) was added. The dark 
solution obtained was stirred for 1 hour at room temperature. The dark solids were 
filtered from the reaction mixture and washed with dichloromethane. The filtrate 
obtained was washed with saturated aqueous sodium hydrogen carbonate (50 mL), 1 M 
aqueous hydrochloric acid (50 mL), saturated brine (100 mL), dried with magnesium 
sulphate, filtered and the solvent removed under reduced pressure. The crude material 
was purified by flash chromatography on silica gel (3% diethyl ether in 40-60 PET,     
Rf = 0.28) to afford a pale yellow solid. Subsequent physicochemical analysis 
confirmed this to be the title compound (5.44) (128.0 mg, 0.84 mmol, 87% yield). 
 
1H NMR (500 MHz, CDCl3) δ 8.75 – 8.71 (m, 1H), 8.49 (ddd, J 8.2, 2.0, 1.0 Hz, 1H), 
8.24 (ddt, J 7.4, 4.6, 1.3 Hz, 1H), 7.77 (t, J 7.9 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 
189.5 (t, JC-D 27.4 Hz), 148.9 (d, JC-13C 3.8 Hz), 137.4 (dt, JC-13C 53.3, JC-D 3.8 Hz), 
134.7 (d, JC-13C 3.7 Hz), 130.5 (d, JC-13C 4.7 Hz), 128.7, 124.7 (d, JC-13C 4.8 Hz); 2H 
NMR (77 MHz, CH2Cl2) δ 10.09 (d, JC-D 27.5 Hz), 7.26 (CDCl3 ref); M.p. 60 - 62 °C 
(from diethyl ether / 40-60 PET); IR (thin film) 2969 (C-H), 1698 (C=O), 1531/1348 
(NO2), 1081/783 (C-H bend) cm
-1; HRMS (HASP) exact mass calculated for 
[C6
13C1H4
2H1N1O3H] requires m/z 154.0439, found m/z 154.0436 [M+H]
+. 
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α-13C-3-azidobenzaldehyde (5.40) 
 
 
 
To a 25 mL round bottom flask, equipped with a magnetic stirrer bar, under nitrogen 
was added ethyl α-13C-3-nitrobenzoate (5.28) (110.0 mg, 0.56 mmol) and palladium on 
carbon (10% w/w) (59.7 mg, 0.056 mmol). Ethyl acetate (5 mL) was added via syringe 
and the flask was sealed with suba-seal rubber septum. Then, hydrogen gas atmosphere 
was introduced through the septum and the reaction was stirred at 25 °C for 2 hours. At 
this point the reaction mixture was passed through a short plug of celite and eluted with 
ethyl acetate (10 mL). The solvent was removed under reduced pressure to afford an 
orange oil. Subsequent physicochemical analysis confirmed this to be ethyl α-13C-3-
aminobenzoate (5.38) (91.0 mg, 0.55 mmol, 97% yield). To a 25 mL round bottom 
flask, equipped with a magnetic stirrer bar, under nitrogen was added ethyl α-13C-3-
aminobenzoate (5.38) (90.0 mg, 0.54 mmol) and 1 M hydrochloric acid (5 mL). The 
flask was cooled to 0 °C and sodium nitrite (41.1 mg, 0.60 mmol) in distilled water (5 
mL) was added. The reaction mixture was stirred for 10 min at 0 °C, sodium azide (42.2 
mg, 0.65 mmol) was added and the mixture was allowed to warm to room temperature 
over 1 hour. The reaction was diluted with ethyl acetate (50 mL) and was washed with 
saturated brine (20 mL), dried with magnesium sulfate, filtered and the solvent removed 
under reduced pressure. The crude material was purified by flash chromatography on 
silica gel (5% diethyl ether in 40-60 PET, Rf = 0.22) to afford an orange oil. Subsequent 
physicochemical analysis confirmed this to be the title compound (5.39) (95.0 mg, 0.49 
mmol, 91% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.84 – 7.80 (m, 1H), 7.72 – 7.70 (m, 1H), 7.42 (td, J 7.9, 
1.1 Hz, 1H), 7.19 (ddd, J 8.0, 2.4, 1.0 Hz, 1H), 4.39 (qd, J 7.1, 3.0 Hz, 2H), 1.40 (t, J 
7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 165.7, 140.5 (d, JC-13C 5.6 Hz), 132.3 (d, 
JC-13C 74.7 Hz), 129.8 (d, JC-13C 5.0 Hz), 126.0 (d, JC-13C 2.3 Hz), 123.3, 119.9 (d, JC-13C 
2.7 Hz), 61.3 (d, JC-13C 2.3 Hz), 14.3 (d, JC-13C 2.1 Hz). IR (thin film) 2984 (C-H), 2121 
(N3), 1682 (C=O), 1289/1241 (C(O)C), 1099 (C-H bend) cm
-1; HRMS (HASP) exact 
mass calculated for [C8
13C1H9N3O2H] requires m/z 192.0712, found m/z 192.0719 
[M+H]+. 
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α-13C-3-azidobenzaldehyde (5.40) 
 
 
To a 50 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, under 
nitrogen was added ethyl α-13C-3-azidobenzoate (5.39) (90.0 mg, 0.47 mmol) and 
anhydrous toluene (10 mL). The flask was cooled to -78 °C and DIBAL-H (0.5 mL of a 
1.2 M solution in toluene) was added dropwise over 20 minutes. The reaction was 
stirred for a further 2 hours at -78 °C, before being quenched by the dropwise addition 
of dry methanol (2 mL). The reaction was allowed to warm to circa -20 °C internal 
temperature, and then poured into a vigorously stirred solution of Rochelle's salt (1.2 M 
aqueous potassium sodium tartrate, 20 mL). The viscous solution was stirred vigorously 
for 1 hour, after which time it settled to two clear phases. The organic layer was 
separated, and the aqueous layer extracted with diethyl ether (3 x 20 mL). The 
combined organic layers were dried over magnesium sulfate and evaporated. The crude 
material was purified by flash chromatography on silica gel (5% diethyl ether in 40-60 
PET, Rf = 0.25) to afford a yellow oil. Subsequent physicochemical analysis confirmed 
this to be the title compound (5.40) (0.57 g, 0.38 mmol, 81% yield). 
 
 
1H NMR (500 MHz, CDCl3) δ 9.99 (d, J13C-H 176.2 Hz, 1H), 7.67 – 7.62 (m, 1H), 7.57 – 
7.50 (m, 2H), 7.30 – 7.24 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 191.3, 141.6 (d,     
JC-13C 5.4 Hz), 137.9 (d, JC-13C 53.2 Hz), 130.6 (d, JC-13C 5.2 Hz), 126.8 (d, JC-13C 4.3 Hz), 
125.0, 119.1 (d, JC-13C 3.9 Hz); IR (thin film) 2994 (C-H), 2114 (N3), 1696 (C=O), 1479 
(C=C aromatic), 1103 (C-H bend) cm-1; HRMS (HASP) exact mass calculated for 
[C6
13C1H5N3O1H] requires m/z 149.0539, found m/z 149.0535 [M+H]
+. 
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8.12. Synthesis of diazoacetates 
tert-butyl diazoacetate (5.4) 
 
To a 500 mL flame dried round bottom flask, equipped with a magnetic stirrer bar, 
under nitrogen was added tert-butyl acetoacetate (8.33) (25.2 mL, 0.15 mol), 
triethylamine (21.3 mL, 0.15 mol) and anhydrous acetonitrile (100 mL). The mixture 
was stirred for 5 minutes at room temperature and then para-toluenesulfonyl azide (23.0 
mL, 0.15 mol) was injected dropwise via syringe over a period of 15 minutes. The 
mixture was left stirring for 2.5 hours and then the solvent was removed under reduced 
pressure. The resulting yellow semi-solid material was triturated with diethyl ether (100 
mL), transferred into a 250 mL separating funnel and washed with potassium hydroxide 
(4.5 g) in distilled water (50 mL), potassium hydroxide (750 mg) in distilled water (25 
mL) and finally just distilled water (25 mL). Organic phase was dried over magnesium 
sulfate and evaporated to obtain orange semisolid (8.34) (24.0 g, 0.13 mol, 86% yield), 
which was used in the subsequent step without any further purification. To a 250 mL 
flame dried three-necked round bottom flask, equipped with a magnetic stirrer bar, 
dropping funnel, internal thermometer, under nitrogen was added tert-butyl 
diazoacetoacetate (20.0 g, 0.11 mol) and anhydrous methanol (50 mL). The reaction 
was cooled down to 0 °C and sodium metal pieces (2.5 g, 0.11 mol), that were dissolved 
in the ice cold anhydrous methanol (50 mL) where added via a dropping funnel slowly 
so the temperature of the reaction does not exceed 5 °C. After the addition was 
completed, the mixture was left stirring at 0 °C for 30 minutes. Then dark red mixture 
was poured into a conical flask with ice cold distilled water (100 mL) and saturated 
brine was added (100 mL). The mixture was transferred into a 1 L separating funnel and 
extracted with diethyl ether (3 x 200 mL). The combined organic layers were washed 
with distilled water (200 mL), dried over magnesium sulfate and evaporated. The crude 
material was purified by flash chromatography on silica gel (5% diethyl ether in 40-60 
PET, Rf = 0.3) to afford a yellow oil. Subsequent physicochemical analysis confirmed 
this to be the title compound (5.4) (10.3 g, 0.07 mol, 65% yield). 
1H NMR (500 MHz, CDCl3) δ 4.59 (s, 1H), 1.44 (s, 9H); 13C NMR (126 MHz, CDCl3) 
δ 166.3, 81.4, 46.7, 28.3. 
The spectroscopic data is consistent with that reported in the literature.193 
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2H-labelled tert-butyl diazoacetate (5.24) 
 
 
 
To a 250 mL flame dried three-necked round bottom flask, equipped with a magnetic 
stirrer bar, under nitrogen was added tert-butyl diazoacetate (5.4) (1.0 g, 7.03 mmol), 
potassium carbonate (0.1 g, 0.70 mmol) and anhydrous acetonitrile/D2O 1:1 mixture (10 
mL). The resulting mixture was stirred vigorously for 2 hours at room temperature and 
then extracted with dichloromethane (3 x 30 mL). The combined organic layers were 
washed with distilled water (200 mL), dried over magnesium sulfate and evaporated to 
afford a yellow oil. Subsequent physicochemical analysis confirmed this to be the title 
compound (5.24) (0.9 g, 6.29 mol, 89% yield). 
 
1H NMR (500 MHz, CDCl3) δ 1.48 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 166.3, 81.5, 
46.5 (d, JC-D 29.9 Hz), 28.4; 
2H NMR (77 MHz, CH2Cl2) δ 7.26 (CDCl3 ref), 4.59 (br s). 
 
 
The spectroscopic data is consistent with that reported in the literature.193 
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8.13. Synthesis of the aziridination catalyst (S)-3,3’-bis(anthracen-9-yl)-[1,1’]-
binaphthalen-2,2’-yl N-triflyl phosphoramide (S)-(5.9) 
 
(S)-2,2'-dimethoxy-1,1'-dinaphthyl (S)-(8.36) 
 
A flame dried 500 mL two-necked round bottom flask, fitted with a reflux condenser 
and a magnetic stirrer bar, under nitrogen was charged with (S)-1,1'-bi-2-naphthol        
(S)-(8.35) (10.0 g, 0.35 mol) in acetone (250 mL) affording a white suspension. 
Iodomethane (6.5 mL, 1.05 mol) and potassium carbonate (14.5 g, 1.05 mol) were 
added and the yellow mixture was refluxed for 12 hours under nitrogen atmosphere. 
The solvent was removed under reduced pressure. The resulting white solid was washed 
with distilled water (150 mL) and dried in a vacuum oven overnight at 80 °C to afford a 
fine white powder. Subsequent physicochemical analysis confirmed this to be the title 
compound (S)-2,2'-dimethoxy-1,1'-dinaphthyl (S)-(8.36) (10.7 g, 0.34 mol, 97% yield). 
 
1H NMR (400 MHz, CDCl3) δ 7.98 (d, J 9.0 Hz, ArH), 7.87 (d, J 9.0 Hz, ArH), 7.48 (d, 
J 9.0 Hz, ArH), 7.31 (t, J 8.1 Hz, ArH), 7.21 (t, J 8.1 Hz, ArH), 7.10 (d, J 8.5 Hz, ArH), 
3.77 (s, 6H, 2xOCH3). 
13C NMR (126 MHz, CDCl3) δ 155.1, 134.1, 129.5, 129.3, 
128.0, 126.4, 125.4, 123.6, 119.7, 114.4, 57.0; [α]D
21
 = -52.0 (c 1.0 CHCl3); IR (thin 
film) 3047/2957 (C-H), 1590/1505/1460 (C=C aromatic), 1262/1248 (C(O)C) cm-1; MS 
(MALDI) 314.0 [M+H]+. 
 
The spectroscopic data is consistent with that reported in the literature.173 
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(S)-2,2'-dimethoxy-1,1'-binaphthyl-3,3'-diyldiboronic acid (S)-(8.37) 
 
A flame dried 500 mL three-necked round bottom flask, fitted with a dropping funnel, a 
magnetic stirrer bar, under nitrogen was charged with N,N,N',N'-
tetramethylethylenediamine (7.1 mL, 0.48 mol) and anhydrous diethyl ether (200 mL). 
A 2.5 M solution of n-butyllithium (22.7 mL, 0.48 mol) in hexanes was added via 
syringe at room temperature. The cloudy yellow solution was stirred for 30 minutes, 
(S)-2,2'-dimethoxy-1,1'-dinaphthyl (S)-(8.36) (5.0 g, 0.16 mol) was added in one portion 
and the reaction mixture was stirred for 3 hours at room temperature. The resulting light 
brown suspension was cooled to -78 °C using a dry ice/acetone bath. Trimethyl borate 
(12.4 mL, 1.11 mol) was added via a dropping funnel over a period of 10 minutes. The 
mixture was allowed to warm slowly to room temperature for 12 hours with continuous 
stirring. A yellow colloid was observed in the solution. The flask was cooled to 0 °C 
and 1 M hydrochloric acid (100 mL) was added slowly. The observed colloid turned 
into a light brown suspension, which was left stirring for 2 hours at room temperature. 
The organic layer was separated and washed with 1 M hydrochloric acid (2 x 50 mL), 
saturated brine (2 x 50 mL), dried with magnesium sulfate and concentrated under 
reduced pressure. Recrystallisation from toluene afforded the desired product as a fine 
white powder. Subsequent physicochemical analysis confirmed this to be the title 
compound (S)-2,2'-dimethoxy-1,1'-binaphthyl-3,3'-diyldiboronic acid (S)-(8.37) (3.9 g, 
0.10 mol, 62% yield). 
 
1H NMR (500 MHz, CDCl3) δ 8.55 (s, 2H, ArH), 7.92 (d, J 8.0 Hz, 2H, ArH), 7.36 (t, J 
7.5 Hz, 2H, ArH), 7.25 (t, J 7.5 Hz, 2H, ArH), 7.09 (d, J 8.0 Hz, 2H, ArH), 5.98 (s, 4H, 
2xB(OH)2), 3.23 (s, 6H, 2xOCH3);
13C NMR (126 MHz, DMSO) δ 159.1, 135.8, 134.7, 
130.1, 129.4, 128.7, 127.0, 125.5, 124.7, 123.2, 61.0; IR (thin film) 3392 (OH) 2941 (C-
H), 1588/1493 (C=C aromatic), 1335 (B-O), 1263/1217 (C(O)C), 1008 (C-B) cm-1; MS 
(MALDI) 401.9 [M+H]+. 
 
The spectroscopic data is consistent with that reported in the literature.173  
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(S)-3,3'-di(anthracen-9-yl)-1,1'-binaphthyl-2,2'-diol (S)-(8.39) 
 
A 25 mL two-necked round bottom flask, fitted with a reflux condenser and a magnetic 
stirrer bar, under nitrogen was charged with (S)-2,2'-dimethoxy-1,1'-binaphthyl-3,3'-
diyldiboronic acid (S)-(8.37) (0.5 g, 1.24 mmol), tetrakis(triphenylphosphine)palladium 
(57.0 mg, 0.05 mmol), barium hydroxide octahydrate (1.2 g, 3.73 mmol) and 9-
bromoanthracene (1.0 g, 3.73 mmol)  in 1,4-dioxane (9 mL) / distilled water (3 mL) 
mixture. The solvent was degassed by nitrogen gas and the mixture was refluxed at 125 
°C for 4 hours. The flask was allowed to cool to room temperature and solvent was 
removed under reduced pressure. The resulting residue was redissolved in 
dichloromethane (50 mL) and washed with 1 M hydrochloric acid (2 x 50 mL), 
saturated brine (2 x 50 mL), dried with anhydrous magnesium sulfate and concentrated 
under reduced pressure to afford a brown solid (S)-(8.38) (0.6 g, 0.9 mmol, 72% yield), 
which was used in the subsequent step without any further purification. 
A flame dried 25 mL round bottom flask, fitted with a magnetic stirrer bar, under 
nitrogen was charged with (S)-(8.38) (0.6 g, 0.9 mmol) and anhydrous dichloromethane 
(50 mL). Boron tribromide (0.5 mL, 5.4 mmol) was added dropwise at 0 °C and the 
mixture was left stirring at room temperature for 4 hours. Then it was cooled to 0 °C 
and quenched with distilled water (10 mL). The organic layer was separated and washed 
with 1 M hydrochloric acid (2 x 30 mL), saturated brine (2 x 30 mL), dried with 
anhydrous magnesium sulfate and concentrated under reduced pressure. The crude 
material was purified by flash chromatography on silica gel (20% ethyl acetate in 40-60 
PET, Rf = 0.28) to afford an orange solid. Subsequent physicochemical analysis 
confirmed this to be the title compound  (S)-3,3'-di(anthracen-9-yl)-1,1'-binaphthyl-2,2'-
diol (S)-(8.39) (0.5 g, 0.80 mmol, 89% yield). 
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1H NMR (400 MHz, CDCl3) δ 8.58 (s, 2H, ArH), 8.10 (d, J 8.3 Hz, 2H, ArH), 8.06 (d, J 
8.3 Hz, 2H, ArH), 8.02 (s, 2H, ArH), 7.86 (d, J 8.6 Hz, 2H, ArH), 7.85 (d, J 6.9 Hz, 2H, 
ArH), 7.67 (d, J 8.8 Hz, 2H, ArH), 7.58 (d, J 8.8 Hz, 2H, ArH), 7.52 – 7.37 (m, 10H, 
ArH), 7.20 – 7.16 (m, 2H, ArH), 5.07 (s, 2H, 2xOH); 13C NMR (101 MHz, CDCl3) δ 
150.1, 133.1, 132.2, 130.7, 130.6, 130.0, 129.9, 129.9, 128.5, 127.8, 127.7, 127.6, 
126.9, 126.6, 126.3, 125.4, 125.3, 125.2, 124.5, 124.50, 124.4, 124.0, 123.4, 112.7; 
[α]D
25
 = -131.3 (c  1.0 CHCl3); IR (thin film) 3530 (OH), 3050 (C-H), 1498 (C=C 
aromatic), 1263/1217 (C-O) cm-1; MS (MALDI) 637.9 [M+H]+. 
 
The spectroscopic data is consistent with that reported in the literature.173 
 
 
 
 
(S)-3,3’-bis(anthracen-9-yl)-[1,1’]-binaphthalen-2,2’-yl N-triflyl phosphoramide 
(S)-(5.9) 
 
 
 
A 25 mL two-necked round bottom flask, fitted with a reflux condenser and a magnetic 
stirrer bar, under nitrogen was charged with (S)-3,3'-di(anthracen-9-yl)-1,1'-binaphthyl-
2,2'-diol (S)-(8.39) (0.2 g, 0.31 mmol) and anhydrous dichloromethane (3 mL). To the 
solution were added in sequence anhydrous triethylamine (0.3 mL, 2.17 mmol), 
phosphorus oxychloride (35.0 µL, 0.37 mmol) and 4-dimethylaminopyridine (77.0 mg, 
0.63 mmol) at 0 °C and the reaction mixture was stirred for 1 hour. Anhydrous 
propionitrile (2 mL) was added followed by trifluoromethanesulfonamide (93.0 mg, 
0.63 mmol). The mixture was refluxed at 100 °C for 2 hours. The mixture was allowed 
to cool to room temperature, quenched with distilled water (1 mL), stirred for 20 
minutes and extracted with diethyl ether (3 x 20 mL). The combined organic layers 
were washed with saturated aqueous sodium hydrogen carbonate solution (2 x 30 mL) 
and 4 M hydrochloric acid (2 x 30 mL). The organic phase was dried over anhydrous 
196 
 
magnesium sulfate and concentrated under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (30% ethyl acetate in 40-60 PET,          
Rf = 0.25) to afford an orange solid, which could be a salt (pH ~7). The solid was 
dissolved in dichloromethane (20 mL) and washed with 6 M hydrochloric acid (2 x 20 
mL). The organic layer was dried over anhydrous magnesium sulfate and concentrated 
under reduced pressure to afford a cream solid (pH ~2). Subsequent physicochemical 
analysis confirmed this to be the title compound (S)-3,3’-bis(anthracen-9-yl)-[1,1’]-
binaphthalen-2,2’-yl N-triflyl phosphoramide (S)-(5.9) (190.0 mg, 0.23 mmol, 73% 
yield).  
 
1H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H, ArH), 8.48 (s, 1H, ArH), 8.18 (m, 2H, ArH), 
8.09 – 7.98 (m, 5H, ArH), 7.90 (d, J 8.3 Hz, 1H, ArH), 7.78 – 7.65 (m, 6H, ArH), 7.65 – 
7.59 (m, 2H, ArH), 7.59 – 7.53 (m, 2H, ArH), 7.46 – 7.39 (m, 3H, ArH), 7.38 – 7.31 
(m, 3H, ArH), 7.24 – 7.11 (m, 2H, ArH); 13C NMR (126 MHz, CDCl3) δ 146.9, 146.8, 
146.4, 146.30, 134.3, 134.1, 132.8, 131.8, 131.6, 131.5, 131.4, 131.3, 131.2, 131.1, 
130.9, 130.8, 130.7, 130.6, 130.5, 130.1, 128.7, 128.5, 128.4, 128.2, 128.1, 127.8, 
127.6, 127.5, 127.4, 127.3, 126.9, 126.8, 126.7, 126.6, 126.5, 126.14, 126.13, 126.0, 
125.7, 125.2, 125.1, 124.7, 124.5, 122.9, 122.8, 122.25, 122.24, 120.2, 117.6; 19F  NMR 
(471 MHz, CDCl3) δ -79.73; 31P NMR (202 MHz, CDCl3) δ 0.35; IR (thin film) 3530 
(NH), 3055 (C-H), 1445 (C=C aromatic), 1303 (CF3), 1296 (P=O), 1261/1199 (C-O), 
1101 (S=O), 956 (P-O), 733 (C-S) cm-1; MS (MALDI) 830.9 [M+H]+. 
 
 
The spectroscopic data is consistent with that reported in the literature.173 
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8.14. Asymmetric synthesis of the model aziridines using catalyst (S)-(5.9) 
 
tert-butyl cis-1-(2-tert-butoxyphenyl)-3-(4-nitrophenyl)aziridine-2-carboxylate    
cis-(5.6) 
 
4-Nitrobenzaldehyde (5.1) (70.0 mg, 0.46 mmol) and tert-butoxyaniline (5.2) (72.7 mg, 
0.44 mmol) were added to a flame dried Biotage 5 mL microwave vial, containing 
activated 4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated 
chloroform/deuterated dichloromethane (8:2) mixture (1 mL) was added, the vial was 
sealed with a PTFE crimp cap and the reaction mixture was left stirring at 25 °C for 2 
hours. Catalyst (S)-(5.9) (38.5 mg, 0.05 mmol, 10 mol%) was added and the vial was 
cooled to -78 °C. After 30 minutes, tert-butyl diazoacetate (5.4) (71 μL, 0.51 mmol) 
was added via syringe, and the reaction mixture was stirred at -80 °C (~ 24 hours). At 
this point the reaction mixture was quenched with triethylamine (0.5 mL), passed 
through a short plug of silica, eluted with diethyl ether and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography on 
silica gel (5% diethyl ether in 40-60 PET, Rf = 0.22) to afford a yellow solid. 
Subsequent physicochemical analysis confirmed this to be the title compound cis-(5.6) 
(141.0 mg, 0.34 mmol, 73% yield). A sample was submitted to chiral analytical HPLC 
analysis [Chiralpak AD-H column, iso-hexane / iso-propanol : 95 / 05, 1 mL / min,  6.3 
min (1st peak),  10.4 min (2nd peak), 96% e.e.].  
1H NMR (500 MHz, CDCl3) δ 8.20 (d, J 8.8 Hz, 2H, ArH), 7.72 (d, J 8.8 Hz, 2H, ArH), 
7.07 – 6.90 (m, 4H, ArH), 3.53 (d, J 6.8 Hz, 1H, C3-H), 3.14 (d, J 6.8 Hz, 1H, C2-H), 
1.35 (s, 9H, C(CH3)3), 1.22 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.4, 
148.1, 147.5, 145.6, 143.1, 129.1, 123.6, 123.2, 123.1, 123.0, 120.9, 82.0, 80.5, 47.8, 
46.8, 28.8, 27.9; FT-IR (thin film) 2980 (C-H), 1742 (C=O), 1603/1520/1489 (C=C 
aromatic), 1345 (NO2), 1225/1162 (C(O)C), 1049 (C-N), 912 (C-H bend) cm
-1. 
 
The spectroscopic data is consistent with that reported in the literature.164 
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tert-butyl cis-1-phenyl-3-(4-nitrophenyl)aziridine-2-carboxylate (±)-cis-(5.8) 
 
 
4-nitrobenzaldehyde (5.1) (20.0 mg, 0.13 mmol), and aniline (8.40) (22.0 mg, 0.12 
mmol) were added to a flame dried Biotage 5 mL microwave vial, containing activated 
4Å molecular sieves (~ 100 mg) under nitrogen. Deuterated chloroform (2 mL) was 
added, the vial was sealed with a PTFE crimp cap and the reaction mixture was left 
stirring at 25 °C for 2 hours. An aliquot was submitted to 1H-NMR analysis, which 
confirmed the formation of the imine intermediate. Pyridinium triflate (5.5) (3.3 mg, 
0.01 mmol, 10 mol%) was added. After 5 minutes, tert-butyl diazoacetate (5.4) (18 μL, 
0.13 mmol) was added via syringe, and the reaction mixture was stirred at 25 °C, 
monitoring by 1H-NMR until the reaction was deemed complete (~ 12 hours). At this 
point the reaction mixture was passed through a short plug of silica, eluted with diethyl 
ether and the solvent was removed under reduced pressure. The crude material was 
purified by flash chromatography on silica gel (5% diethyl ether in 40-60 PET, Rf = 
0.35) to afford an orange solid. Subsequent physicochemical analysis confirmed this to 
be the title compound (±)-cis-(5.8) (32.4 mg, 0.08 mmol, 69% yield).  
1H NMR (500 MHz, CDCl3) δ 8.22 (d, J 8.8 Hz, 2H, ArH), 7.71 (d, J 8.8 Hz, 2H, ArH), 
7.29 (t, J 7.9 Hz, 2H, ArH), 7.10 – 7.02 (m, 3H, ArH), 3.59 (d, J 6.8 Hz, 1H, C3-H), 
3.19 (d, J 6.8 Hz, 1H, C2-H), 1.23 (s, 9H, C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 
166.1, 151.8, 147.6, 142.6, 129.4, 128.9, 123.9, 123.34, 120.0, 82.4, 46.6, 46.1, 27.9; 
FT-IR (thin film) 2972 (C-H), 1741 (C=O), 1605/1512/1494 (C=C aromatic), 1343 
(NO2), 1219/1159 (C(O)C), 1051 (C-N) cm
-1. 
 
The spectroscopic data is consistent with that reported in the literature.173 
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Pitak, UK National Crystallography Service, Southampton. (M.Pitak@soton.ac.uk) 
 
Appendix 1: X-ray crystal structure and crystallographic data for (±)-cis-(5.8). 
 
Figure 1. Molecular structure of 2014ncs0678 (VZ087). Displacement ellipsoids – 50% probability. 
 
Table 1. Crystal data and structure refinement details. 
 
 
Identification code  2014ncs0678 (VZ087)     
 
Empirical formula  C19H20N2O4 
Formula weight  340.37 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Orthorhombic 
Space group  P212121  
Unit cell dimensions a = 6.02830(10) Å  = 90° 
 b = 15.5813(5) Å  = 90° 
 c = 18.3695(12) Å   = 90° 
Volume 1725.42(13) Å3 
Z 4 
Density (calculated) 1.310 Mg / m3 
Absorption coefficient 0.093 mm1 
F(000) 720 
Crystal Shard; colourless 
Crystal size 0.180  0.070  0.020 mm3 
 range for data collection 3.429  27.481° 
Index ranges 7  h  6, 20  k  11, 23  l  23 
Reflections collected 12619 
Independent reflections 3923 [Rint = 0.0262] 
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Completeness to  = 25.242° 99.6 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 1.000 and 0.820 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3923 / 0 / 229 
Goodness-of-fit on F2 1.029 
Final R indices [F2 > 2(F2)] R1 = 0.0328, wR2 = 0.0708 
R indices (all data) R1 = 0.0394, wR2 = 0.0757 
Absolute structure parameter 0.5(4) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.167 and 0.161 e Å3 
 
_________________________________________________________________________________________________________ 
 
Diffractometer: Rigaku AFC12 goniometer equipped with an enhanced sensitivity (HG) Saturn724+ detector mounted at the 
window of an FR-E+ SuperBright molybdenum rotating anode generator with HF Varimax optics (100m focus). Cell 
determination and data collection: CrystalClear-SM Expert 2.0 r11 (Rigaku, 2011). Data reduction, cell refinement and 
absorption correction: CrystalClear-SM Expert 2.1 r29 (Rigaku, 2011). Structure solution: SUPERFLIP (Palatinus, L. & 
Chapuis, G. (2007). J. Appl. Cryst. 40, 786-790). Structure refinement: SHELXL-2013 (Sheldrick, G.M. (2008). Acta Cryst. A64, 
112-122). 
 
 
Special details:  
Absolute configuration cannot be reliably determined based on anomalous dispersion effect due to lack of heavier 
element in the crystal structure (>Si), however the relative configuration can be assigned as R, R or S,S on C7 and 
C14. 
 
Table 2. Atomic coordinates [ 104], equivalent isotropic displacement parameters [Å2  103] and site occupancy 
factors. Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 
Atom  x y z Ueq S.o.f. 
 
C1 546(3) 3072(1) 8601(1) 15(1) 1 
C2 343(3) 2221(1) 8385(1) 19(1) 1 
C3 1647(3) 1594(1) 8712(1) 22(1) 1 
C4 3140(4) 1812(1) 9258(1) 21(1) 1 
C5 3326(3) 2661(1) 9475(1) 19(1) 1 
C6 2051(3) 3293(1) 9147(1) 16(1) 1 
C7 2990(3) 3688(1) 8127(1) 16(1) 1 
C8 3914(3) 4002(1) 7419(1) 16(1) 1 
C9 6020(3) 4366(1) 7415(1) 17(1) 1 
C10 6957(3) 4657(1) 6771(1) 17(1) 1 
C11 5745(3) 4567(1) 6137(1) 17(1) 1 
C12 3627(3) 4225(1) 6123(1) 18(1) 1 
C13 2714(3) 3940(1) 6775(1) 18(1) 1 
C14 1979(3) 4320(1) 8652(1) 15(1) 1 
C15 1927(3) 5247(1) 8440(1) 16(1) 1 
C16 3912(3) 6581(1) 8727(1) 19(1) 1 
C17 1853(4) 7143(1) 8748(1) 27(1) 1 
C18 5447(4) 6790(2) 9358(1) 29(1) 1 
C19 5146(4) 6633(2) 8006(1) 24(1) 1 
N1 597(3) 3739(1) 8227(1) 15(1) 1 
N2 6754(3) 4837(1) 5446(1) 19(1) 1 
O1 5638(3) 4772(1) 4889(1) 26(1) 1 
O2 8663(3) 5107(1) 5453(1) 31(1) 1 
O3 863(2) 5540(1) 7942(1) 21(1) 1 
O4 3334(2) 5673(1) 8870(1) 19(1) 1 
 
 
 
 
Table 3. Bond lengths [Å] and angles [°]. 
 
 
C1C2 1.390(3) 
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C1C6 1.396(3) 
C1N1 1.424(2) 
C2C3 1.390(3) 
C2H2 0.9500 
C3C4 1.390(3) 
C3H3 0.9500 
C4C5 1.386(3) 
C4H4 0.9500 
C5C6 1.386(3) 
C5H5 0.9500 
C6H6 0.9500 
C7N1 1.456(2) 
C7C8 1.498(2) 
C7C14 1.506(3) 
C7H7 1.0000 
C8C13 1.390(3) 
C8C9 1.390(3) 
C9C10 1.387(3) 
C9H9 0.9500 
C10C11 1.382(3) 
C10H10 0.9500 
C11C12 1.384(3) 
C11N2 1.469(2) 
C12C13 1.391(3) 
C12H12 0.9500 
C13H13 0.9500 
C14N1 1.456(2) 
C14C15 1.496(3) 
C14H14 1.0000 
C15O3 1.208(2) 
C15O4 1.336(2) 
C16O4 1.480(2) 
C16C18 1.518(3) 
C16C17 1.520(3) 
C16C19 1.521(3) 
C17H17A 0.9800 
C17H17B 0.9800 
C17H17C 0.9800 
C18H18A 0.9800 
C18H18B 0.9800 
C18H18C 0.9800 
C19H19A 0.9800 
C19H19B 0.9800 
C19H19C 0.9800 
N2O2 1.225(2) 
N2O1 1.230(2) 
 
C2C1C6 119.89(18) 
C2C1N1 121.10(17) 
C6C1N1 118.73(18) 
C1C2C3 119.82(19) 
C1C2H2 120.1 
C3C2H2 120.1 
C4C3C2 120.38(19) 
C4C3H3 119.8 
C2C3H3 119.8 
C5C4C3 119.57(19) 
C5C4H4 120.2 
C3C4H4 120.2 
C6C5C4 120.53(18) 
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C6C5H5 119.7 
C4C5H5 119.7 
C5C6C1 119.81(19) 
C5C6H6 120.1 
C1C6H6 120.1 
N1C7C8 117.41(16) 
N1C7C14 58.85(12) 
C8C7C14 119.59(17) 
N1C7H7 116.2 
C8C7H7 116.2 
C14C7H7 116.2 
C13C8C9 119.99(17) 
C13C8C7 121.53(17) 
C9C8C7 118.49(17) 
C10C9C8 120.60(17) 
C10C9H9 119.7 
C8C9H9 119.7 
C11C10C9 118.08(18) 
C11C10H10 121.0 
C9C10H10 121.0 
C10C11C12 122.86(17) 
C10C11N2 118.71(17) 
C12C11N2 118.43(17) 
C11C12C13 118.14(17) 
C11C12H12 120.9 
C13C12H12 120.9 
C8C13C12 120.29(17) 
C8C13H13 119.9 
C12C13H13 119.9 
N1C14C15 116.61(15) 
N1C14C7 58.88(11) 
C15C14C7 118.18(15) 
N1C14H14 116.9 
C15C14H14 116.9 
C7C14H14 116.9 
O3C15O4 126.61(19) 
O3C15C14 125.05(17) 
O4C15C14 108.26(16) 
O4C16C18 102.29(15) 
O4C16C17 110.74(16) 
C18C16C17 110.76(18) 
O4C16C19 108.68(16) 
C18C16C19 110.79(17) 
C17C16C19 113.04(17) 
C16C17H17A 109.5 
C16C17H17B 109.5 
H17AC17H17B 109.5 
C16C17H17C 109.5 
H17AC17H17C 109.5 
H17BC17H17C 109.5 
C16C18H18A 109.5 
C16C18H18B 109.5 
H18AC18H18B 109.5 
C16C18H18C 109.5 
H18AC18H18C 109.5 
H18BC18H18C 109.5 
C16C19H19A 109.5 
C16C19H19B 109.5 
H19AC19H19B 109.5 
C16C19H19C 109.5 
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H19AC19H19C 109.5 
H19BC19H19C 109.5 
C1N1C14 118.19(15) 
C1N1C7 120.04(16) 
C14N1C7 62.27(12) 
O2N2O1 123.46(17) 
O2N2C11 118.53(16) 
O1N2C11 118.01(16) 
C15O4C16 121.36(15) 
 
 
Symmetry transformations used to generate equivalent atoms:  
  
 
 
 
 
Table 4. Anisotropic displacement parameters [Å2 103]. The anisotropic displacement 
factor exponent takes the form: 2 2[h2a*2U11 + ... + 2 h k a* b* U12 ]. 
 
Atom U11 U22 U33 U23 U13 U12 
 
C1 16(1)  15(1) 16(1)  3(1) 4(1)  2(1) 
C2 22(1)  18(1) 18(1)  2(1) 1(1)  2(1) 
C3 28(1)  14(1) 24(1)  0(1) 2(1)  3(1) 
C4 22(1)  20(1) 21(1)  5(1) 2(1)  8(1) 
C5 17(1)  23(1) 18(1)  2(1) 1(1)  1(1) 
C6 16(1)  15(1) 18(1)  0(1) 3(1)  0(1) 
C7 14(1)  14(1) 19(1)  2(1) 2(1)  1(1) 
C8 17(1)  10(1) 19(1)  1(1) 1(1)  2(1) 
C9 17(1)  16(1) 18(1)  0(1) 3(1)  1(1) 
C10 14(1)  16(1) 22(1)  0(1) 1(1)  0(1) 
C11 20(1)  12(1) 18(1)  1(1) 3(1)  3(1) 
C12 19(1)  15(1) 19(1)  3(1) 4(1)  2(1) 
C13 16(1)  15(1) 23(1)  2(1) 2(1)  0(1) 
C14 17(1)  14(1) 16(1)  1(1) 1(1)  1(1) 
C15 15(1)  15(1) 17(1)  1(1) 3(1)  1(1) 
C16 23(1)  13(1) 22(1)  1(1) 2(1)  6(1) 
C17 29(1)  17(1) 36(1)  3(1) 1(1)  2(1) 
C18 36(1)  20(1) 30(1)  3(1) 8(1)  11(1) 
C19 25(1)  17(1) 28(1)  3(1) 5(1)  5(1) 
N1 15(1)  14(1) 18(1)  2(1) 1(1)  2(1) 
N2 24(1)  16(1) 18(1)  0(1) 2(1)  2(1) 
O1 30(1)  30(1) 18(1)  3(1) 3(1)  1(1) 
O2 24(1)  42(1) 26(1)  1(1) 5(1)  11(1) 
O3 23(1)  17(1) 22(1)  2(1) 5(1)  1(1) 
O4 23(1)  13(1) 21(1)  1(1) 3(1)  5(1) 
 
 
 
 
Table 5. Hydrogen coordinates [ 104] and isotropic displacement parameters [Å2  103]. 
 
Atom  x y z Ueq S.o.f. 
 
H2 685 2068 8015 23 1 
H3 1516 1013 8561 26 1 
H4 4027 1383 9481 25 1 
H5 4335 2812 9851 23 1 
H6 2201 3875 9294 20 1 
H7 3744 3180 8348 19 1 
H9 6825 4416 7858 20 1 
H10 8389 4911 6766 21 1 
H12 2818 4186 5680 21 1 
H13 1263 3701 6780 21 1 
H14 2140 4189 9183 18 1 
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H17A 2293 7749 8743 41 1 
H17B 926 7021 8322 41 1 
H17C 1011 7022 9193 41 1 
H18A 4653 6708 9818 43 1 
H18B 6739 6408 9343 43 1 
H18C 5940 7387 9319 43 1 
H19A 5659 7222 7927 35 1 
H19B 6425 6245 8017 35 1 
H19C 4149 6465 7609 35 1 
 
 
 
 
 
 
 
 
 
Appendix 2: X-ray crystal structure and crystallographic data for (5.63). 
 
Figure 1. Molecular structure 2014ncs0738 (VZ 106). Displacement ellipsoids - 50% probability. 
 
Table 1. Crystal data and structure refinement details. 
 
 
Identification code  2014ncs0738 (VZ 106)     
 
Empirical formula  C21H25Br2NO4 
Formula weight  515.24 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P1  
Unit cell dimensions a = 8.6732(3) Å  = 94.425(7)° 
 b = 9.6569(3) Å  = 106.088(8)° 
 c = 13.4178(9) Å   = 93.023(7)° 
Volume 1073.37(10) Å3 
Z 2 
Density (calculated) 1.594 Mg / m3 
Absorption coefficient 3.802 mm1 
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F(000) 520 
Crystal Block; Colorless 
Crystal size 0.150  0.060  0.030 mm3 
 range for data collection 3.116  27.464° 
Index ranges 11  h  11, 11  k  12, 17  l  17 
Reflections collected 14442 
Independent reflections 4905 [Rint = 0.0276] 
Completeness to  = 25.242° 99.6 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 1.000 and 0.804 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4905 / 0 / 258 
Goodness-of-fit on F2 1.105 
Final R indices [F2 > 2(F2)] R1 = 0.0242, wR2 = 0.0678 
R indices (all data) R1 = 0.0265, wR2 = 0.0691 
Extinction coefficient n/a 
Largest diff. peak and hole 0.915 and 0.814 e Å3 
 
_________________________________________________________________________________________________________ 
 
Diffractometer: Rigaku AFC12 goniometer equipped with an enhanced sensitivity (HG) Saturn724+ detector mounted at the 
window of an FR-E+ SuperBright molybdenum rotating anode generator with HF Varimax optics (100m focus). Cell 
determination and data collection: CrystalClear-SM Expert 2.0 r11 (Rigaku, 2011). Data reduction, cell refinement and 
absorption correction: CrystalClear-SM Expert 2.1 r29 (Rigaku, 2011). Structure solution: SUPERFLIP (Palatinus, L. & 
Chapuis, G. (2007). J. Appl. Cryst. 40, 786-790). Structure refinement: SHELXL-2013 (Sheldrick, G.M. (2008). Acta Cryst. A64, 
112-122). 
 
 
Special details:  
This compound crystallises in centrosymmetric spacegroup. Unit cell contains two opposite enantiomers (racemic 
mixture).  
 
Table 2. Atomic coordinates [ 104], equivalent isotropic displacement parameters [Å2  103] and site occupancy 
factors. Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 
Atom  x y z Ueq S.o.f. 
 
C1 8674(2) 1696(2) 2692(2) 23(1) 1 
C2 9481(2) 4078(2) 3659(2) 21(1) 1 
C3 6883(2) 3644(2) 2200(2) 25(1) 1 
C4 8086(2) 3035(2) 3081(1) 17(1) 1 
C5 6497(2) 3363(2) 4337(1) 15(1) 1 
C6 5637(2) 2507(2) 4980(1) 14(1) 1 
C7 3842(2) 2434(2) 4389(1) 15(1) 1 
C8 3477(2) 1692(2) 3306(1) 14(1) 1 
C9 3944(2) 344(2) 3165(1) 17(1) 1 
C10 3627(2) 349(2) 2179(1) 18(1) 1 
C11 2811(2) 313(2) 1331(1) 19(1) 1 
C12 2341(2) 1648(2) 1440(1) 21(1) 1 
C13 2689(2) 2340(2) 2438(1) 18(1) 1 
C14 7523(2) 3091(2) 6714(1) 15(1) 1 
C15 7824(2) 3669(2) 7757(1) 15(1) 1 
C16 9319(2) 3641(2) 8469(1) 18(1) 1 
C17 10554(2) 3003(2) 8162(1) 17(1) 1 
C18 10284(2) 2411(2) 7155(1) 18(1) 1 
C19 8771(2) 2469(2) 6439(1) 17(1) 1 
C20 6763(2) 4733(2) 9060(1) 21(1) 1 
C21 13275(2) 2399(2) 8650(2) 24(1) 1 
Br1 2580(1) 1433(1) 5179(1) 18(1) 1 
Br2 2315(1) 660(1) 20(1) 30(1) 1 
N1 5964(2) 3095(2) 6044(1) 16(1) 1 
O1 7237(2) 2521(1) 3818(1) 15(1) 1 
O2 6460(2) 4610(1) 4317(1) 21(1) 1 
O3 6523(2) 4214(1) 7997(1) 18(1) 1 
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O4 11993(2) 3043(2) 8936(1) 23(1) 1 
 
 
 
Table 3. Bond lengths [Å] and angles [°]. 
 
 
C1C4 1.522(3) 
C1H1A 0.9800 
C1H1B 0.9800 
C1H1C 0.9800 
C2C4 1.520(2) 
C2H2A 0.9800 
C2H2B 0.9800 
C2H2C 0.9800 
C3C4 1.523(2) 
C3H3A 0.9800 
C3H3B 0.9800 
C3H3C 0.9800 
C4O1 1.486(2) 
C5O2 1.209(2) 
C5O1 1.332(2) 
C5C6 1.544(2) 
C6N1 1.440(2) 
C6C7 1.534(2) 
C6H6 1.0000 
C7C8 1.512(2) 
C7Br1 1.9863(17) 
C7H7 1.0000 
C8C13 1.390(2) 
C8C9 1.397(2) 
C9C10 1.385(2) 
C9H9 0.9500 
C10C11 1.384(3) 
C10H10 0.9500 
C11C12 1.383(3) 
C11Br2 1.9013(18) 
C12C13 1.395(3) 
C12H12 0.9500 
C13H13 0.9500 
C14C19 1.387(2) 
C14N1 1.401(2) 
C14C15 1.414(2) 
C15O3 1.375(2) 
C15C16 1.384(2) 
C16C17 1.404(3) 
C16H16 0.9500 
C17C18 1.378(2) 
C17O4 1.381(2) 
C18C19 1.402(2) 
C18H18 0.9500 
C19H19 0.9500 
C20O3 1.429(2) 
C20H20A 0.9800 
C20H20B 0.9800 
C20H20C 0.9800 
C21O4 1.429(2) 
C21H21A 0.9800 
C21H21B 0.9800 
C21H21C 0.9800 
N1H1 0.8601 
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C4C1H1A 109.5 
C4C1H1B 109.5 
H1AC1H1B 109.5 
C4C1H1C 109.5 
H1AC1H1C 109.5 
H1BC1H1C 109.5 
C4C2H2A 109.5 
C4C2H2B 109.5 
H2AC2H2B 109.5 
C4C2H2C 109.5 
H2AC2H2C 109.5 
H2BC2H2C 109.5 
C4C3H3A 109.5 
C4C3H3B 109.5 
H3AC3H3B 109.5 
C4C3H3C 109.5 
H3AC3H3C 109.5 
H3BC3H3C 109.5 
O1C4C2 110.01(14) 
O1C4C1 101.57(14) 
C2C4C1 111.58(15) 
O1C4C3 109.17(14) 
C2C4C3 112.64(16) 
C1C4C3 111.30(16) 
O2C5O1 126.68(17) 
O2C5C6 123.40(16) 
O1C5C6 109.92(14) 
N1C6C7 112.51(14) 
N1C6C5 112.94(14) 
C7C6C5 105.35(13) 
N1C6H6 108.6 
C7C6H6 108.6 
C5C6H6 108.6 
C8C7C6 112.53(14) 
C8C7Br1 108.58(11) 
C6C7Br1 109.40(11) 
C8C7H7 108.8 
C6C7H7 108.8 
Br1C7H7 108.8 
C13C8C9 119.11(16) 
C13C8C7 120.71(15) 
C9C8C7 120.18(15) 
C10C9C8 120.99(16) 
C10C9H9 119.5 
C8C9H9 119.5 
C11C10C9 118.61(17) 
C11C10H10 120.7 
C9C10H10 120.7 
C12C11C10 121.95(17) 
C12C11Br2 119.38(14) 
C10C11Br2 118.66(14) 
C11C12C13 118.76(17) 
C11C12H12 120.6 
C13C12H12 120.6 
C8C13C12 120.56(17) 
C8C13H13 119.7 
C12C13H13 119.7 
C19C14N1 124.00(16) 
C19C14C15 117.48(16) 
N1C14C15 118.37(15) 
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O3C15C16 123.94(16) 
O3C15C14 114.92(15) 
C16C15C14 121.12(16) 
C15C16C17 119.78(16) 
C15C16H16 120.1 
C17C16H16 120.1 
C18C17O4 125.12(16) 
C18C17C16 120.25(16) 
O4C17C16 114.63(16) 
C17C18C19 119.25(16) 
C17C18H18 120.4 
C19C18H18 120.4 
C14C19C18 122.10(16) 
C14C19H19 118.9 
C18C19H19 118.9 
O3C20H20A 109.5 
O3C20H20B 109.5 
H20AC20H20B 109.5 
O3C20H20C 109.5 
H20AC20H20C 109.5 
H20BC20H20C 109.5 
O4C21H21A 109.5 
O4C21H21B 109.5 
H21AC21H21B 109.5 
O4C21H21C 109.5 
H21AC21H21C 109.5 
H21BC21H21C 109.5 
C14N1C6 119.03(14) 
C14N1H1 110.8 
C6N1H1 111.0 
C5O1C4 122.25(14) 
C15O3C20 116.24(14) 
C17O4C21 116.08(15) 
 
 
Symmetry transformations used to generate equivalent atoms:  
  
 
 
 
 
Table 4. Anisotropic displacement parameters [Å2 103]. The anisotropic displacement 
factor exponent takes the form: 2 2[h2a*2U11 + ... + 2 h k a* b* U12 ]. 
 
Atom U11 U22 U33 U23 U13 U12 
 
C1 21(1)  27(1) 20(1)  6(1) 9(1)  0(1) 
C2 19(1)  22(1) 22(1)  1(1) 7(1)  2(1) 
C3 24(1)  37(1) 16(1)  6(1) 4(1)  4(1) 
C4 16(1)  22(1) 13(1)  2(1) 6(1)  1(1) 
C5 13(1)  19(1) 12(1)  1(1) 2(1)  2(1) 
C6 14(1)  17(1) 11(1)  1(1) 3(1)  2(1) 
C7 15(1)  18(1) 12(1)  2(1) 5(1)  1(1) 
C8 12(1)  16(1) 13(1)  0(1) 3(1)  1(1) 
C9 18(1)  18(1) 15(1)  2(1) 4(1)  2(1) 
C10 21(1)  17(1) 16(1)  1(1) 6(1)  1(1) 
C11 22(1)  22(1) 12(1)  3(1) 5(1)  5(1) 
C12 23(1)  23(1) 14(1)  3(1) 1(1)  0(1) 
C13 17(1)  18(1) 16(1)  2(1) 3(1)  2(1) 
C14 16(1)  16(1) 12(1)  0(1) 3(1)  1(1) 
C15 18(1)  15(1) 13(1)  0(1) 5(1)  1(1) 
C16 19(1)  19(1) 13(1)  2(1) 3(1)  0(1) 
C17 15(1)  20(1) 15(1)  1(1) 1(1)  0(1) 
C18 16(1)  22(1) 17(1)  1(1) 5(1)  2(1) 
C19 19(1)  20(1) 11(1)  1(1) 3(1)  0(1) 
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C20 24(1)  26(1) 12(1)  3(1) 4(1)  4(1) 
C21 17(1)  29(1) 24(1)  2(1) 3(1)  4(1) 
Br1 16(1)  25(1) 15(1)  3(1) 6(1)  2(1) 
Br2 48(1)  27(1) 13(1)  5(1) 6(1)  5(1) 
N1 15(1)  21(1) 10(1)  2(1) 3(1)  1(1) 
O1 16(1)  17(1) 13(1)  1(1) 6(1)  1(1) 
O2 23(1)  16(1) 24(1)  1(1) 10(1)  4(1) 
O3 18(1)  24(1) 12(1)  3(1) 4(1)  4(1) 
O4 17(1)  32(1) 16(1)  2(1) 1(1)  5(1) 
 
 
 
Table 5. Hydrogen coordinates [ 104] and isotropic displacement parameters [Å2  103]. 
 
Atom  x y z Ueq S.o.f. 
 
H1A 9262 1900 2187 34 1 
H1B 7750 1029 2358 34 1 
H1C 9389 1296 3282 34 1 
H2A 10179 3657 4244 31 1 
H2B 9063 4910 3922 31 1 
H2C 10100 4338 3183 31 1 
H3A 7418 3916 1682 38 1 
H3B 6466 4464 2481 38 1 
H3C 5991 2944 1869 38 1 
H6 6004 1543 4979 17 1 
H7 3498 3403 4331 18 1 
H9 4487 103 3755 20 1 
H10 3962 1259 2086 22 1 
H12 1792 2087 847 25 1 
H13 2384 3262 2525 21 1 
H16 9509 4051 9163 21 1 
H18 11113 1967 6948 22 1 
H19 8594 2069 5743 20 1 
H20A 5762 5081 9147 31 1 
H20B 7616 5493 9254 31 1 
H20C 7077 3982 9509 31 1 
H21A 13533 2873 8089 36 1 
H21B 12945 1416 8409 36 1 
H21C 14227 2468 9255 36 1 
H1 5261 2772 6327 19 1 
 
 
 
Table 6. Hydrogen bonds [Å and °]. 
 
 DH···A d(DH) d(H···A) d(D···A) (DHA) 
 
 C1H1A...Br2i 0.98 2.97 3.4990(19) 114.7 
 C2H2B...O2 0.98 2.47 3.044(2) 117.4 
 C3H3B...O2 0.98 2.46 3.046(2) 118.2 
 C7H7...O2ii 1.00 2.53 3.286(2) 132.4 
 C18H18...Br1iii 0.95 3.01 3.8236(19) 144.3 
 C19H19...O1 0.95 2.61 3.403(2) 141.7 
 C20H20B...O4iv 0.98 2.64 3.204(2) 116.7 
 N1H1...Br1 0.86 2.62 3.1410(15) 120.5  
 
Symmetry transformations used to generate equivalent atoms:  
(i) x+1,y,z    (ii) x+1,y+1,z+1    (iii) x+1,y,z  
(iv)  x+2,y+1,z+2   
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